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ABSTRACT
This project examined methodologies used to establish primary cell cultures from non-small cell 
lung carcinoma (NSCLC) tumours. The objective was to enhance the in vitro proliferative 
potential of these clinically important tumours, particularly the squamous cell carcinoma (SCC) 
subtype. Existing techniques were successfully employed and refined here, permitting short-term 
maintenance in vitro and resulting in the establishment of a novel lung SCC cell line, DLRP, 
which was charaterised herein. The ability to generate long-term NSCLC cultures and cell lines 
on a routine basis however, remained elusive. The apparent defecit o f relevant growth factors 
in currently available media for NSCLC was addressed. To this end, two likely sources of 
growth stimulators for malignant epithelial cells were explored.
The first approach pursued literature reports of growth-promoting activités in the malignant 
effusions (MEs) and preliminary evidence in this project detected the presence in these fluids, 
of both stimulatory and inhibitory activity for NSCLC growth (including DLRP) in vitro. 
However, the active stimulatory species did not appear to be tumour-type specific and was 
conceivably a serum-derived systemic species. The second option evolved from the first, with 
evidence for the production of ‘self-stimulating’ autocrine growth factors by the human 
epidermoid carcinoma cell line, HEp-2.
A  bioassay was developed using HEp-2, which detected the presence of growth stimulators in 
MEs and HEp-2 conditioned medium (CM), based on their ability to stimulate the colony 
growth in monolayer of low density HEp-2 cells. Two separate fractions o f HEp-2 CM, 
prepared by ultrafiltration (UF), i.e  a 10-30 kDa and a > 3 0  kDa fraction, both exhibited 
autocrine stimulatory activity (ASA). These fractions were distinguished by differential 
sensitivities to proteinase treatment. Production of several growth factors by HEp-2 is indicated 
by ASA elution profiles from gel-filtration, hydrophobic interaction, and heparin affinity 
chromatographic separations. Both heparin-binding and non-heparin-binding ASA are present 
in HEp-2 CM, but the heterologus elution profile of the heparin-binding ASA indicates that 
more than one high affinity heparin-binding mitogen is involved. Neutralising antibodies suggest 
that at least 60% of the ASA in the 10-30 MW fraction is attributable to a bFGF-like factor, 
and a similar species accounts for 40% of the >  30 kDa activity. Antisense studies designed to 
inhibit bFGF gene expression in HEp-2 cells did not support these findings. The possibility 
remains that one or more of the less well characterised heparin-binding growth factors are 
involved in HEp-2 autocrine growth control.
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INTRODUCTION
1.1 GROWTH CONTROL IN MULTICELLULAR ORGANISMS
Cell proliferation and differentiation are two highly coordinated mechanisms underlying the 
growth and development of multicellular organisms. The study of these fundamental processes 
at all stages of growth from embryo to adult, has revealed that the fate of an organism relies 
not merely upon its inherent genetic program, but also upon the outcome of its interaction with 
that organism’s physical environment. This concept applies equally at the molecular level for 
all facets of growth from conception, through embryogenesis, to tissue maintenance and repair 
in the adult. Physiochemical parameters which influence developmental outcome include 
extracellular matrix components, membrane junctions between apposing cells, cell adhesion 
molecules, and also nutritional factors.
That these processes are highly ordered and controlled, is best exemplified by the observation 
that specific tissues are continuously replenished in the adult. In adult vertebrate tissues, such 
as the skin, intestine, and hematopoietic system, mature or differentiated cells are being replaced 
daily from a limited number of multipotent stem cells that were laid down during 
embryogenesis. In normal growth programs, these stem cells are expanded in number by clonal 
proliferation to produce progenitor cells. Such progenitor cells, already restricted by their 
commitment to a particular differentiation process, proliferate further in their respective lineages 
before they cease to divide, and begin to express the differentiated phenotype characteristic of 
that lineage. In this way cells lost through natural processes or through tissue injury are 
replaced.
In all of these tissues, a balance must be maintained between the renewal of stem cells, and the 
commitment to differentiation needed to maintain tissue integrity. Key players in this complex 
hierarchy of control processes are a diverse group of soluble factors produced by cells, called 
polypeptide growth factors. These molecules have been found to exert both positive and 
negative control over cell proliferation and differentiation. Initially most growth factors were 
named after the biological activity that lead to their isolation. However, later work revealed that 
many of these factors are multifunctional {Sporn & Roberts (1988)}. It was subsequently 
discovered that growth factors affect not only cell proliferation and differentiation during 
embryogenesis and wound repair, but they also mediate chemotactic responses seen during 
inflammation and are involved in modulating the immune response.
Factors originally identified as growth regulatory molecules for hematopoietic (blood) cells have
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been called ‘cytokines’ but it has become increasingly clear in recent years that the action of 
cytokines is not restricted to specific cell lineages, or to stage-specific points during 
differentiation in hematopoietic cells, as initially thought. The terms ‘polypeptide growth factor’ 
and ‘cytokine’ therefore are used interchangeably in this thesis.
Polypeptide growth factors are distinguished from hormones in that growth factors are produced 
and act locally in tissues, while hormones are systemic endocrine products, active mainly as 
metabolic regulators. The actions of polypeptide growth factors are effected through binding to 
specific transmembrane receptors on the plasma membrane of target cells. This interaction 
triggers a cascade of intracellular biochemical pathways which ultimately translates the signal 
to the cell nucleus.
1.1.1 GROWTH FACTOR RECEPTORS AND SIGNAL TRANSDUCTION
Several classes of transmembrane growth factor receptors have been identified. The best 
understood are receptors with tyrosine kinase activities. These contain an extracellular domain 
where the ligand binds, followed by a hydrophobic transmembrane region, and then a 
cytoplasmic domain which contains a tyrosine kinase activity. This kinase activity distinguishes 
this class of receptor from others, and many of the known growth factors including the FGFs, 
the EGF family, and PDGF, all transduce their signals by binding to transmembrane receptors 
tyrosine kinases RTK(s).
Dimérisation of RTKs is associated with ligand binding and accompanies the activation of the 
tyrosine kinase activity {Ullrich et al., (1990)}. This leads to molecular interactions between 
adjacent cytoplasmic receptor domains, and results in the activation of kinase functions in these 
receptors. Autophsophorylation of the occupied receptors is often the first observation of kinase 
activity. However, the phosphorylation of the receptor itself modulates its ability to interact with 
other substrates in the signal transduction pathway {Kock et al., (1991)}.
Many of the intracellular events elicited after binding of growth factors to their receptors 
involve protein phosphorylataion, and some of the substrates for RTKs are themselves kinases. 
These include those which phosphorylate on serine and threonine {Morrison et al., (1988)}, as 
well as tyrosine residues {Ralston & Bishop (1985)}. Phosphorylation therefore, appears to be 
one of the major biochemical mechanisms involved in the transmission and modulation of the 
mitogenic signal for many growth factors.
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Another second messenger event is the breakdown of the inositol lipid, phosphatidylinositol 
bisphosphate. This produces diacylglycerol (DAG) and inositol triphosphate (IP3). The former 
activates a kinase called protein kinase C (PKC) {Nishizuka (1988)}, and the latter mobilises 
intracellular Ca2+ concentrations {Berridge & Irvine (1984)}. A 21 kDa protein called Ras is 
also activated following ligand binding in some receptor complexes. Ras is phosphorylated by 
a guanosine triphosphatase (GTPase) which is a receptor-associated kinase {McCormick
(1989)}. The activation of the Na'/H + antiport also follows receptor activation and the resulting 
ion fluxes across the plasma membrane lead to cytoplasmic alkalinisation.
The biochemical events linking the primary substrates of growth factor receptors to the changes 
in the nucleus are only beginning to be defined. However, transient changes in the expression 
of a set of genes called ‘primary response genes’ (PRGs), or ‘cellular immediate early genes’, 
follow the cascade of signals induced by ligand binding. These PRGs appear to translate the 
growth factor signal into subsequent ‘secondary’ changes in gene expression. A common feature 
of the transcriptional induction of PRGs is that de novo protein synthesis is not required 
{reviewed by McMahon & Monroe (1992); Herschman (1991)}. The proteins encoded by PRGs 
include structural proteins such as actin and tropomyosin, but an important role in the 
proliferative response is played by a subset of PRGs called transcription factors. The critical 
role played by transcription factors such as c-fos, c-jun and c-myc, is related to their ability to 
activate and/or repress the expression of the specific expression of ‘secondary genes’.
Non-tyrosine kinase receptors
A separate class of growth factor receptors do not signal through tyrosine kinase, and most of 
the hematopoietic growth factor receptors cloned to date fall into this category. These include 
erythropoietin, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte 
colony stimulating factor (G-CSF), as well as interleukins 2, 3, 4, 5, 6 , and 7 {Nicola & 
Metcalf (1991)}. Sub-families within this large group of receptor types have been characterised 
{for review see Taga & Kishimoto (1992)}. A distinguishing feature for many of the 
hematopoietic growth factor (cytokine) receptors is that in addition to the specific ligand-binding 
receptor, auxilary components are required to generate functional high affinity complexes 
capable of signal transduction. These so-called ‘transducer’ proteins are frequently shared by 
different ligand-binding receptor molecules, and this mechanism provides a basis for 
understanding the pleiotrophic and redundant effects exhibited by cytokines.
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Another feature which characterises these receptors are their relatively large extracellular 
domains and short cytoplasmic domains. The spacing of cysteine residues in the extracellular 
domains of some hematopoietic growth factor/cytokine receptors defines a sub-group with 
immunoglobulin-like structure. In addition, the post-receptor binding events associated with 
hematopoietic growth factor/cytokine receptor signalling are not yet well understood. However, 
some of the sub-families are known to possess a serine/threonine kinase domain (e.g. type II 
TGF-/3 receptor). Others (e.g IL-3, IL-6) have no associated enzymatic activities, but 
preliminary studies with these indicate that they may interact with intracellular tyrosine kinases 
as a first step in generating their signal {Taga & Kishimoto (1992)}.
Another distinct subfamily of cytokine receptors (e.g. IL-8-R) belong to a larger group of 
guanine nucleotide-binding protein (G-protein)-coupled receptors. This superfamily also includes 
the receptor for bombesin/GRP, and are characterised by seven hydrophobic membrane- 
spanning domains. The three subunit G-proteins associated with these ‘seven-pass’ receptors 
couple ligand-binding to the effectors adenyl cyclase and phospholipase C {Spiegel (1992)}.
1.1.2 THE ROLE OF ONCOGENES IN ABERRANT GROWTH CONTROL
The basis of a mechanistic understanding of the control of cell growth and differentiation has 
been provided by the integration of previously distinct fields of research. These include the 
study of the biology of growth factors and their receptors, viral oncogenes, and the role of 
steroids and retinoids.
It was found that several retroviral oncogene products had protein kinase activity which 
functioned to phosphorylate tyrosine residues, as opposed to the more common serine and 
threonine protein kinases identified previously. The study of abnormal cell growth, in the 
carcinogenic process leading to malignancy, identified growth factors as the mediators of cell 
growth and differentiation. Purification and sequencing of receptors for these growth factors, 
such as the epidermal growth factor receptor (EGF-R), demonstrated that similar tyrosine kinase 
activities resided in the cytoplasmic domains of these receptor proteins. It was also found that 
activation of kinase activity, as well as autophosphorylation of the receptors, followed ligand 
binding. Viral oncogene products were found to encode aberrant growth factor receptors, such 
as the truncated EGF-R encoded by the v-erb  B oncogene {Downward et al., (1984)}. A  
connection between oncogenes and growth factors had also been established by the finding that 
the B-chain of the dimeric platelet-derived growth factor had significant sequence holomogy
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with the predicted product of the transforming v-sis oncogene that was expressed in cells 
‘transformed’ by the simian sarcoma virus {Doolittle et al., (1983)}.
The study of oncogenes has demonstrated the potential of normal cellular genes to become 
deregulated. Alterations in the DNA coding sequences such as point mutations, or more gross 
aberrations affecting the regulatory sequences, can lead to the expression of dysfunctional 
products which have lost important regulatory constraints on their acitivty. Apart from point 
mutations and proviral insertions, other less subtle lesions in chromosomal DNA can lead to the 
activation or loss of specific gene expression. These include, gene amplifications, and alterations 
in chromosome structure such as deletions, and the translocation of entire chromosome 
segments. Normal genes with critical roles in the control o f cell growth, proliferation and 
differentiation, which have the potential to become deregulated, are called proto-oncogenes. 
When the expression of these genes produces protein products with sufficiently impaired 
regulatory constraints to result in deregulated cell growth, they are called oncogenes, and their 
products are referred to as ‘oncoproteins’.
A growing number of ‘altered’ versions of cellular genes have been identified and designated 
as oncogenes. These appear to be important lesions in the carcinogenic process. Investigations 
into the mechanisms of malignant transformation have implicated growth factors, growth 
inhibitors, and their receptors, as proto-oncogenes {Heldin & Westermark (1984)}. Other 
classes include the genes for proteins involved in growth factor-induced signal cascades, and 
also the nuclear transcription factors {Rollins & Stiles (1988)}.
Studies in mouse cells have shown that the signal for cells to divide is coordinated by two sets 
of complementary growth factors. ‘Competence factors’ induce resting or quiescent cells in the 
G0 phase of the cell cycle to enter the Gt phase. Sustained action of competence factors for 
several hours is needed, if stimulated cells are not to revert to the resting state before a second 
group of factors, called ‘progression factors’, can induce their transition through the G, phase, 
and ensure commitment to DNA synthesis. There exists a critical period at the end of G, when 
the simultaneous action of both sets of factors is required, but thereafter only the action of 
progression factors is needed to enable cells to complete the cell cycle. Examples of 
competence factors include, epidermal growth factor (EGF), platelet-derived growth factor 
(PDGF) and fibroblast growth factor (FGF). Insulin and insulin-like growth factor-I (IGF-I) are 
examples of progression factors. The ubiquitous polypeptide growth regulator, TGF-/3, appears
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to exert its inhibitory effects in the Gt phase {Aaronson (1991)}. Some oncogenes appear to be 
capable of substituting for competence factors in the cell cycle if  their expression becomes 
activated. Such oncogenes are classified as ‘dominant’ oncogenes. A  schematic representation 
of the coordinated actions of competance and progression factors in the cell cycle is depicted 
in figure 1. 1. 1.
TGFß
In h ib itio n
Oncogene
substitution
Figure 1.1.1 A schematic representation of the requirements for growth factors during the 
cell cycle of mouse keratinocyte cells (taken from Aaroson, 1991).
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In the context of aberrant expression of proto-oncogenes a number of mechanisms might prevail 
to contribute to uncontrolled cell proliferation. The inappropriate production and/or 
overexpression of a growth factor, in cells already expressing the cognate receptors, or 
conversely, the acquisition of a functional receptor for which cells already expresses the ligand, 
may shift the balance of growth control in favour of proliferation. Another mechanism whereby 
cells escape the normal restrictions on their growth, is through loss of effective negative 
regulation. The loss of functional negative regulation may arise due to the inability of cells to 
express functional inhibitor molecules and/or their receptors. A  similar dysfunction in negative 
regulation may arise if  an inhibitor is not efficiently released or activated by cells, or if  a defect 
exists in the post-receptor signalling pathway.
Studies using cell fusions between normal and immortalised cell lines have concluded that 
cellular senescence is a dominant trait, and that cell immortalisation is a consequence of one or 
more gene deletions. It has been hypothesised that senescence in normal cells is accompanied 
by the production of a protein inhibitor which blocks the entry of cells into the S phase of the 
cell cycle. The cellular response to this negative regulator makes the cell insensitive to 
mitogenic stimuli. Immortalisation of normal cells might occur, as outlined above, by the 
effective loss of function of such an inhibitor. This can be the consequence of an inability to 
produce an effective protein, or failure to respond to it {Periera-Smith & Smith (1988)}. The 
existence of normal genes called ‘tumour suppressor genes’, which function to supress 
tumourigenicity, is now well established, and the failure to induce cellular senescence therefore, 
is one mechanism by which tumour suppressor genes can contribute to tumourigenesis {O’Brien 
e ta l . ,  (1986)}.
The nuclear phosphoprotein, p53, is just one exanple of a tumour suppressor gene. Its normal 
function is to block the entry of cells at the GL/S boundary {Levine et al., (1991)}. Normal p53 
functions are lost by a variety of genetic mechanisms including allelic loss, chromosomal 
rearrangements and deletions. However, point mutations are the most commonly observed 
genetic change associated with this gene, and are a frequent event in many types of human 
cancer {Hollstein et al., (1991)}.
Tumourigenesis requires the concerted action of a number of molecular aberrations in cellular 
growth control mechanisms before cells can progress from being merely hyperproliferative, to 
acquiring a malignant phenotype — characterised by the ability to invade surrounding tissues,
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enter the blood stream, and form colonies in distant organs. The spontaneous activation of 
mitogenic signalling pathways, due to inappropriate growth factor production, is now 
definitively established as one of the critical steps in this process. One mechanism of growth 
factor control which is prone to perturbation is the production of autocrine growth factors 
{Aaronson (1991)}.
1.2 AUTOCRINE GROWTH CONTROL
The concept of autocrine growth control was first proposed by Sporn & Todaro (1980) in the 
context of malignant transformation. It was postulated as a mechanism to explain how tumour 
cells acquired growth autonomy. In this scenario, it was proposed that tumour cells could 
stimulate their own proliferation by secreting a growth factor(s) for which the same cells 
concurrently expressed the cognate receptor(s). Growth factors produced by one cell type, but 
active on another, also in the immediate microenvironment, are called ‘paracrine’ growth 
factors. The original autocrine hypothesis was broadened by Sporn & Roberts (1985) to include 
the regulation of normal cell growth, and to account for the loss cell sensitivity to negative 
regulatory signals. This loss of sensitivity to negative growth regulators may be a consequence 
of the loss of receptor function or the inability of cells to produce and/or activate negative 
growth factors.
In the introduction to this dissertation I present a brief overview of the biological characteristics 
of polypeptide growth factors from the major classes identified to date. Evidence is also 
presented for the involvment of particular polypeptide growth factors in the formation of 
autocrine loops, and the contribution that such growth modulatory pathways may have in the 
genesis of malignant cells. In particular, the potential contribution of autocrine mechanisms to 
the development and progression of non-small cell lung carcinomas in vivo, and their 
maintenance as in vitro cultures, is also addressed.
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1.3 THE BIOLOGY OF POLYPEPTIDE GROWTH FACTORS
1.3.1 EPIDERMAL GROWTH FACTOR-LIKE POLYPEPTIDES
The best characterised members of this family of growth factors are epidermal growth factor 
(EGF), and transforming growth factor a  (TGFa). Both growth factors are homologous 
monomeric polypeptides, and like all of the members in this family, they bind to the same high 
affinity receptor — the epidermal growth factor receptor (EGF-R). This is a single-chain 175 
kDa transmembrane glycoprotein. The ligand-binding domain is located on the 621 amino acid 
(aa) extracellular segment, and is separated by a 23 aa hydrophobic membrane-spanning region 
from the 524 aa intracelllular domain which incorporates a tyrosine kinase activity {Ullrich et 
al., (1984)}.
EGF and TGFa do not have an affinity for immobilised heparin {Besner & Klagsbrun (1988); 
Besner et al. (1990); Higashiyama et al. (1991)}, but two other members of the EGF family, 
heparin-binding epidermal growth factor (HB-EGF), and amphiregulin (AR), both have strong 
affinities for this glycosaminoglycan.
The EGF family also includes three virally encoded polypeptide growth factors, which are all 
encoded by members of the poxvirus family. These include vaccinia growth factor 
(VGF){Stroobant et al., (1985)}, myxomavirus growth factor (MGF) {Upton et al., (1987)}, 
and Shope fibroma growth factor (SFGF) {Chang et al., (1987)}. The structural relationship 
between the EGF family members is based on the so-called ‘EGF unit’ — a 45-50 aa sequence 
containing six cysteine residues located in characteristic positions. Fully processed EGF, TGFa 
and VGF share a sequence identity of about 35%, constituted by one such EGF unit {Derynck 
e ta l . ,  (1992)}.
EGF, TGFa, HB-EGF, AR, and VGF are all synthesised as larger precursors that incorporate 
a hydrophobic domain {Gray et al., (1983); Lee et al., (1985); Higashiyama et al., (1992); 
Plowman et al., (1990); Venkatesan et al., (1982)}. This hydrophobic sequence anchors the 
precursor growth factors in the plasma membrane, before they are released by appropriate 
stim uli Release of precursor TGFa has been shown to be a highly regulated process, effected 
by an elastase-like enzyme {Pandiella & Massague (1991a & 1991b)}. Moreover, membrane- 
bound TGFa can also interact with EGF receptors on adjacent cells to transduce its mitogenic 
signal {Wong et al., (1989); Brachmann et al., (1989)}.
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The EGF unit for each growth factor is found in the extracellular domain o f these 
transmembrane precursors. The suggestion that such membrane-anchored growth factors might 
act as receptors for unknown ligands {Pfeffer & Ullrich (1985)} has been substantiated by the 
demonstration that the HB-EGF precursor is identical to the diptheria toxin receptor {Naglich 
e ta l . ,  (1992)}.
1.3.1.1 Epidermal growth factor
Epidermal growth factor is a 53 aa polypeptide {Carpenter & Cohen (1979)} with six cysteine 
residues which are involved in the formation of three intramolecular disulphide bridges {Savage 
et al., (1972 & 1973)}. The mature 6 kDa EGF is cleaved from the C-terminus the 130 kDa 
EGF precursor {Gray et al., (1983)}.
1.3.1.2 Transforming growth factor of
Transforming growth factor a  is a 50 aa protein with a mature molecular weight of 5 .6  kDa 
{Derynck et al., (1984)}. It shares 40% homology with EGF and conserves the 6 cysteine 
residues {Marquardt et al., (1984)}. The overall three-dimensional fold structure of TGFa has 
been shown to be similar to EGF {Harvey et al., (1991)}. Post-translational glycosylation and 
incomplete proteolytic processing, generates TGFa molecules with varying molecular weights 
{Texido et al., (1988)}.
The target cells for EGF and TGFa include epithelial, mesenchymal and glial cells. Many in 
vitro and in vivo biological activities have been attributed to EGF, but perhaps the most 
documented is its ability to stimulate the proliferation and differentiation of epithelial, and 
mesenchymal cells {Carpenter & Wahl (1990)}. Both EGF and TGFa are angiogenic factors 
in vivo, but TGFa is reported to be more potent than EGF in this respect {Barrandon & Green
(1987)}. In addition, overexpression of TGFa, but not EGF, in several carcinomas implies a 
role for TGFa in the progression of these malignancies.
1.3.1.3 Heparin-binding epidermal growth factor
Heparin-binding EGF-like growth factor (HB-EGF) was purified originally from the medium 
conditioned by the histiocytic lymphoma cell line U-937, and its N-terminal amino acid 
sequence was determined. The mature protein has an apparent MW of 22 kDa, is heat and acid 
stable, and elutes from immobilised heparin in 1.0-2.0 M NaCl. Complementary DNA cloning 
of HB-EGF from a U-937 cDNA library revealed that the unique HB-EGF sequence shared 40-
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53% homology with the other members of the EGF-family, and that the mature 86 amino acid 
(aa) glycosylated protein is synthesised initially as a large precursor of 208 aa. HB-EGF was 
found to stimulate the proliferation of fibroblasts and smooth muscle cells, but not endothelial 
cells {Higashiyama et al., (1991, 1992)}. The mitogenic effect of HB-EGF on smooth muscle 
cells is more potent than that of EGF or TGFa and this appears to be due to its interaction with 
heparan sulphate proteoglycan (HSPG) on the cell surface {Higashiyama et al., (1993)}.
1.3.1.4 Amphiregulin
Amphiregulin is an 88 amino acid glycoprotein. It was first isolated from the conditioned 
medium of a phorbol ester-treated mammary carcinoma cell line, MCF-7. It was also shown 
to be a bifunctional growth regulator in this system {Shoyab et al (1988)}. AR has been shown 
to interact with the EGF receptor {Shoyab et al., (1989)}, and inhibits tumour growth 
{Plowman et al., (1990)}. However, it is mitogenic for normal human keratinocytes {Cook et 
a l ,  (1991a)}.
1.3.2 TRANSFORMING GROWTH FACTOR /3 FAMILY OF POLYPEPTIDES
Transforming growth factor /3 (TGF/3) is the prototype of a family of homlogous polypetides. 
Receptors for TGF/3 have been found on virtually all cell types examined, and most cell types 
studied were also found to produce it. The name of this pleiotrophic protein, ‘transforming 
growth factor /3’, belies the fact that TGF/3 does not cause oncogenic transformation of normal 
cells. The response to TGF/3 depends on both the cell type and/or its cellular context. In general 
however, TGF/3 has an inhibitory effect on the proliferation of normal epithelial cells, whereas 
its effect on cells o f mesenchymal origin tends to be stimulatory. TGF-/3 also affects the 
expression of differentiated functions in many cells, as for example in the maintenance of the 
extracellular matrix, where it can stimulate both the genes for extracellular matrix (ECM) 
structural proteins and those for ECM-degrading enzymes.
The multifunctional nature of TGF/3-like polypeptides, and their ubiquitous distribution in many 
tissues from man to drosophila, indicate the important role this molecule plays in the regulation 
of growth and differentiation. This observation is underscored by the copious volumes of 
literature published in this field since the initial isolation of TGF/3 from human platelets 
{Assoian et al., (1983)}, and its subsequent cloning {Derynck et al., (1985)}. Several reviews 
covering all aspects of the biology of these proteins are available {Barnard et al., (1990);
Massague (1990); Sporn & Roberts (1993);}. The following therefore, is a cursory overview 
of the major biochemical characteristics and biological functions of TGF/3-like polypeptides.
The known TGF/3 family of polypeptides now numbers five. The original TGF/3 has since been 
designated TGF-/31 {Cheifetz et al., (1987)}, and all the subesquently identified members are 
classified numerically thereafter as, TGF-/32, TGF-/33, TGF-/34, and TGF-/35 respectively. 
These dimeric proteins share approximately 70-80% sequence homology, including nine 
conserved cysteine residues. Only the first three TGF/3 isoforms have been detected in mammals 
as yet, but the sequence homology between species for these three is closer to 100%. TGF-/31, 
TGF-/32 and TGF-/33 have also been identified in humans {ten Dijke et al., (1988)}. TGF-/34 
was isolated from chick embryo chondrocyte cDNA library {Jakowlew et al., (1988b)}, and 
TGF-/35 was identified in a Xenopus laevis cDNA library {Kondaiah et al., (1990)}.
All TGF/3 forms are synthesised as inactive precursors (320 amino acids long) which are 
subsequently processed to yield the 25 kDa active dimers {Derynck et al., (1985 and 1988); ten 
Dijke et al., (1988); Jakowlew et al., (1988a and b); Kondaiah et al., (1990)}. The mature 
molecule is proteolytically cleaved by the action of a subtilisin-like proteinase which produces 
two 12.5 kDa monomers from the C-termial half of the precursor {Barr et al., (1991)}. Both 
monomers are disulphide-linked, but remain non-covalently bound to the remaining fragment 
of their precursor molecule during secretion {Gentry & Nash (1990)}. This precursor fragment 
is also a dimer and has been called the ‘latency associated peptide’, (LAP). The latent form of 
TGF-/31 secreted by cultured cells consists of the mature protein non-covalently bound to LAP 
{Lyons et al., (1990)}. However, a large molecular weight ‘binding protein’ (TGF-/3-BP) is also 
found associated with the TGF-/31/LAP complex in platelets {Wakefield et al. (1989); Miyazono 
et al., (1988)}.
All normal cell types, and the majority of malignant cells, have receptors for TGF/3 on their cell 
surface {Tucker et al., (1984); Frolik et al., (1984)}. Three types of high affinity receptors for 
TGF/3 have been identified. These fall into three classes on the basis of size; type 1 (53 kDa), 
type II (70-85 kDa), and type III (250-250 kDa) {Cheifetz et al., (1986); Massague et al.,
(1990); Segarini (1990, 1991) and Cheifetz et al., (1988)}.
Several related families of inhibitory polypeptides have been identified which share 25-40% 
sequence homology with TGF/3, and have at least seven of the nine cysteine residues conserved.
12
Among these are the inhibins and activins {Mason et a l . , (1985)}; miillerian inhibiting substance 
{Cate et al., (1986)}; the decapentaplegic gene from drosophila {Padgett et al., (1987)}; BMP- 
2A, BMP-2B and BMP-3 {Wozney et al., (1988)}; the Vg-1 protein product from Xenopus 
{Weeks et al., (1987)}; and Bg-1, the mammalian homolog of Vg-1 {Lyons et al., (1989)}.
1.3.3 PLATELET-DERIVED GROWTH FACTOR FAMILY
Platelet-derived growth factor (PDGF) is a heat-stable, cationic, disulphide-linked dimeric 
protein, with an affinity for immobilised heparin {Shing et al. (1984)}. The constituent 
polypeptide monomer subunits are called the A- and B-chains respectively, and are the products 
of separate genes. Mature PDGF can therefore be a homodimer of the A  or B chain (PDGF- 
AA, PDGF-BB) or alternatively, a heterodimer of both (PDGF-AB). Molecular weights for 
these isoforms are in the range 28-31 kDa. A 56% homology between amino acid sequences 
of the A and B chains, as well as the conservation of eight cysteine residues in both, suggest 
a similar tertiary structure for both hetero- and homodimeric isoforms {Ross et al., (1986)}.
Two high affinity cell surface receptors have been identified for PDGF and designated type a  
and type j8 respectively. Both receptors are structurally related transmembrane proteins, with 
extracellular portions containing five immunoglobulin-like domains separated from an 
intracellular tyrosine kinase domain by a transmembrane region {Yarden et al., (1986); Matsui 
et al., (1986); Claesson-Welch et al., (1988, 1989)}. Type a  receptors bind PDGF isoforms 
comprising both A- and B-chains, but the type ¡3 receptor binds only isoforms containing the 
PDGF B-chain. Binding of PDGF to its receptor induces receptor dimerisation and 
autophosphorylation {Bishayee et al., (1989); Heldin et al., (1989); Seifert et al., (1989); 
Kanakaraj et al., (1991); and Eriksson et al., (1992)}.
PDGF has potent mitogenic activity for cells of mesenchymal origin (e.g. fibroblasts). 
However, normal endothelial and epithelial cells are largely unresponsive to this mitogen {Ross 
e ta l . ,  (1986)}.
1.3.3.1 Vascular endothelial growth factor (VEGF)
Another member of the PDGF family of growth factors is vascular endothelial growth factor 
(VEGF). VEGF is a heparin-binding, disulphide-linked, homodimeric glycoprotein. It has a 
molecular mass between 32-42 kDa, and is mitogenic for endothelial cells {Gospodarowicz et 
al (1989)}. Synonymous with VEGF are the vascular permeability factor described by Senger
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et al., (1983)} and vasculotropin {Plouet et al, (1989)}.
Alternative splicing of the human VEGF gene produces mature protein with individual chains 
of different length. These include proteins with 121, 165, 189, and 206 aa residues respectively 
{Leung et al., (1989); Tischer et al. ,(1991); Charnock-Jones et al., (1993)}. All forms are 
secreted, but the most abundant form in vivo is the VEGF165 which has an apparent molecular 
mass of 42 kDa. The larger species are cell-surface- or extracellular matrix-bound, due to the 
inclusion of basic sequences which confer higher affinity for polyanions such as heparin. Partial 
proteolysis by plasmin is known to release the angiogenic VEGF protein from the ECM, and 
as such, may act as another control mechanism for neovascularisation {Houck et al., (1992)}.
Two putative receptors for VEGF have been identified, and these share substantial sequence 
homolgy with each other {de Vries et al., (1992); Terman et al., (1992)}. They also share 
homology with the tyrosine kinase family to which they belong. Their tyrosine kinase domains 
contain a 70 aa insert, analagous to the receptor for macrophage colony-stimulating factor (M- 
CSF), the protooncogene c-fins. The extracellular portions contain seven immunoglobulin-like 
domains.
Endothelial cells and monocytes express receptors for VEGF and are currently believed to be 
among the few target cells for VEGF (Terman et al., (1991); Millauer et al., (1993); Shweiki 
et al., (1993)}. VEGF expression has been detected in keratinocytes found at wound edges 
{Brown et al., (1992)}, but VEGF mRNA expression in the non-endothelial cell component of 
many tumours has also been documented {Dvorak et al., (1991)}. These include two carcinoma 
cell lines from which VEGF has also been purified; the human epidermoid carcinoma cell line 
A-431, which also expresses VEGF receptors {Myoken et al., (1991)}, and a rat glioma cell 
line {Conn et al., (1990)}.
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1.3.4 INSULIN-LIKE GROWTH FACTORS
Insulin and the structurally related insulin-like growth factors -I and -II, are homologous 
proteins which constitute a family of growth-promoting peptides. They were originally isolated 
from human serum, and called somatomedins on the basis of their insulin-like effects on muscle 
and adipose tissue (i.e glucose transport and metabolism) {Blundell et al., (1978)}. Growth 
hormone is known to regulate the expression of IGF-I, but it has a lesser effect on IGF-II gene 
expression. IGFs are present in relatively high concentrations (20-80 nM) in blood plasma, and 
at lower concentrations in the majority, and probably all tissues {reviewed in Humbel (1990)}. 
The large body of literature published in this field permits only some of the biology of these 
proteins to be overviewed here.
Insulin-like growth factor-I (IGF-I) and insulin-like growth factor-II (IGF-II) are non­
glycosylated, single chain peptides, with 70 and 68 aa residues, respectively. They share 
approximately 76% sequence homology with each other, and 50% homology with proinsulin. 
In the mature IGF proteins there are four domains. The N-terminal or B domain, preceeds the 
C, A, and D domains, which are structurally homologus to proinsulin. The A and B domains 
are believed to be important for the binding of IGF-I to its receptor {Rotwein (1991)}.
IGF-I and IGF-II are the products of single genes which have been assigned to chromosomes 
12 and 11 respectively {Tricoli et al., (1984)}, with the IGF-I gene located 1.3 kb 3' to the 
insulin gene {Scholfield (1991)}. Analysis of the gene structures revealed the existence of 
alternative promotors, regulating multiple transcription start sites, as well as variable 
polyadenylation sites. Differential splicing also gives rise to multiple mRNA transcripts 
{Kajamoto & Rotwein (1991); Rotwein & Hall (1990)}.
The greater part of the IGFs found in serum (>95% ) exist in association with carrier proteins 
{Zapf et al., (1975)}. IGF binding proteins (IGFBPs) serve as transport molecules for these 
growth factors in serum, but they also regulate their interaction with IGF cell surface receptors. 
Six forms IGFBPs, ranging in size from 24-45 kDa, have been isolated and sequenced, and at 
least four serumproteinases specifically cleave IGFBPs {Clemmons et al., (1993); Bach et al., 
(1993)}. Most of the serum IGF is bound to IGFBP-3 in a 150 kDa complex which includes 
IGF-I or IGF-II, and an 80 kDa acid labile component. IGF-I and IGF-II demonstrate equal 
afinities for IGFBP-3 {Baxter & Martin (1989)}.
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Two types of transmembrane receptors have been identified for IGFs {reviewed Kasuga et al.,
(1991); Nissely & Lopaczynski (1981)}. The type I receptor is a disulphide-linked 
heterotetramer, composed of two a  subunits (115 kDa) that form the ligand binding site, and 
two transmembrane ¡3 subunits (90 kDa) with tyrosine kinase activity in their cytoplasmic 
domain.
A  structurally unrelated type II receptor does not display tyrosine kinase activity. It is 
characterised by a large extracellular domain, connected to a relatively short 164 aa cytoplasmic 
domain by a single-spaning transmembrane region. The cytoplasmic domain of the type II IGF 
receptor is unique {Lobel et al., (1988)}. The human cDNA for mannose 6-phosphate receptor 
is 99.8% identical to that of the type II IGF receptor {Oshima et al., (1988)}, and a soluble 
form consisting of the extracellular domain of this receptor (type II IGF/Mannose 6-phosphate) 
has been isolated {Causin et al., (1988)}. Differential binding patterns are displayed by IGF-I 
and IGF-II for the respective receptors. Higher affinity for the type I receptor is seen with IGF-I 
compared to IGF-II, but IGF-II displays a higher affinity for the type II receptor than IGF-I 
{Massague & Czech (1982)}.
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1.3.5 FIBROBLAST GROWTH FACTORS
Until recently, fibroblast growth factors (FGF) have constituted a family of seven polypeptide 
growth factors displaying significant sequence and structural homologies. In the last year 
however, the purification and cDNA cloning of two new heparin-binding mitogens, now brings 
to nine the number of FGF family members. The number of reviews which have appeared 
recently in the literature, covering all apsects of FGF biology, reflect the widespread interest 
in, and the extent of this field {refer to; Brem & Klagsbrun (1993); Basilico & Moscatelli
(1992); Gospodarowicz (1990); Klagsbrun (1989)}. A  3 intron/2 exon gene structure and the 
conservation of two cysteine residues is common to all FGFs. An important functional property 
shared by these growth factors is their ability to bind heparan sulphate proteoglycans in the 
extracellular matrix. The high affinity of FGFs for the related glysocaminoglycan heparin, also 
provided the basis for the initial purification to homogeneity of the first FGFs described, acidic 
and basic FGF (aFGF, bFGF) {Shing et al., (1983); Gospodarowicz et al., (1984)}. The 
absence of a classical signal sequence in the genes for aFGF and bFGF can no longer be 
considered unique among the FGFs, since sequencing of the complementary DNA for FGF-9 
revealed that it too does not encode a signal for secretion {Miyamoto et al., (1993)}.
The profusion of names for the different FGFS reflects the orignial source and/or biological 
activity that lead to their identification. The term ‘FGF’ has been proposed as a unifying system  
of nomenclature, and although this is being adopted for new members, some of the earlier FGFs 
are commonly referred to by the original designations. In this thesis, the first two members of 
this family described, acidic and basic FGF respectively, are referred to by the original 
nomenclature, rather than by the lesser used designations FGF-1 and FGF-2. Other FGFs 
include int-2 (FGF-3), hstlK-fgf (FGF-4), FGF-5, FGF-6 , keratinocyte growth factor (KGF/or 
FGF-7), andorgen-induced growth factor (AIGF/ or FGF-8) and glia-activating factor (GAF/ 
or FGF-9).
Four of the FGFs were initally identified as oncogenes in transformation assays. Complementary 
DNA cloning revealed that these genes encoded proteins which shared 40-50% homologies with 
the prototype acidic and basic FGFs, and indicated that the homologies were greatest in the 
internal regions of the proteins. These four ’oncogene’ members are rarely found in adult tissues 
{Rifkin & Moscatelli (1989)}. Basic FGF is widely distributed in normal and malignant tissues, 
but acidic FGF is found mainly in brain and neural tissues {Gospodarowicz (1990)}.
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Important roles for FGFs in development, wound repair, angiogenesis and tumourigenesis have 
been described. The variety of biological roles can be attributed to the fact that cells 
representative of meso- ecto- and endodermal embryonic germ cell layers are the targets of 
FGFs. The principal biological properties of each of the FGFs is described here.
1.3.5.1 Acidic and Basic FGF (FGF-1 and FGF-2)
Acidic and basic FGF are homologous proteins thought to have arisen from a single ancestral 
gene. The degree of homology between these multifunctional growth factors is 53% {Esch et 
al., (1985)}. An important biological activity shared by both of these growth factors is their 
potent angiogenic effect in vivo {Folkman & Klagsbrun (1987)}. This can be attributed to the 
ability of these factors to stimulate the proliferation of the endothelial cells lining blood vessels 
{Schweigerer et al., (1987)}, but also because they can modulate the secretion of enzymes 
capable of degrading the extracellular-matrix {Mignati et al., (1989)}, and promote endothelial 
cell migration {Stokes et al., (1990)}.
Acidic and basic FGF are both single-chain polypeptides of 154 aa with mature molecular 
weights ~ 1 8 k D a  {Ueno etal.,  (1986); Thomas et al., (1984)}. However, the isoelectric points 
of the respective proteins are very different. Basic FGF is a cationic protein with a pI  —9.6  
{Gospodarowicz (1989)}, and acidic FGF has a pI  —5.6 {Thomas et al., (1984)}. Human 
bFGF has four cysteine residues, including two which are conserved among the FGFs (except 
FGF-8). By comparison acidic FGF contains three cysteines, but unlike bFGF, none of these 
are required for biological activity {Seno et al., (1988)}. However, site-directed mutagenesis 
studies with bFGF indicate that intrachain disulphide bond formation does not seem to be 
required for biological activity {Klagsbrun (1989)}. Higher MW forms of basic FGF exist. 
These arise from the use of alternative transcription start sites in the bFGF gene (see discussion 
Section 4.3).
Among the plethora of cells whose in vitro proliferation is stimulated by acidic and basic FGF 
are, human keratinocytes and fibroblasts {Shipley et al., (1989)}; vascular smooth muscle cells 
{Weich et al., (1990)}; osteoblasts {Rodan et al., (1987)} and ovarian epithelial cells 
{Gospodarowicz et al., (1989)}.
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1.3.5.2 INT-2 (FGF-3)
The int-2 gene was identified originally in mouse mammary tumours. This normal cellular gene 
became activated following the integration of mouse mammary tumour virus (MMTV) into the 
mouse genome, resulting in tumour formation {Dickson et al., (1984)}. The int-2 gene encodes 
a 231 aa protein which is 46% homologous to bFGF {Dickson & Peters (1987)}. A short signal 
sequence accounts for the detection of int-2 protein in the golgi-endoplasmic recticulum of 
transfected cells, but the protein appears to be inefficiently secreted {Dixon et al., (1989)}. A
28.5 kDa primary translation product is processed by glycosylation, giving rise to 30.5 and 31.5 
kDa forms {Dixon et al., (1989)}. In humans, a larger 271 aa form of int-2 is produced from 
transcripts initiated at an alternative CUG start site, and like the bFGF N-terminal extended 
forms, these are localised in the nucleus {Acland et al., (1990)}.
Expression of int-2 is developmental^ regulated, being restricted to several specific stages in 
embryogenesis {Jakobovits et al., (1986)}. It is not expressed in normal adult tissues, but 
expression has been detected in a variety of solid tumours where it is associated with 
amplification of the gene. These include squamous cell carcinomas of the head and neck 
{Merritt et al., (1990)}, and breast carcinomas {Zhou et al., (1988)}.
1.3.5.3 K-fgf/hst (FGF-4)
The gene for FGF-4 was identified by two groups independently as a transforming gene in 
mouse NIH3T3 fibroblasts transfected with human stomach tumour DNA (thus the name hst) 
{Yoshida et al., (1987); Koda et al., (1987)}, and also DNA from Kaposi’s sarcoma {Delli- 
Bovi et al., (1987 & 1988)}. The gene encodes for a 206 aa protein containing a signal 
sequence. The first 80 aa of the N-terminal are unique but the remaining sequence shares 38% 
homology with human bFGF. There exists one potential N-linked glycosylation site, and 
glycoslylation brings the MW of the mature secreted product to approximately 23 kDa {Delli- 
Bovi et al., (1988)}.
Like the other oncogenic FGFs, expression of FGF-4 appears to be developmentally restricted. 
It is expressed mainly during embryogenesis {Paterno et al., (1989)}, but its has been detected 
in some solid tumours including, oesophageal {Tsuda et al., (1991)}, gastric {Sakamoto et al., 
(19886)}, and breast tumours {Theillet et al., (1991)}. Like aFGF, heparin enhances the 
mitogenic activity of FGF-4 {Delli-Bovi et al., (1988)}.
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1.3.5.4 FGF-5
The FGF-5 gene, initially isolated from human bladder tumour DNA in the NIH3T3 
transformation assay, was found to be secreted by endometrial carcinoma, bladder carcinoma 
and human hepatoma cell lines {Zhan et al., (1988)}. The gene encodes a single chain 267 aa 
residue protein with an extended N-terminal hydrophobic sequence that enables it to be 
efficiently secreted. A  29.5 kDa protein is predicted from the primary translation product, but 
cleavage of the signal peptide, and glycosylation on at least one residue, yield molecules of 
32.5-38.5 kDa {Bates et al., (1991)}.
The biological functions of FGF-5 are not very clear, but its prolonged expression during 
embryogenesis {Herbert et al., (1990)}, and in exponentially growing normal adult human 
fibroblasts {Werner et al., (1991)} suggests an important role for this growth factor in rapidly 
dividing cells. Moreover, the fact that FGF-5 expression in quiescent fibroblasts can be induced 
in response to growth factors such as PDGF, EGF, and TGFa, without the requirement for de 
novo protein synthesis, implicated it as a member of the family of primary response genes.
1.3.5.5 FGF-6
FGF-6 is the least characterised member of the FGF family. It was isolated from a mouse 
cosmid library using a probe to the K-fgf/hst gene, and displays 70% homology to the hst 
product at the C-terminus {Maries et al., (1989)}. It has also been shown to be secreted 
{deLapeyriere et al., (1990)}
1.3.5.6 Keratinocyte growth factor (KGF/FGF-7)
Keratinocyte growth factor (KGF) was isolated from medium conditioned by a human 
embryonic lung fibroblast cell line. It is an acid and heat labile, epithelial-specific paracrine- 
acting mitogen {Rubin el al., (1989)}. The complementary DNA sequence of KGF identified 
it as the seventh member of the FGF family {Finch et al., (1989)}. The KGF gene encodes a 
194 aa protein with a unique N-terminal sequence, but the remainder of the sequence shares 
39% homology with bFGF. The mature 28 kDa protein is glycosylated and secreted.
1.3.5.7 FGF-8
The heparin-binding ‘androgen-induced growth factor’ (AIGF), detected in the conditioned 
medium of the mouse mammary carcinoma cell line, SC-3 {Nonomura et al., (1988)}, has 
recently been purified. Partial amino acid sequence has identified it as the eight member of the
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FGF family. A cDNA clone of FGF-8 encodes a unique 215 amino acid protein with a putative 
signal sequence. Sequence analysis revealed that FGF-8 shares 30-40 % sequence homology with 
basic FGF, KGF, FGF-5, FGF-6 , FGF-3 (int-2) and FGF-4 (hst-l/K-fgf) but not with aFGF. 
In addition only one of the two highly conserved cycteine residues in the mouse FGF family is 
conserved in AIGF (FGF-8) {Tanaka et al., (1992)}.
1.3.5.8 FGF-9
A heparin-binding glia-activating factor (GAF), isolated from the culture supernatant of a human 
glioma cell line {Naruo et al., (1993)}, has recently been cloned. Sequence analysis revealed 
that it shares 30% homology with other FGFs, as well as conserving two of the cysteines 
common to all FGFs. Like acidic and basic FGF, FGF-9 does not encode a typical signal 
sequence. The degree of homology with rat FGF-9 (also cloned by these workers), suggests that 
FGF-9 is a highly conserved gene {Miyamoto et al., (1993)}.
1.3.5.9 FGF receptors
Both high and low affinity receptors have been described for FGFs (for review see Klagsbrun 
& Baird (1991)}. Most of the information available to date stems from studies with basic FGF 
(see discussion Section 4.3). Briefly, heparan sulphate proteoglycans comprise the low affinity 
receptors, and the high affinity FGF receptors are transmembrane proteins. Five distinct high 
affinity receptors have now been cloned and sequenced, and are designated FGFR-1, -2, -3, -4, 
and -5 respectively. All of these transmembrane receptors belong to a tyrosine kinase gene 
family and their extracellular domains are characterised by three immunoglobulin-like regions 
(3-Ig). A number of isoforms of FGFR-1 and -2 exist in certain cell types as a result of 
alternative exon splicing, some of which lack the first immunoglobulin-like region generating 
a two-immunoglobulin form (2-Ig) {Jaye et al., (1992)}. Two structural elements determining 
the ligand specificity of mouse FGF receptors 1 & 2 have been localised in the C-terminal half 
of the third Ig-like domain, as well as a region in the second Ig domain. This region is encoded 
by two distinct exons, and the alternative splicing of FGFR mRNA or ‘exon switching’ results 
in changes in ligand specificity, and is responsible for the observed redundancy among FGF 
receptors {Zimmer et al., (1993)}. ‘Exon switching’ has more recently been found to generate 
a novel form of FGFR-3 {Avivi et al., (1993)}.
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1.3.6 Pleiotrophin
Pleiotrophin (PTN) is a developmentally regulated heparin-binding, neurotrophic factor, which 
is synthesised as a 168 aa precursor, and processed by the removal of a 32 aa signal sequence 
to give a 136 aa polypeptide with a molecular mass of 18 kDa. It is found mainly in the brain 
and acts as a growth and differentiation factor for cultured perinatal neurons. It is highly 
conserved among mammalian species {Li et al., (1990)}. Courty et al., (1991) reported the loss 
of PTN mitogenic activity following its storage in acid conditions. In the same study PTN was 
found to be mitogenic for bovine brain capillary endothelial cells and was angiogenic in the 
rabbit corneal-pocket assay. The acid sensitivity of PTN would appear to account for earlier 
conflicting reports concerning the mitogenic potential of PTN. Synonyms for PTN are heparin- 
binding growth associated molecule (HB-GAM), heparin-affinity regulatory peptide (HARP), 
heparin-binding neurotrophic factor (HBNF), p 18 and osteoblast-specific factor (OSF-1) {Bohlen 
& Kovesdi (1991)}. A high affinity receptor for PTN was recently identified on NIH3T3 cells 
{Neame et al., (1993)}.
PTN shares 55% sequence homology with a highly basic, 13.2 kDa heparin-binding protein, 
called midkine (MK), and these polypeptides have been proposed to constitute a family of 
developmentally regulated genes {Li et al., (1992)}. Midkine is a retinoic acid-induced 
differentiation factor which is expressed during the mid-gestation period of mouse 
embryogenesis {Kadomatsu et a l ., (1988)}.
A  role in tumourigenesis was suggested for PTN by the detection of PTN mRNA in 
meningioma cells {Mailleaux et al., (1992)}. In another study, PTN was expressed in over half 
of the primary breast cancer samples screened {Fang et al., (1992)}. High levels of PTN are 
also expressed in melanomas {Wellstein et al., (1992)}. Further evidence to support an 
important role for PTN in growth control was provided in a recent publication by Chauhan et 
al., (1993). These authors demonstrated that overexpression of PTN in NIH3T3 fibroblasts 
resulted in phenotypic transformation of these cells. This was manifested by increased cell 
number of HIH3T3 at confluence, as well as focus formation, anchorage-independent growth, 
and tumour formation in nude mice. In another recent publication, comparing the expression 
in resected normal and malignant lung tissues (non-small cell carcinomas), a reciprocal pattern 
of expression for PTN and the homologous midkine (MK) gene was noted. PTN was expressed 
in all o f the normal samples (n=17), but only two expressed MK. Conversely, only 1/20 
malignant lung samples expressed PTN, but all expressed MK {Garver et al., (1993)}. The
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biolgical significance of these findings remain to be determined.
1.3.7 INTERLEUKINS
Interleukins (ILs) are the principal mediators of interactions between the immune and 
inflammatory cells. Twelve members of the interleukin family have been identified to date, and 
their genes have been cloned. These cytokines function as regulators of cell proliferation and 
differentiation in white blood cells {reviewed by Mizel (1989)}. Some interleukins have recently 
been seen to have a role in the regulation of nonhematopoietic cell growth. These include 
interleukins 1 , 3 , 4  and 6 . For this reason, a brief summary of the biological properties of these 
cytokines is included.
1.3.7.1 Interleukin 1
Interleukin 1 (IL-1) exists in two forms, IL-1 a  and IL-1/3. These cytokines are the products of 
separate genes and share 25 % amino acid sequence homology {Oppenheim et a l . , (1986)}. They 
are produced in response to stimulation of macrophages by inflammatory agents, but some cells 
in healthy individuals (such as skin keratinocytes) also produce these cytokines. A 
comprehensive review of the biological properties of IL-1 was published recently by Dinarello 
& W olff (1993). IL-1 plays a critical role in the normal immune response to injury and 
infection, affecting not only the induction of specific cell types, but also entire cell systems. In 
this respect it mediates the induction of its own production, as well as that of other cytokines 
including IL-4 and granulocyte-macrophage colony-stimulating factor (GM-CSF) {Herrmann 
et al. (1988)}. Production of IL-6 and tumour necrosis factor (TNF) are also induced by IL-1 
{Levett et al., (1986); Navarro et al. (1988)}. The mature IL-1 a  and IL-1/3 have molecular 
weights of approximately 17 kDa, but these are the products of 31 kDa precursors {Giri, et a l . ,
(1985); Hazudu et al., (1988)}.
There are two distinct receptors which bind both forms of IL-1. The first, an 80 kDa, type I 
receptor (IL-lRtI) is found on T cells, fibroblasts, keratinocytes, endothelial cells and 
hepatocytes {Dinarello (1991); Urdal et al. (1988)}. IL-lRtI is a member of the 
Immunoglobulin (Ig) superfamily, and has been cloned from human and mouse cells {Sims et 
al. (1988)}. The second receptor, IL-lRtll, with an apparent MW of 68 kDa, is also a member 
of the Ig superfamily, and is found in bone marrow cells, neutrophils, and B cells {Dinarello 
(1991)}. A  third ligand exists in the IL-1 family which functions as a receptor antagonist (IL- 
lra) for IL-1 {Dinarello & Thompson (1991)}. Receptor-bound IL-lra does not transduce a
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signal.
1.3.7.2 Interleukin 3
Interleukin 3 (IL-3) is a 28 kDa pleiotrophic glycoprotein, which is expressed mainly by 
activated T cells. It is capable of stimulating proliferation and differentiation in several 
committed (lineage specific progenitor cells) and non-committed (stem cells) hematopoietic cells 
{Ihle et al., (1981)}. IL-3 production by nonhematopoietic cells has also been reported. These 
include human thymic epithelial cells {Dalloul et al., (1991)} and murine keratinocytes 
{Peterseim et al., (1993)}.
Two receptor subunits are required to generate a functional signal-transducing IL-3 receptor. 
These have been designated IL-3Ra (70 kDa) and IL-3R/3 (120-140 kDa), and both have been 
cloned in humans {Kitamura, et al., (1991)}. Only low affinity binding of IL-3 is possible in 
the absence of the IL-3R/3 subunit, which IL-3Ra shares in common with the cytokines 
interleukin-5 (IL-5), and granulocyte-macrophage colony-stimulating factor (GM-CSF), for the 
generation of a high affinity receptor complex {Goodall et al., (1993)}.
1.3.7.3 Interleukin 4
Interleukin 4 (IL-4) is a pleiotrophic cytokine, produced mainly by activated T cells. Murine 
IL-4 is a glycoprotein of approximately 19 kDa {Grabstein (1986)}. Human and murine IL-4 
cDNAs encode signal sequences which are cleaved to produce mature proteins with 129 and 120 
aa residues respectively {Carr et al., (1991)}. The receptor for IL-4 has been detected on 
hematopoietic and non-hematopoietic cells {Lowenthal et al. (1988)}. The mouse and human 
receptor genes have been cloned and these encode a high affinity transmembrane protein with 
a MW of 140 kDa {Mosley et al. (1989); Idzerda et al. (1990)}.
The paracrine production of IL-4 in tissues has been shown to inhibit the growth of both breast 
and colon carcinoma cells {Toi et al., (1992)}.
1.3.7.4 Interleukin 6
The multifunctional cytokine interleukin-6 is produced by normal and transformed cells of 
lymphoid and non-lymphoid origin. A 212 aa precursor is predicted from the human IL-6 
cDNA sequence with two potential N glycosylation sites. After cleavage of the signal sequence, 
a 184 aa mature protein is predicted, with a molecular weight of 21 kDa {Haegeman et al.,
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(1986); Hirano, e ta l . ,  (1986); May e ta l . ,  (1986); Zilberstein e ta l . ,  (1986)}. One of the major 
functions of IL-6 is the induction of acute phase protein synthesis by liver hepatocytes following 
infection {Bauman et al., (1984)}, but this cytokine has also been implicated in the pathology 
of a variety of proliferative diseases including psoriasis, plasmacytomas, and melanomas, as 
well as the autoimmune disease, rheumatoid arthritis {Gastl et al., (1993)}.
The IL-6 receptor consists of two glycoprotein subunits. An 80 kDa subunit acts as a low 
affinity receptor (IL-6R) in the absence of the signal transducing protein gpl30. Both subunits 
have been sequenced and cloned {Hibi et al., (1990); Baumann et al., (1990); Yamasaki et al.,
(1988)}. The gpl30 subunit is also involved in the formation of signal complexes for other 
cytokines including interleukin 11, leukemia inhibitory factor (LIF), oncostatin M, and ciliary 
neurotrophic factor (CNTF) {Kishimoto et al., (1992); Yin et al., (1993)}.
1.3.8 HEMATOPOIETIC GROWTH FACTORS
Non-interleukin cytokines include erythropoietin (Epo), three colony stimulating factors, the 
interferons (IFN) a, /3, and 7 , tumour necrosis factor (TNF) -a  and -/5, as well as two recently 
identified inhibitory cytokines, leukemia inhibitory factor (LIF) and oncostatin M (OSM). Some 
of these cytokines with nonhematopoietic activities are discussed below.
1.3.8.1 Colony-stimulating factors
Colony stimulating functions derive their name from the biological activity used to characterise 
them initially. These cytokines were found to stimulate the colony formation of hematopoietic 
progenitor cells grown in vitro in soft agar. Some CSFs have been reassigned as interleukins 
since their original discovery, but three are still classified as colony stimulating factors. These 
include granulocyte-macrophage CSF (GM-CSF), macrophage CSF (M-CSF), and granulocyte 
CSF (G-CSF). GM-CSF is mentioned here because of its potential involvment as a modulator 
of cell growth in some solid human tumours, and derived cell lines {Foulke et al., (1990)}.
Human GM-CSF cDNA encodes a 141 aa residue precursor which is processed by removal of 
a 17 aa signal sequence. Multiple glycosylation sites exist in this protein, as well as two 
intramolecular disulphide bonds essential for biological function {Burgess et al., (1990)}. Apart 
from hematopoietic cells, fibroblasts and endothelial cells in the bone marrow stroma have been 
shown to secrete GM-CSF {Adreef & Welte (1979)}.
Both high and low affinity receptors for GM-CSF have been characterised in humans and mouse 
{Goodall et al., (1993)}. In a situation reminiscent of the interleukin 3 receptor system, the a  
subunit of the GM-CSF receptor binds the ligand with low affinity, but cannot transduce a 
signal without the /8 subunit (which is also the ‘convertor’ used by the IL-3 receptor to generate 
a functional IL-3 receptor).
1.3.8.2 Leukemia inhibitory factor and Oncostatin M
Leukenia ihibitory factor (LIF), and oncostatin M (OSM), were originally identified by their 
ability to inhibit the proliferation of macrophages and melanoma cells respectively {Kurzrock 
et al., (1991); Zarling et al., (1986); Brown et al., (1987)}. Both cytokines were subsequently 
found to be pleiotrophic, with activities on both hematopoietic, and nonhematopoietic cells.
Among the inhibitory actions of oncostatin M, was its tumouristatic effect on the growth of a 
neuroblastoma cell line (HTB 10), and a similar effect was demonstrated with the breast 
carcinoma cell line MCF-7. However, OSM also exhibits a positive regulatory role, as 
demonstrated by its mitogenic effects on the growth of normal fibroblasts and Karposi’s sarcoma 
cells {Horn et al., (1990); Miles et al., (1992); Nair et al., (1992)}. LIF is expressed in a 
variety of cell lines and primary tissues, including thymic epithelial cells, liver fibroblasts, 
embryonic stem cells, brain glial cells, as well as activated T lymphocytes and monocytes 
{Metcalf (1992); Bhatt et al., (1991)}. In nonhematopoietic cells, LIF appears to modulate 
differentiation functions such as enhancing the synthesis of acute phase proteins in hepatocytes. 
A  more direct growth regulatory role for LIF in bone osteoblasts has been shown {Vlasselar 
e ta l . ,  (1992)}.
Human cDNA for LIF encodes a 180 aa protein with a predicted molecular mass of 20 kDa. 
In the mouse an alternate mRNA transcript encodes for a protein with a variant signal sequence 
which directs the mature protein into the extracellular matrix {Rathjen., et al., (1990)}.
OSM is a heat and acid stable, single chain glycoprotein {Zarling et al., (1986); Rose & Bruce 
(1991)}. Human cDNA from the U937 lymphoma line predicts a 252 aa peptide with a 25 aa 
signal sequence. Cleavage of the signal peptide produces a protein that is then further processed 
by cleavage at the C-terminal to form the 195-196 aa mature peptide {Linsley et al., (1990)}. 
The human gene shares 22% sequence homology with human LIF, and displays 19% homology 
with human IL-6 . At the protein level OSM shares a common structural motif with IL-6 , IL-11,
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and ciliary neurotrophic factor (CNTF). These cytokines are thought to be descended from a 
common ancestral gene {Bazan (1991); Bruce et al., (1992)}.
LIF exerts its biological effects though a receptor complex which include a low affinity receptor 
(LIF-R/5), and the gpl30 transducer common to the IL-6 receptor system {Gearing et al., 
(1991)}. The LIF-R/3/gpl30 complex constitutes a high affinity binding site for LIF, but it also 
binds OSM {Davis et al., (1993)}. A separate low affinity receptor specific to OSM has not yet 
been identified, but recent evidence in the lung cancer cell line H2981 suggests that one may 
yet be found {Liu et al., (1992)}.
1.3.9 CHEMOKINES
Chemokines are members of a superfamily of small (8-10 kDa) pro-inflammatory, inducible 
cytokines, which act mainly as chemoattractants and activators of specific leukocytes. They 
share 20-50% sequence homology at the amino acid level and are sub-divided into two groups 
on the basis of a difference in a conserved aa sequence motif consisting of four cysteines. In 
one group, the a  subfamily, the two cysteines are separated by another amino acid (C-X-C), 
but in the second or ¡3 subfamily, these cysteines are contiguous.
The a  group includes interleukin-8 (IL-8), GROa/melanoma growth stimulating activity 
(MGSA), platelet factor-4 (PF-4), IP-10, ENA-78, as well as platelet basic protein and its 
derivatives (from proteolytic processing) - CTAP III and ¡3 thromboglobulin. The /3 subfamily 
of chemokines includes macrophage inflammatory protein-la (M IP-la) and -1/3 (MIP-1/3), 
RANTES, MCP-1/MCAF, MCP-2, MCP-3 and 1-309 {reviewed in Oppenheim et a l . , (1991)}.
Chemokines bind to heparin and glycosaminoglycans, a factor that may facilitate their 
chemoattr actant functions by allowing them to bind to endothelial cells and/or extracellular 
matrices {Tanaka et al., (1993)}. Evidence for growth regulatory effects on keratinocytes, 
fibroblasts and melanoma cell lines is also beginning to emerge, and suggests that chemokines 
play a role in wound healing.
Receptors for most chemokines of both families have been found on red blood cells {Neote et 
al. (1993)}.
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1.3.9.1 GROa/Melanoma growth-stimulating activity
Melanoma growth-stimulating activity (MGSA) was originally isolated and cloned from the 
human melanoma cell line Hs294T {Richmond and Thomas (1986)}, but an identical gene 
(designated GROa) was discovered in Chinese hamster embryo cells using subtractive 
hybridization techniques in normal and tumorogenic fibroblasts. Moreover, in many o f these 
cell lines, production of GROa was associated with its constitutive overexpression {Sager et a l. ,
(1991)}. Several stimuli including serum, PDGF and the inflammatory mediators IL-1 and TNF, 
induce GROa expression in fibroblasts, mammary epithelial cells, umbilical vein endothelial 
cells, and monocytes {Oppenheim et al., (1991); Sager et al., (1991)}.
The cDNA for GROa encodes a 107 aa precursor which includes a 34 aa residue signal 
sequence. The mature 73 aa peptide does not appear to be post-translationally modified. GROa 
binds to one of two receptors for IL-8 {Lee et al., (1992)}. This receptor is a member of the 
rhodopsin-like ‘seven-pass’ superfamily. These transmembrane receptors are characterised by 
seven hydrophobic transmembrane domains coupled to G-proteins, as described above (Section 
1.1.1). In addition, the recently described multispecific chemokine receptor is also reported to 
bind GROa {Neote et al., (1993)}.
1.4 MOTOGENIC CYTOKINES
Several cytokines have been described to date which function as stimulators of cell motility in 
vitro. These proteins have been implicated in the spread of cancer cells from their primary sites 
in vivo by a process called metastasis. Some of these motogenic cytokines are also mitogenic, 
and may be involved in autocrine and paracrine mechanisms in the producer tissues.
1.4.1 Hepatocyte growth factor/Scatter factor
Hepatocyte growth factor (also known as Hepatopoietin A) and Scatter factor (HGF/SF) are 
synoymns for a distinct 82 kDa, 674 aa heterodimeric glycoprotein. It was isolated originally 
on the basis of different biological functions, firstly from rat platelets as a mitogen for 
hepatocytes, and secondly, as an activity secreted by human embryo fibroblsts which caused the 
scattering of cells from compact epithelial colonies. The mature HGF/SF protein is derived from 
a 728 aa single-chain precursor, and this is proteolytically processed to yield a heterodimer with 
69 kDa and 34 kDa subunits, linked by a disulphide bond {Furlong et al., (1992)}. The 
receptor for HGF/SF was identified as the protooncogene c-met. The HGF/SF receptor
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comprises a 190 kDa heterodimeric transmembrane protein possessing tyrosine kinase activity, 
disulphide-linked to an a  subunit of 45 kDa. The kinase activity is located on the cytoplasmic 
side of a 145 kDa (8 subunit that spans the cell membrane {Bottaro et al., (1991)}. Considerable 
post-translational modifications, particulary on the eleven potential N-linked glycosylation sites 
results in the production of different isoforms {Giordano et al., (1988)}.
HGF/SF has been shown to be secreted by a variety of cell types, including fibroblasts, smooth 
muscle cells, and also by a non-differentiated keratinocyte cell line {Adams et al., (1991)}. The 
scatter factor purified by Rosen et al., (1989) from bovine smooth muscle cells was found to 
be a heparin-binding factor, eluting from heparin-Sepharose between 1.3 and 1.4 M NaCl.
HGF/SF is mitogenic for a variety of different cell types including epithelial cells, melanocytes 
and endothelial cells, but it is not mitogenic for fibroblasts {Rubin et al., (1991)}. It has also 
demonstrated affects on the motility of epithelial {Stoker (1989)}, and endothelial cells 
{Morimoto et al., (1991)}. In some epidermoid and sarcoma cell lines, HGF/SF acts as an 
inhibitor of cell proliferation {Higashio et al., (1990); Shima et al., (1991)}.
1.4.2 Autocrine Motility Factor
Another factor also displaying motogenic activity for tumour cells is autocrine motility factor 
(AMF). This 55 kDa protein was initally purified from serum-free medium conditioned by a 
melanoma cell line {Liotta et al., (1986)}. It was subsequently purified from the serum-free 
conditioned medium of a fibrosarcoma cell line HT-1080. A 78 kDa glycoprotein identified as 
the AMF receptor, was cloned from a HT-1080 cDNA library {Watanabe et al., (1991)}.
1.4.3 Migration stimulating factor
A  migration-stimulating factor purified from the conditioned medium of foetal and breast cancer 
patient fibroblasts has also been described {Grey et al., (1989)}. This species was purified to 
homogeneity by a sequential fractionation scheme employing ammonium sulphate precipitation, 
heparin-affmity, gel filtration, and reverse-phase chromatography. The 70 kDa protein purified 
in this way, had a moderate affinity for heparin-agarose, eluting at 0.3 and 0.6 M NaCl. It was 
also found to be distinct from AMF.
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1.5 AUTOCRINE GROWTH FACTOR MECHANISMS
Private versus public autocrine loops
As originally proposed, the autocrine hypothesis suggested that self-stimulatory polypeptides 
were secreted by cells, and interacted with their cognate receptors on the surface of the same 
producer cell, or on cells of the same type in the immediate microenvironemnt. However, for 
several growth factors, there is now evidence that the ligand may induce its mitogenic signal 
by interacting with its receptor intracellularly. This mechanism, called a ‘private autocrine 
loop’, avoids the requirement for growth factor secretion, and may provide one explanation for 
the failure of neutralising antibodies to act as effective inhibitors of cell proliferation in some 
cell systems where coexpression of receptors and their cognate ligands have been detected 
{Browder et al., (1989)}.
Evidence fo r  operative autocrine loops
Two approaches have been taken to meet the rigorous evidence required to establish the 
presence of an operative in vitro autocrine growth stimulatory mechanism. Both involve the use 
of an antagonist, and require the demonstration of growth inhibition as a direct consequence of 
blocking the action of the putative autocrine growth factor loop. To this end, anti-receptor and 
anti-growth factor antibodies have been used to inhibit ligand/receptor interactions. A  more 
specific approach has been the use of antisense RNA oligodeoxynucleotide sequences. The latter 
technique permits the expression of specific genes to be inhibited.
Several growth factors have been implicated in autocrine growth control mechanisms and 
examples of these are discussed below.
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1.5.1 PLATELET-DERIVED GROWTH FACTOR AS AN AUTOCRINE GROWTH 
REGULATOR
Platelet-derived growth factor (PDGF) was one of the first growth factors to be implicated as 
a positive autocrine growth regulator in malignantly transformed cells. The discovery that the 
gene for the B-chain of this growth factor was the normal cellular counterpart of the virally 
encoded v-sis oncogene (of the simian sarcoma virus, SSV) provided the first direct link 
between oncogenes, and the normal cellular genes involved in cell proliferation and 
differentiation {Devare et al., (1983); Doolittle et al., (1983); Waterfield (1983)}. Much work 
has since been done in the elucidation of the PDGF signal transduction mechanism.
An autocrine role for PDGF in a wide variety of malignancies has been implied by the observed 
coexpression of this growth factor and its receptors, in sarcomas {Leveen et al., (1990); Smits 
et al., (1992)}, mesotheliomas {Versnel et al., (1991)}, gliomas {Nister et al., (1988); 
Hermansson et al., (1992)} and lung carcinomas {Antoniades et al., (1992)}. However, there 
have been conflicting results concerning the mechanism of autocrine PDGF stimulation. Studies 
with the simian sarcoma virus (SSV), have shown that the cell transformation induced by this 
virus, is mediated by the activation of cell surface receptors {Hannink & Donoghue (1988)}. 
However, other reports present evidence for a private autocrine loop, with the initiation of the 
ligand-induced receptor signal arising intracellularly {Keating & Williams (1989)}. In support 
of a public PDGF autocrine mechanism, Johnsson et al (1985) were able to block the PDGF 
B-chain/SS V transformation with anti-PDGF antibodies. Similar results were obtained by Huang 
et al., (1984) using suramin, a drug known to displace several growth factors, including PDGF, 
from their receptors {Hosang (1985); Coffey et al., (1987); Poliak & Richard (1990)}.
Despite a report demonstrating the endogenous activation of PDGF receptors in sarcoma cells 
{Fleming et al., (1992)}, clear evidence that PDGF-dependent autocrine pathways mediate the 
proliferation of human tumour cells has only emerged recently. Vassbotn et al., (1994) have 
now presented evidence for a direct link between the activation of the PDGF autocrine growth 
factor pathway and the transformed phenotype in a spontaneous human glioblastoma cell line, 
A172. Concomitant expression of PDGF-BB and its receptor (PDGF-R type ¡3) were reported 
in this cell line, and constitutive autophosphorylation of the receptor was apparent in the absence 
of exogenously supplied ligand. Moreover, endogenous tyrosine kinase activity could be blocked 
using a neutralising antibody against PDGF. The same antibody was also capable of inhibiting 
DNA synthesis in these cells, as well as their ability to form colonies in soft agar (a
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characteristic of malignantly transformed cells). Moreover, the anti-PDGF antibody also 
inhibited the growth of A172 cells in monolayer, and reversed their transformed phenotype 
morphology in this system.
1.5.2 AUTOCRINE GROWTH CONTROL WITH MEMBERS OF THE EPIDERMAL 
GROWTH FACTOR FAMILY
EGF-like growth factors in autocrine growth control o f normal cells
Transforming growth factor a  has been shown to act as an autocrine stimulator in human 
keratinocytes where it was found to regulate its own production. This is achieved by inducing 
TGFa mRNA in response to TGFa stimulation {Coffey et al., (1987)}. Further evidence for 
autocrine growth control by TGFa in keratinocytes has been presented by Cook et al., (1991) 
who were able to inhibit the autonomous growth of human keratinocytes with an antibody that 
bound to the EGF receptor, thereby blocking the binding of TGFa.
EGF-like growth factors in malignantly transformed cells
TGFa and its receptor appear to be expressed by a majority of malignant cells derived from 
solid tumours, particularly carcinomas, but not by hematopoietic tumour cell lines {Derynck et 
al., (1987)}. However, Madtes et al., (1988) have shown that activated macrophages produce 
TGFa.
TGFa in Lung Cancer
Imanishi et al., (1988) implicated TGFa as a possible autocrine growth factor for human lung 
adenocarcinoma cells, and the same group subsequently inhibited the growth of two human lung 
adenocarcinoma cell lines (A549 and PC-9) using anti-TGFa neutralising antibodies {Imanishi 
e ta l . ,  (1989)}.
More recently Burton & Knight (1992) demonstrated that an autocrine TGFa loop may 
indirectly stimulate the growth of the human lung cancer cell line BEN-57 by inducing the 
secretion of parathyroid hormone-related peptide (PTHrP). Both proteins were stimulatory for 
BEN-57 cells, but anti-PTHrP polyclonal antisera, and a PThrP receptor antagonist, inhibited 
cell growth in this system.
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TGFoi in Ovarian Cancer
In a recent study of 17 ovarian carcinoma cell lines of epithelial origin, 16 were found to 
secrete TGFa, and all expressed the EGF receptor. In the same, study 8/13 of the cell lines 
examined demonstrated a mitogenic response to exogenous TGFa, and of these, five were 
capable of serum-free propagation. The growth of four of the cell lines capable of serum-free 
propagation could be inhibited by the addition of an anti-TGFa neutralising monoclonal 
antibody to the culture medium of these cell lines. Taken together these findings suggest that 
TGFa may act as an autocrine growth stimulator in ovarian carcinomas {Stromberg et al.,
(1992)}.
TGFa in Pancreatic Cancer
TGFa was implicated as one of two autocrine growth stimulators in the human pancreatic 
carcinoma cell line MIA-PaCa 2. These cells were capable of serum-free proliferation, and 
elaborated multiple immunoreactice forms of TGFa. In addition, MIA-PaCa 2 cells were 
growth stimulated by 1.5-fold in the presence of authentic TGFa {Ohmura et al., (1990)}.
TGFa in Prostate Cancer
Liu et al . , (1994) recently presented evidence that a TGFa autocrine loop may act as a mediator 
of the androgen-induced cell proliferation in the androgen-dependent prostate cancer cell line 
ALVA101. These workers found that testosterone, (T) and a-dihydrotestosterone (DHT), both 
induced the mRNA for TGFa and its receptor (TGFa/EGF receptor) in serum-free culture 
conditions. Both androgens, as well as TGFa and EGF, stimulated cell growth and in either 
case the mitogenic response could be inhibited by an anti-TGFa/EGF receptor antibody.
TGFa in Breast Cancer
Estrogen-dependent epithelial breast cancer cell lines secrete high levels of TGFa-like activity 
info their culture medium {Dickson et al., (1986)}, and detection of the EGF receptor has also 
been reported on such cell lines {Davidson et al., (1987)}. An autocrine role for TGFa in these 
tumours is supported by the demonstration that an anti-EGF receptor antibody was capable of 
inhibiting the growth of the MDA-468 breast carcinoma cell line {Ennis et al., (1989)}.
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Amphiregulin as an autocrine growth factor
The previously idenitifed 25 kDa, EGF receptor-binding autocrine growth factor, CRDGF 
(Colorectum Cell-Derived Growth Factor), produced by the human colon adenocarcinoma cell 
line HT29 {Colouscou et al., (1988)}, has subsequently been identified as amphiregulin after 
immunological and partial N-terminal amino acid sequence analysis revealed its identity with 
this member of the EGF family {Colouscou et al., (1992)}.
Amphiregulin has been shown to act as an autocrine growth stimulator in normal human 
epidermal keratinocytes {Cook et al., (1991a)}. However, in the context of the production of 
other positive autocrine growth factors, then AR, acting in its capacity as a negative regulator 
of cell proliferation, might contribute to the hyperproliferative state if  its expression were 
reduced or functionally inactivated.
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1.5.3 AUTOCRINE GROWTH CONTROL BY FGFs
Basic FGF in autocrine growth control
While evidence supporting a role for basic FGF as an autocrine growth stimulator continues to 
emerge, the mechanism by which its action is effected is still uncertain. In some cell systems, 
studies support the existence of a ‘private’ autocrine loop (also called an ‘intracrine’ loop), but 
other findings are consistent with an external or ‘public’ autocrine pathway.
Basic FGF in Melanoma
Strong evidence has emerged in recent years to implicate basic FGF as an autocrine growth 
factor for melanoma cells {reviewed by Rodeck et al., (1991)}. The development of a serum- 
free medium for normal melanocytes provided an ideal model with which to study growth factor 
requirements, and other events associated with the progression from the benign to the malignant 
phenotype in this system. In humans, at least three distinct stages of the disease can be 
distinguished histopathologically, and clinically. Initially the growth of benign proliferative 
lesions in stage 1 results in the formation of ‘acquired’ or ‘dysplastic’ nevi. This is followed 
in stage 2 by the development of primary melanoma — characterised by an increased capacity 
to disseminate in vitro. Rapid metastasis characterises the development of malignant melanoma 
in stage 3.
Four components are essential for long-term proliferation of normal melanocytes in vitro. These 
include IGF-I, a phorbol ester {e.g. 12-0-tetradecanoyl-phorbol-13-acetate (TPA)}, an inducer 
of cAMP formation, such as a-melanocyte-stimulating hormone, and basic FGF {Herlyn et al.,
(1987)}.
Basic FGF is not produced by normal melanocytes, but constitutive production of this growth 
factor is an early event in melanoma progression. The acquisition of an endogenous source of 
bFGF is accompanied by a concommitant loss in the requirement for exogenous bFGF by these 
cells in culture {Rodeck et al., (1991)}. The most convincing evidence for the role of bFGF as 
an autocrine regulator in melanoma however, comes from experiments with anti-basic FGF 
n eu tra lis in g  antibodies, and antisense oligodeoxynucleotides. Antisense oligonucleotides directed 
against the AUG codon, and the donor/splice acceptor sites of bFGF mRNA, were found to 
inhibit in vitro growth of primary and metastatic melanoma cells by 70-90% {Becker et al., 
(1989)}. By comparison, only anti-bFGF neutralising antibodies injected into melanoma cells, 
but not those added to their culture medium, inhibited melanoma growth (by approximately
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60%). The fact that anti-bFGF antibodies added to the culture medium were incapable of 
inhibiting melanoma cell proliferation, as opposed to those delivered intracellularly, suggested 
that an intracrine bFGF mechanism was operative in these cells {Halaban et ah, (1988)}.
Basic FGF in Gliomas
The involvment of bFGF as an autocrine growth factor in gliomas was suggested by a report 
that the C6 rat glioma cell line produced a bFGF-like immunoreactive species, and that bFGF 
stimulated the proliferation of these cells in a serum-free system. An intracrine stimulatory 
mechanism was implied by the finding that C6 cells did not secrete this FGF {Okumura et ah,
(1989)}.
In another study Morrison et al., (1990) demonstrated that the human glioma cell line SNB-19 
expressed bFGF mRNA and synthesised a non-secreted bFGF-immunoreactive species. SNB-19 
cells also expressed high affinity FGF receptors and were stimulated to produce colonies in soft 
agar by the addition of exogenous bFGF. A subsequent publication by Morrison (1991) 
demonstrated 80% inhibition of SNB-19 monolayer growth, using a specific antisense 
oligodeoxynucleotide directed against the AUG initiation site, or against the first splice/donor 
acceptor site of bFGF mRNA.
Further evidence to support the autocrine role of bFGF in human gliomas was presented in a 
recent publication by Takahashi et ah, (1992). These workers detected the presence of bFGF 
in 18 of 19 human gliomas, and correlated a proportionate increase in the expression of bFGF 
protein with an increase in the number of nuclear organiser regions (a marker for the degree 
of malignant progression) in these tumour cells. In this same study, the degree of 
vascularisation, and the relatively high levels of bFGF expression detected in these glioma 
tumours, suggested a paracrine role for bFGF.
Basic FGF in Colon Cancer
The role of bFGF as an autocrine growth stimulator in colon carcinoma was suggested by a 
report demonstrating the expression of FGF receptors and a bFGF-immunoreactive species in 
five colon carcinoma cell lines {New & Yeoman (1992)}.
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AIGF/FGF-8 — an autocrine mediator in Mammary Carcinoma
The androgen-dependent mouse mammary cell line SC-3, was shown to secrete a growth- 
promoting activity in response to testosterone. This species, called androgen-induced growth 
factor (AIGF), was found to have a high affinity for immobilised heparin {Nonomura et al.,
(1988)}. Yamanishi et al., (1991) subsequently demonstrated that androgen-stimulated growth 
of SC-3 cells, as well as their mitogenic response to partially purified AIGF, was inhibited by 
an anti-basic FGF polyclonal antibodies. This suggested that an autocrine loop involving a 
bFGF-like growth factor mediated the mitogenic effect of testosterone in these cells. The 
subsequent purification and cloning of AIGF revealed that it was distinct from bFGF and could 
be considered as an eight member of the FGF family {Tanaka et al., (1992)}
Acidic FGF-like growth factor in oesophageal carcinoma
A  murine model for the study of malignant progression in immortalised oesophageal epithelial 
cells was described by Katayama & Kan (1991), and presents evidence for the involvement of 
an aFGF-like growth factor in the autocrine growth control of these cells. Using a serum-free 
medium containing neural extract, these authors were able to select rapidly proliferating 
immortalised premalignant epithelial cells from normal cultures. When neural extract was 
removed, these premalignant oesohpageal cells were most sensitive to exogenously added EGF 
and aFGF. Moreover, extracts of actively proliferating premalignant cells were found to contain 
an aFGF-like activity. While premalignant cells formed only small keratinized tumours in 
syngenic hosts, a clone was selected from this population on the basis of its ability to grow in 
the absence of neural extract. This clone displayed constitutive cytosolic aFGF production at 
all stages of the growth cycle, and formed large invasive tumours in syngenic hosts.
Acidic FGF in the control o f parathyroid cell growth
Evidence that an autocrine acidic FGF loop mediates the calcium-regulated growth of
parathyroid cells was presented by Sakaguchi (1992). Hormone secretion and growth stimulation 
are negatively regulated by extracellular calcium in the rat cell line used in this study, and these 
cells have also previously been reported to express two high affinity receptors for aFGF
{Sakaguchi et al., (1991)}. More aFGF mRNA and protein were detected at low Ca2+
concentrations, and the FGF receptors for this ligand were translocated from intracellular sites 
to the plasma membrane under these low Ca2+ conditions. Significantly, anti-aFGF antibody 
only inhibited cell growth at low Ca2+ concentrations.
37
Evidence fo r  the involvment o f the oncogenic FGF members in autocrine growth control 
The oncogenic FGFs int-2 (FGF-3), hst/K-igi (FGF-4), FGF-5 and FGF-6 , all have the 
potential to be involved in public autocrine growth loops because they posses signal sequences, 
and are therefore capable of being secreted. However, although the expression of these genes 
have been detected in tumours, there has been little direct evidence for their involvement in 
autocrine growth stimulation in these systems.
A  role fo r  FGF receptors in autocrine growth control
A recent study by Kobrin e ta l., (1993) compared mRNA expression levels for the 2-Ig and 3-Ig 
isoforms of FGFR-1 in normal and malignant human pancreas tissues using PCR and an RNAse 
protection assay. Both forms were expressed in relatively equal proportions in normal tissue, 
with a tendancy for predominance of the 3-Ig form. However, in the cancerous tissues, the 2-Ig 
FGFR-1 form predominated, and was overexpressed (by 4-fold) relative to that in normal tissue. 
This group had previously reported the overexpression of aFGF and bFGF mRNA by human 
pancreatic cancer cells {Korc et al., (1992)}, and although both acidic and basic FGF were 
known to bind the 3-Ig and 2-Ig isoforms of FGFR-1 {Jaye et al., (1992)}, only bFGF 
expression in pancreatic cancer cells correlated with a shorter patient post-operative survial time 
(unpublished observations). This led Kobrin et al., (1993) to suggest that bFGF might 
preferentially activate the overexpressed 2-Ig FGFR-1 isoform in pancreatic cancer cells.
FGFR-1 gene amplification has also been reported recently in ovarian carcinoma {Theillet et 
al., (1993)}.
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1.5.4 INVOLVEMENT OF INSULIN-LIKE GROWTH FACTORS IN AUTOCRINE 
GROWTH CONTROL
In addition to their endocrine functions, it is now widely accepted that IGF I and IGF II can act 
locally as paracrine and autocrine growth factors {Humbel (1990)}.
IGFs in Normal Lung
Evidence for an IGF-I autocrine stimulatory loop in the human embryonic lung fibroblast cell 
line, WI-38, was presented recently. In this report, the presence of 2 ¿iM of a 15-base pair 
antisense oligodeoxynucleotide directed against the start site for translation of IGF-I mRNA, 
reduced levels of the growth factor in WI-38 CM by 83%. The same oligonucleotide caused a 
dose dependent reduction in pH] thymidine uptake into DNA, ranging from 77% at 2 /¿M to 
95% at 20 /¿M. {Moats-Staats et al., (1993)}.
IGFs in Lung Cancer
The human lung adenocarcinoma CaLu-6 was shown to secrete increasing amounts of 
immunoreactive IGF-I into its culture medium as a function of time, and these cells were also 
found to respond mitogenically to the exogenously supplied growth factor. An autocrine loop 
was suggested by the finding that anti-IGF-I monoclonal antibody could completely abolish the 
mitogenic effect of autocrine and exogenous IGF-I {Minuto et al., (1988)}. Evidence for an 
IGF-I autocrine loop has also been presented for small cell lung cancer cell lines in vitro 
{Jaques et al., (1988); Nakanishi et al., (1988)}.
IGFs in Breast Cancer
The MCF-7 breast carcinoma cell line secretes immunoreactive IGF-I, expresses mRNA for 
IGF-I, and is stimulated to proliferate by exogenous IGF-I {Huff et al., (1986)}. Moreover, in 
serum-free conditions, the growth of MCF-7 was inhibited by an anti-IGF-I monoclonal 
antibody {Freed & Herington (1989)}.
An anti-IGF-I receptor monoclonal antibody (aIR3) also inhibited the mitogenic effect of IGF-II 
on two other breast carcinoma cell lines, MCF-7L and MDA-231 implying that this receptor 
mediates the effects of IGF-II {Kent Osborne et al., (1989)}. However aIR3 was not 
physiologically inert because binding to the receptor resulted in receptor phosphorylation 
{Steele-Perkins et al., (1988)}. A role for IGF-I in breast cancer is also supported by the fact 
that in vitro these cells secrete and are responsive to this growth factor {Perroteau et al.,
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(1986); Huff et al . , (1986)}.
IGFs in Pancreatic Cancer
Besides the production of a TGFa-like factor, Ohumura et al., (1990) also reported the 
detection of immunoreactive IGF-I in the serum-free medium conditioned by the human 
pancreatic carcinoma cell line MIA-PaCa 2, mentioned above. Evidence for an autocrine loop 
involving IGF-I in these cells was implicit in the discovery that authentic IGF-1 stimulated MIA- 
PaCa 2 cell growth by 1.45 fold, and an anti-IGF-I receptor monoclonal antibody inhibited their 
prolifertion. It appears therefore that both IGF-I, and TGFa, are involved in autocrine 
stimulation of pancreatic carcinoma cell proliferation.
IGFs in other cancers
A teratoma-derived cell line, 1246-3A, produces an insulin-like protein, and its growth was 
inhibited by an anti-insulin antibody, suggesting autocrine growth control in these cells by an 
insulin-like protein {Yamada et al., (1988)}.
The possibility of an IGF-I autocrine loop in ovarina cancer cells is suggested by the report of 
IGFT and IGF-I receptor coexpression in these cells {Yee et al., (1991)}.
Similarly the growth and differentiation of human colon cancer cells has also been reported to 
be regulated by IGF-I {Baghdiguian et al., (1992)}.
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1.5.5.1 Interleukin 3 in Hematopoietic Neoplasias 
IL-3 in Leukemias
A common translocation event in pre-B-Cell leukemias (chromosome 5 -> 14) which results in 
the juxtaposition of the IL-3 gene behind an IgH enhancer, results in overexpression of the 
translocated IL-3 gene. This creates a functional autocrine loop in these cells which is thought 
to favour leukemogenesis {Grimaldi et al., (1989)}.
Further evidence for the involvement of IL-3 in autocrine transformation was presented recently 
by Algate & McCubrey (1993). These workers isolated IL-3 independent hematopoietic cell 
lines from an IL-3 dependent cell line, and found that autocrine transformation was associated 
with increased IL-3 mRNA stability. This was due to the insertion of an intracisternal A particle 
provirus into the 3' untranslated region of the IL-3 gene. The sequence at the site of insertion 
is associated with cytokine and oncogene mRNA stability. An increase in IL-3 cytokine levels 
resulting from a more stable transcript, may explain the mechanism of autocrine transformation 
in these cells.
1.5.5.2 Interleukin 6 in Hematopoietic Neoplasias 
IL-6 in Myelomas
Interleukin 6 has been implicated as an autocrine growth factor in human mulitple myelomas 
{Kawano et al., (1988)}, but evidence for a clear role for IL-6 as an autocrine stimulator in 
myeloma, as opposed to a paracrine effector, had been lacking {Klien et al., (1989)}. More 
recent work supports an autocrine mechanism for the action of IL-6 in these malignancies. 
Takahashi et al., (1993) demonstrated that a non-IL-6 producing myeloma cell line (S6B45) 
transfected with IL-6 cDNA produced cells that proliferated in vitro, and in vivo, with the 
requirement for exogenous IL-6 . These cells were shown to express IL-6 mRNA and protein, 
and could be inhibited by anti-IL-6 , and anti-Il-6 receptor monoclonal antibodies.
In another study, the separation of human myeloma cells from a pleural fluid, and bone marrow 
samples of multiple myeloma patients, was achieved using an immunomagnetic separation 
technique. This provided cultures of myeloma cells which were 99% pure. Using these cultures,
1.5.5 INTERLEUKINS AND HEMATOPOIETIC GROW TH FACTORS AS
AUTOCRINE GROWTH REGULTORS IN HAEMATOPOIETIC NEOPLASIAS
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Borset el al., (1993) found that myeloma cells were not directly responsible for the 
overproduction of IL-1 and 1L-6 which is associated with these disorders. This was because the 
pure myeloma cultures isolated produced no IL-1 and only small amounts of IL-6 .
However, more recently, a cell surface antigen CD40 expressed on the surface of freshly 
isolated myeloma cells and myeloma cell lines was found to mediate the induction of autocrine 
IL-6 production in the IL-6-dependent myeloma cell line ANBL-6 {Westendorf et a l., (1994)}.
IL-6 in Lymphomas and Plasmacytomas
An autocrine role for IL-6 in plasmacytomas was proposed by Van Damme et al., (1987), and 
others have presented evidence for a similar involvment in lymphomas {Yee et a l., (1989); 
Shimizu et al., (1988)}.
1.5.6 CYTOKINES AS AUTOCRINE GROWTH REGULATORS IN 
NONHEMATOPOIETIC NEOPLASIAS
In the last number of years, evidence has emerged for the involvment of hematopoietic growth 
factors in the growth control of nonhematopoietic malignant cell lines {Berdel et a l., (1989); 
Foulke, et al., (1990); Serve, et al., (1991)}. Some examples of hematopoietic growth factor 
autocrine loops in nonhematopoietic cancers are discussed below.
1.5.6.1 Interleukin 6 in nonhematopoietic Malignancies
IL-6 in Renal Carcinoma
Interleukin-6 (IL-6) has been reported as a positive autocrine growth factor in human renal cell 
carcinoma {Miki et al., (1989)}. A more recent publication demonstrated a functional IL-6 
autocrine loop in the human renal carcinoma cell line, ACHN {Gruss et al., (1992)}. ACHN 
cells constitutively expressed IL-6 ligand and its receptor, and were growth arrested by exposure 
to a neutralising monoclonal antibody against human recombinant IL-6 . The same study 
demonstrated that the expression of IL-6 , and its induction of ACHN proliferation, could be 
inhibited in a specific manner by interferon-7 , and that this inhibition was reversible by 
recombinant human IL-6 .
IL-6 in Melanoma
Evidence has emerged from a series of investigations into melanoma progression to support an 
autocrine role for IL-6 in this process. Cornil et al., (1991) found that an activity identical to 
IL-6 , which was elaborated by normal dermal fibroblasts, inhibited the growth of early stage 
melanoma lesions, but not advanced stage melanomas. In a subsequent publication from the 
same laboratory, purified recombinant IL-6 demonstrated the same stage-specific inhibition, 
even though melanomas at all stages expressed IL-6 receptor and its signal transducer gpl30. 
Measurement of IL-6 mRNA, and its secreted protein product, revealed that 5/8 melanoma cell 
lines, resistant to IL-6 induced inhibition, also expressed the transcript of this gene and the IL-6 
protein could also be measured in the respective CM. Moreover, antisense oligonucleotides 
directed against IL-6 were inhibitory in endogenous producer cell lines only, whereas 
neutralising antibodies against this cytokine were ineffective in reducing growth. Taken 
together, these results suggested a switch from a paracrine inhibitory role for IL-6 , to that of 
a ‘private’ autocrine stimulator during the malignant progression in melanomas {Lu et al., 
(1993)}.
IL-6 in Ovarian Cancer
An autocrine stimulatory role for IL-6 in ovarian cancers was suggested by Watson et al., 
(1990) who reported the constitutive expession of production o f this cytokine in ovarian cells. 
Using antisense oligonucleotides directed against IL-6 , the same group of workers were able to 
inhibit the proliferation of the three ovarian carcinoma cell lines, OVCAR-3, CAOV-3 and OC- 
436, by 80-85% with 1-5 /¿M of antisense oligonucleotide {Watson et a l. , (1993)}. In the same 
report, IL-6 neutralising antibodies did not consistently inhibit proliferation, suggesting that the 
induction of cell proliferation by IL-6 in these cells was effected indirectly. A  previous 
publication from this group using OVCAR-3 and CAOV-3, as well as primary ovarian tumour 
cultures, found that these cells constitutively produce biologically active IL-6 , but their 
proliferation was not inhibited by anti-IL-6 neutralising antibodies. Proliferation in the same 
cultures was not affected by exogenously supplied IL-6 {Watson et al., (1990)}.
IL-6 in Lung Cancer
Takizawa et a l. , (1993) have recently implicated IL-6 as an autocrine growth inhibitor in human 
lung cancer cell lines in vitro (see discussion, Section 4.1.2.2).
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1.5.7 BOMBESIN/GRP AS AN AUTOCRINE GROW TH REGULATOR
Gastrin-releasing peptide (GRP), the mammalian equivalent of the amphibian peptide bombesin, 
was shown to act as an autocrine growth factor for small cell lung cancer in vivo {Cuttitta et 
a l., (1985)}. However, it seems that not all SCLCs are dependent on this autocrine loop because 
Layton et a l. , (1988) demonstrated that the inhibitory effect of bombesin antagonists on SCLC 
growth was not mediated through the bombesin receptor. Moreover, not all SCLC cell lines 
were dependent on bombesin in vitro.
1.5.8 AUTOCRINE MOTILITY FACTOR AS AN AUTOCRINE GROWTH FACTOR
It was initially believed that the biological function of autocrine motility factor (AMF) was 
solely motogenic. However, the first evidence that this factor also has mitogenic activity, as a 
paracrine factor in normal tissue regeneration, and in tumour dissemination, emerged recently 
{Silletti & Raz (1993)}. Internalisation of AMF as a complex with its receptor (gp78), following 
cell surface binding, was shown to be involved in the control of cell motility during metastasis. 
AMF is also reported to stimulate the lung colonising ability of tumours in vivo {Watanabe et 
a l., (1993).
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1.6 PRIMARY CELL CULTURE OF LUNG CARCINOMAS
The cellular origin of lung cancers is still a contentious issue. However, there is biological and 
histological evidence for the existence of a common progenitor cell type {Carney & De Leij 
(1988)}. Histologically, four major types of lung cancer are defined, namely, squamous cell 
carcinoma, adenocarcinoma, large cell carcinoma, and small cell carcinoma (SCLC). For 
clinical and therapeutic purposes lung cancers are divided into two groups, Small Cell and Non- 
Small Cell Lung Carcinomas. Small cell lung cancers (SCLC), which account for approximately 
25-30% of all lung cancers, are distinguished from non-small cell lung carcinomas (NSCLC) 
by their etiology, pathology and clinical features. SCLC has traditionally been divided into two 
‘classic’ and ‘variant’ subtypes {Carney et al., (1985); Gazdar et a l., (1985)}. The small cell 
or classic type of SCLC accounts for approximately 70% of all SCLCs, and is distinguished 
from the variant form by its relatively more differentiated status, and by expression of high 
levels of neuroendocrine markers (e.g the enzymes neuron specific enolase, creatine kinase, and 
L-dopa decarboxylase, as well as neuropeptides such as bombesin and neurotensin). Classic 
SCLCs also demonstrate slower proliferation rates in vitro in comparison to the variant 
subgroup. A recently revised histological classification system {Cook et al., (1993)} takes into 
account the existence of a ‘transitional’ type of SCLC which exhibit some of the properties of 
classic and variant subgropus.
Non-small cell lung carcinomas exhibit more phenotypic heterogeneity than SCLC {Gazdar et 
al., (1985)} and are less sensitive to cytotoxic therapies. The degree of differentiation varies 
from being primarily undifferentiated in large cell carcinoma, through poor, to moderate, to 
well differentiated in the case of adeno- and squamous cell carcinomas. Due to their propensity 
to undergo terminal keratinisation, squamous cell carcinomas have been particularly difficult 
to establish as continuous cell lines.
The very low frequency of establishment of permanent NSCLC tumours in vitro from primary 
tumours has already been documented {Sherwin & Richters (1975)}. Successful primary cultures 
of these tumours would have many important applications in the study of the biology of 
NSCLC. An application of particular interest concerns the possibility of using individual 
tumours as a source of cells for in vitro cultures. These cultures might then be used to predict 
drug sensitivity profiles for the donor patient in vivo. If this procedure could be performed 
routinely then it would enable clinicians to design more rational chemotherapy regimen for this 
otherwise clinically resistant class of lung cancer. Recent studies examining such an approach
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with NSCLC tumours have used dye exclusion-based assays to assess drug sensitivity profiles 
{Wilbur et al., (1992)}. However, difficulty in the routine establishment of NSCLC tumours 
in vitro has hampered progress in this direction, especially when the initial numbers of tumour 
cells obtained at biopsy are limited {Shaw et al., (1993)}. In general, the relevant epithelial 
component of NSCLC tumours tends to undergo terminal differentiation, thereby losing its 
capacity to proliferate in vitro.
1.6.1 Proliferation and differentiation of NSCLC tumour cells in vitro
The reasons for the loss of in vitro proliferative potential by epithelial-derived tumour cells is 
as yet poorly understood. However, given the heterogeneous composition of tumour tissue, a 
complex series of growth factor interactions, operating via autocrine and paracrine systems, can 
be hypothesised in vivo. Functional loss of one or more pathways, as a consequence of in vitro 
isolation, may explain the reduced proliferative capacity of NSCLCs in culture. The associated 
induction of growth-inhibitory or differentiation-promoting pathways may therefore be a 
response to, or a consequence of, this loss in proliferative potential.
In normal human bronchial epithelial (NHBE) cells grown in serum-containing medium, 
transforming growth factor /31 (TGF-/31) was implicated as the major growth inhibitor present 
in serum. Growth inhibition by TGF-/31 was correlated with the initiation of terminal squamous 
differentiation of NHBE cells {Masui et al., (1986)}. These workers used the ‘immortalised’ 
normal human bronchial epithelial cell line, BEAS-2B, as a model for lung carcinogenesis, and 
demonstrated that these non-tumourigenic cells were growth inhibited, and induced to 
differentiate terminally, in response to TGF-/31. However, Masui et al., (1988) and other 
investigators {Coffey e ta l., (1988)} demonstrated that lung carcinomas are relatively insensitive 
to differentiation-inducing and inhibitory effects of serum and TGF-/31. Subsequent studies have 
also found that cells which had been transfected with oncogenes, and became tumourigenic, also 
developed a resistance to the inhibitory effects of TGF-/31 {Pfeifer et a l., (1989)}.
Transfection studies in normal human bronchial cells with mutants of the p53 tumour suppressor 
gene, also support a connection between the loss of sensitivity to TGF-/31, and the tumourigenic 
conversion induced by this genetic lesion {Gerwin et al., (1992)}. Using the same model cell 
line as Masui et al., (1986), these investigators found that transfected wild-type (WT) p53 
suppressed the colony forming efficiency of BEAS-2B cells in monolayer culture, while mutant 
(MT) p53 enhanced it. Clones of BEAS-2B transfected with MT p53 were less responsive to
the induction of terminal squamous differentiation by TGF-/3 I and serum than the parent BEAS- 
2B cells, and these TGF-/31-resistant clones also formed tumours in athymic mice.
The role of polypeptide growth factors as positive and negative regulators in the development 
of lung carcinomas may be viewed in the context of cellular senescence where the default 
program for cell growth is to stop dividing and differentiate terminally.
Another facet of the in vitro culture of primary tissue in serum-supplemented medium, is the 
presence of stromal cells. Fibroblasts are the main type of stromal cells associated with tumour 
tissue, and these tend to outgrow their epithelial counterparts in in vitro cultures. Careful 
preparatory techniques are the only satisfactory alternative to selective media in avoiding 
excessive numbers of fibroblasts. The disruptive techniques required to liberate epithelial cells 
from tumours can significantly influence the yield of stromal cells obtained, and the presence 
in serum of the powerful fibroblast mitogen and chemoattractant, platelet-derived growth factor 
{Ross et a l., (1986)}, is probably one of the principal contributers to excessive fibroblast 
proliferation.
1.6.2 The role of stromal cells in the growth of NSCLC cells in vivo and in vitro — 
paracrine interactions
The function of stromal cells in the generation of tumour stroma is similar to that seen in the 
normal wound healing process. An understanding of the respective processes may help to 
explain the role of stromal cells in tumourigenesis and lead to new intervention therapies. 
Dvorak (1986) has compared the two processes in detail and described tumours as ‘wounds that 
do not heal’. In this hypothesis, he suggests that the generation of a temporary extravascular 
fibrin-fibrinogen gel — an important process in the initial stage of normal wound healing, is 
pre-empted and subverted in successful tumours, by means of their ability to continuously 
deposit a fibrin-fibrinogenmatrix. This matrix facilitates progressive tumour growth, principally 
by encouraging neoangiogenesis. A supply of nutrients and oxygen via the blood is essential if 
any tumour is to grow beyond 1-2 mm3. The fibrin-fibrinogen gel may also block the host’s 
immune response to the malignantly transformed cells by inhibiting the infiltration of 
macrophages and lymophocytes into the tumour. In support of this hypothesis, Seitz et al., 
(1993) have measured higher plasma levels of a number of markers for coagulation and 
fibrinolysis in patients with small and non-small cell carcinomas. These included the thrombin- 
antithrombin III complex, prothrombin activation fragment FI and F2, plasmin-a2-antiplasmin
47
complex, and D-dimer. No difference was reported in the levels of activation markers between 
the SCLC and NSCLC patients, but those with limited disease had lower levels than those with 
extensive disease.
The main difference between the deposition of the fibrin-fibrinogen gel in the normal process 
versus that seen in tumour tissue, is the trigger initiating matrix and/or clot formation. In the 
normal process, initiation is induced by wounding, and the associated increase in vascular 
permeability is temporal. In tumours however, the ability of these cells to constitutively secrete 
a vascular permeability factor (VPF), {also known as vascular endothelial growth factor, 
(VEGF)}, results in continuous leakage of fibrinogen, plasminogen and clotting factors into the 
extravascular space by inducing increased permeability of the microvasculature. This leads to 
continuous matrix deposition {Senger et al., (1983)}.
In the normal wound healing process, the movement and proliferation of fibroblasts into the 
wound is stimulated by the release of PDGF from platelets at the site of injury. Given that 
platelets are largely absent in tumour tissues, the role of a mitogen and chemoattractant for 
fibroblasts was previously ascribed to other growth factors such as TGFa. However, recent 
studies examining the expression of genes for the c-sis/platelet-derived growth factor (PDGF)-2 
protooncogene (i.e. PDGF-BB) and its receptor, the type ¡3 form of the platelet-derived growth 
factor receptor (PDGF-R/J), have provided a molecular basis to connect chronic injury of 
epithelial cells with the induction of the genes for c-m /PDGF-2 and the PDGF-RjS in such cells, 
leading to the development of proliferative disorders. For example, reversible co-expression of 
mRNA for the growth factor c-sis/PDGF-2 and its receptor, PDGF-R/3, was demonstrated in 
vivo in swine skin epithelial cells, in response to chronic injury {Antoniades et a l., (1991)}.
Chronic injury has also been implicated in the development of proliferative disorders such as 
idiopathic pulmonary fibrosis (IPF) and lung cancer in humans {Antoniades (1991); Thornton 
et al., (1992)}. In vivo expression of c-sis/PDGF-2 mRNA and protein, but not its receptor in 
IPF, has been demonstrated by Antoniades et al., (1990). The same group went on to show that 
the mRNAs for both c-sis/PDGF-2 and its receptor, as well as the specified proteins, were 
expressed in lung cancer epithelial cells in vivo, but not in their nonmalignant counterparts 
{Antoniades et a l., (1992)}. In a more recent publication, Forberg et a l., (1993) have 
demonstrated the expression of functional type /3 PDGF receptors in the large cell lung 
carcinoma cell line H-157.
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Taken together, these studies provide evidence to suggest that IPF may be a stage in the 
malignant progression in lung epithelial cells. In this scenario, paracrine production of PDGF 
by epithelial cells in response to injury would lead to fibrosis in cases of chronic injury. The 
growth factor would become an autocrine stimulator for these cells only after they had acquired 
the ability to express functional PDGF type j8 receptors, either in the process, or as a 
consequence of malignant progression. If such a mechanism is operative in lung cancer it 
supports the notion that a normal physiologic wound healing process may be subverted in cancer 
cells resulting in unregulated autonomous growth.
Given that lung epithelial cells can secrete PDGF, it seems plausible that the excessive 
proliferation of fibroblasts in primary cultures of malignant lung epithelia may be due in part 
to paracrine action of PDGF produced by malignant epithelial cells.
In contrast to the results obtained in this project, some workers have reported that the presence 
of fibroblasts were beneficial to the establishment of primary epithelial cell cultures {Dietal et 
al., (1987)}. In support of a paracrine function for stromal cells in lung epithelial cell growth, 
Stuart Aaronson’s group isolated two paracrine-acting mitogens for epithelial cells in medium 
conditioned by a human embryonic lung fibroblast cell line. The first such factor characterised 
was keratinocyte growth factor (KGF) {Rubin et a l . , (1989)}. Unlike other members of the FGF 
family, KGF is not mitogenic for fibroblasts, but it does stimulate the growth of 
tracheobronchial epithelial cells {Finch et al (1989)}. In normal skin epithelial cells, KGF has 
been implicated as the major player in mesenchyme-driven epithelial cell proliferation, from the 
observation that KGF mRNA expression was induced 160-fold, one day after injury {Werner 
et a l., (1992)}. The induction of KGF mRNA was accompanied by increased expression of its 
receptor, and secretion of the growth factor preceeded epithelial cell proliferation. The 
corresponding induction of aFGF, bFGF and FGF-5 mRNAs in the same cells, was in the order 
of 2-10 fold, and no expression of mRNA for FGFs -3, -4 or -6 were detected.
The second paracrine mitogen for epithelial cells in the lung was found to be a variant form of 
hepatocyte growth factor/scatter factor (HGF/SF) and this was expressed by stromal fibroblasts 
derived from adult lung, skin, gastrointestinal tract and prostate {Rubin et al., (1991)}.
A more recent publication from this group reported the purification of KGF and HGF/SF from 
medium conditioned by human adult lung fibroblasts. The KGF and HGF/SF proteins isolated
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from this fibroblast-conditioned medium (by heparin-Sepharose chromatography), were found 
to be the principal heparin-binding mitogens for primary adult rat alveolar type II cells, 
produced by these lung fibroblasts. Whether such fibroblast-derived growth factors have a 
paracrine function in malignant lung tissues remains to be established, but a role in lung injury 
was proposed by the authors {Panos et al., (1993)}. Changes in the level of expression of KGF 
by fibroblasts in adult lung, in response to injury, might contribute to the neoplastic progression 
in lung epithelial cells by stimulating the proliferation of epithelial cells. This expanded 
population of epithelial cells, might then give rise to a more malignant subpopulation, by the 
acquisition of the ability of a single cell (or cells) to coexpresses the KGF ligand; thereby 
generating an autocrine loop in this system.
Yoshinaga et a l . , (1992) detected a protein with indistinguishable immunological and biological 
properties to HGF/SF which was produced by two human lung cancer cell lines, namely PC-1 
and PC-13. However, these authors were not able to detect the HGF/SF receptor (the c-met 
proto-oncogene) by western analysis in either cell line, and neither responded to exogenous 
HGF/SF. More recent evidence has implicated HGF/SF as an autocrine growth regulator for 
normal human bronchial epithelial (NHBE) cells and NSCLC cell lines. In this case, the 
investigators were able to detect HGF/SF mRNA in NHBE and NSCLC cells, and they detected 
immunoreactive HGF-like protein in the cytoplasm of these cells in culture using an anti­
recombinant human (rh) HGF/SF antiserum. The level of phosphorylation of the c-met/HGF/SF 
receptor, which was constitutively phosphorylated in these cultured cells, was decreased in the 
presence o f anti-rhHGF/SF antiserum. Interestingly, while the growth of the NSCLC lines 
studied was inhibited by 45 % using the anti-rhHGF/SF antiserum, the proliferation of NHBE 
cells were stimulated with this antibody. The authors suggest that this might be explained if  the 
antiserum neutralises a mitogenically incative variant of the HGF/SF gene encoded by an 
alternately spliced 1.3 kb transcript of the gene. The 1.3 kb HGF/SF transcript, which encodes 
a 28 kDa protein, is present at a ten-fold higher concentration in NHBE cells than the 6 kb 
transcript which encodes the active 63 kDa form. However, the smaller HGF/SF acts as a 
competitor for the HGF receptor and may effectively neutralise the mitogenic effects of the 
larger HGF/SF species in NHBE cells. The anti-rhHGF/SF may be acting to unmask the 
mitogenic effects the co-expressed larger HGF/SF isoform in NHBE cells {Tsao et al., (1993)}. 
Such a shift in growth factor expression patterns resulting in the acquisition of a functional 
HGF/SF autocrine loop may represent another example of the changes in growth regulation 
pathways that occur in the malignant progression of NSCLC. This idea is supported by reports
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that the majority of primary NSCLCs examined demonstrate expression of the c-wer/HGF/SF 
receptor {Prat et al., (1991)}. In contrast to these results, other investigators have reported that 
HGF/SF inhibited the in vitro growth of selected SCLCs {Rygaard et a l., (1993)}. This 
observation underlines the potential for different growth regulatory pathways in these two types 
of lung cancer.
Other recent work supporting this hypothesis was aimed at defining the factors governing the 
ability of NSCLC primary tumours to be established as monolayer cell lines in vitro {Liu & 
Tsao (1993)}. These authors found that samples from which cell lines arose, had higher mean 
mRNA levels for TGFa and the c-met-protooncogene, than tumours which did not. They also 
found it easier to establish cell lines from poorly differentiated tumours, especially 
adenocarcinomas. In the same study, 8/29 unselected human NSCLCs were successfully 
established as cell lines with heterogeneous nutritional requirements.
Aggressive cancer cells often display characteristics typical of mesenchymal cells such as 
fibroblasts. These features include the production of growth factors which are normally 
elaborated by stromal cells, for example HGF/SF {Yoshinga et a l., (1992)}. Release of tumour 
cells from stromal dependency appears to be a recurrent theme in the malignant progression of 
a number of different types of cancer. An example was outlined above, with acquisition of a 
functional IL-6 autocrine loop in the malignant progression of melanoma. In yet another 
example of this mechanism of malignant progression, the influence of heparin-binding FGFs and 
stromal cells on the development of growth autonomy in prostate epithelial cells was examined. 
Using a slow growing, nonmalignant, rat prostate tumour model grown in syngenic hosts, the 
authors found that a change in the ligand specificity of the FGF-2 receptor from recognising the 
stromally elaborated FGF-7 (also called KGF) to an isoform which recognised FGF-2 (i.e. 
bFGF) accompanied growth factor independence from stromal cells. The change in ligand 
specificity was effected at the level o f RNA processing by an ‘exon-switching’ mechanism, and 
this was also followed by the activation of the gene for its cognate ligand, bFGF. Activation of 
embryonic FGF-3 and FGF-5 ligand genes, along with the normally stromal FGF-R1 gene, also 
coincided with malignant progression in this model system {Yan et a l., (1993)}.
The clonal proliferation of normal respiratory rat tracheal epithelial (RTE) cells has been 
optimised in Ham’s F12 basal medium supplemented with bovine serum albumin (BSA), bovine 
pituitary extract (BPE), insulin, hydrocortisone, epidermal growth factor and cholera toxin
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{Nettesheim et a l. , (1987)}. Using a chemically-induced carcinogenesis model in this serum-free 
system, Thomassen (1993) studied the in vitro growth factor requirements in the malignant 
progression of RTE cells. By measuring monolayer colony forming efficiencies of RTE cultures 
initiated from cells at sequential stages of the malignant progression, it was found that these 
cells displayed reductions in the requirement for supplements concomitant with malignant 
progression. Preneoplastic cells, capable of enhanced proliferation with respect to their normal 
counterparts, no longer required EGF and cholera toxin. However, in previous studies, such 
cells were found to be incapable of forming tumours when injected into nude mice, but these 
populations did contain cells which could progress to adeno- and squamous cell carcinomas in 
vivo {Pai et al., (1983)}. In the study of Thomassen (1993), it was demonstrated that 
neoplastically transformed RTE cells could proliferate with only BSA and BPE.
Although these studies did not lead to a complete definition of the growth requirements of RTE 
cells, they did support the hypothesis that preneoplastic transformation of RTE cells was 
associated with a reduction in the number of exogenously added growth factors required for 
their clonal proliferation, and not as a consequence of their acquired resistance to inhibitory 
factors in selective media which contained serum. This conclusion was supported by the results 
of Terzaghi-Howe (1989) who found that serum added to serum-free culutres of RTE cells did 
not affect the long-term proliferative potential of these cells.
Excessive proliferation of fibroblasts may be expected to cause depletion of essential media 
nutrients which are deleterious to primary epithelial cells in in vitro culture. However, in the 
light of recent evidence for the elaboration of paracrine-acting growth factors by lung 
fibroblasts, the production of paracrine inhibitory factors, or differentiation-inducing factors, 
by stromal cells, may also account for the negative regulation of NSCLC cells in vitro.
In order to separate the complex processes involved in the regulation of growth and 
differentiation in normal and neoplastic lung tissue, the unique nutritional requirements and the 
contribution of cell-secreted factors to the overall biology of malignant lung must be established. 
This can best be achieved by isolating the constitutive cell types that make up these tissues. In 
this way the complex interactions within tissues can begin to be deciphered. The physical 
separation of interactive cell types in tissues, and the selective nature of the in vitro culture 
technique, together combine to highlight the deficiency of appropriate growth requirements for 
particular cell types, and as such, can be helpful in the identification of these factors.
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1.6.3 Selective media for NSCLC
The search for selective media for particular cell types has been a long and painstaking process. 
To date, the number of cell types for which selective media have been developed are relatively 
few. Most notable in terms of their selectivity is the MCDB series which were devised to meet 
the different requirements of non-transformed cells such as normal skin keratinocytes and 
fibroblasts {Ham & McKeehan (1979)}. A significant finding in the development of these media 
was that low Ca2+ levels avoided the induction of differentiation in skin epitlelial cells. This 
is manifested in kerationocytes by the expression of keratins and the formation o f cornified 
envelopes. The MCDB series of media have since formed the basis of many other defined media 
including a modification of MCDB 151 for normal human bronchial epithelial cells {Lechner 
& LaVeck (1985)}. However, the inclusion of cholera toxin in such media appears to be of 
limited benefit, given that this agent only partially antagonised the differentiating effects of 
TGF-/3 in the studies of Masui et al., (1986). Several approaches have been outlined for the 
development of serum-free media {Maurer (1992)}.
Simms et al., (1980) developed a selective medium for SCLC based on RPMI-1640 basal 
nutrient medium supplemented with hydrocortisone, insulin, transferrin, 17/3-estradiol and 
selenium. However, this medium, designated ‘HITES’, did not support the growth of NSCLC 
{Gazdar & Oie (1986)}. It was subsequently found that substitution of HITES medium with 
2.5% foetal calf serum was beneficial for the initiation of some SCLCs {Carney et al., (1985)} 
and some workers routinely split tissue samples between supplemented and non-supplemented 
HITES medium in an effort to improve success rates with SCLC {Baillie-Johnson et al., 
(1985)}. The fact that serum supplementation may still be necessary in some cases of small cell 
carcinoma underlines the variability in growth factor requirements, even for tissues of the same 
cell types (as they are currently classified). In any event, the majority of SCLCs grow as 
floating aggregates {Carney et al., (1985)} — a factor which facilitates the removal of adherent 
fibroblasts. In addition, the principal source of tissue for in vitro culture of SCLC (bone marrow 
aspirates) ensures that a significantly lower percentage of stromal cells are harvested in samples 
of this type of lung cancer.
Another modification of RPMI-1640 basal medium was developed as a selective medium for 
human lung adenocarcinomas using collagen/fibronectin precoated flasks and called ACL-3 
{Brower et al., (1986)}. The supplements used in the ACL-3 formulation were, insulin, 
transferrin, hydrocortisone, selenium, epidermal growth factor, bovine serum albumin, sodium
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pyruvate, glutamine and triiodothyronine. Of these supplements, only insulin and transferrrin 
were essential for optimal growth. Further modification of ACL-3 by Gazdar & Oie (1986b) 
involved reducing the quantities of EGF and BSA. This made ACL-4 a cheaper and more useful 
formulation for the primary culture of human lung adenocarcinoma cells, but the resulting 
formulation, designated ACL-4, like the original ACL-3, did not support the growth of 
squamous cell carcinomas or small cell carcinomas.
Although RPMI-1640, the basal medium used to prepare the ACL-4 formulation, could be 
substituted with a 1:1 mixture of Ham’s F12 and Dulbecco’s modified essential medium 
(DMEM), serum supplementation was still required in the initial stages for the optimal growth 
of some tumours. This was because neither ACL-3 nor ACL-4 contained high molecular weight 
attachment factors and therefore tended to select for non-adherent cell strains. Attachment 
factors appear to be particularly important for the in vitro growth of squamous cell carcinomas 
and these are present in serum. Using a serum supplemented partially defined medium, based 
on Rheinwald’s basal medium formulation, Gazdar & Oie (1986a) were able to achieve a 20% 
success rate in the establishment of human squamous cell lung carcinomas in vitro.
One hypothesis which might explain the restricted in vitro growth of lung squamous cell 
carcinomas is the differentiation status of the lesion at the time of resection. In the normal 
bronchial tree and alveoli, any one of a number of proliferating epithelial cells, may in theory 
give rise to a precancerous lesion. These include type II pneumonocytes, Clara cells, mucus 
cells, and basal cells. It is noteworthy too that in histological terms, squamous metaplasia has 
not yet been considered a true malignant state {Brambilla et al., (1993)}. If this hypothesis can 
be translated into biological terms to mean that a greater part of a tumour cell population may 
not yet have acquired an appropriate functional autocrine growth factor loop(s) in vivo at the 
time of resection, then cultures of tumour cells established from such lesions may be incapable 
of liberating themselves from dependence upon either autologus, or heterologously produced, 
growth factors. Therefore, tumour cells isolated in vitro at this particular stage of malignant 
progression in vivo w ill produce insufficinet endogenous quantities (or none at all), of the 
growth factor(s) vital for proliferation in vitro. If these factors are not supplied by the growth 
medium, then proliferation will not occur. This notion is supported by reports in the literature 
that cell lines are more readily established as in vitro cultures from metastatic NSCLC lesions 
than from primary tumour sites {Shaw et al., (1993)}. It is also consistent with the documented 
cases of malignant progression outlined above, where the transition from paracrine growth
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factor dependency in the premalignant state accompanies the autonomous production of these 
growth factors by malignant cells.
A  candidate for such an autocrine loop in squamous cell carcinomas of the lung, is transforming 
growth factor a. Overexpression of the receptor for this ligand (EGF receptor) has been widely 
reported in human squamous cell lung carcinomas {Berger et a l., (1987); Harris (1990); Veale 
et al., (1989)} and amplification of the EGF-R gene has frequently been associated with 
overexpression {Ozanne et al., (1986); Hunts et al., (1985)}. These findings have implicated 
TGFa and amphiregulin as autocrine growth regulators in this cell type. Furthermore, TGFa 
has been found to be most frequently mitogenic in serum-free media for malignant cells in 
culture {Herlyn et a l., (1990)}. The proliferative response of two lung squamous cell carcinoma 
cell lines established in this laboratory DLRP and DLKP to TGFa was not very significant.
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1.7 THE PURPOSE OF THIS THESIS
In view of the poor success rates reported for the successful primary culture and establishment 
of permanent cell lines from NSCLCs, particularly squamous cell carcinomas (SCCs), attempts 
were made in the work described in this thesis to improve the in vitro culture methodology for 
this type of lung carcinoma.
1.7.1 The use of malignant effusions in primary cell culture
A report in the literature presented evidence for the presence of a growth stimulator(s) in 
malignant effusions (ME) associated with primary tumours of different histopathological type, 
which stimulated the efficiency of colony formation by fresh human tumour cells in soft agar 
{Yen et al., (1986)}. This factor(s) appeared to be particularly active on lung and colon 
cancers, especially at low plating densities, but it was not source specific. Another study 
presented evidence for a tumour-specific growth factor present in ascitic fluid from patients with 
ovarian carcinoma, which stimulated the monolayer growth of primary ovarian tumour cells as 
well as the growth of an established ovarian carcinoma cell line, HEY. On the basis of the 
change in cytoplasmic Ca2+ levels induced in HEY cells by fluid-derived growth factor(s), the 
species involved appeared to be distinct from purified prepartions of PDGF, TGF/3, EGF, TNF, 
IL-1, IL-2, FGF, insulin, thrombin, vasopressin, angiotensin, as well as a  and y-interferons 
{Mills et a l., (1988)}.
In view of the need to improve methods for primary culture of lung tumour tissues, the 
possibility that malignant effusions might contain growth stimulators for the squamous cell type 
of lung cancer cells in monolayer cultures, was investigated in this project. Three human lung 
SCC cell lines DLRP, DLKP, and SK-MES-1 were used as indicator cell lines in preliminary 
experiments. Two of these lung cell lines, DLRP and DLKP, had recently been established in 
this laboratory; the former in the course of this project.
The long-established cell line HEp-2 {Moore et al,. (1955)} was used as a reference cell line 
to assess the specificity of stimulatory activity in MEs, and when tested, was found to respond 
to mitogenic species in all of MEs assayed. HEp-2 displays marker chromosomes for the cell 
line HeLa (which appears to have contaminated many of the cell lines established during this 
period) and is considered therefore to be a variant of HeLa. In practice, HEp-2 was found to 
be a useful indicator cell line for the detection of growth-promoting activity in MEs. This was 
due to the growth characteristics of this cell line, which include its shorter doubling time and
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reduced serum requirement at clonal plating densities, relative to the lung cell lines used. In 
addition, the minimum number of HEp-2 cells required to give a detectable level o f growth in 
a monolayer assay system was ten-fold lower than that required for the lung cell lines DLRP, 
DLKP, and SK-MES-1.
1.7.2 The potential of the Hep-2 cell system as a source of growth factors for human lung 
squamous epithelial cells in vitro
Pilot experiments with HEp-2 at low serum concentrations and low plating densities were 
impressive in terms of proliferative capacity. The growth performance of HEp-2 under these 
stringent conditions provided an additional incentive for using HEp-2, because it suggested the 
production of autocrine growth factor activity by this cell line in vitro. This was supported by 
the mitogenic response of HEp-2 to a panel of growth factors, including at least two growth 
factors (TGFa and IGF-I) which may be important in the proliferation of NSCLCs in vitro. In 
addition, HEp-2 growth was stimulated by media conditioned by a variety of histologically 
different carcinoma cell lines, including the lung cell line DLKP (data not shown).
It was in this context that the HEp-2 cell system was examined in the hope of isolating a 
hitherto unidentified growth factor(s) for primary lung epithelial cells. An obvious starting point 
in the search for a putative NSCLC growth factor(s) would have been in cell lines derived from 
NSCLC tumours. Unfortunately, preliminary attempts to identify autocrine stimulatory species 
in the two newly estasblished NSCLC cell lines DLKP and DLRP were not encouraging 
(Section 3.1.8). The inability to detect autocrine activity in either DLRP or DLKP, together 
with the relatively slow growth rates associated with the maintenance of lung SCCs, mitigated 
against further investigation of these systems in the pursuit of growth factor(s) with the potential 
for improving lung SCC growth in vitro.
By comparison, HEp-2 provided a promising alternative to either of the lung cell lines tested. 
The elucidation of the HEp-2 autocrine mechanisms and the partial characterisation of the 
responsible growth factors supported the original suppostion that multiple growth stimulatory 
species might be active in the autocrine stimulation of this cell line. Fractionation of HEp-2 
conditioned medium (CM) on the basis of molecular mass was performed by ultrafiltration. This 
provided initial evidence for the presence of several autocrine stimulatory species. These 
appeared in the intermediate (10-30 kDa or R10-30 fraction) and large molecular weight (MW) 
range (i.e. >  30 kDa, i.e. the R30 fraction). The stimulatory activity in a lOx concentrate of
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the R30 fraction was masked by an inhibitory activity which could be removed by dilution to 
manifest the presence of the stimulatory species in the same fraction. A  low MW inhibitory 
species was also identified in the 1-5 kDa MW range, but there was no evidence for bifunctional 
growth regulation in this fraction. When these findings were verified by gel filtration 
chromatography, the HEp-2 autocrine stimulatory activity was separable into several sizes, and 
one band of low MW inhibitory activity was confirmed. Physicochemical stability studies on 
stimulatory activity in CM revealed that the 10-30 kDa fraction might be more sensitive to 
protease than the larger MW fraction. A similar difference in sensitivity was noted between the 
mitogenic activity in late versus early collections of unfractionated (crude) CM taken from the 
same culture, with the earlier collection being more resistant to proteinase inactivation. The 
autocrine effect in the 10-30 kDa fraction, and to a lesser extent that in the >  30 kDa fraction, 
was sensitive to inhibition by soyabean trypsin inhibitor, suggesting a role for a trypsin-like 
proteinase in HEp-2 autocrine growth control.
A number of chromatographic systems were employed to try to separate and characterise the 
stimulatory activities in HEp-2 CM. Phenyl-Sepharose chromatography of the 10-30 kDa 
fraction confirmed the presence of several stimulators; one of which appeared to be 
hydrophobic, while crude CM was found to contain several autocrine stimulatory species with 
varying degrees of affinity for immobilised heparin. Apart from the FGF and non-FGF family 
of heparin-binding growth factors, several other classes of proteins are known to have an 
affinity for immobilised heparin {Zhou et al., (1992)}. These include adhesive matrix proteins, 
and serine proteinase inhibitors; both of which are implicated in the control of cellular 
proliferation. The elaboration of several heparin-binding mitogens by HEp-2 also supported the 
possibility that more than one such species might be active in the autocrine effect. It was 
important therefore to further characterise the nature of this activity.
When cation-exchange chromatography was investigated as a potential step in the separation of 
the active stimulatory species in crude HEp-2 CM, two mitogenic activities and a third species 
with inhibitory activity bound to the matrix. The most active mitogenic fraction from the ion- 
exchange step was further separated by heparin affinity chromatography. This protocol had been 
used by others in the purification of acidic and basic FGFs, and it was attempted here to check 
for growth factor activity with similar affinity in the HEp-2 system. The results of an 
exploratory two-step separation protocol demonstrated the presence of heparin-binding mitogens 
with affinities coincidental with those of FGF-1 and FGF-2 at 1.0 M and 1.5 M NaCl
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respectively {Gospodarowicz et al., (1984); Klagsbrun & Shing (1985)} but it was clear that 
not all of the autocrine mitogenic activity in this semi-pure ion-exchange fraction was heparin- 
binding.
The heparin-binding HEp-2 mitogens were considered of more interest in terms of further 
characterisation, given that abundant levels of two members of the FGF receptor family, FGFR- 
3 and FGFR-4, have been detected in human foetal lung tissue {Partanen et al., (1991)}. More 
recently, the FGFR-1 gene product was detected by immunolocalisation in the basal epithelial 
cell layer of the human respiratory tract {Hughes & Hall (1993)}. In the context of the FGF 
receptor expression pattern in lung tissue, and the known redundancy of FGF receptors due to 
exon swtiching, the prospect of isolating a novel FGF with mitogenic activity for lung epithelial 
cells in medium conditioned by HEp-2 was considered worthy of pursuit. Although little is 
known of the receptor specificities of the oncogenic FGFs, as distinct from the prototypic acidic 
and basic FGFs, a complex network of ligand/receptor interactions is implied from the data 
gathered to date. In addition, a role for the normally developmentally regulated FGFs in the 
carcinogenic process has been emerging in recent publications.
Before any further purification work was contemplated, the contribution of FGF-1 (aFGF) and 
FGF-2 (bFGF) to the overall autocrine effect in crude HEp-2 CM was examined. The use of 
anti-FGF neutralising antibodies revealed that a significant amount of the autocrine stimulatory 
activity in crude HEp-2 CM, and fractions separated by ultrafiltration, could be attributed to 
a bFGF-like species. However, attempts to investigate the effects o f more specific inhibition of 
aFGF and bFGF gene expression using antisense oligodeoxynucleotides did not support a major 
role for bFGF in HEp-2 cell proliferation.
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MATERIALS AND METHODS
2.1 PREPARATION OF CELL CULTURE MEDIA
2.1.1 Water quality
Highly purified water is essential for the preparation of cell culture media. Even trace quantities 
of some elements can result in toxicity if  not removed from the water source. Water used in the 
production of media and all solutions coming in contact with cells in culture was purified to 
HPLC grade before use. The qualitiy of mains water supply necessitated prefiltration of the 
supply to remove gross particulates. This was followed by a double distillation step (ELGA) or 
by passage through a reverse osmosis system (Milli-Q). It was then passaged through two ion- 
exchange filters, and a carbon filter to remove organic solutes. Finally a 0.22 /xm cellulose 
acetate filter produced ‘ultrapure’ water which was monitered for purity with an on-line 
conductivity meter. Water with a resistivity in the range 10-18 megaOhms/cm was sufficiently 
pure for use in tissue culture media preparation.
2.1.2 Glassware Treatment
Items of glassware used for cell culture (roller bottles, media bottles, spinner flasks, glass 
universals for conditioned media treatment etc.) were first soaked in a warm 1 % (v/v) solution 
of the non-toxic detergent RBS (R. Borghraef) for 1-2 hours. They were then individually 
scrubbed with bottle brushes before being rinsed in tap water (at least once). This was followed 
by three separate rinses in distilled water before a final rinse in ultrapure water. Metal bottle 
caps were washed and rinsed separately to avoid contamination of bottle rinses with leached 
metal ions.
2.1.3 Sterilisation
All non-sterile glassware such as media bottles, spinner flasks, roller bottles, etc. as well as 
non-sterile plastics were autoclaved before use (121°C/15 psi/20 minutes). Instruments for 
primary cell culture including scalpels, blades, scissors, were sterilised under the above 
conditions, as were phosphate buffered saline (PBS-A, Ca2+ and Mg2+ free), HEPES (4-[2- 
H y d ro x y E th y l]-P ip era z in eE th a n eS u lp h o n ic  acid) b u ffer , N a H C 0 3, E D T A  
(EthyleneDiamineTetraacetic Acid), HC1 and NaOH solutions as well as water for media 
preparation. For unstable reagents such as cell culture media, protein solutions etc, filter- 
sterilisation was employed using a sterile disposable 0.22 /xm filter (Millex-GY, 
Cat.No:SLGV025BS). Low protein-binding filters were used where appropriate. Larger 
volumes of liquid for tilter-sterilisation, such as culture medium were filtered through a ‘bell’ 
filter (Gelman, G. 14238) into sterile 500 ml bottles using a peristaltic pump (Braun FE411).
2.1.4 Siliconisation
Spinner flasks washed in the prescribed way must be coated with trimethyldichlorsilane before 
use to avoid attachment and growth of cells on the vessel walls. To this end a 2% solution of 
this agent in 1,1,1-trichloroethane (BDH, Cat.No:33164) was rinsed onto all the inner surfaces 
of the vessel. This procedure must be performed in a fume hood using a glass pipette. Excess 
reagent is poured off and the vessel allowed to dry at room temperature in the fume hood 
followed by 2 hours at 37 °C. The vessel was then rinsed three times in distilled H20  followed 
by a rinse in ultrapure H20  before autoclaving.
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The preparation of basal media were carried out under sterile conditions in a class II laminar 
flow cabinet. Basal media are available commercially as lOx sterile liquid concentrates or in 
powdered form. The liquid concentrates are convenient for the preparation of smaller quantities 
but sometimes problems arise with solute precipitation during storage. Powdered media require 
filter-sterilisation but have the advantage of being prepared fresh. In this work a 1:1 mixture 
of Ham’s F12 and Dulbecco’s Modified Eagle Medium (DMEM) was used for routine 
maintenance of most cell cultures. Most basal media were prepared from liquid concentrates but 
DMEM was prepared from both liquid and powdered stocks.
2.1.5 Basal growth media
2 .1.5.1 Preparation of media from powder
Ham’s F12 was made up exclusively from a powdered stock in batches of 5 litres (Gibco, 
Cat.No: 072-1700). The powder was dissolved together with 5.88g of NaHC03 in 4750 mis of 
ultrapure H20  while stirring. 100 mis of 1M-HEPES (Sigma, Cat.No: H9136) was added and 
the pH adjusted to 0.2-0.3 pH units below the desired final pH (pH 7.4 - 7.5) using 5M-NaOH. 
The solution was brought up to 5 litres with ultrapure H20  and then sterilised by filtration in 
a laminar flow cabinet. The entire batch was dispensed into 500 ml lots and aliquots of each 
were removed for sterility checks. The freshly prepared media were labelled with the date and 
pH at preparation and stored in the dark at 4°C. They were used only after the sterility checks 
showed no signs of contamination.
2.1.5.2 Preparation of media from liquid concentrates
Table 2 .1 .5 .2  contains a list the constituents for the preparation of 500 ml lots of three basal 
media used in these studies.
Table 2.1.5.2 Preparation of basal media from lOx liquid stocks
BASAL MEDIUM MEM DMEM RPMI-1640
Supplier Gibco Gibco Gibco
Cat. No: 042-01430M 042-02501M 042-2511M
lOx Stock 50 mis 50 mis 50 mis
Ultrapure H20 420 mis 420 mis 420 mis
1M-HEPES 10 mis 10 mis 10 mis
7.5% (w/v) NaHC03 4.5 mis 4.5 mis 4.5 mis
NEAA(100x)a 10 mis - -
Adjust to pH 7.4-7.5 with lM-NaOH/lM-HCl
a NEAA:- Non-essential amino acids (Gibco Cat.No: 043-1140H).
Preparation o f HEPES
HEPES buffer was made up as a 1M solution in ultrapure H20 .  23.83g of solid are dissolved 
in 80 mis of H20  and then autoclaved. The volume of the solution after sterilisation should be 
95 mis (aprox). 5 mis of sterile 5M-NaOH (BDH Cat.No: 301667), also prepared with ultrapure 
H20  are added to bring the pH to 7.2.
Preparation o f NaHC03
7.5g of solid NaHC03 (Riedel-de-Haen Cat.No: 31437) was dissolved in 100 mis of ultrapure 
H20  and autoclaved before use.
p H  adjustment o f media
lM-NaOH (BDH, Cat.No: 30167) and 1M-HC1 (BDH Cat.No: 28507) were prepared from 
analar stock solutions in ultrapure H20  and sterilised by autoclaving. These solutions were used 
dropwise to adjust the final pH of the media.
2.1.6 Supplements to basal media 
L-Glutamine
A 200 mM L-glutamine solution (Gibco Cat.No: 043-05030H) was added to basal media as a 
1/100 dilution for the preparation of growth media for cell cultures. This amino acid is a 
relatively unstable component of culture media and is therefore stored in 10 ml lots at -20°C  
and thawed before use.
Sodium Pyruvate
Additional carbohydrate sources were added to some basal media. The Krebs cycle precursor 
pyruvate, in its sodium salt form was purchased from Gibco (Cat.No: 043-01360H) and used 
to supplement the growth medium for the cell lines SK-MES-1 and SK-LU-1.
Hydrocortisone
Hydrocortisone (Sigma, Cat.No: H-0135) was prepared by dissolving lm g in 250 ¡A o f absolute 
ethanol and bringing the volume to 25 mis with serum-free basal growth medium 
(DMEM:Ham’sF12). This stock solution at 40 /zg/ml (lOOx) was filter-sterilised and stored at - 
2 0 °C. It was diluted in the growth medium of some squamous cell carcinoma cell lines such 
as SCC-9 to a final concentration of 0.4  ¿ig/ml.
2.1.7 Serum
Serum is a costly, highly variable but essential supplement to the majority of animal cell culture 
media. Batch to batch variability necessitated routine batch testing to select a batch which suited 
the particular cell lines being used, and where possible to achieve this aim with economy. The 
batches selected for use in this work are listed in Table 2.1.7. These were purchased in bulk 
(minimum amount 5 litres) and stored at -20 °C until required for the preparation of growth 
media.
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Table 2.1.7 Serum batches and sources used in this work
SERUM TYPE BATCH N® MANUFACTURER / SUPPLIER
Foetal Calf 801017 Seralabs / P.J. Brennan
Foetal Calf 701113 Seralabs / P.J. Brennan
Newborn Calf 10F6182 Gibco / Medlabs
Foetal Calf 10F Gibco / Medlabs
Foetal Calf AF1201 Advanced ProteinProducts / Medical Supply Co.
2.1.8 Sterility checks
Prior to the preparation of growth medium (i.e. addition of serum and L-glutamine to basal 
medium), all bottles of freshly prepared basal medium were tested for sterility. A portion of the 
aliquot removed for testing was incubated with thioglycollate broth (Oxoid, CM 173) to test for 
anerobic bacteria; another was incubated with Sabourand broth (Oxoid, CM 143) to test for 
fungal contamination; and a the remainder was streaked on blood agar plates (Medlabs) which 
supports the growth of aerobic bacteria and yeast. Another aliquot of medium alone (in a sterile 
universal) was incubated to test for bacterial contamination. All samples for sterility checks 
were incubated at 37°C. Bacterial contamination was normally visible after 3-7 days, but tests 
for yeast or fungal contamination were left for a minimum of 14 days. In practice media were 
only used after they had not manifested signs of contaminants in any of the sterility checks.
2.1.9 Preparation of growth media
Growth medium consisted of a suitable basal medium supplemented with 5-10% serum plus 
2 mM L-glutamine and any other supplements required by the particular cell type. The 
supplements were added to the basal media 2-3 days before they were needed for cell culture 
to allow sufficient time for another sterility check to be performed after supplementation. A  
sample of the growth medium was removed asceptically to a sterile universal for this purpose 
and incubated as described in the Section 2.1.8 above.
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2.2 ROUTINE MAINTENANCE OF ESTABLISHED CELL LINES
2.2.1 Cell lines used in this work
All cell culture work performed here was carried out in Class II vertical recirculating laminar 
flow cabinets. Table 2.2.1.1 contains a list of the human cell lines used in this work.
Table 2.2.1.1 Source and description of Human Cell Lines used and basal media required 
for their in vitro maintenance
CELL LINE Sourcc Description BASAL MEDIUM“
HEp-2 ATCCb (CCL 23) Epidermoid carcinoma of Larynx DMEMrHam’s F12
DLRP This work Poorly differentiated Lung SCC° DMEM:Ham’s F12
DLKP NCTCCd Poorly differentiated Lung SCC DMEM:Ham’s F12
SK-MES-1 ATCC (HTB 58) Lung Squamous cell carcinoma DMEMrHam’s F12e
SK-LU-1 ATCC (HTB 57) Poorly differentiated Lung Adenocarcinoma DMEM.-Ham’s F12c
MRC-5 ATCC (CCL 171) Foetal Lung Fibroblast Cell Line DMEM:Ham’s F12
RPMI-2650 ATCC (CCL 30) SCC of nasal septum MEM
SCC-9 ATCC (CRL 1629) SCC of the tongue DMEM:Ham’s F 12
A-431 ATCC (CRL 1555) Vulval Epidermoid carcinoma DMEM
BAC This work Breast Adenocarcinoma DMEM:Ham’s F12
a Basal medium used here, all supplemented with 10% FCS. b American Tissue Culture Collection, Rockville, MD, 
USA. c Squamous cell carcinoma. d Cell Depository at the National Cell & Tissue Culture Centre, Dublin City 
University. 6 Supplemented with 1 mM Sodium pyruvate.
A  list of rodent cell lines used in this work is given in Table 2 .2 .1.2  below. The rapidly 
proliferating NRK and 3T3 cell lines grew as adherent cultures. The hybridoma cell lines 
attached only loosely without spreading out, retaining a ‘rounded up’ morphology.
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Table 2.2.1.2 Source and description of Rodent Cell Lines used and their basal media 
requirements
CELL LINE Source Description BASAL MEDIUM11 % res*
NRK Ian Pragnallb Normal Rat Kidney Fibroblasts DMEM 5
NIH/3T3 ECACC 85111801 Mouse Embryo Fibroblasts DM EM 10
Ep-16 ATCC (HB 155) Mouse Hybridoma RPMI 1650 15
703D4 ATCC (HB 8301) Mouse Hybridoma DMEM:Ham’F12 10
704A1 ATCC (HB 8302) Mouse Hybridoma DMEM:Ham’F12 20
2 Basal medium and serum concentration used in this work. b At the Beatson Institute for Cancer Research, Glasgow, 
Scotland.
2.2.2 In vitro culture systems
Several types of culture vessels are available commercially. Most are made from polystyrene, 
electrostatically treated to make it negatively charged and wettable and thereby facilitate cell 
attachment. The so-called ‘open’ culture systems are useful in particular applications where 
gaseous exchange is critical, e.g. C 02 exchange for the buffering of certain media pH. This can 
be supplied in special C 02 incubators which provide a positive C 02 pressure and humid 
atmosphere. Covered petri dishes such as the 35 mm size used in soft agar assays (Section 
2.12.3) and the flat-bottomed 24-well (Costar, Cat.No: 3524) and 96-well plates (Costar, 
Cat.No: 3599) are examples o f open culture systems used in this work.
Sealed flat-bottomed flasks were used for routine cell maintenance to reduce the risk of 
contamination associated with open culture systems. 7-10 mis of growth medium was used for 
start-up cultures in 25 cm2 flasks (Cell Cult, Cat.No: 32025) and 20-25 mis for cultures in 75 
cm2 flasks (Costar, Cat.No: 307S) which were employed for general stock maintenance.
The use of glass as a substrate for cells in culture is nowadays restricted to non-static culture 
systems. Examples of these include roller bottles (Bellco) and spinner flasks (Sections 2.7 .2  and
2.7.3 below).
2.2.3 Feeding cultures
Cells in culture metabolise media nutrients and produce waste products such as lactic acid. The 
inclusion of the pH indicator phenol red in basal media provides an indirect means of estimating 
nutrient depletion and pH acidification. Medium was changed before the pH fell below pH 7.2. 
Rapidly proliferating cultures such as HEp-2 required more regular feeding than slower growing 
cell lines such as SCC-9.
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2.2.4 Subculturing
When confluency is reached in monolayer cultures, farther growth of most cell lines is 
restricted either by contact inhibition (e.g. in non-transformed cells) and/or nutrient depletion. 
Some malignantly transformed cell lines derived from carcinomas may continue to grow by 
forming multilayers after confluency. To ensure that a higher number of viable cells are 
recovered, cultures are generally subcultured before they reach confluency (i.e. while they are 
in log phase growth). Suspension cultures (e.g. hybridomas) can be subcultured easily by a 
simple dilution, but adherent cell lines must be detached from their substrata.
Adherent cells were detached from flasks using a 0.25% (w/v) trypsin/0.02% (w/v) EDTA 
solution in PBS-A. Briefly, cell monolayers were rinsed in sterile PBS-A to remove traces of 
serum (which contains trypsin inhibitors) followed by rinsing in a small volume of the 
trypsin/EDTA solution at 4°C (e.g. 2-3 mis per 25 cm2 flask). 2-3 mis of trypsin/EDTA were 
then added and incubated until a single cell suspension was achieved (monitored 
microscopically). The incubation temperature for subculturing (trypsinisation) was either room 
temperature or 37°C, depending on the cell line being used. Cold trypsinisation prevents 
excessive damage to cells by slowing down the rate of proteolysis but pre-warmed trypsin 
and/or incubation at 37°C was employed for cell lines which were more difficult to detach. 
Tapping of the flasks helped to dislodge the monolayers and facilitated the generation of a single 
cell suspension.
The single cell suspensions were removed from the culture flask and transferred asceptically to 
sterile universals. Cells were then pelleted by centrifugation in a bench top centriguge at 800- 
1000 rpm for 4-5 minutes. The supernatnant medium was decanted to a waste bottle, taking care 
not to dislodge the cell pellet which was resuspended in 5 mis of fresh growth medium (pre­
warmed at 37 °C). If a cell count was required, an aliquot of this suspension was removed using 
a sterile pasteur pipette. Subcultured cells were reseeded at the desired concentration. (Note: 
In the maintenance of routinely used cell lines, a specific split ratio was employed for each cell 
line based on experience of their individual growth characterisitics).
Stock Solutions
Crude trypsin (2.5% w/v) was purchased from Gibco (Cat.No: 043-05090) and stored frozen 
at -20°C. PBS-A was purchased (Oxoid, Cat.No: BR12a) in tablet form and dissolved in 
ultrapure H20  (1 tablet per 100 ml) before autoclaving. 1% (w/v) EDTA (Sigma, Cat.No: 
ED2SS) was prepared in ultrapure H20 ,  autoclaved and stored at room temperature.
Preparation o f working stocks o f trypsin/EDTA
Periodically as required, 500 ml lots of 0.25% trypsin/0.02 (w/v) EDTA in PBS-A were 
prepared from stock solutions. For practical purposes these working stocks were dispensed into 
20 ml sterile universals {from S ter il in (Cat. No: 128A) or Greiner (Cat.No: 201175)} and stored 
at 4°C for short-term use (1-4 weeks) or at -20°C for longer storage periods.
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A homogeneous single cell suspension was needed for accurate determination of cell numbers. 
Therefore, before cell numbers were measured, every effort was made to ensure that the cell 
suspension was adequately mixed. A small aliquot (aproximately 50 /¿l) was withdrawn for 
counting using a sterile pasteur or micropipette tip and removed to a Waber haemocytometer 
(improved Neubauer). The suspension was allowed to move into the space between the 
haemocytometer grid and the coverslide by capillary action. Using 40x magnification on the 
inverted microscope the number of cells on each of the four corner squares (subdivided into 16 
smaller squares) was counted. The volume of medium covering each of these squares is 104 ml. 
Cells on either two of the sides of each square ( l x l  mm) were scored and the average value 
for the four counts was calculated and multiplied by 104 to give the cell number per ml.
2.2.5 Counting cell suspensions
2.2.5.1 Determination of viable cell numbers
After the preparation of a single cell suspension, a percentage of the total cell number will 
always be non-viable. Viability of cells cannot be determined absolutely by microscopic 
appearance but the determination of plasma membrane intergity gives a better indication of non- 
viable cells. Exclusion of the dye Trypan Blue (Gibco, Cat. No: 043-05250H) from viable cells 
distinguishes them visibly from cells with damaged or ‘leaky’ membranes which take up the dye 
and stain a dark blue/brown colour.
Counting the total cell number of cells and the number of ‘dead’ or stained cells using the 
haemocytometer as described, above permits the number of viable cells/ml to be calculated. The 
percentage viability after cell manipulations was also be determined in this way. The dye 
solution was added to an aliquot of uniform cell suspension at a ratio of 1:6 (v/v) and left for 
5 minutes before counting. The percentage of viable cells in the suspension was calculated as 
follows;
%  v ia b le  c e l l  n u m b e r  e  'ilftM.Qfl. Numher/ml - Dead Cells/ml x d i lu t i o n  f a c t o «  x ion
Total Cell Number/ml
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2.3 LONG TERM STORAGE OF CELL LINES
Animal cells may be stored long-term at -196°C in a liquid N2 refrigerator. Master stocks were 
generated for all cell lines used in this work. Thawed vials were replaced as soon as possible 
after their successful recovery from liquid N2. Only mycoplasma-free cultures in good condition 
(i.e. harvested in log growth phase) were used for freezing. Vials were labelled indelibly with 
the cell line name, passage number, date of storage, and the operator’s initials and all vials 
removed from the liquid N2 refirgerator were meticulously recorded together with the storage 
loction of vials deposited. Protective visors covering face and neck as well as gloves were used 
during the retrieval and deposition of ampoules in liquid N2. While the percentage recovery 
from frozen stocks varies between different cell lines (being especially low for hybridoma cell 
lines) a number of parameters which contribute to successful freezing and recovery can be 
controlled.
2.3.1 Cell freezing
Cells for freezing were trypsinised and the viability of these single cell suspensions determined 
as described in Section 2.2.5.1 above. Cell suspensions with a minimum concentration of 4 x  
107 viable cells/ml were prepared in growth medium supplemented with 25% FCS. To these 
cell supsensions an equal volume of a 10% (v/v) DMSO (dimethylsulphoxide, Sigma, Cat.No: 
D8386) in growth medium with 25% FCS, was added dropwise while swirling. No more than 
half of the DMSO solution was added in the first minute. After all the DMSO solution was 
added, the cell suspension was transferred asceptically in 1 ml aliquots to cryovials (Greiner, 
Cat.No: 122278). These were sealed and labelled before being placed in the vapour phase 
(at -135°C) of the liquid N2 refrigerator. After 3 hours they were moved to the liquid phase and 
catalogued. Liquid N2 levels in the refrigerator were monitored and replenished regularly.
2.3.2 Cell thawing
The presence of the cryoprotectant DMSO in freezing medium prevents the potentially 
destructive formation of intracellular ice crystals and osmotic effects in cells during freezing. 
However, this agent is highly reactive at room temperature and for this reason must be removed 
as quickly as possible after thawing. The thaw process therefore, should be as rapid as possible. 
Frozen vials were thawed in water at 37°C taking care not to submerge the seal. Ampoules 
were swabbed in 70% IMS and brought into the laminar flow cabinet. Their contents were 
transferred to sterile universals, diluted in 5 mis of pre-warmed growth medium containing 10% 
FCS and then centrifuged at 1000 rpm for 4 minutes. After decanting the supernatant medium, 
the cell pellet was resuspended in 5 mis of growth medium and an aliquot removed to determine 
the percentage viability as described in Section 2.2 .5 .1 . Cultures were set up at high inoculum 
concentrations (106 cells per 25 cm2 flask) in a minimum volume of medium (5 mis per 25 cm2 
flask). Thawed cultures were incubated overnight and refed the following day with fresh 
medium, after inspection for signs of contamination. The same precautions were taken with 
thawing frozen stocks as for the use of live cultures (Section 2.4.3.1).
2.4 CONTAMINATION CONTROL
2.4.1 Microbial
Because of the rich media used, bacterial contamination of animal cell cultures generally 
becomes rapidly obvious due to sudden pH changes and gross cloudiness in the growth medium. 
Vigilant examination of cultures using an inverted microspope (especially before feeding) should 
alert the trained observer to lower levels of contamination. Evidence of cryptic bacterial 
contamination include ‘motile grains’ or clusters of dark debris-like material. Other forms of 
microbial contamination including yeast and fungus are usually slower to appear and may be 
more difficult to detect due to their slower growth rates. Such contaminants may go undetected 
for long periods, especially if the culture is being refed or subcultured frequently. Yeast are 
characterised by their distinctive ‘budding’ morphology and are often seen in ‘chains’ of such 
‘budding’ cells. Fungal species are more diverse but become visible macroscopically after 
sporulation when they produce dendritic-like structures.
Good asceptic technique, thorough sterility checks and working in a class II vertical laminar 
flow cabinet minimise such contamination incidents. However in this work, when contamination 
was detected the cultures in question were discarded unopened and autoclaved. All media and 
solutions that had come in contact with these cultures were re-screened for sterility and 
discarded if  positive. Fresh sterile stocks of all solutions were used if master stocks were 
thawed from frozen stocks.
2.4.1.1 Use of antibiotics
The use of antibiotics was restricted in this work to bioassays and primary cell culture. 
Antibiotics used in bioassays were penicillin/streptomycin (Gibco, Cat.No: 043-05140) or 
gentamicin (Gibco, Cat.No: 043-0570D). General prophylactic use of antibiotics was avoided 
in cell line maintenance because this practice can mask the presence of cryptic contamination 
and lead to the evolution of more virulent antibiotic resistant strains. In general the presence of 
microbial contamination almost certainly indicates co-infection with mycoplasma (Section 2.4.2).
In the case of primary cell cultures, the use of antibiotics and other antimicrobial agents is 
recommended because absolute sterility cannot be assured. This is due to the nature of the 
sample collection process. Every effort was made to prevent contamination of primary tissues 
in this work, but the possibility of endemic levels of bacteria or yeast etc. in some samples 
could not be excluded. For this reason, all primary tissue samples were collected in a transport 
medium which contained a cocktail of antibiotics and anti-fungal agents.
2.4.1.2 Anti-fungal agents
The anti-fungal agent amphotericin B was purchased commercilly as fungizone (Gibco 
Cat.No: 043-05290D). It was included at a concentration of 250 ¿ig/ml in ‘transport’ medium 
for the carriage of primary tissue cultures from the hospital theatre to the laboratory. Fungizone 
is active against fungus and yeast, but it also has a cytostatic effect on mammalian cells and for 
this reason its use even in primary cultures was avoided where possible.
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2.4.2 Mycoplasma
Unlike other forms of microbial contamination, mycoplasma are not visible microscopically 
even at high-powered magnification under the inverted microscope. Although mycoplasma- 
infected cultures may continue to grow without any obvious effects, decreased proliferation 
rates, rapid changes in medium pH after feeding, changes in cell morphology and granulation 
of the cytoplasm are all indicative of this type of contamination. Despite the often benign effects 
of this insidious contaminant, the validity of studies using cultures harbouring mycoplasma must 
be suspect, if  not invalid.
Sources of mycoplasma infection include primary tissue material, animal sera, media, trypsin 
and the operator. They are difficult to remove due to their small size (typically <  0.1/xm long) 
and plasticity (they lack a cell wall), but double filtration through a 0.1 /xm filter is 
recommended for this purpose. Given the many possible sources of infection, such a procedure 
is not a practical proposition. Instead, cell lines used in this work (as in other laboratories) were 
regularly screened for the presence of mycoplasma during in vitro maintenance and before the 
preparation of frozen cell stocks.
2.4.2.1 Detection of mycoplasma
An ‘indirect’ test based on the method of Chen (1977) was used in this work to detect 
mycoplasma contamination. This procedure employs a bisbenzimidazole fluorochrome stain 
(Hoeschst 33258) for DNA. Mycoplasma DNA appears as particulate or fibrillar fluorescent 
staining in the cytoplasm of infected cells. In heavily infected cultures, this may be localised 
at the plasma membrane and intracellular spaces. Only nuclear staining is apparent in uninfected 
cells.
To avoid the problems of interpretation associated with ‘direct’ staining of suspect cultures 
(arising from the different growth kinetics, spreading patterns, and fragility of nuclear 
membranes of some cell lines to the fixation process) a mycoplasma-free rodent cell line, NRK 
was used as an ‘indirect indicator’ cell line. Low passage NRK can be infected with 
mycoplasma derived from the spent medium of contaminated cells and many such tests can be 
carried out in the same cellular background, thereby facilitating comparative staining. It is 
important that growth medium from suspect cultures has been in contact with the respective 
cells for at least 3 days and is free from antimycoplasma agents before testing (to avoid false 
negative results).
Method:
Preparation o f indicator NRK monolayers
22 mm2 coverslips (Chance N21) were pretreated by washing in 2% RBS followed by rinsing in 
ultrapure H20 ,  and then in 70% IMS (Industrial Methylated Spirits, Lennox, Cat.No: 1170). 
They were dried in lint-free cloth and then autoclaved in a glass petri-dish.
The sterile coverslips were then asceptically transferred to individual 30 mm sterile petri dishes 
(non-tissue culture grade). 1 ml of low passage mycoplasma-free NRK cells at 5 x 102 cells/ml 
were seeded in DMEM -I- 5% FCS on each dish and these were incubated in a 5% C 02 
atmosphere at 37 °C overnight.
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After removal of the overnight growth medium, 1 ml of antibiotic-free spent growth medium 
from suspect cultures was addded to duplicate dishes. A control in the form of fresh growth 
medium (DMEM + 5 %  FCS) was set up on duplicate wells.It is important that cultures do not 
become confluent because the cells do not spread sufficiently in this case for adequate staining 
with Hoechst 33258. Cells were allowed to reach 20-50% confluency before they were fixed 
and stained. This took 3-4 days approximately.
Fixing, Staining and Mounting
After the removal of growth medium, cells on the coverslips were rinsed twice in PBS, followed 
by a single rinse in a 1:1 dilution of cold Carnoy’s reagent (Glacial Acetic acid:Methanol, 1:3 
v/v). Glacial acetic acid (BDH, Cat.No: 27013) and methanol (BDH, Cat.No: 10158) were both 
purchased from BDH}. The cells were then fixed in 2 mis of Carnoy’s reagent for 10 minutes. 
It is important that the cells are well covered and not allowed to dry out before fixing as this 
may induce artifacts.
After removal of fixative the coverslips were air-dried and washed twice with ultrapure HzO and 
then stained with 2 mis of a 50 ng/ml solution of Hoeschst 33258 (Sigma, Cat.No: B2883) in 
PBS for 10 minutes. The Hoechst 33258 stain is sensitive to light and heat. For this reason, 
staining was carried out in the dark (under aluminium foil).[It was also stored wrapped in 
aluminium foil at 4°C as a lOOOx concentrate (50 /¿g/ml) and diluted on the day as required].
The stain was aspirated and excess liquid removed by rinsing three times in ultrapure H20 .  The 
coverslips were mounted on a microscope slide in a drop of glycerol mounting medium (50% 
v/v glycerol (Sigma, Cat.No: G5516) in 0.044 N citrate, 0.111M  phosphate at pH 5.5). The 
cells were first examined under the phase contrast condenser of the fluorescent microscope at 
40x to check for cellular integrity before being examined under oil immersion at lOOx using the 
fluorescence filters {a 50 barrier filter LP 440 nm, and a BG12 exciter 330/380 should be 
used}. The absence of extranuclear fluorescence in the controls was confirmed before any 
staining patterns in the test samples could be verified.
Positive identification of mycoplasma contamination was followed by disposal of those stocks 
and the cleaning and fumigation of incubators and laminar flow cabinets used for their 
manipulation. In the case of unique primary cell lines, mycoplasma contamination was treated 
with a mycoplasma removal regime purchased in kit form. Contaminated cultures and associated 
solutions were quarantined from all other routine cell culture work (using separate primary 
culture facilities).
2.4.2.2 Elimination of mycoplasma
A two-solution antibiotic kit called BM-Cycline was purchased from Boehringer Mannheim 
(Cat.No: 799050). According to the suppliers this combination of antibiotics is effective against 
25 mycoplasma species, bacteria and Candida.
250x stocks of BM-Cycline solutions 1 & 2 were made by dissolving the powdered sample in 
10 ml steile PBS. To ensure sterility, the PBS was injected through the rubber cap as instructed 
by the manufacturers. This procedure was performed in a laminar flow cabinet and 100 ¡A lots 
of the respective solutions were aliquoted into sterile eppendorfs and stored at -20°C until 
required for use. These antibiotics are stable to repeated freezing and thawing for at least 12 
months.
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Treatment Protcol:
Three cycles of exposure to BM-Cycline 1 and 2 solutions in tandem were employed. In each 
case 40 fx 1 of the stock solution was added to cells in 10 ml of growth medium in a 25 cm2 flask 
( =  1/250 dilution). Solution 1 was added on Day 1 and this was incubated without a change 
of medium for three days. On Day 4 the medium was removed as completely as possible and 
10 ml of BM-Cycline 2 containing medium added. After 4 days in the second solution, the cycle 
was repeated( on Day 8). Cell cultures treated with two such cycles of BM-Cycline containing 
medium were removed and rinsed with sterile PBS before being returned to antibiotic-free 
medium. An aliquot of the culture medium from treated cultures was removed for mycoplasma 
analysis after one medium change in antibiotic-free growth medium. Clean cultures were 
exposed to a third cycle of BM-Cycline treatment before they were used for experiments. 
Cultures which remained mycoplasma positive after two cycles were exposed to further cycles 
of BM-Cycline treatment until they were clear, and an extra cycle was then employed before 
they were used for experiments.
As with the use of other antibiotics, the continuous use of BM-Cycline was not employed in 
these studies. Similarly the simultaneous use of BM-Cycline solutions 1 & 2 was avoided on 
the manufacturer’s advise.
Other Anti-mycoplasma agents used
Two other antimycoplasma agents used in this work were tylocine (Anti-PPLO agent, Gibco, 
Cat.No: 043-05220) purchased as a lOOx liquid concentrate (6000 /xg/ml) and gentamicin 
(Gibco, Cat.No: 043-0570D) also purchased as a lOOx concentrate (50000 /xg/ml).
2.4.3 Cross-contamination by other cell lines
The inadvertant mixing or cross-contamination of different cell lines is a relatively rare but 
nonetheless likely risk in the culture of animal cells. Judging from the presence of marker 
chromosomes for HeLa (one of the first human carcinoma cell lines established) in many of the 
other cell lines derived during this period, this constitutes a real risk unless proper vigilence is 
maintained in separating different lines. Cross-contamination occurs due to human error. An 
obvious inference from this is that an increase in the number of cell lines being handled by any 
one operator and/or laboratory where facilities are shared, increases the potential for this form 
of error. Cross-contamination between two animal cell lines may not always be immediately 
obvious. A number of changes in culture properties should alert the experienced cell biologist 
to the possiblity of this event. Changes in growth rates and morphology in particular lines, with 
perhaps the associated loss of a particular differentiated function may all result from a cross­
contamination event.
Traditionally cell line integrity was assessed using isoenzyme analysis and the cytogenetic 
analysis of marker chromosomes. More recently the advent of DNA fingerprinting technology 
has provided a more rapid and unequivocol method for the validation of unique cell lines. This 
method was employed in the characterisation of new cell lines derived from human primary 
tissues in this laboratory. Certified cell lines purchased from Cell Depositories such as the 
American Tissue Culture Collection (ATCC) were expanded immediately after receipt to 
prepare master stocks of the particular cell line. Enough vials were frozen to ensure a 
continuous back-up during the anticipated period of use. Master stocks were deposited in liquid 
N2 as described in Section 2.3.1 above.
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2.4.3.1 Procedures employed to avoid cross-cell line contamination
In order to minimise the possibility of cross-cell line contamination the following guidelines
were incorporated into standard operating procedures used in this lab.
1. Cultures were clearly labelled and indexed in a catalogue before freezing and after thawing 
from liquid N2 storage. Dubiously labelled or illegibly labelled vials were discarded.
2. Separate labelled growth media, trypsin, waste bottles and any other solutions coming into 
contact with cells were used for each cell line.
3. No more than one cell line was handelled in the laminar flow cabinet at any one time. 
After removal of aH materials, the cabinet was swabbed with 70% IMS (Industrial 
methylated spirits) and left for 15 minutes before being used again.
4. Disposable pipettes which came into contact with cell suspensions or with culture 
supernatants were discarded immediately after use (avoiding the temptation to re-use the 
same pipette to feed another flask of the same cell line and risk introducing cells into the 
stock growth media).
5. Clear labelling of aU cell-containing universals before removal from laminar flow cabinet 
for centrifugation and discarding of used and unlabelled universals.
6 . Culture flasks were labelled with the name of the cell line and incubated in discrete 
positions in incubators. Markings were checked before and after manipulations.
7. Preparation of stock media and other solutions in the laminar flow cabinet were performed 
only after a 15 minute quarantine, as for other sterile procedures in the hood.
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2.5 PRIMARY CELL CULTURE TECHNIQUES
2.5.1 Collection of tumour tissue samples and transportation medium
Primary tissue was collected in theatre directly after surgical resection at St Vincents Hospital, 
Elm Park, Stillorgan, Dublin 4. This material was kindly provided by thorasic surgeon 
Mr. Vincent Lynch only after the requirements of the hospital’s histopathology service for such 
tissue had been met. Tissue samples were placed in a transportation medium immediately and 
placed on ice or at 4°C until they were taken to DCU for processing on the same day.
Transportation Medium:
This consisted of a 1:1 DMEM/Ham’s F12 basal medium supplemented with 20% FCS, 2 mM 
L-glutamine and containing 500 U/ml penicillin and 0.5 mg/ml streptomycin {diluted from a 
combination stock of both antibiotics (called P/S) at 100x} and 500 /xg/ml fungizone.
2.5.2 Dissection of tumour tissue
Samples were rinsed in PBS (2-3 times) to remove blood cells before dissection. Fatty deposits, 
necrotic tissue and blood vessels were removed where possible using sterile surgical scalples. 
Care was taken to avoid tearing of the tissue as this may trigger fibroblast proliferation. These 
manipulations were performed on sterile petri dishes (100 mm Greiner, Cat.No: 633171) in 
sterile PBS.
2.5.3 Mechanical disaggregation
The tissue remaining after removal of the unwanted components was sliced into the smallest 
sized pieces possible (typically in the order of 1 mm3). These manipulations were performed in 
10 mis of growth medium (plus 2% P/S) on a fresh sterile petri dish. Cells which had spilled 
into the medium during disaggregation were recovered by aspirating the medium and pelleting 
the suspension in a sterile universal (5-10 minutes at 1000 rpm). This fraction of the tissue was 
called ‘Disection Medium’ (DM) and in some cases the cell pellet showed signs of erythrocyte 
contamination. Such pellets were resuspended in growth medium and separated on a Ficoll 
gradient (Section 2.5.6) to remove blood cells. Other DM fractions were plated directly after 
resuspension in growth medium.
Some of the tissue fragments produced by mechanical disaggregation were used to set up 
explant cultures, but the bulk of the sample was incubated with proteolytic enzymes in an effort 
to release more cells from the tissue matrix.
2.5.4 Explant technique
Small tissue fragments ( ~  1mm3) with clean (straight) edges were asceptically transferred to 
the growth surface of 25 cm2 flasks which had beenpre-wetted with 2.5 mis of growth medium 
and allowed to stand upright. 15-20 such fragments were added per flask using either the tip 
of the scalpel blade or a sterile needle. They were allowed to adhere in this position for 
approximately 30 minutes with the lids loosened slightly. A further 2.5 mis of medium was then 
added, taking care not to dislodge the explants, and the flasks were incubated at 37°C.
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A  200 U/ml solution of type V collagenase (Sigma, Cat.No: C9263) in sterile PBS was used 
alone or in combination with a 0.2% (w/v) dispase (neutral protease, Boehringer Mannheim, 
Cat.No: 165-859)) to digest the extracellular matrices of tumour tissue. The tissue was 
incubated while stirring with a sterile magnetic stirrer at 37 °C in flat-bottomed 60 ml universals 
(Sterilin, Cat.No: 125AP). Periodically (every 30 minutes at most) small aliquots of the 
supernatant were removed to a 35 mm petri dish and examined under the inverted microscope 
for release of single cells and/or cell aggregates. When sufficient numbers of cells appeared in 
the supernatant, the incubation mixture was allowed to settle by gravity. Large pieces of tissue 
and cell clumps were separated from the smaller single cells and aggregates in solution by 
decanting the supernatant into a sterile universal, leaving the last 1-2 mis behind. Cells released 
in this way were recovered by centrifugation at 1000 rpm for 5 minutes, resuspended in fresh 
growth medium (prewarmed to 37°C) and then plated at high density (at least 105 cells per 25 
cm2 flask). The enzyme solution remaining after recovery of cells was returned to the 
undigested tissue in the flat-bottomed universal. Further quantities of cells were liberated from 
the matrix up to three hours after the start of enzyme treatment but the viability and yields in 
these fractions decreased with time.
2.5.5 Enzymatic disaggregation
2.5.6 Ficoll density gradient
Blood cells in tumour cell suspensions were removed by density gradient centrifugation using 
Ficoll (Pharmacia, Cat.No: ). Tumour cells suspended in 5 mis of growth medium were layered 
carefully, using a sterile pasteur pipette, on top of 10 mis of Ficoll in a sterile universal. 
Without disturbing the interface which forms between the two solutions, the universal was spun 
at 3500 rpm for 10 minutes. After centrifugation and careful removal of the universal, the layer 
of cells which had formed at the interface (‘buffy layer’) was recovered by aspiration using a 
sterile pasteur pipetted (blood cells should be visible in a pellet at the bottom of the universal). 
5 mis of growth medium was added to the buffy layer and the cells were pelleted by 
centrifugation as before. A further round of Ficoll treatment was performed if  the recovered 
pellet still showed signs of blood cell contamination after the initial treatment.
2.5.7 Harvesting cells from malignant effusions
Malignant effusions were centrifuged at 2000-3000 rpm in 50 ml sterile universals at 4°C to 
pellet cells in suspension. In many cases the cell pellets recovered were heavily blood stained. 
Blood cells were removed as described in the Section 2 .5 .6  above.
2.5.8 Fibroblast elimination
2.5.8.1 Selective trypsinisation of fibroblasts and epithelial cells
The progress of trypsinisation in primary cultures was monitored continuously under 40x and 
lOOx magnification using an inverted microscope. The procedure was terminated by the addition 
of growth medium as soon as the majority of either fibroblasts or epithelial cells appeared to 
have detached. Unnecessary agitation of the flasks was avoided until the detached cells had been 
removed by aspiration of the medium. The different compositions of trypsin/EDTA and the 
protcols used here are described in more detail in Section 3.1 .5 .1 .
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2.5.8.2 Selective toxicity of fibroblasts to G418 sulphate
Geneticin (G418 sulphate) was purchased from Gibco (Cat.No:066-1811). A lOOx stock solution 
(lOmg/ml) was prepared in complete medium. Mixed fibroblast/epithelial cultures were treated 
with 100 /xg/ml G418 in complete medium. After 6 days without medium change, the agent was 
removed and the cultures returned to normal growth medium.
2.5.9 3T3 feeder layers
NIH3T3 cells were set up in 25 cm2 flasks at 2.3 X 10s cells/flask. The cells were exposed to 
Mitomycin C (Sigma, Cat.No: M0503) for 3 hours at a concentration of 4 /xg/ml in growth 
medium (prepared fresh from a 200 /xg/ml stock solution in PBS stored at -20°C in the dark). 
After treatment, the Mitomycin C-containing medium was completely removed and cultures 
were washed with 10 mis of sterile PBS (x2) and refed in fresh growth medium. On the next 
day they were examined for signs of growth and growth-arrested cultures were seeded with 
primary cultures of tumour cells at a minimum concentration of 106 cells per flask.
2.5.10 Collagen coating of tissue culture flasks
Collagen type III (from rat tail) was used to coat 25 cm2 flasks for primary cultures of tumour 
cells. A 100 /xg/ml solution was made up in PBS and filter-sterilised before use. 2 mis was 
added to each flask for coating and after all the growth surface had been wetted, they were left 
for 30-40 minutes before the solution was removed. The flasks were allowed to dry, with lids 
slightly loosened, in the laminar flow cabinet. Dry coated flasks were stored at room 
temperature with lids sealed until required for use.
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2.6 CELL LINE CHARACTERISATION
2.6.1 Immunohistochemical identification
Antibodies directed against differentiation-specific antigens can be used to discriminate between 
different cell types and lineages and different species. Binding of specific ‘primary’ antibodies 
raised in one species (e.g. rabbit) can be visualised indirectly by the use of a second antibody 
raised against antibody types of the primary antibody species. Labelling of the secondary 
antibody avoids the need to label the primary antibodies and provides even more specific 
staining patterns by minimising non-specific binding. Commonly used labels which are 
conjugated to the secondary antibody include enzymes with chromogenic substrates (e.g. 
alkaline phosphatase) and fluorescent dyes. A secondary antibody labelled with the fluorescent 
dye, fluorescein thiocyanate (FITC) was employed in this work.
2.6.1.1 Preparation of slides
Eight-well H.T.C. blue autoclavable 6 mm slides were used for mounting adherent cells. These 
were sterilised by autoclaving in glass petri-dishes. Individual slides were transferred 
asceptically to sterile plastic petri-dishes before seeding with cells. These slides were re-usable 
i f  soaked in 5% (v/v) RBS for 1-2 hours followed by rinsing in distilled water for 10 minutes. 
Such slides were stored in methanol at 4°C until required and then sterilised by passage through 
a bunsen flame or by autoclaving.
20 n 1 of cells at a concentration of 105 cells/ml in complete medium were seeded per w ell using 
a micropipette with sterile tips and the slides were incubated at 37 °C in a covered perti dish for 
24 hours in humidified, 5 % C 02 atmosphere. Non-adherent cells were mounted on non-sterile 
Gold star microslides at a concentration of 105 cells/ml in PBS and air-dried on the day of 
analysis.
Slides were washed (x 3 )  in PBS and excess solution removed using filter paper. Care was 
taken not to remove the cell monolayer. The cellular location of the target antigen dictated the 
fixation method used.
2.6.1.2 Surface epithelium specific antibody
The antigen recognised by the Ep-16 IgM/c monoclonal antibody is present on the plasma 
membrane of cells which express it. The procdure employed to fix cells for analysis with an 
antibody directed against as surface antigen was as follows. A 5 minute soak in 3% (v/v) 
formalin (BDH, 101113) at room temperature followed by 5 minutes in acetone (BDH, Cat.No: 
27023) at -20°C. The slides were then air dried and 20 /zl of EP16 antibody (in the form of Ep- 
16 CM) was added to all but one of the eight wells. The eighth well was left to act as a control 
for non-specific binding with the labelled secondary antibody. The slides were incubated with 
the primary antibody in a humid environment for 1 hour at 37°C.
2.6.1.3 Anti-cytokeratin antibody
Anti-cytokeratin Nfi18 (Bohreingher Mannheim, Cat. No: 814-385) recognises an intracellular 
protein expressed in epithelial but not fibroblast cell types. The fixation procedure employed
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for analysis of intracellular antigens was as follows. Slides were placed in methonal (BDH, 
Cat.No: 10158) at -20°C for 7 minutes followed by 2 minutes in acetone at -20°C. To all but 
one of the eight wells, 20 ¡x 1 of a l^g/ml solution of anti-cytokeration antibody was added and 
incubated for 1 hour in a humid environment at 37 °C. The remaining well served as a control 
for non-specific binding with the second antibody as above.
2.6.1.4 Non-small cell lung carcinoma specific antibody
Two murine IgG2A/c monoclonal antibodies 703D4 and 704A1, raised against a human large 
cell lung cancer line (NCI-H157) are secreted by hybridomas produced by Mulshine et al., 
(1983). 703D4 and 704A1 were obtained from the ATCC. The antibodies were reactive against 
non-small cell lung carcinomas but not small cell carcinomas. Their staining pattern suggested 
that the epitopes they recognised were associated with cytoskeletal elements. The cells for this 
analysis therefore were fixed as for the anti-cytokeratin antigen above. CM was used as a source 
of the antibodies and 20 /xl of the relevant CM was added to all but one of the eight wells on 
each slide and they were incubated for 1 hour at 37 °C as described above.
2.1.6.5 Visualisation of primary antibody binding pattern with an FITC-labelled 
second antibody
After the 1 hour incubation unbound primary antibody was removed by three 10 minute 
washings in PBS. The binding pattern was visualised by the addition of 20 ¡il to all wells of an 
FITC-labelled goat anti-mouse antibody IgM (Sigma F9259) used at a dilution of 1/30, The 
second antibody was incubated in the dark for 1 hour in a humid environment followed by three 
10 minute washes in PBS under darkness. Slides were then mounted in a 9:1 glycerol:PBS 
mixture and the coverslips sealed with clear nail varnish. The staining patterns were viewed and 
photographed in the dark using a Nikon fluorescent microscope. An oil immersion lens was 
used for higher resolution.
2.6.2 Preparation for shipment of cell lines and tumour biopsy samples for DNA 
fingerprint analysis
Cell lines for DNA fingerprint analysis were shipped to Cellmark Diagnostics (ICI, Abingdon, 
U.K.) as live cultures. One confluent 75 cm2 flask provided sufficient DNA for analysis. 
Cultures were left in the incubator until just before shippment. Flasks were completely filled 
with growth medium plus antibiotics and lids sealed with parafilm before being packed in sturdy 
boxes with adequate shock absorbant insulating material. An overnight express delivery service 
was used. Frozen tissue was sent on dry ice in cryovials (Greiner, Cat.No: 122278).
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2.7 COLLECTION OF CONDITIONED MEDIUM (CM)
Serum-free basal medium used for the preparation of conditioned medium (CM) was checked 
for sterility before use as described in the preparation of growth medium. Antibiotics were not 
used in order to avoid cryptic contamination. The basal medium was supplemented with 2 mM 
L-glutamine just before the collection commenced.
2.7.1 75 cm2 flasks
For the preparation of small volumes (< 1 0 0  mis) of CM, cultures were grown to 70-80% 
confluency in 75 cm2 flasks. Growth medium was removed and cell monolayers washed twice 
with 20 ml lots of sterile PBS followed by a 30 minute incubation in 20 mis of PBS. 20 mis of 
serum-free basal medium was used for conditioning, and this was replaced every 24 hours with 
fresh medium. CM was centrifuged in sterile universals at 5000 RPM for 10 minutes at 4°C  
to remove cell debris. The clarified CM was stored at 4°C (or at -20°C) until required.
2.7.2 Roller bottle culture
Bellco glass roller bottles with an internal surface area of 670 cm2 were routinely used for the 
collection of larger volumes of CM (>  100 mis). Bottles were washed as described for media 
bottles and autoclaved with the lids slightly ajar. Cells were seeded in prewarmed bottles to 
prevent cell clumping. 100 ml aliquots of growth medium were used per roller bottle. Inoculum 
concentrations of single cells depended on the growth properties of the cells being used. HEp-2 
cells could be set up at 1 X 107 cells (approximately 1 confluent 75 cm2 flask, but in practice 
2 subconfluent 75 cm2 flasks were used). In general, higher inocula were needed for cell lines 
with longer doubling times (typically a minimum equivalent of 2-3 confluent flasks were used 
for such cell lines). Bottles were rotated for 24 hours initially at a speed of 0.25 rpm 
(revolutions per minute) on a roller bottle apparatus. After this time (or after the cells had 
attached) the rotation speed was increased to 0.75 rpm.
Cultures were grown to 70-80% subconfluency (as judged by microscopic observation) with 
regular feeding. Before CM collection was initiated, the growth medium was entirely removed 
and the cell monolayer was washed with 2 x  100 mis of sterile PBS followed by a final 30 
minute incubation, also in 100 mis of sterile PBS. 100 mis of serum-free basal medium 
supplemented with 2 mM L-glutamine was used for each collection of CM. The first 24 hour 
collection was discarded to avoid carry over of serum-derived proteins, but subsequent lots of 
CM were collected at regular intervals thereafter (24-48 hours) until the cultures showed signs 
of deterioration (i.e. detachment). CM lots were centrifuged as described in Section 2.7.1 and 
stored at 4°C (or at -20°C) before processing for assay.
2.7.3 Suspension cultures
HEp-2 were grown in suspension culture for CM collection. The 250 ml and 500 ml spinner 
flasks used for this purpose were supplied by Techne (Cambridge, U.K .). Pre-warmed growth 
medium was added to the flasks while the single cell suspension was being prepared. Inocula 
of 50 mis and 100 mis were started in the 250 and 500 ml vessels respectively at a density of 
1 x  105 cells/ml. The spinner flasks were incubated at 37°C with continuous stirring at 20 rpm 
initially for a 100 ml culture.
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Suspension cultures were monitered for cell growth by periodically removing an aliquot of the 
cells in suspension. When these cultures had reached a density of 4 X 105 cells/ml (day 3) the 
agitation was increased to 30 rpm. When the culture density reached 8.5 x 10s cells/ml, cells 
were removed from suspension by centriiugation at 1000 rpm for 10 minutes in sterile 50 ml 
universals (Elkay, Cat.No:2094-STR). The cell pellets were washed twice by resuspension and 
centriiugation in sterile PBS and were finally set up in serum-free Ham’s F12 plus 2 mM L- 
glutamine and stirred at 40 rpm during the conditioning process. CM was collected by 
centrifugation of the suspension cultures.
2.7.4 Cell factory system for very large scale CM production
This system has some advantages over the roller bottle and spinner systems for collecting large 
volumes of CM from adherent cells. There is less physical stress to cells in this static system, 
a factor which may influence the growth factor productivity of such cultures. Manipulation of 
large cell numbers is greatly facilitated by the increased growth surface area in a single vessel 
and unlike roller and suspension cultures, no specilised mechanical equipment is required with 
this system.
A ten-tier Nunc Cell Factory system was used for ‘litre volume scale’ production of CM. Each 
pre-sterilised unit consists of ten 335 x 205 mm polystyrene trays (total surface area 600 cm2 
per tray). The compartments formed by the stacked trays are interconnected via two openings 
into vertical channels at opposite corners of one end of the trays. The design is such that, with 
the liquid connection in one position, an equal volume of medium or cell suspension w ill fill 
each compartment. The vertical channels terminate in two adaptor caps which allowed for the 
insertion of a bacterial airfilter (Gelman Cat.No:4210) and a Nunc tube connector (Cat.No: 
171838) respectively. Media and cell suspensions were added through the latter from an 
aspirator bottle mounted with sterile tubing, tube connector and clamp. {Note: All the 
accessories such as filters, adaptor, caps, tube-connector, silicone tube, and clamp can be 
purchased as a ‘Start-up kit’ from Nunc (Cat.No: 170769)}.
Filling and emptying the unit through the inlet is achieved by raising the aspirator bottle to 
approximately lm  above the Cell Factory or vice versa. Care must be taken to ensure adequate 
distribution of cells during the inocculation procedure by mixing the cell suspension well 
beforehand. All these procedures were performed in a laminar flow cabinet. The inlet can be 
sealed with a cap or attached to a C 02 supply if gassing is required during incubation and the 
entire unit can be housed in a regular 37 °C warm room.
HEp-2 cells were loaded at a density of 5 x 107ml in 1.5 litres of growth medium. After 7 
days the medium was removed and the subconfluent monolayers were washed with 1 litre of 
sterile PBS (prewarmed to 37°C) followed by a 30 minute incubation in the same. 1.5 litres of 
serum-free Ham’s F12 (supplemented with 2 mM L-glutamine) was added. After two days the 
CM was removed asceptically and replaced with fresh serum-free medium. CM was centrifuged 
and stored as described in Section 2.7.1 above.
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2.8 PROCESSING OF CM
CM was stored in sterile glass bottles (or plastic universals for small quantities) at 4°C. In 
general, lots of CM were stored for up to 6 months under these conditions without appreciable 
loss of growth-promoting activity (i.e. HEp-2 autocrine activity). CM fractionated by 
ultrafiltration or column chromatography was only stored at 4°C for short periods (1-4 weeks) 
depending on the degree of separation (purification). In general such samples were stored at - 
20°C.
2.8.1 Ultrafiltration
Ultrafiltration was used to concentrate and fractionate the CM collected. A stirred cell apparatus 
(Amicon, Cat.No: 8499) was employed for this purpose. This apparatus consisted of a chamber 
with a 400 ml volume capacity which contained a magnetic stirring bar. CM was filtered under 
a N2 pressure head, through one of a series of membranes with a variety of molecular weight 
(MW) cut-off points (Amicon or Millipore). To avoid the build up of a hydrated gel layer at 
the surface of the membrane, CM in the chamber was stirred during filtration by placing the 
ultrafiltration unit on a magnetic stirring apparatus. Molecules in the CM with a molecular 
weight above the nominal cut-off point for the membrane used were concentrated by being 
retained in solution while the overall solution volume was reduced by filtration. Such a 
concentrate was called a retentate. Ultrafiltration was always performed at 4°C.
2.8.1.1 Fractionation of CM by ultrafiltration
By taking advantage of membranes with different MW cut-off points it was possible to generate 
CM retentâtes that contained molecules within defined (approximately) molecular weight ranges. 
This was achieved by taking the filtrate produced by passage through one membrane and 
subsequently filtering it through a second membrane with a lower MW cut-off point. The 
following is a list of the different membranes used in this work together with their nominal MW 
cut-off points and the designation of the retentâtes and filtrates produced using these 
membranes.
Amicon Membrane Nominal MW cut-off Retentate & Filtrate Designations
YM 30 30,000 daltons R 30&  F30
YM !0 10,000 daltons RIO & F10
YM 5 5,000 daltons R5 & F5
YM 1 1.000 daltons R1 & FI
Using the same lot of CM, filtration of the F30 through the YM 10 membrane produced a 
retentate with molecular species >  10 kDa but <  30 kDa. This retentate was designated R10-30 
and the filtrate from this process was designated F10(F30). Similarly, CM was separated into 
fractions with MWs between 1 and 5 kDa, 5 and 10 kDa and 10 and 30 kDa were designated 
R l-5, R5-10 and R.10-30 respectively. All concentrated and/or fractionated CM samples were 
filter-sterilised immediately using a low protein binding 0.22 /xm filter (Millex-GV).
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2.8.2 Dialysis
Concentrated CM and fractions from column chromatography were dialysed against 50 volumes 
of PBS or double distilled H20  followed by 25 volumes of serum-free medium (Ham’s F I2) 
using either (benzoylated) 1,200 MW cut-off (Sigma, Cat.No: D7884) or 10,000 MW (visking) 
dialysis tubing. Dialysis was performed at 4°C with two changes of buffer daily.
Dialysis tubing needed to be pretreated before dialysis to remove toxic residues (resulting from 
the manufacturing process and/or present in the storage solution). For this reason the tubing was 
soaked in ultrapure H20  and then boiled in 10 mM EDTA for 5-10 minutes. It was then washed 
several times in distilled H20  and allowed to soak overnight in ultrapure H20 . It was rinsed 
again several times in ultrapure H20  before use.
2.8.3 Lyophilisation
Samples for lyophilisation in open vessels were covered in parafilm which was pierced many 
times using a fine a needle. They were then place in a Consol 4.5 freeze-drier (Virtis Comp Inc, 
Gardiner, HY, USA) and frozen to - 40°C overnight. The following day the condenser was 
switched on and the refrigeration unit was switched off. When the condensor had reached -50 °C 
(10-20 mins) the vacuum was switched on and the air evacuated from the chamber. The 
pressure in the chanmber reached 50 miliTorr within 1 hour if the samples were sufficiently 
frozen. After all the liquid had evaporated, the vacuum was released slowly and the samples 
retrieved and sealed immediately to avoid absorption of moisture from the atmosphere.
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2.9 PHYSICOCHEMICAL TREATMENT OF CM
A  series of physicochemical treatments were performed on crude (unprocessed) and fractionated 
CM (from HEp-2) in an attempt to characterise the active growth stimulator(s) therein. A  
combination of the treatments described below was performed for some experiments.
2.9.1 Temperature treatment
CM and control medium for heat treatments were transferred in aliquots of 10 mis to clean 
sterile glass universals (30 mis). A water bath set to 6 5 °C was used for heat treatment at this 
temperature and the universals were sealed during the incubation periods which lasted 10, 20, 
30, and 60 minutes. Treatment by boiling was performed by placing the opened universals into 
a beaker of boiling water over a bunsen flame. A thermometer placed in a control universal was 
used to monitor the rise in temperature to 100°C, and the treatment time began at that point. 
Boiled samples were centrifuged at 3,000 rpm for 15 minutes to remove insoluble precipitate 
and the samples were filter-sterilised after cooling.
2.9.2 Adjustment of CM pH
The pH of CM and control medium was adjusted and exposed to acid and alkaline pH using 
HC1 and NaOH respectively. Initially 1M solutions of acid and alkali were used but this resulted 
in significant volume changes in the media. A freeze-drying step was then required in order to 
reconstitute samples at their original concentration.
To avoid the need for a freeze drying step, 5 M acid and alkali were used thereafter. Significant 
changes in osmolarity resulted from the use of solutions with higher molarity so these values 
were monitored as described in the next Section. Exposure to a range of pHs was performed 
at 4°C and the pH of samples then re-adjusted to pH 7.4 after the appropriate exposure time.
2.9.3 Measurement of Osmolarity
Osmolarity determinations were performed using an Gonotec Osmomat 0300 osmometer 
(Clandon). The instrument was calibrated immediately before use using a standard salt solution 
(0.300 Osmols/Kg H20 ). The basis for the measurement of osmolarity is the depression o f the 
freezing point of water by the presence of dissolved solutes.
2.9.4 Exposure to proteinase
Samples of CM and control medium were mixed with a crude trypsin preparation (Gibco, 
Cat.No: 043-05090H) to give a final concentration of 10 /xg/ml trypsin and this was incubated 
at 37°C for 2-3 hours (in one case 250 /xg/ml trypsin was used). In some experiments, purified 
bovine trypsin (Sigma grade III, from bovine pancreas, Cat.No: T5266) was used at a final 
concentration of 10 /xg/ml in CM. The action of trypsin in all cases was stopped by the addition 
of soyabean trypsin inhibitor (Sigma, Cat.No: T6522) added to give a final concentration of 20 
¿ig/ml.
2.9.5 Addition of heparin
Heparin from bovine intestinal mucosa (Sigma, Cat.No: H5271) was prepared as a stock 
solution in Ham’s F12 basal medium at 1 mg/ml. It was added to CM and control media to a 
final concentration of 10 ¿ig/ml before other treatments were performed to assess its ability to 
inhibit the negative effects of such treatments on the autocrine species.
2.10 PREPARATION OF CELL EXTRACTS
Cells for the preparation of extracts were grown in 75 cm2 flasks until confluency was reached. 
For HEp-2 extracts, three flasks were used per preparation.
2.10.1 Extraction buffers
The two extraction buffers used were modifications of those reported by Tiesman et a l . , (1988). 
Both contained 0.1% w/v CHAPS {(3-[(3-Cholaminodopropyl)dimethylammonio]-l-propane 
sulfonate; Sigma, Cat.No: 1300C-2} and the following cocktail of protease inhibitors; Leupeptin 
(Sigma, Cat.No: L2023) at 1 /¿g/ml; Pepstatin A (Sigma, P4265) at 2.75 /¿g/ml; and 1 mM 
PMSF (Phenylmethylsulphonylfluoride, Sigma, Cat.No: P7626). The protease inhibitors were 
diluted from concentrated stocks stored at -20 °C (Pepstatin at 1 mg/ml; Leupeptin at 1 mg/ml 
and PMSF at 0.1 M). The high and low salt buffers were as follows.
High Salt Buffer: 1.5M NaCl adjusted to pH 7.54.
Low Salt Buffer: Ham’s F12 (lx ) adjusted to pH 7.54.
2.10.2 Cell harvesting and extraction
Flasks were trypsinised and the combined cell suspensions pelleted in growth medium in a 
bench top centrifuge (at 800 rpm). Cell pellets were resuspended in PBS and pelleted by 
centrifugation. This step was repeated. After the final wash the supernatant PBS was decanted 
and the cell pellet was resuspended in the extraction buffer and placed on ice. Using a Labsonic 
U sonicator (Braun), cell suspensions were treated to three cycles o f 20 pulses each, with 20 
second intervals between cycles (Power setting =  045). Lysates were then pelleted in 
polypropylene tubes at 25,000g for 30 minutes in a Sorval using the SM-24 rotor (see Appendix 
A for calculation of settings in rev/min for this rotor).
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2.11 PURIFICATION PROTOCOLS
2.11.1 Gel filtration chromatography
Bio-Gel P30, with a 100-200 mesh gel bed was purchased from Bio-Rad (Cat.No: 150 1340) 
and used to prepare sufficient matrix for a 58 x  1.9 cm column. The gel was pre-equilibrated 
in phosphate buffer (100 mM, pH 7.4) before it was poured by a downward flow technique 
ensuring even packing of the gel.
Two separations were performed using this column, both of which were performed at 4°C. The 
gel was equilibrated in the running buffer before samples were loaded. In the first separation 
a 100 mM phosphate buffer (pH 7.4) containing 100 mM NaCl was used. A 20x concentrate 
of HEp-2 conditioned medium (R1 fraction, see Section 2 .8 .1 .1) was separated in this system. 
110 x  1.5 ml fractions were collected at a flow rate of 8 ml/hour using a fraction collector 
(LKB 2070 Ultrorack II) and protein levels in the column eluate were measured on line by a 
uv monitor set to read at 280 nm. Fractions 1-3 and every three consecutive fractions thereafter 
were pooled before being dialysed overnight in low MW pore-size tubing (cut-off 1200 daltons) 
against distilled H20 .  They were then lyophilised as described in Section 2.8.3 before being 
reconstituted in 2.5 ml of serum-free Ham’s F12.
In the second separation a more concentrated sample of HEp-2 conditioned medium (a 60x R1 
fraction prepared by ultrafiltration as described in Section 2.8.1.1 above) was applied to the 
column (which had been treated by passing 10 column volumes of running buffer through the 
column). The separation was carried out in 25 mM phosphate buffer (pH 7.4) to avoid the need 
for dialysis. 60 x  2 ml fractions were collected as before. The protein concentrations of the 
respective fractions were determined using the BioRad protein assay (Section 2.11.6). All 
fractions were lyophilised as described in Section 2.8.3 above and then reconstituted into 4 ml 
of serum-free Ham’s F12.
Samples from both separations were filter-sterilised before assay (see Section 2.1.3).
2.11.1.1 Desalting of Conditioned Medium / equilibration in running buffer
A  500 ml Sephadex G-15 (Pharmacia, Cat.Mo: 17-0020-02) gel filtration column was used to 
equilibrate 300 mis of unconcentrated HEp-2 CM in 100 mM phosphate (pH 7.4), the running 
buffer for heparin-Sepharose chromatography. The CM was applied to the column in 3 x  100 
ml lots. The peaks of protein excluded from the gel on each separation were pooled (giving 350 
mis total volume). The column was run using a ‘BIOPILOT’ FPLC system (Pharmacia). 
Operating parameters for column separations such as sample application, flow rates (15 
ml/min), buffer mixing for gradient formation, can be pre-determined using the system’s 
programmable contol unit which operates a system of valves and pumps. On-line uv and 
conductivity monitors connected to a chart recorder measure protein and salt concentrations in 
the eluate.
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Heparin-Sepharose was purchased in powdered form as Heparin-Sepharose CL-6B from 
Pharmacia (Cat. No: 17-0467-01). The gel was hydrated before use ( lg  powder yields 4 mis 
gel aproximately) and washed extensively in buffer A  (100 mM potassium phosphate, pH 7.4) 
to remove particulate material and preservatives (250 mis of buffer per lg  of powder was 
recommended by the manufacturers). The swollen gel was stored at 4°C before pouring the 
column. All separations using this couumn were performed at 4°C.
2.11.2 Heparin-Sepharose chromatography
2.11.2.1 Batch elution
A  5 ml heparin-Sepharose column was prepared and equilibrated in running buffer {buffer A, 
(100 mM postassium phosphate buffer, pH 7.4)}. A 2ml concentrate (60x, R1 as described in 
Section 2.8.1) of Hep-2 CM was loaded onto the column and the column was washed with 4 
column volumes of running buffer. The ‘wash’ contained unbound material and was pooled for 
analysis. Heparin-bound material was eluted using 10 ml batches of buffer A containing 
incremental increases in NaCl concentrations from 0.1 M through 0.5 M, 1.0 M, 1.5 M, 2.0  
M, and 5.0 M respectively. 10 ml fractions were collected after every batch application and 
these were dialysed as described in Section 2 .8 .2  above. All fractions were filter-sterilised after 
dialysis (Section 2.1.3). The volume change in all fractions (due to loss during handling and 
osmosis effects) was accounted for in determining the dilution factor required to give a lx  
equivalent in the assay.
2.11.2.2 Gradient elution
A 10 ml column was poured and equilibrated in running buffer (100 mM potassium phosphate 
buffer, pH 7.4). The system was controlled using the ‘BIOPILOT’ FPLC system described in 
Section 2.11.1.1 above. Pre-equilibrated HEp-2 CM (Section 2.11.1.1) above was applied to 
the column at a rate of 1 ml/minute (i.e. 300 mis of the total volume of 350 ml). After sample 
loading the column was washed with 50 ml of buffer A and a 10 column volume continuous 
gradient was applied using buffer B (2.5M NaCl in 100 mM phosphate buffer, pH 7.4) at a 
flow rate of 1 ml/minute. The first 132 mis of eluate was collected and pooled. 5 ml fractions 
were collected thereafter. All fractions for analysis were dialysed as described in Section 2 .8 .2  
above and filter-sterilised before assay (Section 2.1.3).
In the case of cell extracts, the same column was used after it had been washed through with 
10 column volumes of 0.5 M-NaCl in 0.1 M-Tris/HCl, pH 8.5 followed by 10 column volumes 
of 0.5 m-NaCl in 0.1 M sodium acetate, pH 5.5. It was then finally re-equilibrated in 10 
column volumes of buffer A {which included 0.1% CHAPS (w/v) for these separations}. The 
high and low salt extracts were loaded as 8 and 10 ml samples respectively at a flow rate of 1 
ml/minute in separate subsequent runs on the same column. After sample application, the 
column was washed with 75 mis of buffer A. A 0-3M NaCl continuous gradient was developed 
in this system with 3M NaCl in 100 mM phosphate buffer (buffer B). 3 ml fractions were 
collected from the start of the wash through to the end of the gradient. Both separations of 
extracts were run using the same programme. Where appropriate, samples were dialysed as 
described in Section 2 .8 .2 , or filter-sterilised directly.
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2.11.3 Cation-exchange chromatography
CM Sepharose fastflow matrix was purchased from Pharmacia (Cat.No: 17-0719-01) in a pre­
swollen form. A 10 ml column of this cation-exchange resin was poured and equilibrated with 
50 mM potassium phosphate buffer pH 6.0. To improve the stability of FGF-like or other 
unstable proteins 0.1% (w/v) CHAPS was included in the sample and running buffer. The 
conductivity of 200 mis of unconcentrated HEp-2 conditioned medium was reduced from 10 mS 
to 6 mS by diluting it with 180 mis ultrapure of H20  and 20 mis of 200 mM potassium 
phosphate (pH 6.0). The pH of a Vi dilution of CM was reduced to pH 6.0 before it was 
applied to the column at rate of 5 mls/minute.
After sample application the column was washed with 60 mis of equilibration buffer (50 mM 
phosphate, pH 6.0 containing 0.1% w/v CHAPS) and then eluted by irrigating with 4 column 
volumes of buffer containing 0.25M , 0.5M, 0.75M and 1M-KC1 respectively. This separation 
was run at 4°C under controlled conditions using the ‘BIOPILOT’ FPLC system described 
above (Section 2.11.1.1). Fractions of 20 mis were collected from the start o f the KC1 gradient. 
5 ml samples of these were dialysed in pretreated low MW pore-size dialysis tubing (Section 
2.8 .2 .) against distilled water, followed by dialysis against Ham’s F12 (serum free medium).
2.11.4 Hydrophobic interaction chromatography
Phenyl Sepharose CL4B was purchased from Pharmacia (Cat.No: 17-0467-01). A  1 ml column 
of this material was poured and equilibrated with Ham’s F12 medium (serum-free). A  2 ml 
sample of HEp-2 CM concentrate (R10-30, lOx) was applied to the column. Fractions of 2 mis 
were collected as the column was washed through first with 2 mis of Ham’s F12 followed by 
successive 6 ml volumes of 1M and 0.5M (NH4)2S 0 4 (Sigma, grade III, Cat.No: A6387). This 
was followed by 6 mis of distilled H20  and by successive 6 ml volumes of 10%, 20% and 30% 
glycerol (Sigma, Cat.No: G5516). All fractions were dialysed in dialysis tubing with a MW cut­
off of 1200 daltons (pretreated as described in Section 2 .8 .2  above) against three changes of 
distilled H20  followed by overnight dialysis against serum-free Ham’s F I2 medium (buffered 
to pH 7.45 with 20 mM HEPES). All samples were filter-sterilised (Section 2.1.3) before being 
tested for mitogenic activity in the HEp-2 assay.
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2.11.5 Ammonium sulphate fractionation of a biological fluid
A  100 ml sample of an effusion derived from a patient with ovarian cancer was subjected to 
several salt cuts using ammonium sulphate (Sigma, grade III, Cat.No: A6387) as follows.
The percentage (NH4)2S 0 4 in the effusion sample was brought to 20% (w/v) by adding 25 mis 
of a saturated (NH4)2S 0 4 soultion in a dropwise manner, while stirring the fluid on ice. The 
sample was then centrifuged at 15,000 rpm in a Sorval for 30 minutes and a 25 ml aliquot of 
the supernatant removed. The remaining supernatant was returned to the beaker on ice and the 
protein pellet resuspended in 10 mis ultrapure H20  (thereby concentrating this fraction x  10). 
The % salt in the fluid sample was increased to 30% as described above by the addition of 14.3 
mis of the saturated (NH4)2S 0 4 solution and then centrifuged as before. 14.4 mis of the 
supernatant was removed before bringing the % salt to 50% by the addition of another 40 mis 
of the saturated salt solution. 10 mis of the 50% saturated fluid supernatant was removed after 
centrifugation. Precipitate collected at the respective salt concentrations were centrifuged for 30 
minutes at 15,000 rpm and then resuspended in 10 mis ultrapure H20 . A ll samples were then 
dialysed against distilled H20  and lyophilised before being resuspended in PBS (to ensure a 
uniform and physiological salt concentrations in all samples).
2.11.6 BioRad protein assay
The BioRad protein microassay was used in this work to determine the protein concentration 
of ultrafiltration concentrates, fractions eluted from the separation of HEp-2 CM on the Biogel 
P30 column, as well as biological fluids. A standard curve for protein was generated using 
bovine serum albumin (Sigma, Cat.No: A7031) as a reference. Stock BSA was serially diluted 
in the range 1-25 /¿g/ml. 0.2 ml of dye reagent (BioRad, Cat.No: 500-0006) was added to 0.8 
ml of standards and samples in clean dry test tubes. Test tubes covered in parafilm were mixed 
by gentle inversion and left at room temperature for 5 minutes before the absorbance at 595 nm 
was determined. All measurements were taken within 1 hour from the time of adding the dye 
and the absorbance versus protein concentration then plotted. The concentration of unknowns 
were read from this standard curve.
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2.12 BIOASSAYS
2.12.1 Pretreatment of cells
All stocks of cells used for bioassay were mycoplasma-free and in log phase growth at the time 
of harvesting. To minimise inter-assay variability and to ensure that cultures were actively 
dividing when harvested, cells for use in bioassays were pretreated by subculturing two days 
before required for assay and refed on the morning of the preceeding day. The plating densities 
used in each bioassay depended on the particular cell line used. Growth medium used for cell 
pretreatment was supplemented with 10% serum. It is important to maintain this level even with 
cell lines such as HEp-2 which otherwise will grow at much lower concentrations. For example, 
HEp-2 pretreated in 5% FCS will not grow at the low plating density used in the autocrine 
assay. Table 2.12.1 shows the plating densities used for the different cell lines used here.
Table 2.12.1 Plating densities of cell lines used for bioassays in this work
CELL LINE ASSAY TYPE Cell W 7 5  cm1 flask
HEp-2 Monolayer growth 2 .0  x 106
DLRP Monolayer & Soft agar growth 2 .0  x 106
DLKP Monolayer & Soft agar growth 1.0 x 10®
SK-MES-1 Monolayer growth 1.5 x 106
NRK Soft agar growth 0.9 x 10s
2.12.2 Preparation of cell suspensions
In general it was easier to prepare single cell suspensions from subconfluent monolayers. 
Longer exposure times to trypsin also caused difficulties in generating single cell suspensions 
because individual cells tended to become ‘sticky’ and formed clumps. After pelleting cells 
following trypsinisation (Section 2.2.4) cells for bioassay were washed by being resuspended 
and pelleted in serum-free medium (to remove traces of serum and debris). They were then 
resuspended in plating medium. A small volume of serum-free medium (1ml) was used initially 
to make the stock cell suspension with a micropipette tip and the final volume was brought to 
no more than 2-5 mis depending on the expected yield. The viable cell number in this ‘stock’ 
suspension of cells (often diluted to facilitate counting) was determined (Section 2.2 .5 .1) before 
the appropriate diltions were made to give the ‘working’ cell suspensions in the relevant assay 
plating medium.
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2.12.3 Soft agar assays
The ability of cell lines to form three-dimensional colonies in semi-solid media has been 
correlated with the tumourigenicity of such cells in syngeneic hosts. Consequently this property 
has been used as an index of malignant transformation. The double agar method developed by 
Hamburger et a l. , (1978) was used here to quantify this property in the new lung carcinoma cell 
lines established in this lab.
2.12.3.1 Colony counting in soft agar
Colonies formed in soft agar were viewed at 40x using a CK Olympus inverted microscope, 
(Tokyo, Japan). The eye-piece graticule had a stage micrometer which was used to score 
colonies of a particular size. A  transparent grid was placed over the light aperture on the 
microscope stage. The grids formed 4 mm2 squares which were visible through the agar and 
facilitated the counting of colonies on the plate. 35 such squares were viewed by moving the 
focus through the agar and the number of colonies per square were recorded. The total number 
of colonies per plate was extrapolated from the number of colonies on this protion o f the plate 
( =  14.55% of the total plate area). An even distribution of cells at plating was assumed.
The percentage colony forming efficiency (% C.F.E.) was then calculated from this figure as 
follows:
% C.F.E. = Number of colonies ner plate x 
Number of cells plated
For every sample set up (in triplicate) the mean % C.F.E. was determined and standard error 
of the mean for these determinations were calculated using the following formula.
S.E.M.=\ ( « - 1)\fn
Where n =  number of replicates per sample, 
x  =  C.F.E. of each replicate.
£  =  sum of the samples from 1 to n.
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2.12.3.2 Transforming growth factor a-Iike assay
Only cultures of NRK cells between passages 19 and 21 were used in this assay.
Assay Protocol:
On the day of assay, 1.548g of bacto-agar (Difco, Detroit USA) was dissolved in 100 mis of 
ultrapure H20 ,  autoclaved and allowed to cool to 44°C in a water bath at this temperature.
A sufficient volume of an ‘agar growth medium‘ (AgM) was prepared in the following ratio;
Preparation o f  Agar Growth Medium: Preparation o f  2x DMEM:
DMEM 2x 50 nils DMEM lOx 2 0 .0  mis
HEPES (1 raM) 2  mis Ultrapure H ,0 73.0 mis
NaHCO, 1 ml HEPES (1 mM) 4.0 mis
P/S (!00x) 1 ml NaHCOa 2 .2  mis
Growth mediun (-FCS)f 14 mis Adjust to pH 7.4 (IM-NaOH)
' This was DMEM supplemented with 2mM L-glutamine and 2% P/S.
Freshly prepared AgM was equilibrated in the water bath at 44°C.
Samples were assayed in triplicate on appropriately labelled 35 mm petri dishes (Greiner, 
Cat.No: 627160). The empty labelled dishes were arranged on clean trays which had been 
swabbed with 70% IMS in the laminar flow cabinet.
The thermo-labile components of the AgM, L-glutamine (1 ml) and FCS (10 mis) were added 
just before equal volumes of the agar and AgM were mixed.
The AgM/agar solution was mixed well and 1.5 mls/plate of this mixture dispensed quickly 
before it was returned to the water bath. The temperature in the water bath was reduced to 
41 °C and allowed to equilibrate while the agar on the plates was allowed to set. The agar in 
this layer was 0.6% (w/v).
The NRK cells were trypsinised and a single cell suspension prepared and counted as described 
in Sections 2.2.4 & 2.2.5 above. A concentration of 4 x 10* NRK cells/ml was prepared in 
growth medium without serum such that the final plating number per 35 mm plate would be 6 
x 103 cells per plate after the following dilutions; 0.5 ml of this suspension was added to each 
test sample (2mls) in a sterile universal and this was mixed with 2.5 mis of agar growth medium 
(plus serum). After adequate mixing (achieved by pipetting up and down), 1.5 mls/plate of this 
diluted cell suspension was dispensed onto the relevant plates (x3). Cells were thus plated in 
0.3% (w/v) agar at 41 °C. This effectively diluted the original test sample concentration by a 
factor of 1/5.
The AgM solution was re-equilibrated at 41 °C after every five samples to avoid solidification.
Trays were covered in aluminium foil before being incubated for 10 days at 37 °C in a humid 
atmosphere with 5% C 0 2. The number of colonies which were 50 (im (microns) or greater in 
diameter were counted as described in Section 2.12.3.3 below.
2.12.3.3 Clonogenic assay
The protocol for the clonogenic assays was the same as that described for the TGFa-like assay 
above except that a range of cell concentrations were plated in the top agar layers. Cell 
suspensions were made up at 6.66x the desired final number/ml to allow for dilution in the agar 
growth medium. Serial dilutions of the highest cell concentration were made in growth medium.
Colonies with diameters of 50 /xm and greater were counted (i.e. scored as a colony) in the 
clonogenic assay and the percentage colony forming efficiency was calculated as described in 
Section 2.12.3.1.
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2.12.4 Monolayer assays
Monolayer staining with crystal violet
Growth medium was aspirated from plates, taking care not to remove cells attached in 
monolayer. Wells were rinsed with PBS ( x l )  and fixed with 3% formalin (BDH, Cat.No: 
101113). They were then stained for 10 minutes with a 0.25% (w/v) aqueous solution of crystal 
violet (Gurr, BDH Cat.No:30424). The crystal violet solution was pre-filtered through Wattman 
N21 filter paper before use. The plates were washed in tap water to remove excess dye and then 
dried, inverted on tissue paper to avoid water stains.
2.12.4.1 Measurement of colony area and number by image analysis
The area (mm2) covered by crystal violet-stained colonies was measured using an AMS 40-10 
image analyser. The instrument was callibrated to read in a defined area (in this case a circular 
area delineated by the circumferance of a well on the 24-well culture plate) These settings were 
programmed into the microprocessor and recalled for subsequent readings. The image scored 
by the instrument is calculated by the relative difference in the degree of shading between the 
amount of dark staining on the plate (i.e. the area covered by cells) and the background 
unstained surface. Detection sensitivity was set immediately before reading the assay. The 
choice of setting for sensitivity was a compromise between the detection of very low staining 
levels (e.g. in control wells of the autocrine assay) and that of higher levels of staining (e.g. in 
growth stimulated wells). In practice this was adjusted for optimum detection. Sensitivity was 
also subject to variations in voltage. In order to minimise these fluctuations, a voltage stabiliser 
was employed and the instrument was switched on overnight before use.
2.12.4.2 HEp-2 autocrine assay in 24-well plates
A single cell suspension of HEp-2 cells was prepared (Section 2.2.5.1) at a concentrations of 
8 x  102 cells/ml in DMEM containing supplements at 2x their final concentration such that 
there was 1% FCS, 500 U/ml penicillin/500 /xg/ml streptomycin or 250 /¿g/ml gentamicin and 
2 mM L-glutamine in the assay medium after addition of the test samples. 0.5 ml of cell 
suspension was plated in each well with mixing of the cell suspension after every 6 wells plated.
Test samples of CM or growth factors were added to the plated cells in a total volume o f 0.5 
ml (in quadruplicate or triplicate per determination), bringing the final volume per well to 1 ml. 
All dilutions of test samples for assay were diluted in serum- and supplement-free Ham’s F12. 
Controls consisting of assay medium only (DMEM/Ham’s F12 plus supplements) were included 
on each plate. When all the wells had been plated with cells and test samples the individual 
plates were mixed carefully to ensure even spreading of cells. These were then incubated at 
37°C in a humidified 5% C 02 atmosphere. After 7 days the plates were removed and checked 
for signs of contamination before they were stained with crystal violet (Section 2.12.4) and the 
colony areas determined by image analysis (Section 2.12.4.1 above).
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2.12.4.3 Monolayer assays for human lung squamous cell carcinomas cell lines
The protocol for all the monolayer growth assays was essentially the same. Indicator cells were 
plated in DMEM with 2x supplements such that the final concentrations in the assay were 
1% FCS, 500 U/ml penicillin/500 /xg/ml streptomycin or 250 ¿ig/ml gentamicin and 2 mM L- 
glutamine. This was to allow for dilution by the addition of test samples in a total volume of 
0.5  ml/determination, bringing the final volume per well to 1 ml.
Samples for testing in the growth assays were added either as undiluted solutions or diluted in 
serum- and supplement-free Ham’s F12. Growth factors diluted from stock solutions (Section
2.13.2 below) containing 1 mg/ml bovine serum albumin (Sigma, fraction V, Cat.No: A9418) 
were diluted to 2x their desired concentration in the assay to allow for the dilution factor upon 
addition to the cell suspension in the assay.
The plating densities used for the three human lung squamous cell carcinoma cell lines in the 
various applications of the 24-well monolayer growth assays are given in Table 2 .12.4.3 .
Table 2.12.4.3 Plating densities of DLRP, DLKP and SK-MES-1 in monolayer growth 
assays used for differnent applications
CELL LINE ASSAY TYPE Cell hP/wcll
DLRP Growth factor assay 3.0 x 103
DLRP Autocrine assay and ME1' 5.0 x 103
DLKP Autocrine assay and M E 1.0  x 103
SK-MES-1 Growth assay with ME 5.0 x 103
 ^ Growth response to malignant effusions.
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2.12.5 Acid phosphatase measurement
The acid phosphatase activity was determined by measuring the dephosphorylation of the 
substrate PNP (p-nitrophenyl phosphate) resulting in the appearance of the product p-nitrophenol 
with a for absorbance at 405 nm. The absorbance measured at this wavelength is 
proportional to the activity of acid phosphatase which in turn is proportional to cell number.
Method:
Preparation o f Substrate
A 10 mM p-nitrophenyl phosphate (Sigma, Cat.No: C l04) was prepared iust before use in a 
lysis buffer containing 0.1% Triton X-100 (BDH, Cat. No: 30632), 0.1M Sodium Acetate 
(Sigma, Cat.No: S2889) at pH 5.5. The lysis buffer was stored at 4°C before use and the 
phosphatase substrate was stored in the dark at -20°C.
Measurement o f Acid Phosphatase Activity
Growth medium was carefully removed from wells to avoid disruption of cells on the monolayer 
(This is particularly important for loosely adherent cell lines). Wells were rinsed with 100 /xl 
of PBS and this was carefully removed as per growth medium.
100 ¡A of 10 mM PNP substrate in lysis buffer was added to each well and the plates incubated 
at 37°C for 2 hours. After this time bubbles were removed using an 18 gauge syringe needle 
(to avoid light scattering effects) and the absorbance was measured. If after 2 hours the intensity 
of absorbance due to the p-nitrophenol chromophore was insufficient for adequate measurement, 
then the reaction was either incubated for a longer time (e.g. a further 1-2 hours) or ‘stopped’ 
by the addition of 50 of lM-NaOH per well which has the effect of causing an electrophillic 
shift in the chromophore and therefore increases the absorbance in the yellow wavelength range 
(405 nm).
Absorbance at 405nm was measured on a dual wavelength ELISA plate reader (Titertek 
Multiskan) using the 620nm filter as a reference wavelength. Absorbance at 620 nm was due 
to the plastic plate and automatically is subtracted from the total absorbance before readout of 
the results.
2.12.5.1 HEp-2 autocrine assay in 96-well plates
HEp-2 cells for use in the 96-well autocrine assay system were pretreated as described for the 
24-well assay. The working cell suspension was prepared at 3 x  103 cells/ml in DMEM plus 
2x supplements. 100 ¡A of this cell suspension was plated per well on the 96-well plate using 
an eight-well multichannel micropipette. Test samples were added in 100 ¡A of Ham’s F12 and 
the plates were incubated at 37°C in a humidified atmosphere of 5% C 0 2.
95
2.12.6 ‘“I-EGF radioreceptor assay
This assay is based on the competition for binding between ligands with an affinity for the 
Epidermal growth factor receptor. TGFa competes with EGF for the EGF receptor on a mole 
per mole basis {Todaro et al., (1980)}. Displacement of a fixed concentration of radioactively 
labelled EGF by increasing concentrations of unlabelled EGF permits a standard curve to be 
drawn from which the concentration of an unknown EGF competitor can be estimated.
Method:
A431 cells were plated in 24-well plates (Costar 3524) at 10s cells per well in 1 ml of DMEM 
+  10% FCS. Cultures were incubated overnight at 37°C in an atmosphere of 5% C 02. The 
next day the medium was removed carefully (to avoid removing the attached cells) and the cell 
monolayer was washed in cold binding buffer {DMEM +  lm g % BSA, (Sigma A7031)}.
I25I-EGF (Amersham 1M 124) was prepared in binding buffer to give a final activity of 0.01 /¿Ci 
per 100 of binding buffer. EGF standards were prepared from a 10 ng/ml stock of 
‘unlabelled’ EGF (Sigma, Cat.No: E1257) freshly thawed from storage at -20°C (prepared in 
lots of 450 fi 1). The following dilutions were prepared for the standard curve; 10000, 500, 100, 
50, 10, 5 and 1 ng/ml. All standards and samples were kept on ice until required.
100 fil of each standard was added to triplicate wells together with 100 /xl of l2il-EGF solution. 
Samples were mixed by swirling and incubated at 20°C for 1 hour. 100 /xl of CM concentrates 
for analysis were mixed with 100 /xl of l25l-EGF solution and treated in the same way.
Non-specific binding o f 1251-EGF was determined in the presence of excess unlabelled EGF. For 
this purpose 100 /x 1 of 10 /xg/ml EGF was incubated instead of the standard EGF concentration.
Supernatants were removed without disturbing the cell monolayers and these were rinsed three 
times with 1 ml of cold binding buffer. Finally the cells in each well were dissolved in 0.5 ml 
of 0.5M NaOH and transferred to counting vials (Rohren tubes 55.44 Starsted). Each well was 
rinsed twice with 0.5 M NaOH and combined with the original extract for the respective well 
(in the counting tube).
Samples were counted for 1 minute on a mini gamma counter (LKB 125). The results were 
calculated as the percentage inhibition of each sample over total l25I-EGF bound in the absence 
of a competitor.
% INHIBITION = 100 - CPM bound per .samBl.y..Non-specificCPM x 100 
TOTAL CPM - Non-specific CPM
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2.13 PURE GROWTH FACTORS
2.13.1 Source
Purified growth factors with the exception of TGFa (which was kindly donated by Majorie 
Winkler, Genentech) were purchased from several commercial suppliers. A list of suppliers and 
the source of the purified growth factors are given in Table 2.13.1.
Table 2.13.1 Source of pure growth factors used in the course of this project
GROWTH FACTOR Source/Supplier CatalORue N*
Acidic FGF (aFGF)t Bovine brain/British Biotechnology Ltd. (BBL) BDP-12
Basic FGF (bFGF)t Bovine brain/British Biotechnology Ltd. BDP-13
Interleukin la  (IL-la)^ Human recombinant protein from E. coK/BBL. BDP-15
Interleukin 1/3 (IL-l/3)t Human recombinant protein from E.colUBBL. BDP-17
Insulin Bovine pancreas/Sigma. 1-1882
Insulin-like growth factor I (IGF-I) Human recombinant, li.coS/Boehringer Mannheim. BCL1048-066
Insulin-like growth factor II (IGF-II) BRL-3A cell conditioned medium/Sigma. M-9145
Epidermal growth factor (EGF) Mouse submaxillary gland/Sigma. E-4127
Transforming growth factor a  (TGFa) Human recombinant/Genentech. PD-1
Transforming growth factor /S (TGF/3) Human platelets/Peninsula Labs, Europe Ltd. IP-1085
Platelet-derived growth factor (PDGF) Human platelets Peninsula Labs, Europe Ltd. IP-1080
Bombesin/Gastrin releasing peptide Sigma. B-5508
t Manufactured by R&D systems, ine, Minneapolis, MN, USA.
2.13.2 Preparation
Stock solutions of growth factors were prepared in the appropriate buffers, all of which 
contained bovine serum albumin (fraction V, Sigma, Cat.No: A9418) at a concentration of 1 
mg/ml (except in the case of Bombesin). Bovine serum albumin (BSA) was included to prevent 
loss of growth factors due to non-specific binding of these proteins to the walls of storage vials 
at low concentrations.
In the case of particularly ‘sticky’ and labile proteins such as the FGFs, the zwitterionic 
detergent CHAPS was included in the buffer for the preparation of stock solutions at 0.1 % w/v. 
Matuo et al., (1988) reported that this agent stabilised FGFs during frozen storage. All growth 
factor stocks were stored at -20°C and thawed as required. Repeated freeze/thaw cycles were 
avoided by dispensing stocks in smaller volumes after initial preparation.
A list of the buffers and concentrations used in the preparation of growth factor stock solutions 
is given in Table 2.13.2.
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Table 2.13.2 Preparation of stock solutions of pure growth factors
GROWTH FACTOR Reconstitution buffer Stock concentration
Acidic FGF (aFGF) PBS-A + 0.1% (w/v) CHAPS 10 /¿g/ml
Basic FGF (bFGF) PBS-A + 0.1% (w/v) CHAPS 10 fig/ml
Interleukin la  (IL-la) PBS-A 1
Interleukin 1/3 (IL-1/3) PBS-A 1 fJig/ml
Insulin 0.1 M Acetic Acid 200 mg/ml
Insulin-like growth factor I (IGF-I) 10 mM HC1 100 jig/ml
Insulin-like growth factor II (IGF-II) 10 mM HC1 20 /ig/ml
Epidermal growth factor (EGF) DMEM/Ham’s F12 (1:1) 1 ix g/ml
Transforming growth factor a  (TGFa) Phosphate buffered saline (PBS) 100 /¿g/ml
Transforming growth factor (1 (TGF|S) 0.1 M Acetic Acid 10 g/ml
Platelet-derived growth factor (PDGF) 0.15 M-NaCl 25 TJ/ml
Bombesin/Gastrin releasing peptide DMEM + 1 mg% BSA 1 mg/ml
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2.14 NEUTRALISING ANTIBODY EXPERIEMTS
The ability of antibodies to neutralise the mitogenic activity of the growth factors against which 
they are directed depends on the target cell line and the incubation conditions used. The two 
different lots of anti-FGF neutralising antibodies used in this work were purchased from British 
Biotechnology Ltd (Abingdon, Oxon 0X 14 3YS, England).
2.14.1 Source and specifications of anti-FGF antibodies
Anti-aFGF (Cat.No: BDA 6) and anti-bFGF (Cat.No: BDA 4) IgG antibodies raised in rabbits 
against highly purified bovine bFGF (homogeneous on silver stained SDS-PAGE gels) were 
isolated by Protein A chromatography and filter-sterilised by passage through a 0.2 /xm filter 
(R&D systems inc, Minneapolis, MN, USA). They were supplied lyophilised from a solution 
containing PBS, pH 7.5, in 1 mg quantities (British Biotechnology Ltd, and stored at -20°C  
(Stable for 6-12 months lyophilised).
Lot 1 Efficacy
The efficacy of the first lot of anti-FGF antibodies purchased had been determined by the 
manufacturers using the NR6-3T3 fibroblast cell line. The amount of antibody required to 
neutralise 80% of acidic FGF mitogenic activity (when aFGF was present at a concentration 
sufficient to give maximal stimulation) was quoted as 20-30 /xg/ml for anti-acidic FGF antibody. 
Using the same criteria, anti-basic FGF at 30 /xg/ml inhibited 90% of the mitogenic response 
to bFGF. According to the manufacturers specifications both anti-FGF antibodies were non­
cross reactive with a number of different polypeptide growth factors from various growth factor 
classes (as determined by Western blotting or ELISA). Similarily neither anti-FGF antibody 
cross reacted with the other. Furthermore neither antibody demonstrated mitogenic activity in 
their normal working concentration range (0-100 /xg/ml) for the indicator cel] line used, NR6- 
3T3.
L ot 2 Efficacy
The efficacy of the second lot of antibodies purchased (Lot.No:P083, anti-aFGF; Lot.No:Q177, 
Anti-bFGF) was expressed in terms of their neutralising doseS0 (NDJ0) values. These values had 
also been determined using the NR6-3T3 fibroblast cell line. The ND50 value was defined as,
" that concentration of antibody required to yield one-half maximal 
inhibition of the cytokine, when that cytokine is present at 5 times 
its normal EDS0 concentration"
In the NR6-3T3 fibroblast system, 5 times the ED50 concentration of cytokine (growth factor) 
gave 100% activity (stimulation). Under these conditions the ND50 values determined were 
quoted as 2 /xg/ml for both neutralising antibodies respectively.
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The antibodies were reconstituted in 1 ml of sterile ultrapure H20 to make stock solutions of 
1 mg/ml. The recommended storage time for these solutions at 4°C was 1 month or 3-6 months 
at frozen at -20°C.
2.14.2 Preparation of antibodies
2.14.3 Preincubation of antibodies with CM and pure growth factors
Anti-FGF neutralising antibodies stocks were thawed from previously unused (since initial 
preparation) frozen stocks on the day of the experiment and were diluted in Ham’s F12 (minus 
BSA) to working stocks of 1 /xg/rnl and 0.1 /xg/ml. Similarly fresh stocks of acidic and basic 
FGF growth factors were thawed on the day and working stocks made by dilution only after the 
antibody dilutions were complete. Growth factor dilutions were made in Ham’s F12 with and 
without BSA to give working stock solutions at 1 /xg/ml and 0.1 /xg/ml respectively. These 
working stocks were kept at 4°C and diluted to the final concentrations just before mixing with 
the antibodies. Growth factor controls were mixed with the appropriate amount of antibodies 
in a total volume of 40 /x 1 incubated for 90 minutes at 37 °C before being brought to 1.5 mis 
with serum-free Ham’s F12. The CM samples were also incubated with antibodies for 90 
minutes in a total volume of 1.5 mis of the respective sample. After incubation with antibody, 
all samples were added directly to pre-plated HEp-2 cells set up for the autocrine assay (Section 
2.12.4.2).
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2.15 ANTISENSE OLIGODEOXYNUCLEOTIDES
2.15.1 Source
Customised 15 base pair oligonucleotides were produced by British Biotechnology Ltd in an 
unmodified form on an Applied Biosystems 380B DNA synthesiser. Approximately 400 /xg of 
each HPLC-purified oligodeoxynucleotides were recovered from a 1.0 /xmole scale synthesis 
and supplied in a lyophilised form.
2.15.2 Preparation
Oligonucleotides were reconstituted in 100 /xl o f sterile ultrapure H20 . The DNA concentration 
was determined spectrophotometrically as described below. 1 /xl was removed for testing the 
acidity of this solution (using indicator paper).
2.15.3 Spectrophotometric quantification of oligodeoxynucleotides
Oligonucleotides were quantified by measuring the absorbance of a dilute aqueous solution (in 
ultrapure H20 ). Concentrations were calculated on the basis that one OD260 unit corresponds to 
30 /xg/ml of single-stranded DNA (for short sequences). Absorbance measurements were 
performed in quartz cuvettes using a dual beam spectrophotometer (UV-160A, Shimadzu, 
Japan). 3 /xl aliquots of the stock solutions were diluted in 3 ml of ultrapure H20  ( x  1000 fold) 
and mixed well by inversion before absorbance was measured.
2.15.4 Calibration of multichannel micropipettes
The percentage errors on plating for an electronic multiwell pipette (Rainin EDP plus), used 
with the appropriate tips (Rainin RT 96) was compared to that of a manual multichannel 
micropipette (SLT 40-200 /xl, Labinstrunebts, Austria). The coefficient of variation with each 
pipette was determined by dispensing 100 /xl/well of a 0 .2 % w/v solution (in 1% acetic acid) 
of the dye Sulforhodamine B (Sigma, Cat.No: S9012). The difference in absorbance was at 570 
and 620 nm was measured using a Titertek Multiskan ELISA plate reader which calculated the 
coefficient of variation for each channel on the micropipette. The errors with both instruments 
was generally very low but the performance of the electronic pipette was better in this respect 
and this instrument was used to dispense the small volumes employed in the antisense 
experiments.
2.15.5 Protocol for antisense experiments with HEp-2
A  2 x  107ml cell suspension in DMEM/Ham’s F12 medium plus 1% heat-inactivated FCS, 
2 mM L-glutamine and 500 U/ml penicillin/500 /xg/ml streptomycin was plated at 50 /xl/well 
in 96-well plates 24 hours prior to the addition of the oligonucleotides. No cells were plated on 
the outside wells but instead 50 /xl of growth medium was plated here. Although the optimum 
time for addition of the oligonucleotides was not known, the oligonucleotides were addded after 
the cells had been plated and allowed to attach overnight. This was in order to avoid any 
potentially inhibitory effect on cell attachment. On the next day, all the growth medium was 
removed before the addition of oligonucleotides.
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Oligonucleotides were diluted from stock solutions in growth medium (DMEM:Ham’s F12 +  
1% heat-inactivated FCS, 2 mM L-glutamine, 250 /xg/ml gentamycin). In parallel, a control 
with no added oligonucleotide was refed with fresh medium. Separate controls were included 
on each plate. Acidic FGF sense and antisense oligonucleotides were assayed on the same plate 
and the bFGF oligonucleotidess were tested on a second plate to avoid plating errors resulting 
from variations due to cell density changes.
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RESULTS
3.1 PRIMARY CULTURE OF HUMAN THORASIC TUMOUR TISSUE
Over a three year period from 1986-1989, 55 solid human tumour tissue samples were received 
from thorasic surgery. The samples were taken directly at the time of resection and collected 
in cell culture growth medium containing antibiotics and an antifungal agent (Section 2.4.1). 
While the majority of samples were of lung origin, non-lung thorasic samples were also 
obtained. These included oesophageal and thymic tissue samples. Attempts were made to 
develop a regime for the in vitro culture of the tissue obtained using a number of established 
techniques. In addition, 8 malignant effusions were collected during this period from patients 
with different carcinomas and an effort was made to culture cells obtained from these fluids.
3.1.1 Source and composition of tissue samples
The nature of the samples obtained varied considerably in terms of size, texture, accessory 
adipose tissue, degree of necrosis and vascularisation. In addition, the histological status of the 
tissue received was not always known at the time of processing for in vitro culture (i.e. 
im m ediately  after carriage to the laboratory). This was generally the case with investigative 
surgical procedures where patients first presented with disease symptoms. These include 
bronchoscopy, involving the removal of tissue with a bronchoscope lowered down the trachea 
into the bronchus, and mediastinoscopy, which requires an incision in the upper chest to 
examine and/or resect mediastinal nodes for histology. Where appropriate, both procedures were 
often performed by the surgeon in tandem. The amount of tissue removed for these biopsies was 
small and that available for tissue culture (after sufficient material was removed for hospital 
histology) was limited (usually less than 1 cm3). More tissue was generally removed during 
mediastinoscopies than bronchoscopies, but as a rule, neither procedure provided as much 
material as the resection of entire tumours.
In the case of lung cancers, removal of tumour masses were performed by surgical procedures 
which excised the entire lung (pneumonectomy), or one or more of the constituent lobes 
(lobectomy). The composition of such tumour material was no less heterogeneous than biopsy 
sized samples. However, resection for the removal of entire lung tumours was normally only 
considered where non-small cell lung carcinoma had been diagnosed following bronchoscopy 
or mediastinoscopy. For this reason large samples formed a histologically selected subset of 
lung tumours.
A small number of the tumours resected from the lung were benign or were metastases from 
primary tumours in other organs. For presentation purposes samples were classified as follows;
(1) Pneumonectomy / Lobectomy
(2) Mediastinoscopy / Bronchoscopy
(3) Thoracotomy
(4) Oesophageal
(5) Malignant effusions
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3.1.2 TISSUE PROCESSING TECHNIQUES
Samples were carried to the cell culture laboratory in transportation medium on ice. All 
manipulations of the tissue were carried out under sterile conditions as described in Section 2.5. 
The amount of tissue received dictated the type of processing employed.
After the removal of vascular, adipose, and necrotic tissue, the objective was to release the 
epithelial cell component from the tissue matrix with minimum cellular damage. Two methods 
have been used traditionally to achieve this end, namely mechanical and enzymatic 
disaggregation. In this work, the former method was the method of choice where the amount 
of tissue was small and/or loosely bound. Where the texture was tougher, mechanically sliced 
fragments were also subjected to enzymatic treatment in an effort to digest the stromal 
extracellular matrix and release the epithelial cell component.
A  common problem with primary epithelial cell cultures not grown in selective media is 
overgrowth by cells from the stromal cell component of the tissue, namely fibroblasts. These 
cells appear to have less stringent growth requirements than their epithelial counterparts. It is 
also possible that the isolation conditions and/or the culture media components used, 
mitogenically activate fibroblasts in preference to epithelial cells. Because the maj ority of human 
tumours arise from epithelial cells, these are the cells which are of interest in growing. 
However, excessive proliferation of fibroblasts causes problems with nutrient depletion of the 
medium and limited growth surface area (which can lead to a physical restriction on growth of 
epithelial cells). The percentage of stromal cells in different tissues varies. The same is true for 
m alignant tissue. The following investigation considered this problem with respect to the 
methodology used, but also looked at ways to remove unwanted fibroblasts. Other sources of 
growth stimulators for primary epithelial cells were investigated, with a view to identifying 
factors that might promote in vitro growth of lung squamous cell carcinomas.
3.1 .2 .1  Mechanical disaggregation of tissue samples
This procedure was performed in cell culture growth medium or in sterile PBS in the case of 
heavily bloodstained samples as described in Section 2.5.3. Experience during this work has 
shown that mechanical disaggregation did not yield a higher number of fibroblasts compared 
to the enzymatic treatment of the same tissue samples.
In cases where the total sample mass was less than 1 cm3 mechanical disaggregation was used 
to produce tissue fragments of approximately 1 mm2 which were suitable for setting up as 
explants (Section 2.5.4). The explant technique was found to be time consuming and unreliable 
in terms of successful attachment, and the degree of subsequent outgrowth of epithelial cells. 
It was therefore only used for very small samples with a hard texture. A  more successful 
approach derived from the observation that mechanical dissection of many samples resulted in 
the spillage of tiny tissue fragments, smaller clumps of cells, and single cells into the medium. 
This fraction of the dissociated tissue was called the dissection medium. It was found that tissue 
disrupted in this way resulted more frequently in successful attachment and subsequent 
proliferation of epithelial cells.
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Even with soft tissue, the ability to completely disaggregate a sample mechanically is limited. 
Further digestion of tissue pieces was attempted using a mixture of proteolytic enzymes. Type 
IV collagenase and dispase were used for this reason. This cocktail o f enzymes was particularly 
useful for samples with a hard texture that yielded few cells after mechanical disaggregation. 
Enzymatic disaggregation was attempted after mechanical disruption with all samples of 
sufficient size (1 cm3 or greater).
Incubations in enzyme were carried out for 1-3 hours depending on tissue texture. Cells released 
from the tissue matrix in this way were harvested periodically as described in Section 2 .5 .5 . It 
was observed that later collections from the same tissue samples contained greater numbers of 
fibroblasts. For this reason, but also to avoid cell damage, incubation times were kept to a 
minimum. In spite of this, treatment with enzymes resulted in more rapid establishment of 
fibroblast overgrowth than purely mechanical procedures.
An example of this can be seen in photographs in figures 3.1.1 & 3.1.2, which are taken after 
three days in culture. In the dissection medium fraction, outgrowth can be seen at the edge of 
the attached cell clumps with a noticeable absence of fibroblasts at this stage. However, in the 
1 hour incubation with collagenase/dispase, the single cell suspension achieved using this 
procedure resulted in widespread proliferation of fibroblasts with few epithelial cells 
interspersed.
Enzymatic treatment of samples did not always result in such a good dispersion of the tissue 
into single cells. In other samples disruption under the same conditions (1 hour with 
collagenase/dispase) often resulted in a mixture of single cells and smaller clumps of cells 
and/or tissue fragments. This pattern of disruption may reflect the intrinsic composition of the 
tissue sample, but it also appeared to favour the establishment of localised epithelial colonies. 
An example of this in figure 3.1.3 shows a squamous cell lung carcinoma after four days in 
culture. In this case epithelial cells are found associated with a small tissue fragment. A  
considerable number of fibroblasts are also visible but many of these were successfully removed 
from the sample in question on the tenth day in culture (figures 3 .1 .4  & 3.1.5 Section 3.1.5.1).
3.1.2.2 Enzymatic disaggregation of tissue samples
3.1.2.3. Malignant effusions as a source of epithelial cells for primary culture
Pleural effusions and peritoneal (ascites) fluids produced symptomatically in association with 
malignancy are often a source of metastatic cancer cells. Samples taken from such patients for 
palliative purposes were used initially as a source of cells for primary culture. Cells were 
separated from the fluids by centrifugation. Fibroblast contamination was not a problem with 
these samples (in the limited number of cases studied). In later work the remaining fluid was 
also assayed for growth factor activity (Sections 3.1.9 and 3.1.10 below).
3.1.3 REMOVAL OF BLOOD CELLS
Some tissue samples were so bloodstained, or vascularised to such an extent, that dissection 
resulted in spillage of large numbers of red blood cells (RBC) into suspension. Initial experience 
suggested that epithelial cell attachment was not successful in the presence of blood cells. 
Erythrocytes therefore were separated in such cases by differential centrifugation on a ficoll 
gradient (Section 2.5.6). This technique was also usefully employed in the removal of 
erythrocytes from cell pellets from pleural effusions and ascites fluid samples.
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Figure 3.1.1 Growth of mechanically disaggregated squamous cell lung carcinoma after 3 
days in culture, showing absence of fibroblasts. (150X magnification).
Figure 3.1.2 Growth of the same lung tumour sample as in figure 3.1, three days after 
digestion with collagenase/dispase. Arrows indicate the few epithelial-like 
ceils, the majority are fibroblasts (150X magnification).
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Figure 3.1.3 Outgrowth of primary lung epithelial and fibroblast cells from a tissue
fragment three days in culture after incubation of tumour with collagenase/ 
dispase (X50X magnification). Arrows indicate areas of epithelial cell monolayers.
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3.1.4 IN  VITRO GROWTH OF TUMOUR SAMPLES
The growth performance of thoracic tissue samples is outlined in Table 3 .1 .4 .1 . Samples have 
been catergorised according to the site/operative procedure used, as outlined in Section 3.1.1  
above. In this scheme performance was graded from no growth {NG} through to the various 
degrees of attachment and proliferation thereafter. In general, no growth assumes no attachment, 
but in one case (a small cell lung carcinoma, cultured from a bronchoscopy sample) cells grew 
as clumps in suspension. This is the typical growth pattern for small cell carcinoma in vitro. 
This type of lung carcinoma was only expected in bronchoscopy and mediastinoscopy samples 
for the reasons outlined above.
Cells that attach and demonstrate signs of metabolism (acidification of the growth medium) are 
called ‘primary cultures’. These are taken to be at ‘passage zero’. After these primary cultures 
reach confluency they are subcultured and replated (usually at a lower density), and from this 
point onwards they are considered a ‘cell line’. However, a distinction is made between 
‘continuous’ or ‘established’ cell lines, and those with a limited capacity to proliferate in vitro 
before terminal differentiation occurs. In this project, where cell attachment was observed, it 
was categorised as follows.
(1) Cultures where only fibroblasts were obtained {Fibs}, and epithelial cells were absent. 
In all cases where fibroblasts attached, they continued to proliferate and could be 
subcultured for several passages before eventually differentiating and/or senescing.
(2) In some cultures primary epithelial colonies were obtained {l°E p} which displayed a 
limited capacity for subsequent proliferation. These too were eventually lost before they 
could be subcultured (passaged). In all cases however, fibroblasts were also present. Loss 
of such epithelial cultures was associated with overgrowth by fibroblasts but this factor 
alone did not contribute to the demise of epithelial cell proliferation. In most cases signs 
of differentiation were visible and this may be the cause of senecence in epithelial 
monolayers.
(3) Other cultures with primary epithelial cells proliferated sufficiently to permit one or more 
subcultures {Ep >  1°}. This was achieved with a relatively small number of samples 
{5/55 solid tumour samples and 1/8 malignant effusion-derived cultures, excluding one 
continuous cell line established in each category.
(4) A continuous cell line {CL} is assumed to be immortal in terms of its capacity to 
continue replication while maintained as an in vitro culture. Two permanent cell lines 
were established in the course of this work, one from a lymph node taken from a patient 
with prolific metastases of a poorly differentiated squamous cell lung carcinoma, and the 
second from a pleural effusion from a patient with breast adenoacarcinoma. The 
establishment of these cell lines and their subsequent characterisation is described in 
Sections 3.1.6, 3.1.11 and 3.1.12 respectively).
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Table 3.1.4.1 Growth performance of solid tissue samples and malignant effusions 
in vitro
GROWTH C.L. Ep > 1° 1° Ep UBS N.G. TOTAL
PNEUMONECTOMY/
LOBECTOMY 0 3 (13.0)1 12 (52.2) 3 (13.0) 5 (21.8) 23
BRONCHOSCOPY/
MEDIASTINOSCOPY 0 0 (0.0) 7 (30.4) 5 (21.7) 11 (47.8) 23
OESOPHAGEAL 0 2 (33.3) 2 (33.3) 1 (16.7) 1 (16.7) 6
THORACOTOMY 0 0 1 0 1 2
MALIGNANT
EFFUSIONS
1 1 4 1 1 8
OTHER” 1 0 0 0 0 1
Abbreviations: C.L, Cell line established. Ep >  1°, Epithelial cells passaged after primary colonies. 1° Ep, Primary 
epithelial colonies only. Fibs, Fibroblasts only. N.G, No growth. 1 Figures in brackets are the numbers expressed as 
a percentage of the total in that category. b A secondary lung tumour (poorly differentiated squamous cell carcinoma) 
metastatic to the cervical lymph node.
A number of general empirical observations were made with respect to successful establishment 
of primary epithelial cultures. These apply particularly in the case of unpromising techniques 
attempted where the observation was made three times or less.
(1) Epithelial colonies became visible within the first seven days after inititiation of the 
primary culture from the tissue sample.
(2) When differentiation occured in primary epithelial colonies it became apparent 2-3 weeks 
after the initiation of the culture.
(3) Substitution of the foetal calf serum (FCS) component o f the growth medium with 
autologus serum did not appear to improve epithelial growth substantially with respect 
to the growth of the same culture grown in FCS-containing medium. However, the level 
of fibroblast growth did appear to be reduced with autologus serum substitution.
(4) The use of growth-arrested mouse 3T3 fibroblasts as feeder layers did not inhibit 
overgrowth of the epithelial component by tumour-derived stromal cells (Section 2.5.9).
(5) Collagen coating of culture flasks (Section 2.5.10) was similarly ineffective in retarding 
fibroblast proliferation but epithelial cells were trypsinised from these flasks in preference 
to fibroblasts using only 0.25% (w/v) trypsin at 4°C.
(6) Only large samples gave rise to cultures of epithelial cells which could be passaged 
beyond the initial primary culture. Details of the histology of this set and the ultimate 
passage number achieved are shown in Table 3.1.4.2.
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Table 3.1.4.2 Histology of 6 samples passaged after initiation of primary epithelial 
culture
SAMPLE
ORIGIN
OPERATIVE
PROCEDURES
SAMPLE
HISTOLOGY '• v .....■ :: 7 :: x • • . . . : '
FINAL 
PASSAGE N» ;
Oesophagus Oesophageal brushings Moderately Differentiated Squamous Cell Carcinoma
P i
Oesophagus Oesophageal tumour removal
Moderately Differentiated Squamous Cell 
Carcinoma
P i
Lung Lobectomy Squamous Cell Carcinoma P3
Lung Lobectomy Recurrent Malignant thymoma PI
Lung Lobectomy Benign tumour P2
Lung Pleural effusion Moderately Differentiated Squamous Cell Carcinoma
P2
Although this represents only a small number of samples, and may not predict growth 
performances in a larger survey, preliminary indications would suggest that oesophageal 
tumours tend to establish with a higher frequency compared to other thorasic samples. Clinical 
histology of the pleural effusion did not detect any malignant cells but this patient was 
subsequently found to have a tumour in the right main bronchus. The growth of a benign 
tumour sample from the lung emphasises the need for in vitro characterisation of primary 
cultures (see Section 3.1.12).
3.1.5 CONTROL OF FIBROBLAST PROLIFERATION
As mentioned earlier, stromal fibroblasts proliferate with greater facility in vitro than their 
epithelial counterparts from the same tissue. This behaviour causes problems where the objective 
is to selectively cultivate the epithelial element of a tissue sample.
Studies with established cell lines suggest that the number of cells (malignant or normal) in a 
culture at the time of plating (plating density) is critical to their successful cycle o f proliferation 
thereafter. A  lower limit to the number of epithelial cells which can effect this sustained growth 
cycle is characteristic of every tissue type in vitro. This phenomenon is thought to reflect the 
production of self-stimulating (autocrine) growth factors elaborated by a stem cell population 
in normal regenerative tissue such as the skin, and, by analogy, malignantly transformed cells 
in tumour tissue.
The approach taken here was to endeavour to restrict fibroblast growth and/or to stimulate 
epithelial proliferation. It was reasoned that if a tumour contains a subpopulation of ‘immortal’ 
cells, then it should be possible (in theory) to expand this fraction with suitable in vitro culture 
conditions, so that they might eventually outgrow all other cell types present in the initial 
primary culture. The first step in this approach therefore, was the selective removal of 
fibroblasts from cultures displaying epithelial cell growth. In this way it was hoped to maintain 
epithelial cell density at the expense of fibroblasts.
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Epithelial cells tend to grow in tightly associated monolayers with outgrowth occuring from the 
edges of the colony, whereas fibroblasts produced migrating "whorls" as well as very motile 
individual cells which proliferated rapidly, encircling epithelial colonies and thereby physically 
restricting further epithelial outgrowth. This often resulted in piling up and/or tight packing of 
the epithelial cells, causing senescence or necrosis at the centre o f colonies.
A number of methods using different combinations and concentrations of crude trypsin and/or 
EDTA were employed in the selective detachment of epithelial and fibroblasts respectively. A  
description of these trypsin/EDTA formulations and methodology used is given in Table 3.1.5.1  
below. All the following protocols were monitered microscopically as described in Section 
2.5 .8 .1 .
3.1.5.1 Differential trypsinisation of epithelial and fibroblast cell types
Table 3.1.5.1 Methods used to selectively remove fibroblasts from epithelial cells in 
primary cultures
Method N® PROTOCOL DESCRIPTION
1 0.04% EDTA for 5 minutes at room temperature, followed by incubation in 0.01% trypsin/0.04% EDTA at R.T.
2 0.01 %trypsin/0.04%EDTA at 4°C
3 0.02% trypsin/0.04% EDTA at 4°C.
4 0.001% trypsin/0.04% EDTA at 4°C.
5 0.25% trypsin only at4°C.
The relative success in the physical separation of fibroblast and epithelial cell populations is 
summarised as follows:
Method 1
Under these conditions fibroblasts and epithelial cells deteched simultaneously upon the addition 
of the trypsin/EDTA mixture. No preferential detachment was noted.
Method 2
In one case >  90% of the fibroblasts were removed using this technique but typically fewer 
than this could be detached before epithelial cells were also removed. The incubation time for 
this method varied between samples but 4 minutes was the average exposure time.
Method 3
Similar to (2) above but fibroblasts left after treatment appeared to be resistant to this procedure 
in subsequent attempts to remove them.
Method 4
Longer incubation periods were required for this protocol (typically 30 minutes). This 
methodology was only partially selective in the removal of fibroblasts. Fibroblasts removed in 
this way were seen to contain epithelial cells three days after replating in growth medium.
Il l
Method 5
Where the number of epithelial cells exceeded that o f fibroblasts (as judged empirically by eye) 
this method was successful in selectively detaching epithelial cells in preference to fibroblasts.
It was also generally observed that selective trypsinisationwas less successful where epithelial 
cells were scattered in small colonies or as single cells interspersed by fibroblasts. Differential 
separation of both cell types was easier to achieve when epithelial cells formed large compact 
and/or discreet colonies. In these cases the epithelial-fibroblast contact was limited to the edges 
of such colonies. A  successful procedure following protocol N®2 above is illustrated in figures
3.1 .4  & 3.1.5.
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Figure 3.1.4 A colony of human lung squamous cell epitlelial surrounded by fibroblasts 
Arrows indicate the presence of fibroblasts. (60X magnification)
Figure 3.1.5 The same colony of squamous epithelial cells as shown in figure 3.1.4, after 
removal of fibroblasts using 0.01% trypsin/0.04% EDTA at 4°C. (60X)
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An alternative approach to the elimination of fibroblasts from epithelial cultures was based on 
work carried out in this laboratory with primary fibroblasts and established epithelial cell lines 
{McDonnell (1987)}. McDonnell found a differential in the toxicity of fibroblasts and the cell 
lines to geneticin (G418); 100 ¿ig/ml G418 for two days was preferentially toxic to fibroblasts. 
In this work preliminary experiments with the same concentration of G418 displayed an 
encouraging reduction in the number of fibroblasts after a 6 day incubation in G418. However, 
complete recovery of fibroblast numbers were seen 24 hours after removal of the selective 
agent.
Further work by Martin (1992) using this treatment with lung fibroblast cultures indicated that 
higher concentrations of this agent might be required (200-250 /¿g/ml) to kill 80-100% of 
fibroblasts, but a variation in the efficacy of G418 toxicity on different fibroblast cultures was 
seen.
This method was not preferred to the use of selective trypsinisation in this work for a number 
of reasons; (1) the variation in efficacy, (2) the rapid tendancy to recovery of fibroblasts after 
treatment, (3) the lack of data on the selective effects of G418 toxicity in primary epithelial 
cells, and (4) the potential hazzards associated with its use.
3.1.5.2 Differential toxicity of geneticin to fibroblasts and epithelial cells
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3.1.6 ESTABLISHMENT OF A CONTINUOUS HUMAN LUNG SQUAMOUS CELL 
CARCINOMA CELL LINE - DLRP
3.1.6.1 Clinical History of DLRP
A continuous cell line was established from a cervical lymph node biopsy taken from a sixty- 
one-year-old male with a history of smoking. Bronchoscopy revealed the presence of tumour 
at the orifice of the bronchus to the left upper lobe. A  biopsy performed on the left cervical 
node showed that the lymph node architecture was completely replaced by metastatic poorly 
differentiated squamous cell lung carcinoma. The patient died one month after bronchoscopy.
The following is a description of the primary culture history of this sample which was 
subsequently passaged forty times and is considered to be an established cell line.
Day 1. The sample of tissue received was devoid of vascular tissue and seemed to have an 
outer layer encapsulating its inner mass. There were no macroscopic signs of 
necrosis visible. Approximately half of the entire lymph node was made available 
for cell culture (2-3 cm3 of tissue). The outer layer was dissected separately after 
careful removal, but both sections were processed identically thereafter.
Dissection was performed in complete medium (Section 2.5.2) and explants were set­
up from tissue fragments of suitable size (1 mm2). Larger fragments were allowed 
to settle under gravity in complete medium and the supernatant (dissection medium) 
was plated directly into tissue culture flasks. The remaining tissue pieces were 
digested in collagenase (Sigma type IV, at 2000 U/ml) for 3 hours with stirring. The 
resulting cell suspension was pelleted by centrifugation and the cells were 
resuspended in complete medium. Enzyme digests of the outer layer yielded fewer 
cells (as judged empirically by eye).
Day 2. Epithelial colonies were visible in the dissection medium (DM) platings and these
appeared to be growing outward from cell clumps. The medium in these cultures 
contained many unattached cells and was therefore replated into fresh flasks and the 
' original flasks were refed.
Day 5. A small number of fibroblasts were visible in DM platings but epithelial monolayers 
continued to expand. Limited epithelial growth was seen in enzyme digest of the 
inner node mass and in the explant cultures. All cultures were refed.
Day 6. Epithelial colonies in cultures from the DM fraction began to reach confluency.
Evidence of colonies arising from smaller groups of cells, with individual cells 
dividing away from the main colonies was also noted in these flasks. Explants and 
enzyme fractions continued to form epithelial monolayers but many fibroblasts were 
also visible.
Day 8 . Attempted to remove fibroblasts present in enzyme digest culture using method N21 
in Section 3.1.5.1 above. This resulted in the simultaneous removal of fibroblasts, 
therefore all cells were replated. These cells at passage 1 (PI) were plated onto 
collagen coated tissue culture flasks (Section 2.5.10).
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Day 12. Second attempt to remove fibroblasts from an enzyme digest using method N2 2 in 
Section 3.1.5.1 above. This was partially more successful than method N2 1.
Day 13. Removed an aliquot of spent growth medium from passage 1 cells for mycoplasma 
analysis.
Day 19. Subcultured primary cultures from DM fraction using method N2 5 {0.25% trypsin 
only at 4°C }, Section 3.1.5.1. The majority of fibroblasts were left behind by this 
procedure.
Day 22. Passage 1 cells on collagen-coated flasks (day 8) were subcultured (P1-»P2) using 
0.25% trypsin only at 4°C. The trypsinisation process took 30 minutes but 
fibroblasts remained firmly attached.
Day 26. Removed culture medium from P2 cells for mycoplasma analysis. Passaged these to 
P3 using 0.25% trypsin only at 4°C.
Day 34. Passage 3 cells are free of fibroblasts but appear very ‘grainy’ in their cytoplasm and 
their medium was becomming quickly very acidic. This suggested mycoplasma 
contamination. All flasks of this cell line were refed with fresh medium containing 
60 /xg/ml of the antibiotic tylocine (anti-PPLO agent) {Section 2.4 .2 .2}.
Day 40. Medium from passages 1 & 3 from this cell line were positive for mycoplasma.
Day 42. Improvement in growth rate and less granulation in cultures treated with tylocine. 
Gentamicin included in growth medium of all stocks (with tylocine).
Day 46. Made frozen stocks from cultures at passages 3, 4 & 5.
Day 47. Frozen stocks made from cultures at passage 6 made.
Day 54. All stocks remaining in culture with antibiotics showed continued improvement in 
growth rate with less granulation in their cytoplasmic space.
Day 56. Discontinued the use of gentamicin and tylocine.
Day 58. Made frozen stocks at passages 6 & 8 . Yields from 25 cm2 flasks (approximately 70- 
80% confluent) were in the order 7 .5 x  105 cells per flask.
Day 62. A ll stocks in antibiotic-free medium show no signs of deterioration with respect to 
growth rates and granulation of the cytoplasm. Frozen stocks prepared from cultures 
at passages 6 , 8 & 9 respectively.
Day 63. Morphology change noted at passage 10. Some of the cell population has become 
elongted with dendritic-like protrusions (‘spindly’). The original squamous (cuboidal) 
phenotype can still be distinguished in the population.
Day 68. Returned all stocks to tylocine-containing growth medium after increased granulation 
noted in the cytoplasm. Passaged all P10 stocks into new flasks.
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Day 75. Passage 11 cells in new flasks have improved growth rates and the original 
squamous cell morphological phenotype was the only one discernable.
Day 79.
Day 84.
Day 89. All remaining stocks were discarded due to a rapid deterioration in their growth rates 
and gross moprhology changes similar to those seen at passage 10. Rapid 
acidification of culture medium immediately after plating suggested mycoplasma 
contamination.
3 .1 .6.2  Elimination of mycoplasma contamination in the cell line DLRP
Passage 9 DLRP cells (frozen on day 62 after six days in antibiotic-free growth medium) were 
thawed. Recovery from frozen stocks was extremely poor (< 4 0 %  attached). The culture was 
refed with fresh medium after 24 hours and anti-mycoplasma agent BM cycline was added three 
days after thawing. The procedure took three weeks and is described in Section 2.4.2 .2. 
Cultures were passaged during this treatment process and the previously noted change in 
morphology (i.e at passage 10 on day 63) was seen again in this stock culture at P10. Cells 
proceeded through this ‘crisis’ and by passage 12 had recovered their original phenotype.
After three cycles of BM Cycline treatment cultures were mycoplasma negative as determined 
by the indirect detection method (Section 2.4 .2.1). A separate stock (passage 6 , from day 62) 
was thawed and treated in this way. The morphology change observed in previous transtitions 
to passage 10 was recorded yet again. All subsequent frozen stocks were derived from the latter 
cultures.
This cell line consistently grew better when plated regularly into new culture flasks. This was 
contrary to the generally observed phenomenon (in animal cell culture folklore) that replating 
the cells into the same flasks permits better attachment and faster growth thereafter. The 
squamous cell-like morphology which is characteristic of DLRP can be seen in figures 3.1.6  
& 3.1.7.
Figure 3.1.6 Monolayer growth of DLRP at passage 7, grown in antibiotic-free medium 
(60X magnification).
Figure 3.1.7 The same culture of DLRP as figure 6 above with cells at passage 9
Cells with multiple nucleoli indicated by arrows (150X magnification).
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The high levels of expression reported in human squamous cell lung carcinomas for epidermal 
growth factor receptor (EGF-R) {Berger et al., (1987)} have implicated the ligands for this 
receptor as potential autocrine growth factors as mentioned earlier. Among these are the 
mitogens epidermal growth factor, transforming growth factor a . Many studies have 
demonstrated the production of TGFa by carcinoma cells but until recently EGF production had 
not been detected in tumour tissues.
In the context of successful in vitro growth of DLRP, it was of considerable interest to establish 
whether this cell line produced an EGF-like mitogenic activity. To this end, medium conditioned 
by the cell line at passage 21 was concentrated lOOx by ultrafiltration (Section 2.8.1). A  
radioreceptor assay for the detection of EGF-like activity based on competitive binding to the 
EGF-R-rich membrane of the cell line A431 was used for this purpose (Section 2.12.6). 
Conditioned medium (CM) from the rapidly growing human epidermoid carcinoma cell line 
HEp-2 (concentrated 50x by ultrafiltration) was also assayed in this experiment. The results are 
presented in Table 3.1.6.3 and a standard curve for ‘cold’ EGF is presented in figure 3.1.8.
Table 3.1.6.3 Detection of EGF-like activity in CM from DLRP and HEp-2
3.1.6.3 Measurement of epidermal growth factor-like activity in medium conditioned
by the cell line DLRP
CONCENTRATION 
COLD EGF (nji/ml)
C.P.M. ±  S.E.M.*
10000 61 ±  4
500 282 ±  11
100 924 ±  35
50 1064 ±  72
10 1251 ±  19
5 1343 + 90
1 1523 ±  55
Control Mediumb 1615 ±  67
DLRP CM
lOOx 1478 ±  27
75x 1505 ±  33
50x 1490 +  23
25x 1632 ±  37
lOx 1592 ±  95
HEp-2 CM
50x 1507 ±  72
25x 1585 ±  74
a Counts per minute + standard error of the mean. b Ham’s FI (n=3).
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The presence of EGF-like activity was indicated in the lOOx concentrate of DLRP conditioned 
medium (CM). The reading indicated that between 1-5 ng/ml of EGF-like activity was present 
in this sample, but this measurement was at the lower end of the detection range on the standard 
curve (figure 3.1.8). Accurate quantification cannot be assured at this level of detection. No 
acitvity was detected in the 50x HEp-2 CM concentrate.
3 .1 .6 .4  C om parison o f  the percentage colony form ing efficien cies o f  D L R P  and another  
poorly differentiated hum an lung squam ous cell carcinom a line D L K P in soft  
agar
A  characteristic of the growth of malignant cell lines in vitro is their abililty to form colonies 
in semi-solid agar growth medium. This property has been used as an indicator of malignancy 
by workers in the field. DLRP and another human lung squamous cell carcinoma line, DLK P, 
(also recently established in this laboratory) were plated in a 0.3% agar overlay of 0 .6 % agar 
on 35 mm petri dishes and incubated for 10 days in a C 02 incubator (Section 2.12.3.3). Both 
cell lines were plated at several densities. Colonies greater than 50 ¡xm were counted (i.e. scored 
as a colony) and the percentage colony forming efficiency (% C.F.E.) was determined (see 
Section 2.12.3.1 for details of calculations). The morphology of DLRP colonies in this soft agar 
growth system can be seen in figure 3.1.9 and the results of replicate experiments are shown 
in Table 3.1.6.4.
T able 3 .1 .6 .4  The % colony form ing efficiency o f  D L R P  and D L K P  in soft agar
Plating
Density
Experiment 1
DLRP <P33>* DLKP CPU)*
% C.F.E, ±  S.E.M. % C.F.E. ±  $.E.M.
5.0 x 105 0.42 ± 0.04 N.R.”
2.5 x 10s 0.73 + 0.01 N.R.
1.0 x 105 0.79 ±  0.05 N.R.
5.0 x 104 0.00 ± 0.00 5.34 ± 0.49
1.0 x 104 0.00 ± 0.00 0.00 + 0.00
5.0 x 103 0.00 + 0.00 0.00 ±  0.00
Experiment 2
5.0 x 105 1.34 + 0.05 N.D.C
2.5 x 105 2.66 ± 0.30 N.D.
1.0 x 105 3.28 ± 0.42 N.D
5.0 X 10" 2.12 ±  0.50 2.32 + 1.31
1.0 x 104 0.00 + 0.00 0.00 ±  0.00
5.0 x 103 0.00 ± 0.00 0.00 ±  0.00
n= 3 for all determinations. a Passage number in the assay. b Not readable. 0 Not determined.
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Although every effort was made to ensure identical assay conditions between replicate assays 
significant inter assay variation in growth was noted. This phenomenon is a feature of bioassays 
but is particularly apparent with soft agar assays. The percentage colony forming efficiency 
(% CFE) o f DLRP was higher in the repeat assay, but the trends were similar between assays. 
% CFE was maximal at plating densities between 1 x 10s and 2.5  x 105 cells/plate. Higher 
plating densities resulted in reduced % CFE for this line. A lower limit to the plating density 
was reached in both assays below which no colonies formed. This was between 5 x 10* and 
1 x  105 cells/plate for DLRP.
The limiting plating density for DLKP in this system was 5 x 104 cells/plate. However, a plating 
density of 1 x 105 cells/plate gave so many colonies in the first experiment that accurate 
counting was impossible. For this reason, densities in this range were not plated for DLKP in 
the repeat assay.
Figure 3.1.9 The growth of a DLRP cell colony after 14 days in agar (150X magnification).
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Animal serum is an essential supplement to the chemically defined component of cell culture 
growth medium for the majority of animal cell lines cultured in vitro. As mentioned earlier, 
currently there are no commercially available serum-free media formulations for the culture of 
human lung squamous cell carcinomas. Therefore serum supplementation of basal media for 
these cell types continues to be necessary.
By virtue of their biological source and subsequent processing, animal sera display considerable 
variation in their ability to sustain in vitro growth of animal cell lines. Experience in this and 
other laboratories has shown that batch testing is required to ensure a supply of serum with 
good growth-promoting properties. In this respect it is important to consider the nature of the 
work to be undertaken. A  batch of serum considered for use in general cell maintenance should 
be tested for its growth-promoting potential on all the cell lines in use. This is because the 
growth performance in different serum batches is also dependent on the target cell line. 
Therefore, a good batch for one cell line may prove to be a poor batch for another in terms of 
its ability to stimulate cell proliferation.
In this work, batches of serum were selected for use on the basis o f their ability to support the 
growth of monolayer cultures of particular cell lines. In some cases batches were reserved 
exclusively for use with one cell line, and where appropriate, others were used in general cell 
line maintenance. Growth was quantified by measuring the area of colonies stained with the dye 
crystal violet (Section 2.12.4). In order to get a better idea of batch performance it was 
necessary to measure growth at a number of serum concentrations. To this end batches were 
tested at low serum concentrations between 1-3% v/v, at routinely used levels, i.e 10% v/v, and 
one concentration in between, at 5% v/v.
A preliminary experiment was designed to determine the serum batch preference of the new 
lung cell lines DLRP and DLKP. Cells were plated at a final concentration of 5 X 103 cells per 
well in a volume of 1 ml on 24-well plates. Cells were plated as describe in Section 2.12.4.3 . 
Sera for testing were prepared at 2x the final concentrationsin Ham’s F12. The cell plating 
densities chosen were designed to give sufficient readable growth at the lowest serum 
concentrations tested and to avoid excessive growth at the highest concentration (which would 
also prohibit accurate measurement of colony area by image analysis).
Four batches of bovine serum, two newborn calf (NCS) and two foetal calf (FCS), were tested. 
The response of a non-lung-derived carcinoma line HEp-2 was measured to check for any tissue 
specificity in batch performance. The latter cell line is well-established in vitro and displays a 
relatively short doubling time even at low serum concentrations. A  much lower plating density, 
4 x  102 cells/well was used for batch testing with this line based on the results in Section 3.2.1  
above. The results of these these batch tests are given in Table 3.1.6.5.
3.1.6.5 Determination of serum batch preference for the cell lines DLRP, DLKP & HEp-2
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Table 3 .1 .6 .5  D eterm ination o f serum  batch preference in the cell lines D L R P , D L K P  
and H Ep-2
Serum Batch FCS:801017 FCS:701113 NCS:F6182 NCS:30F7079
Cell
Line
%
Serum
Colony ±  S.E.M. 
Area
mm1 mm1
Colony ±  S.E.M, 
Area
mm1 mm1
Colony ±  S.E.M. 
Area
mm1 mm1
Colony ±  S.E.M. 
Area
miu* mm*
DLRP
2.5 4.01 ±  0.80 5.79 ± 0.81 1.50 ±  0.24 1.21 ±  0.10
5.0 7.05 ±  1.22 9.54 ± 0.45 4.90 ±  0.32 2.21 ± 0.20
10.0 7.95 ±  0.70 12.76 ±  0.74 6.78 ±  0.72 3.32 + 0.32
DLKP
1.0 19.77 ± 1.78 20.36 ± 2.26 38.35 ±  2.41 36.62 ±  3.07
5.0 83.40 ± 4.67 80.66 ±  4.00 84.33 ±  3.00 74.95 ±  5.79
10.0 86.59 ± 3.68 73.51 ±  5.56 76.17 ± 4.67 67.77 ±  1.56
HEp-2
1.0 0.05 ± 0.06 2.31 ± 0.20 1.22 ±  0.68 2.28 ± 0.39
5.0 2.33 ±  1.09 4.09 ± 0.76 3.25 ±  0.45 10.83 ± 1.50
10.0 12.97 ±  2.33 5.26 ± 0.46 19.15 ±  0.94 17.22 ±  3.28
n= 3 for all determinations.
The growth of DLRP was clearly better in foetal calf serum than in either of the newborn 
batches tested. At this plating density, more growth was evident at all concentrations of FCS 
than at the same concentrations of NCS.
The plating density used for DLKP resulted in very high growth even at low serum 
concentrations. The only significant differences in growth levels therefore were seen at 1% 
serum. At this plating density better growth was evident in the NCS batches than in either of 
the FCS batches. At higher serum concentrations no significant differences between batches are 
apparent. This suggested that a lower plating density should be used for DLKP in this system  
(24-well plate). This would facilitate the detection of growth promoters (in serum or as purified 
growth factors) by making the conditions of growth more stringent.
Batch preference for HEp-2 was not confined to either type (newborn or foetal calf serum), but 
the plating density used for this cell line discriminated between all batches with the same 
ranking order at each concentration tested.
Batches 701113-FCS and 10F6182-NCS were purchased in bulk and used for these cell lines.
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3 .1 .7  TH E EFFEC T O F PU R IFIE D  G RO W TH  F A C T O R S O N  TH E PR O L IF E R A T IO N  
O F D L R P A N D  D LK P
The evidence for an EGF-like activity in the medium conditioned by DLRP (Section 3.1.6.2) 
suggested that such a growth factor(s) might be important for the proliferation of this and other 
squamous cell carcinomas of the lung. It was reasoned that the effect of this and other growth 
factors produced in an autocrine manner might be more easily detected at low serum and low 
cell densities (minimising any potential self-feeding effect) where their contribution to the 
overall population growth would be more important. Preliminary experiments designed to define 
more stringent growth conditions in the 24-well plate system (lowest plating densities giving 
sufficient ‘readable’ growth in 1 % serum) were performed for DLRP and DLKP using the same 
batch of FCS (Batch N2AF1201). The results of these experiments are presented in Table 3.1.7.
Table 3 .1 .7  Growth o f  D L R P and D LK P at different p lating densities using 1% F C S in 
the 24-w ell plate system
CELL LINE DLUP DLKP
Plating Density 
Cells/well
Colony ±  S.E.M. 
Area
ram1 mm3
Colony ±  S.E.M. 
Area
mm1 mni1
8 X  103 40.97 ±  2.22 92.39 ±  2.63
6 x 103 19.86 ±  2.53 60.81 ±  14.25
5 X 103 12.77 ±  2.77 78.77 ±  10.36
4 X  103 10.67 ± 1.74 91.38 ±  0.72
3 x 103 3.70 + 0.77 69.55 ±  5.93
2 X 103 1.67 ±  0.57 42.28 ±1 .66
1 x 103 0.14 + 0.07 22.32 ±  2.39
n=3 for all determinations.
These experiments illustrate the very different growth rates of these two squamous cell lung 
carcinoma lines. At plating densities greater than 4 x  103 cells/well, overgrowth of DLKP was 
responsible for the lack of linearity between colony area measured and the number of cells 
plated. This may be explained by the fact that DLKP tends to detach very easily when 
confluency is reached in monolayer cultures. In subsequent growth factor experiments this cell 
line was plated at 1 x  103 cells/well. (Section 3.1 .7 .2). The plating density chosen for DLRP 
was 3 x  103 cells/well (Section 3.1.7.1).
3 .1 .7 .1  The effect o f  a  selection o f growth factors on D L R P proliferation
The mitogenic response of DLRP to purified growth factors from three different growth factor 
classes was determined. Cells were seeded in 24-well plates for this experiment (Section 2.12.4) 
The growth factors assayed were transforming growth factor a , interleukin l a  (IL -la) and 
interleukin 1/3 (IL-1/3), and acidic and basic fibroblast growth factors (aFGF & bFGF).
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One growth factor was assayed per 24-well plate. Seven concentrations of each growth factor 
were assayed together with a ‘medium only’ control (plus 1 mg/ml BSA , fraction V). Controls 
on each plate were included to allow for interplate variations in growth (n = 3 determinations 
per plate). An experiment control mean was calculated from the control readings (in colony 
area) from all 5 plates in the experiment (n=15).
Growth factors were scored as mitogenic if the numerical value of the sample mean minus the 
standard error on that determination was in excess of the control mean value plus  the standard 
error on that value. The results of this experiment are presented in Table 3.1.7.1.
Table 3 .1 .7 .1  The effect o f  T G F a, I L - la  & IL-l/S, and aFG F & bFG F on D L R P  grow th
Growth
Factor
Cone“
Colony ±  S.E.M. 
Area
mm1 nun1
Growth
Factor
Cone"
Colony ±  S.E.M. 
Area
mm2 nun1
Growth
Factor
Cone”
Colony i  S.E.M. 
Area
mm1 mm1
ng/ml Addic FGF pg/ml Basic FGF pg/ml TGFoe
25.00 4.65 ±  0.39 500 1.94 ±  0.72 500 2.21 ±  0.33
5.00 6.11 ± 0.89 250 2.65 ±  0.17 250 3.07 ±  0.33
2.50 6.35 +1.14 100 3.41 ±  0.24 100 2.62 ±  0.19
1.50 4.25 + 0.72 50 2.83 ± 0.74 50 3.19 + 0.94
0.50 5.21 ±  0.76 10 3.08 ±  0.65 10 3.44 +  1.01
0.25 5.19 ±  0.72 5 4.49 ± 1.68 5 3.02 ±  0.20
0.10 4.77 ±  0.74 1 3.79 ± 0.22 1 3.42 ±  0.43
Control 
+ BSA 3.39 ±  0.64
Control 
+ BSA 2.34 ±  0.22
Control 
+ BSA 2.41 +  0.06
pg/ml Interleukin la pg/ml Interleukin Iß EXPERIMENT CONTRLS
500 3.63 ±  0.92 500 3.27 ±  0.86
Control Medium 
+ 1 mg/ml BSA
(n=15) 2.23 ±  0.89
250 4.43 ±  0.34 250 3.75 ± 0.39
100 4.85 ±  1.19 100 3.44 ±  1.00
50 2.56 ±  0.66 50 2.02 + 0.15
10 3.00 ±  0.65 10 3.20 + 0.50
Control Medium 
minus BSA
(n= 16) 1.66 +0.72
5 3.44 + 1.03 5 3.49 ±  0.71
1 3.11 ±  0.15 1 2.38 ± 0.37
Control 
+ BSA 1.81 ± 0.87
Control 
+ BSA 1.21 ± 0.34
n= 3 unless otherwise stated.
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A considerable inter-plate variation in control growth was seen in this experiment. Increased 
growth was scored using the experiment control and the plate control for each growth factor 
assayed. Positive stimulation was scored only if the level of growth in growth factor wells was 
greater than both controls as outlined. On this basis, aFGF was mitogenic for DLRP in 
monolayer. The stimulation appeared to be biphasic because significant growth over the controls 
was detected between 0.25 and 0.5 ng/ml and in a higher concentration range between 2.5  and 
5.0 ng/ml. At 25 ng/ml aFGF stimulation was still detected but at a reduced level. Maximal 
stimulation with growth factor under these conditions was detected at 2.5 ng/ml and this induced 
a 2.85 fold increase in growth with respect to the experiment control mean.
Basic FGF was also mitogenic for DLRP. At 1 pg/ml the fold increase in growth was 1.7 (w.r.t 
experiment control mean). The differential in the concentrations of acidic and basic FGF 
required to induce mitogenic activity in DLRP was consistent with the pattern of stimulation 
seen in other cell systems for these homologous growth factors.
Interleukin-la was mitogenically active between 100 and 250 pg/ml on DLRP inducing 1.98 
and 2.17 fold increases in growth at these concentrations respectively. Activity with IL-1/3 was 
also detected at 250 pg/ml where a 1.68 fold increase in growth over control (experiment 
control mean) was measured.
Transforming growth factor a  was not mitogenic for DLRP under these conditions.
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3.1.7.2 The proliferative response of DLKP to growth factors from three different 
growth factors classes
The same stocks of growth factors used in the DLRP assay above were tested on the cell line 
DLKP under the same assay conditions as in Section 3.1.7 .1. One growth factor was assayed 
per plate and medium controls were included on each plate. The results of this experiment are 
shown in Table 3.1.7.2.
Table 3.1.7.2 The effect of TGFa, IL -la & IL-1/3 and aFGF & bFGF on DLKP growth
Growth
Factor
Cone“
Colony ±  S.E.M. 
Area
mm2 mm1
Growth
Factor
Cone"
Colony ±  S.E.M. 
Area
mm2 mm1
Growth
Factor
Cone"
Colonv ±  S.E.M. 
Area
mm1 ram1
ng/inl Addle FGF pg/ml Bask FGF pg/ral TGFa
25.00 0.52 ±  0.01 500 0.66 ±  0.03 500 2.44 ±  0.50
5.00 0.90 ±  0.28 250 1.31 ±  0.28 250 2.94 ±  0.47
2.50 1.77 ±  0.32 100 1.77 ±  0.40 100 3.22 ±  0.26
1.50 1.30 ±  0.24 50 2.28 ±  0.65 50 3.19 ±  0.46
0.50 2.75 ±  0.26 10 2.80 ±  0.30 10 3.22 ±  0.43
0.25 3.82 ±  0.52 5 5.22 ±  0.62 5 4.93 ±  1.61
0.10 3.58 ±  0.41 1 4.34 ±  0.67 1 3.24 +  0.65
Control 
+ BSA 2.69 ±  0.44
Control 
+ BSA 3.07 ±  0.70
Control 
+  BSA 2.69 ±  0.65
pg/ml Interleukin la pg/ml Interleukin 1/3 EXPERIMENT CONTRES
500 2.20 ±  0.73 500 2.69 ±  0.23
Control Medium 
+  1 mg/ml BSA
(n= 15) 2.79 ±  0.69
250 2.78 ±  0.21 250 4.06 ±  1.05
100 3.60 ±  1.42 100 3.47 ±  0.85
50 2.81 ±  0.39 50 3.16 ±  0.59
10 1.79 ±  0.44 10 3.71 ±  0.17
Control Medium 
minus BSA
(n= 16) 1.76 ± 0 .4 4
5 3.54 ±  0.86 5 5.36 ±  0.20
1 2.91 ±  0.77 1 4.23 ±  0.71
Control 
+  BSA 2.22 ±  0.34
Control 
+ BSA 3.25 ±  0.73
n=3 unless otherwise stated.
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Inter-plate variation in control DLKP growth was not as great as with DLRP in the previous 
experiment. However, this cell line displayed a different pattern of growth factor sensitivity 
profile than DLRP. High concentrations of aFGF (>  0.5 ng/ml) were inhibitory for DLKP 
growth in monolayer. Weak growth stimulation was indicated with 0.25ng/m l aFGF with
respect to the plate control ( x  1.4 fold), but this was not significant with respect to the
experiment control.
A  similar sensitivity pattern was seen with bFGF. Concentrations between 1 and 5 pg/ml bFGF 
were mitogenic for DLKP giving fold stimulations of 1.56 and 1.87 respectively with respect 
to the experiment control. However, concentrations greater than 10 pg/ml were inhibitory to 
DLKP with growth reduction directly proportional to the increase in bFGF concentration.
No significant activity was detected with IL -la , but IL-1/3 was stimulatory at 5 pg/ml inducing 
a 1.92 fold increase in growth (w.r.t the experiment control).
TGFa was not active on DLKP over the range of concentrations assayed.
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3.1.8 INVESTIGATION OF POSSIBLE AUTOCRINE GROWTH FACTOR 
PRODUCTION BY DLRP AND DLKP
The possibility that the NSCLC cell lines established in this laboratory produced autocrine 
growth factors was investigated. If such factors exist, then it they might prove beneficial in 
supporting the growth of primary lung epithelial cells in vitro. Preliminary experiments designed 
to test this hypothesis using Ham’s F12 conditioned by DLRP and DLKP (Section 2 .7 .2) are 
described below.
3.1.8.1 Preliminary autocrine assay development for DLRP
DLRP cells were plated as described in Section 2 .12.4.3. A number of attempts to measure the 
effects of DLRP conditioned medium at low serum concentrations were unsuccessful. No 
growth was obtained in assays using 0.5% FCS but the results of an experiment using 2% FCS 
(Batch N^O 1113) are shown in Table 3.1 .8.1 . In this experiment, collections of Ham’s F12 
medium conditioned in a roller bottle culture of DLRP were assayed for growth-promoting 
activity on DLRP in monolayer.
Table 3.1.8.1 The effect of DLRP CM on the growth of DLRP in monolayer 
(collected from DLRP over 31 days)
CM COLLECTION 
NUMBER
DLRP Conditioned Medium
■Undiluted Diluted '/>
Colony ±  S.E.M. 
Area
mm1 mm1
Colony ±  S.E.M. 
Area
mm1 mm*
CM 1 3.04 ±  1.35 0.75 ±  0.39
CM 2 3.78 ±  1.91 3.75 ±  2.69
CM 3 1.75 ±  0.67 1.37 ±  1.62
CM 4 1.27 ±  0.37 2.87 ±  2.81
CM 5 1.92 ±  0.88 3.56 ±  1.19
CM 6 3.36 ±  2.41 1.29 ±  0.91
CM 7 2.85 ±  1.73 2.35 ±  2.06
CM 8 2.06 ±  1.41 3.06 ±  0.87
CM 9 2.21 ±  1.79 3.66 ±  2.06
CM 10 2.97 ± 1 .1 9 2.37 ±  1.66
CM 11 3.40 ±  3.57 5.37 ±  2.03
CM 12 4.37 ±  0.98 N.D
Control Ham’s F12 3.09 ±  1.73
n=4 for all determinations.
130
No evidence for autocrine stimulatory activity was detected in any of the 12 collections of 
DLRP CM.
3.1 .8 .2  Preliminary autocrine assay development for DLKP
DLKP were plated at three plating densities initially, at 1 X 103, 1.5 x  103 and 2 x  103 cells 
per well in 24-well plates, as described in Section 2.12.4. Two concentrations of serum were 
used at each cell density, 1 and 2% FCS (batch Na 701113). Unconcentrated Ham’s F12 
conditioned by DLKP was incubated with DLKP in this system for 7 days and growth (colony 
area, mm2) in the assay was then measured by image analysis. The results of this experiment 
are presented in Table 3.1.8.2.
Table 3 .1 .8 .2  The effect of DLKP conditioned medium on the growth o f DLKP in 
monolayer
Plating Density 1 X 103 Cells/well 1.5 xlO5 Cells/well 2.0 x 10* Cells/well
DLKP CM
Colony ±  S.E.M 
Area
mm1 mm1
Colony +  S.E.M 
Area
mm1 mm2
Colony ±  S.E.M 
Area
mm2 mm2
1% F'oetal Calf Serum
Undiluted 1.81 ±  0.30 4.19 ±  0.63 13.56 ±  2.06
Diluted 'h N.D. 8.67 ±  1.00 N.D.
Control 3.38 ±  0.58 9.07 + 2.40 26.77 ±  2.40
2% Foetal Calf Serum
Undiluted 11.96 ±  0.73 18.71 ±  4.54 4.73 ±  0.66
Diluted 'A N.D. 22.90 +  3.14 N.D.
Control 14.75 ±  1.81 23.52 + 1.87 22.71 + 1.76
n=3 for all determinations.
No evidence for autocrine activity was detected in the medium conditioned by DLKP. In low  
serum, addition of undiluted DLKP CM caused growth inhibition. Dilution of this CM restored 
DLKP cell growth to the control level at a cell plating density of 1.5 x  103 cells/well. The 
degree of inhibition was in the same order at each plating density (aproximately 50%), but it 
was was less obvious at the higher serum concentration.
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3.1 .9  EVIDENCE FOR A  SUBSTANCE IN HUMAN M ALIGNANT EFFUSIONS W ITH  
GROWTH-PROMOTING ACTIVITY FOR HUMAN LUNG SQUAMOUS 
CELL CARCINOMA CELL LINES IN  VITRO
The potential benefit of biological fluids in the primary culture of squamous cell lung 
carcinomas in monolayer culture was addressed in this work. The effect of malignant effusions 
on human squamous cell lung carcinomas was examined because of the poor success to date of 
these tumour types in vitro. Monolayer assay systems were preferred for this analysis because 
of the technically cumbersome protocols required for agar assays and the added time factor 
involved with these systems.
DLRP and DLKP were chosen as model cell lines for this investigation together with another 
squamous cell carcinoma line of human origin, SK-MES-1. The latter cell line was not 
established in this laboratory. The cell line HEp-2 was included as a non-lung-derived control 
to determine the specificity of any effects on the lung cell lines. In a preliminary series of 
experiments, the effect on monolayer growth of an ascites fluid from a patient with ovarian 
carcinoma was determined.
3.1 .9 .1  The effect of ascites fluid on the growth of DLRP in monolayer
An ascites fluid from a patient with ovarian carcinoma (Ovarian 1) was processed as described 
in Section.2.5.7) before being filter-sterilised (0.22 ¡xm low-protein-binding filter, Millex) and 
assayed with and without dilution, using the same the monolayer growth assay described in 
Section 2.12.4.3. A  medium only control containing 1 % (v/v) FCS was included and the results 
are presented in Table 3.1.9.1.
Table 3.1.9.1 Stimulation of DLRP monolayer growth by a malignant effusion from a 
patient with ovarian carcinoma
OVARIAN M.F. 
(Dilutions)
Colony ±  S.E.M. 
Area
mm1 mm1
Fold Stimulation 
w.r.t. Control*
Undiluted 0.00 ±  0.00 -
Diluted 3/5 0.00 + 0.00 -
Diluted 1/2 0.00 ± 0.00 -
Diluted 2/5 0.00 ± 0.00 -
Diluted 1/5 0.03 ±  0.02 -
Diluted 1/10 9.99 ±  3.59 9.00
Diluted 1/20 14.52 + 1.54 13.08
Control1 1.11 ±  0.10
n=3 for all determinations. a Fold stimulation with respect to the growth in 
the control. b Ham’s F12.
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DLRP was inhibited completely with neat fluid and at all dilutions of this sample down to 1/5. 
However, a nine-fold increase in growth over control was apparent at a dilution of 1/10 ( =  5 % 
v/v) fluid. Further dilution to 1/20 increased the apparent fold stimulation to 13.
3 .1.9.2 The effect of ascites fluid on DLKP growth in monolayer
The same fluid (Ovarian 1) used in the previous experiment was assayed with DLKP in the 24- 
well plate system as described in Section 2.12.4.3. Medium controls were included as before 
and the results of this experiment are shown in Table 3.1.9.2.
Table 3 .1.9.2 Stimulation of DLKP growth in monolayer by a malignant effusion from 
a patient with ovarian carcinoma
OVARIAN M.F. 
(Dilutions)
Colony ±  S.E.M. 
Area
mm3 mm2
Fold Stimulation 
w.r.t. Control’
Undiluted 0.00 ±  0.00 -
Diliuted 1/2 0.00 ±  0.00 -
Diluted 1/5 0.04 + 0.03 -
Diluted 1/10 2.75 ±  1.34 2.25
Diluited 1/15 2.06 ±  0.38 1.69
Diliuted 1/20 2.97 ±  0.36 2.43
Diluted 1/40 3.31 ±  0.52 2.71
Control* 1.22 ±  0.65 .
n=3 for all determinations. a Fold stimulation with respect to the growth in 
the control. b Ham’s F12.
A similar response to this fluid was observed with DLKP. Dilutions down to 1/5 were 
completely inhibitory for growth but at 1/10 a two-fold increase in growth over the control was 
apparent. However, further dilution of the fluid did not result in significantly greater increases 
in stimulation.
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3.1.9.3 The effect of ascites fluid on the growth in monolayer of SK-MES-1
Under the same conditions as those used in Section 3.1.9.1 above the response of SK-MES-1 
to the fluid ‘Ovarian 1’ was investigated as described in Section 2 .12 .4 .3 . The same background 
serum batch was used here as in Sections 3.1.9.1 & 2 respectively. The results are presented 
in Table 3.1.9.3
Table 3.1.9.3 Stimulation of SK-MES-1 growth by a malignant effusion from a patient 
with ovarian carcinoma
OVARIAN M.F. 
(Dilutions)
Colony ±  S.E.M. 
Area
mm2 min1
Fold Stimulation 
w.r.t. Control*
Undiluted 0.00 + 0.00 -
| Diluted 1/2 0.00 ±  0.00 -
Diluted 1/5 0.04 ±  0.03 -
Diluted 1/10 16.80 ±  13.64 6.24
Diliuted 1/15 30.24 ±  7.49 11.24
Diluted 1/20 26.29 + 11.81 9.77
Diluted 1/40 3.51 ±  1.36 1.30
Controlb 2.69 ±  0.55
n=3 for all determinations. a Fold stimulation with respect to the level of 
growth in the control. b Ham’s F12.
The response of SK-MES-1 was consistent with that observed for DLRP in Section 3.1.9.1  
above. Inhibition was seen down to a dilution of 1/5. Fold stimulation over the control was in 
the same order at equivalent dilutions. In this case the level of stimulation was reduced to the 
control level at a dilution of 1/40 ( =  1.25% v/v).
3.1.9.4 The effect of ascites fluid on the growth of HEp-2
The growth response of HEp-2 to the ascites effusion designated ‘Ovarian 1’ was investigated 
to determine the specificity of the growth-promoting activity detected with the lung cell lines.
HEp-2 was plated at 2 x  102 cells per well in the 24-well plate system but all other assay 
parameters were the same as described for the same experiments with the lung carcinoma cell 
lines (Sections 3.1.9.1, 2 & 3 above). The results of this experiment are shown in Table
3.1.9.4.
Table 3.1.9.4 Stimulation of HEp-2 growth by a malignant effusion from a patient with 
with ovarian carcinoma
OVARIAN M.F. 
(Dilutions)
Colony ±  S.E.M. 
Area
mm1 mm1
Fold Stimulation 
w.r.t. Control*
Undiluted 0.00 ±  0.00 -
Diluted 1/2 0.00 ±  0.00 -
Diluted 1/5 12.51 ±  1.45 1.89
Diluted 1/10 26.32 ±  4.83 3.97
Diluted 1/15 24.64 ±  1.32 3.72
Diluted 1/20 21.50 ±  2.41 3.24
Diluted 1/40 16.26 ±  2.02 2.45
Control” 6.63 ±  0.14
n=3 for all determinations. a Fold stimulation with, respect to the level 
of growth in the control. b Ham’s F12.
The stimulatory effect of this malignant effusion was not specific to lung carcinoma lines.
As in the previous experiments with this fluid, a similar pattern of inhibition and stimulation 
of HEp-2 growth was observed at low and high dilutions of the fluid respectively. In this case 
however, inhibition was replaced by stimulation below a Vi dilution. Maximal fold stimulation 
over control was seen at a 1/10 dilution at approximately 4-fold.
3.1.10 HEp-2 AS AN INDICATOR CELL LINE FOR DETECTING GROWTH- 
PROMOTING ACTIVITY IN EFFUSIONS DERIVED FROM HUMAN 
CARCINOMAS OF DIFFERENT HISTOLOGICAL TYPE
The preliminary results with the NSCLC lines DLRP, DLKP, and SK-MES-1 (Section 3.1 .9  
above) indicated that a growth factor(s) activity present in a malignant effusion from a patient 
with ovarian carcinoma could stimulate the proliferation of these squamous cell lung 
carcinomas. The laryngeal carcinoma cell line HEp-2 was also shown to be sensitive to growth 
stimulatory activity in this effusion.
The potential usefulness of HEp-2 as an indicator cell line for the detection of growth-promoting 
activity in malignant effusions was considered for the following reasons. HEp-2 has a much 
faster rate of proliferation than any of the lung cell lines used in this work. This cell line could 
proliferate rapidly even in low serum concentrations and at low plating densities. Such growth 
properties facilitated the maintenance of in vitro stocks on a continuous basis in preparation for 
the receipt of fluid samples. Samples arrived with only a couple of hours warning, and on an 
infrequent basis. The HEp-2 assay system also required ten-fold fewer cells than the lung cell 
lines DLRP, DLKP, and SK-MES-1. HEp-2 therefore had several advantages over the lung cell 
lines as candidates for use as an indicator cell line.
In addition, at this time the growth performance of HEp-2 under stringent conditions (low serum 
concentration and low plating density) suggested the possibility that this cell line might be 
producing a growth factor or a repertoire of autocrine growth factors which diminished its 
serum requirement and reduced its minimum plating density at low serum levels in vitro.
Many of the autocrine growth factors characterised to date have also been shown to be active 
in cell types whose origins are histologically distinct to the originally identified producer cell 
type. Preliminary attempts to identify autocrine growth factor activity in the cell lines DLKP 
and DLRP were not encouraging (Section 3.1.8). For this reason, but also for the technical 
difficulties already mentioned, and the time factor involved, further development of these 
systems was not considered.
However, HEp-2 provided a facile cell line with which to work in these respects and 
preliminary experiments designed to detect autocrine growth factor activity in medium 
conditioned by this cell line were successful (Section 3.2.1.2). Further investigation of this 
autocrine system was pursued to characterise and purify the responsible autocrine species 
involved. The illucidation of such a mechanism, and the prospect of isolating in the process a 
novel growth factor(s) with growth promoting activity on primary epithelial cells, provided the 
incentive for this pursuit.
In the following series of experiments HEp-2 cells were plated under autocrine assay conditions 
(Section 2.12.4.2) and used to screen for growth-promoting activity in malignant effusions from 
patients with ovarian, breast, lung and kidney cancer, as well as a non-Hodgkins lymphoma. 
A sample of ascites from a patient with a non-malignant proliferative dissorder in the peritoneal 
cavity was also assayed. Fluids were filter-sterilised before assay and diluted in serum-free 
Ham’s F12. Because there was a considerable variation in control growth between experiments 
the results of these experiments were also presented as the fold stimulation with respect to 
(w.r.t.) the experiment control ( =  sample mean +  control mean). The results of the first 
experiment presented in Table 3 .1 .10(i) include as a reference the original sample of malignant 
effusion (Ovarian 1) assayed in Sections 3.1.9.1, 2, 3 & 4 above. The protein concentrations 
of these samples were determined using the BioRad protein assay (Section 2.11.6).
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Table 3.1.10(i) Detection of growth-promoting activity for HEp-2 in ascitic fluids 
associated with malignant and non-malignant disease
Origin of Associated 
Carcinoma
[Protein]
g/L
Sample
Dilution
Colony ±  S.E.M. 
Area
mm' mnr
Fold Stimulation 
w.r.t Control*
Ovarian (1) N.D.
None 0.00 ±  0.00 -
1/10 0.12 ±  0.06 -
1/30 7.89 ±  2.27 4.15
Ovarian (2)
None 7.98 +  1.94 4.20
55 1/10 12.11 ±  2.14 6.37
1/30 9.65 + 0.32 5.08
Breast (1) 43
None 50.24 ±  6.62 26.44
1/10 16.21 ±  0.26 8.53
1/30 6.89 ±  0.10 3.63
Breast (2) 33
None 14.75 +  3.55 7.76
1/10 8.81 ±  2.03 4.64
1/30 4.78 ±  0.74 2.52
Non-Mai ignant 
Proliferative 
Disorder of the 
Peritoneal Cavity
6.5
None 37.78 ±  5.14 19.88
1/10 9.39 ±  2.79 4.94
1/30 4.48 ±  1.05 2.36
Experiment Conl rol Gro\vthb (n=28) 1.90 ±  0.69 -
n=3 unless otherwise stated. a Fold stimulation with respect to the level of growth in the control. b Ham’s F12.
This experiment confirmed previous observations of growth inhibition with the sample 
‘Ovarian 1’. In this case the inhibition was detected at an even lower dilution (1/10). This 
suggested either a loss of stimulatory activity in this sample or an increase in the inhibitory 
species, or both, over time. Stimulation was also detected in a second ovarian sample but 
inhibition was not detected in the undiluted sample. However, further dilution of Ovarian 2 (to 
1/ 10) augmented the apparent stimulation detected suggesting that an inhibitory species was 
being diluted out.
Relatively high levels of stimulatory activity were not confined to the malignant effusions, as 
shown by the 20-fold stimulation observed with undiluted ascites fluid taken from a patient with 
a non-malignant proliferative dissorder. Stimulatory activity in this sample was also dilutable.
Stimulatory activity was detected in both sample of fluids from breast carcinoma patients and 
although this appeared to be greater in breast sample 1, the effect was dilutable in both cases. 
In the following experiment both of the fluids from breast carcinomas were assayed again 
together with the first fluid sample tested (Ovarian 1), as well as a non-Hodgkins lymphoma 
associated peritoneal fluid. The results are presented in Table 3 .1 .10.(ii).
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Table 3.1.10.(ii) Comparison of growth effects on HEp-2 of effusions associaed with 
non-Hodgkins lymphoma, ovarian and breast carcinomas
Origin of Associated 
Carcinoma
Samplc
Dilution
Colony ±  S.E.M. 
Area
mmJ mm1
Fold Stimulation 
w.r.t Control"
Ovarian (1)
None 0.00 +  0.00 .
1/10 0.00 ±  0.00 -
1/30 5.28 ±  1.32 1.55
Breast (1)
None 109.30 ±  1.77 32.15
1/10 56.63 ±  4.30 16.66
1/30 27.13 ±  3.12 7.98
Breast (2)
None 72.91 ± 1 .1 4 21.44
1/10 24.71 ±  1.14 7.27
1/30 15.75 + 2.13 4.63
Non-Hodgkins
Lymphoma
None 0.00 + 0.00 -
1/10 0.00 + 1.32 -
1/30 5.30 ±  1.32 1.56
Experiment Control growth b (n=57) 3.40 ±  1.08 -
n=3 unless otherwise stated. a Fold stimulation with respect to the level of growth in the control. b Ham’s F12.
This experiment confirmed the loss o f stimulatory activity and the concomitant rise of inhibitory 
activity in the original ovarian sample with time (sample were stored at 4°C). A  similar pattern 
of inhibition was detected in the non-Hodgkins lymphoma sample. The two breast samples were 
again shown to be stimulatory and this effect was dilutable.
In the last experiment in this series, pleural effusions from two patients with lung cancer were 
assayed together with pleural effusions from patients with kidney and breast cancers. Also 
included was an ascitic fluid from an ovarian carcinoma patient. The results are shown in Table 
3.1.10(iii).
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Table 3.1.10(iii) HEp-2 growth-promoting activity in effusions associated with lung & 
kidney carcinomas: comparison of activities in ovarian and breast 
samples
Origin of Associated 
Carcinoma
[Protein]
g/L
Sample
Dilution
Colony ±  S.E.M. 
Area
mmJ mm1
Fold Stimulation 
w.r.t Control*
Ovarian (3) N.D.
None 0.89 ±  0.15 -
1/10 8.84 + 2.03 1.40
1/30 12.43 ±  1.28 1.97
Breast (3) 31
None 55.25 ±  5.08 8.74
1/10 30.85 ±  3.25 4.88
1/30 14.01 ±  1.83 2.22
Kidney (1) 35
None 76.48 ±  4.18 12.10
1/10 40.90 ±  7.38 6.47
1/30 22.78 ±  3.94 3.60
Lung (1) N.D.
None 9.60 ±  0.88 1.52
1/10 7.65 ±  1.61 1.21
1/30 6.69 ±  1.20 1.06
Lung (2) N.D.
None 13.08 ±  8.04 2.07
1/10 10.77 ±  3.45 1.70
1/30 6.47 ±  1.90 1.02
Experiment Control Growthb (n=45) 6.32 ±  2.12 .
n=3 unless otherwise stated. a Fold stimulation with respect to the level of growth in the control. b Ham’s F12.
The highest fold stimulation was detected in the kidney carcinoma sample. Stimulatory activity 
in this fluid was dilutable. Relatively high activity was detected in a third sample of pleural 
effusion taken from a patient with a breast adenoacarcinoma (Breast 3). A  continuous cell line 
was established from cells harvested from this effusion (Section 3.1.11). The inhibition seen 
with the ovarian ascites was consistent with the pattern for other ovarian samples. Dilution of 
the latter sample to 1/10 abolished the apparent inhibition and at 1/30 this sample gave an 
apparent 2-fold stimulation in growth over the control. Activity in the lung samples was 
relatively low in both samples assayed.
139
3.1.10.1 Ammonium sulphate fractionation of an ovarian malignant effusion
Salt fractionation is a useful first step in the purification of protein from complex mixtures in 
solutions. The potential with this technique to differentially precipitate proteins from solution 
by incrementally increasing salt concentrations can be usefully employed to separate interesting 
proteins if these precipitate at salt concentrations other than those where the bulk of proteins 
precipitate (i.e. at low or high salt concentrations). Given that the majority of animal cell 
growth factors identified to date are proteinacious species, it was anticipated that some or all 
of the active species in human effusions might be protein. For this reason ammonium sulphate 
fractionation was applied to the task of characterising, by means of separation, the growth- 
promoting species for human lung squamous cell carcinomas detected in fluids associated with 
various histological types of cancer. This approach has also been employed by others in the 
purification and characterisation of growth factors and inhibitors from biological fluids {Mills 
et al., (1988); Podolsky et al., (1988)}.
A 100 ml sample of ‘Ovarian 1’ was subjected to several salt cuts as described in Section 
2.11.5. Protein pellets from the respective salt cuts resuspended in PBS were filter-sterilised 
before assay and diluted in Ham’s F12 (serum-free). A  PBS ‘dilution control’ was included to 
allow for dilution of nutrients in the assay and the results are presented in Table 3.1.10.2a.
Table 3.1.10.1 Growth factor activity in a salt fractionated malignant effusion from  
an ovarian carcinoma patient
SAMPLES DILUTIONS
1/10 1/30 1/60
% (NH^SO, Colony ±  S.E.M. 
Area
mm1 mm1
Colony ±  S.E.M. 
Area
mm* mm1
Colony ±  S.E.M. 
Area
mm1 mmJ
20% Pellet 4.57 ±  1.07 6.40 ±  0.97 4.87 ±  0.84
20% Supernatant 8.39 ±  1.61 6.00 ±  1.08 6.84 ±  0.64
20-30% Pellet 11.52 ±  1.61 9.59 + 1.35 6.95 ±  0.70
20-30% Supernatant 7.37 ±  0.54 8.53 ±  0.32 6.33 ±  0.44
30-50% Pellet 9.17 ±  1.12 7.07 ±  1.03 7.30 ±  0.48
30-50% Supernatant 3.25 ±  0.36 5.47 ±  0.76 6.90 ±  0.61
PBS Dilution Control“ 1.74 ±  0.28 3.05 ± 1 .1 4 4.12 ±  0.68
CONTROLS
Untreated Effusion 20.64 ±  1.28 14.00 ±  1.83 N.D.b
Experiment Control Growth0 (n=  15) 4.56 ±  0.78
n=3 unless otherwise stated. a Ham’s F12 diluted with PBS to allow for the dilution effect of fluid reconstituted 
in phosphate buffered saline. b Not determined. c Ham’s F12.
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The fold stimulation in all of the above samples assayed in table 3.1.10. la  were calculated with 
respect to the appropriate control for the sake of comparison.
Table 3.1.10.1b Fold stimulation in the ammonium sulphate fractionated malignant 
effusion
SAMPLES DILUTIONS
........................ —......
1/10 1/30 1/60
% (NH^SO, Fold Stimulation“ Fold Stimulation Fold Stimulation
20% Pellet 2.62 2.10 1.18
20% Supernatant 4.82 1.97 1.66
20-30% Pellet 6.62 3.14 1.69
20-30% Supernatant 4.24 2.80 1.54
30-50% Pellet 5.27 2.32 1.77
30-50% Supernatant 1.87 1.79 1.67
FOLD STIMULATION IN THE UNTREATED EFFUSION”
4.53 3.07 0.00
a Fold stimulation, in the samples with respect to the PBS controls. b With respect to Ham’s F12 control.
Analysis of the results in Table 3.1.10.1b indicate that the greatest fold increase over the 
respective dilution controls were in the precipitates at the 20-30% and 30-50% salt cuts. The 
magnitude of stimulation over the dilution controls was in the same order for both of these 
precipitates over the range of dilutions assayed. However, the relative concentration of proteins 
in each of these precipitates was at least 2x after fractionation and resuspension (with respect 
to the untreated fluid). Comparing the fold stimulation in the precipitates at 20-30% and 30-50% 
salt cuts to the fold stimulation in the untreated sample, only the precipitate at 20-30% salt 
diluted 1/10 shows a significant increase in fold stimulation (with respect to the untreated fluid 
at this dilution).
The activity in this fluid therefore appears to be comprised of more than one species the 
majority of which (but not all) precipitates at 20-30% ammonium sulphate concentration.
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3.1.10.2 Growth stimulatory activity in malignant effusions compared to that in serum 
and plasma from autologus donors
Effusions associated with human disease are classified clinically as either transudates or 
exudates on the basis of total protein concentration. Samples with protein concentrations 
<  30 g/L are considered transudates and those with total protein concentrations >  30 g/L are 
classified as exudates. Transudates are normally associated with changes in membrane 
permeability, but exudates are associated with infection and malignancy. Pleural fluid can have 
total protein concentrations from 1 g/L up to concentrations in the normal range for plasma, 66- 
87 g/L. On this basis the majority of effusions received were classified as exudates. Two 
samples had total protein concentrations in the transudate range. One of these was from a patient 
with non-Hodgkins lymphoma and the other from a patient with a non-malignant proliferative 
disorder of the peritoneal cavity (leiomyosarcoma). No direct correlation between total protein 
and growth stimulatory activity in the HEp-2 assay was apparent with the samples assayed, and 
the detection of comparable growth stimulatory activity in the fluid associated with the 
proliderative dissorder indicated that this activity was not restricted to malignant effusions.
In an effort to understand the nature of the growth factor activity in these effusions, the 
possibility that this species was derived from systemic factors, carried in the serum or plasma, 
was investigated. Unfortunately samples of autologus serum and/or plasma were available in 
only two of the cases studied in this work. In the first example a serum and plasma sample from 
the patient designated ‘Breast 3’ were assayed over the same range of dilutions in the HEp-2 
assay. The plasma sample was collected in a Li-heparin tube. The serum was collected from 
clotted blood after centrifugation. The results of this preliminary experiment are presented in 
Table 3.1.10.2(i).
Table 3.1.10.2(i) Comparison of growth-promoting activity in a malignant effusion 
with that in autologus serum and plasma from a patient with 
breast carcinoma
Sample EFFUSION SERUM PLASMA
Dilution
Colony ±  S.E.M. 
Area
mm2 mm2
Fold* Colony ±  S.E.M. 
Area
mm2 mm2
Fold Colony ±  S.E.M. 
Area
mm2 mm2
Fold
None 78.33 ±  0.31 18.65 78.08 (n=l) 18.59 N.D.b 12.46
1/5 52.86 +  4.08 12.59 72.08 ±  2.65 17.16 52.35 + 2.87 N.D.
1/10 38.83 ±  1.43 9.25 69.00 ±  4.42 16.43 77.03 + 16.45 18.34
1/20 25.11 ±  1.53 5.98 55.88 ±  2.42 13.30 27.44 ±  1.40 6.53
1/40 18.41 ±  1.61 4.38 41.08 + 2.33 9.78 12.89 ±  3.15 3.07
1/80 15.19 ±  1.05 3.62 29.23 + 1.42 6.96 12.58 ± 11.02 2.99
1/100 10.47 + 1.09 2.49 24.93 ±  1.73 5.93 13.54 ±  7.35 3.22
Experiment Control Gr owthc (n=9) 4.20 ±  0.73
n=3 for all determinations unless otherwise stated. a Fold stimulation with respect to the control. b Not determined. 
0 Ham’s 12.
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The degree of stimulation in the serum sample was higher at all concentrations assayed than in 
the corresponding fluid at these dilutions, but the levels of stimulation supported by the plasma 
sample were in the same order as the effusion over the entire range of concentrations tested (the 
value for the 1/10 dilution of plasma was an exception, but the standard error on this 
determination was also very high). Although no value for the plasma protein concentration was 
established, that of the associated effusion from the same donor was 31 g/L which is at least 
half the concentration expected for normal plasma. If the same mitogenic species is active in 
both samples then this would imply that the specific activity in the effusion sample was higher.
In the second example a peritoneal fluid from a patient with mixed mesodermal ovarian 
carcinoma (‘Ovarian 4 ’) was compared to an autologus plasma sample (collected using EDTA 
as an anticoagulant) for growth-promoting activity. The results are shown in Table 3 .1 .10.2(ii).
Table 3.1.10.2(ii) Comparison of growth-promoting activity in an ovarian ascitic fluid 
with that in plasma from the same donor
Sample ASCITES PLASMA
Dilutions
Colony ±  S.E.M. 
Area
mm1 mm2
Colony ±  S.E.M. 
Area
mm2 mm2
None 68.01 ±  2.53 N.D.*
1/5 40.59 ±  3.27 0.07 ±  0.07
1/10 34.02 ±  8.92 2.72 ±  0.52
1/30 19.38 ±  3.22 9.90 ±  1.25
1/50 16.98 ±  1.04 20.26 ±  2.67
1/100 12.74 ±  1.77 12.41 ±  1.89
1/200 9.62 ±  1.07 11.17 ±  0.72
Experiment Control Growth*1 5.77 ±  0.67
n=3 unless otherwise stated. a Not determined. b Ham’s F12.
Inhibition was detected at low dilutions of the plasma sample. This was most likely explained 
by the clotting which was observed in this sample. At dilutions below 1/30 the same order of 
stimulation was seen in both fluid and plasma sample in agreement with the results of the 
previous experiment.
Although it was possible to compare growth-promoting activity in autologus fluid and plasma 
from only two donors, the indications from this preliminary work were that a species of 
equivalent potency exists in the plasma of these patients. A  greater number of samples need to 
be assayed together with normal plasma and/or serum samples to determine whether this activity 
is a normal systemically produced factor, or a factor produced by cells associated with diseased 
states such as inflamation or malignancy.
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3.1.11 ESTABLISHMENT OF A  CONTINUOUS HUMAN BREAST  
ADENOCARCINOMA CELL LINE - BAC
3.1.11.1 Clinical History of BAC
A pleural effusion taken for palliative treatment from a patient post bilateral mastectomy, 
radiotherapy, and chemotherapy (Novantrone) was processed as described Section 2.5.7. Two 
rounds of ficoll treatment removed red blood cells from the initial cell pellet and a dense layer 
of tumour cells remained at the ficoll/medium interface after centrifugation. Microscopic 
examination revealed that cells in this ‘buffy’ layer comprised almost exclusively of large cells 
(too large to be macrophages) existing in clumps with tubular shaped morphology. A  portion 
of this original tissue was stored in liquid N2 for DNA fingerprint analysis. The remainder was 
cultured in DMEM/Ham’s F12 supplemented with 10F6182-NCS. A synopsis of the primary 
history of this cell line in vitro is given here. Stocks were refed at 2-7 day intervals as 
necessary.
Day 1. Cells in suspension were plated in 75 cm2 tissue culture flasks.
Day 10. All non-attached cells were replated in fresh flasks. No signs of fibroblast growth 
in the original flasks.
Day 44. First passage of this breast adenocarcinoma cell line (designated BAC). Cells
were found difficult to trypsinise and, after detaching from the monolayer in 
clumps, were refractory to forming a single cell suspension — even after 15 
minutes in standard trypsin (0.25% w/v)/ EDTA (0.02% w/v) solution. Cells were 
replated as clumps.
Day 68. Similar difficulty was encountered in achieving detachment of monolayer and single 
cell suspension at the second passage of this line.
Day 93. Passage 3 of BAC.
Day 109. Passage 4.
Day 121. Passage 5.
The growth rate of BAC was relatively slow. Multiple nucleoli were clearly visible in many 
cells of this cell population at passage 2 (figure 3.1.10). Actively dividing cells (characterised 
by a rounded up morphology and highlighted by light refraction around cell doublets), are also 
visible in this culture. Cell migration at the leading edge of these colonies was slow, forming 
tightly-packed colonies which contacted to form confluent monolayers that began to stratify, i.e. 
growing upward to from double layers (see figure 3.1.11). Stratification was accompanied by 
a change in the appearance of cells on the ‘visible’ upper layer. The main feature of this 
different morphology was a more clearly discernable and what appeared to be a wider inter-cell 
junction (compare photographs in figures 3.1.10 and 3.1.11 taken at the same magnification). 
A subconfluent monolayer displaying the characteristic rounded and discreet nature of BAC 
colonies in monolayer is shown in figure 3.1.12.
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Figure 3.1.10 A 150X magnification of a tightly-packed monolayer colony of passage 2 
BAC cells. Actively dividing cells are visible and indicated by arrows. 
Cells with multiple nuceoli can also be seen.
Figure 3.1.11 Stratification of passage 3 BAC cells at confluency in monolayer. Dividing 
cells are still visible and indicated by arrows (150X magnification).
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Figure 3.1.12 Colony morphology of passage 3 BAC cells in monolayer culture at passage 3. 
(60X magnification).
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3.1.12 CHARACTERISATION OF NEW HUMAN CARCINOMA CELL LINES
It is important to determine the biological and genetic character of newly established cell lines 
for a number of reasons. Principally, the risk of cross-contamination of cell lines would appear 
to a more common occurance than acknowledged. Precautions taken in this laboratory to avoid 
cross-contamination of cell lines are outlined in Section 2 .4 .3 .1 . The expression of a tissue- 
specific differentiated phenotype or some other special property may be required for particular 
applications and therefore both the origin of the cell line, and expression of the specific 
determinant, should be validated.
Several methods have been used to distinguish cell lines from different species and to 
discriminate between lines from the same species. These include chromosomal, immunological, 
and enzymological (isoenzyme) analysis of cell line or species specific markers. Commercial 
kits are available for measuring polymorphic enzyme loci. Although the measurement of these 
unique isoenzyme phenotypes can be useful in distinguishing a small number of cell lines, when 
larger numbers of cell lines need to be distinguished the technique is limited by the low  
frequency of unique phenotypes. A  number of such isoenzymes were analysed for the cell lines 
established here but these were not found to be useful for discriminating between human cell 
lines (data not shown).
A  detailed cytogenetic comparison of the cell lines DLRP and DLKP was undertaken by 
Elizabeth Law in this laboratory {Law et al., (1992)}. This technique can detect inter-species 
cross-contamination, but it is a highly specialised and time consuming procedure.
A  recently developed alternative method for cell line characterisation is the DNA ‘fingerprint’ 
techology, based on the discovery by Jeffreys et a l., (1985a) of hypervariable sequences in the 
human genome, can be used to prepare individual-specfic ‘fingerprints’ of human DNA  
{Jeffreys et al., (1985b)}. In the same way the origin of cell lines can be determined using tiny 
quantities of DNA from the original tissue donor (where available) and the resulting cell line. 
In the absence of original tissue this technique can discriminate between different cell lines on 
the basis of their unique band pattern {Thacker et a l., (1988); Gilbert et al., (1990)}. The 
uniqueness of an individual’s DNA ensures that the chances of discovering an identical banding 
between differnt cell lines is negligible. It is therefore a powerful technique for detecting cross­
contamination.
3.1.12.1 DNA fingerprint analysis of the cell lines DLRP and BAC
At the time of establishment of the cell Une DLRP DNA fingerprinting was not a commercially 
available service. None of the original tumour tissue (from which the line was established) was 
available for analysis therefore. In order to distinguish DLRP using this technique, all the cell 
lines in culture at the time of its inception were included in the analysis. These were the human 
cell lines SCC-9, RPMI-2650, SW900, A-549, and HEp-2. Other cell lines used later in this 
work were also included in this analysis. These were the cell lines A -431, SK-MES-1, SK-LU-1 
and HTB 120. Stocks of these cell lines together with DLRP were shipped as live cultures to 
Cellmark Diagnostics for analysis (Section 2.6.2)
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Human-specific single locus probes were used to produce the banding profiles in figure 3.1.13. 
The profile o f DLRP was completely unique with respect to those of the other cell lines. In the 
case of BAC two separate samples of the original tissue stored at -196°C in liquid Nj were sent 
for analysis together with a live culture of the cell line. The profile obtained after radiography 
with a multi locus probe is shown in figure 3.1.14. The band patterns of the tumour tissue and 
cell line DNA are identical.
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figure 3.1.13 DNA fingerprint of DLRP and several olhcr cell lines in use at the lime of its inception. The profile 
for DLRP is distinct compared to that of the other cell lines analysed.
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figure 3.1.14 DNA fingerprint obtained with a multi-locus probe. The banding pattern for BAC and two samples
of the original tumour DNA are identical.
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3.1.12.2 Histopathology
Patholigists use a number of criteria to characterise malignant cells in tissue biopsy sections. 
One such feature is abnormal mitotic figures in the dividing cells. These abnormalities include 
tripolar and multipolar mitoses and are characterisitc of the malignant phenotype. Studies by 
Gilvarry et al., (1990) indicated that this criterion may also be used to characterise malignant 
cells in vitro. One such abnormal mitotic figure in a population of DLRP cells is shown in 
figure 3.1.15 indicating the malignant character of these cells.
Figure 3.1.15 A multipolar mitoses in a DLRP cell (indicated by the arrow), stained 
with Carazzi’s hematoxylin and 0.5% eosin stain.
3.1.12.3 Immunohistochemical characterisation of the cell lines DLRP and BAC
The availability of monoclonal antibodies which recognise cell type-specific antigens permits 
the classification of cells on this basis. Fluorescently labelled antibodies were used in this work 
to visualise the binding of monoclonals specific to epithelial- (Ep-16 and cytokeratin N2 18), and 
NSCLC-specific antigens.
Epithelial-specific antigens
The mouse hybridoma cell line Ep-16 isolated by Hamburger et a l., (1985) produces an IgMx 
monoclonal antibody which is directed against an antigen present on the plasma membrane of 
human foreskin keratinocytes, but does not react with mesodermal cells, lymphocytes, or 
internal epithelia. SCC-9, a carcinoma cell line derived from an external epithelium, was used 
as a positive control for staining with this antibody and MRC-5, a human lung embryonic 
fibroblast cell line, was used as negative control. The staining patterns of these positive and 
negative controls are compared in figures 3.1.16 & 3.1.17. The staining pattern of DLRP with 
this antibody is shown in figure 3.1.18.
Cytokeratin N2 18
The filamentous protein keratin is a major component of the network of intermediate filaments 
which constitute the cytoskeleton of epithelial cells. The fact that it is absent from fibroblast-like 
cells makes it useful diagnostically for distinguishing these two cell types. DLRP and BAC were 
examined for the presence of intracellular keratin expression and compared to the staining 
patterns for the negative control, MRC-5, and the characterised epithelial cell line SCC-9 which 
was used as a positive control. The results of these positive and negative staining patterns with 
anti-cytokeratin antibody are shown in figures 3.1.19 & 3.1.20 respectively. The presence of 
cytokeratin in DLRP is shown in figures 3.1.21 & 3.1.22. BAC staining with anti-cytokeratin 
antibody was very strong as seen in figures 3.1.23 & 3.1.24. The definition in the black and 
white photo in figure 3.1.24 demonstrates a well-defined cytokeratin network.
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Figure 3.1.16 SCC-9 cells are positive for the surface antigen recognised by Ep-16. (Magnification, 40X).
Figure 3.1.17 The negative staining pattern of MRC-5 cells obtained with the Ep-16 epithelial-specific antibody. 
(Magnification, 40X).
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Figure 3.1.19 Positive staining of the epithelial cell line SCC-9 with anti-cytokeratin N* 18 antibody.
(Magnification, 40X).
Figure 3.1.20 MRC-S human embryonic fibroblasts are negative for cytokeratin expression (Magnification, 40X).
Figure 3.1.21 DLRP staining positive for cytokeratin, viewed at 40X magnification.
Figure 3.1.22 Positive cytokeratin staining of DLRP, viewed at a higher power (160X).
Cytokeration-stained filaments are more clearly visible at this magnification.
Figure 3.1.23 The pattern of BAG viewed at 40X reveals intense cytokeratin staining with little definition of 
filament structure, possibly due to the tight packing of these cells in monolayer culture.
Figure 3.1.24 BAC stained for cytokeratin and viewed at a higher power. The cytoskeletal network is more 
clearly defined in this field. (Magnification 160X).
NSCLC-specific antibodies
Two murine monoclonal antibodies 703D4 and 704A1 raised against a human large cell lung 
cancer line (NCI-H157) were reported to bind to non-small cell lung carcinomas but not small 
cell carcinomas {Mulshine et al., (1983)}. The epitopes recognised by these antibodies were 
also expressed on melanomas and on a osteogenic sarcoma and renal cell carcinoma. The 
antibodies did not recognise a variety of normal tissue types, or carcinomas of lymphoid, 
neuroblastoma, colon and breast origin. The staining pattern of both antibodies suggested that 
the epitopes were associated with cytoskeletal elements in squamous cell carcinomas.
In this work the staining patterns of the newly established NSCLC cell lines DLRP and DLKP 
and the breast carcinoma cell line BAC were compared to those of a human small cell 
carcinoma cell line, HTB 120, as well as a human embryonic lung fibroblast cell line, MRC-5. 
Two other NSCLC (not established in this laboratory), SK-MES-1 (a squamous cell carcinoma) 
and SK-LU-1 (an adenocarcinoma), were included as controls. A ll cell lines were maintained 
in culture, plated, fixed and stained as described in Section 2 .6 .1.
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Figure 3.1.25 Positive staining of the NSCLC cell line SK-LU-1 with antibody 703D4.
(Magnification 40X).
Figure 3.1.26 The SCLC cell line HTB 120 does not expresses the 703D4 NSCLC-specific antigen 
(Magnification 40X).
Figure 3.1.27 DLRP demonstrates a positive staining pattern with the 703D4 antibody.
(Magnification 40X)
Figure 3.1.28 Positive staining pattern with 703D4 in the human lung squamous cell carcinoma line, SK-MES-1.
(Magnification 40X).
Figure 3.1.29 The human breast adenocarcinoma cell line, BAG, also demonstrates positive staining with the
anti-NSCLC antibody 703D4. (Magnification 40X).
Figure 3.1.30 The second anti-NSCLC antibody, 704A1, also reacts w ith an  antigen expressed on BAG. 
(M agnification, 40X).
Figure 3.1.31 HTB 120 also dem onstrates a negative staining pattern  fo r 704A1. (M agnification, 40X).
Figure 3.1.32 Positive staining pattern  w ith 704A1 antibody in SK-MES-1 cells. (Magnification, 40X).
Figure 3.1.33 DLRP gives a positive staining pattern with the anti-NSCLC antibody, 704A1 (Magnification, 40X).
Figure 3.1.34 MRC-5 cells demonstrate negative staining tor the 704A1 antibody (Magnification, 40X).
3.2 DEVELOPMENT OF A BIO ASSAY FOR THE DETECTION OF 
AUTOCRINE GROWTH FACTORS PRODUCED BY THE HUMAN 
LARYNGEAL CARCINOMA CELL LINE HEP-2
A 1:1 volume/volume mixture o f DM EM /Ham’s F12 was used for routine maintenance o f HEp- 
2 cell stocks. This formulation is widely used as a basal medium in the development o f serum- 
free media and in the maintenance o f many established cell lines {Maurer (1992)}. Ideally the 
growth medium used in an autocrine assay should be completely defined (in terms o f salts, 
carbohydrate source, amino acids, vitamins, hormones, polypeptide growth modulators, 
attachment factors etc.), in order to discriminate the contribution made by cell-secreted factors 
to the overall growth control.
W hile it has been possible to develop serum-free media for a limited number o f cell types, the 
fastidious growth requirements o f animal cells in vitro usually necessitate the optimisation o f  
such media to suit a particular cell type. A n alternative approach is to design an assay where 
the minimum concentration o f serum is used. The latter approach was taken in the development 
o f the HEp-2 autocrine assay.
For animal cells grown in vitro in a particular concentration o f serum, a minimum plating 
density exists. Plating densities less than this ‘cut-off point will not support cell growth. This 
value is dependent on other parameters in the system, such as basal medium and serum types, 
as w ell as growth surface to media volume ratios (for adherent cell types). In addition, for any 
given set o f growth paramenters, the minimum plating density w ill ultimately depend on the 
particular cell type (cell line) under investigation.
3.2.1 Preliminary determination of cell plating density for HEp-2 in 24-well plates
Due to the reduced scale, a 24-w ell assay plate system was chosen initially for development 
with HEp-2. Reduced quantities o f costly cell culture materials can therefore be used. In 
addition, the potential number o f determinations which can practically be performed in a single 
assay is greater than with larger plate sizes.
Experience with the handling o f HEp-2 cells suggested that the minimum plating density for this 
cell line was very low compared to more recently established cell lines. This was confirmed in 
a preliminary experiment shown in Table 3.2.1 which was designed to explore the minimum  
plating density for this cell line in the 24-well plate system. HEp-2 were plated in 5 % serum 
down to a concentration o f 1 x  1 0 2 cells/w ell.
Table 3.2.1 Determination of the minimum plating density for HEp-2 at 5% serum
Plating Density 
Cells/well
Colony ±  S.E.M. 
Area
mm2 mm3
5 x  103 26.51 ±  8.57
1 x  103 21.11 ±  6.85
5 x  102 6.55 ±  0.98
1 x  102 2.24 ±  1.17
n=4 for all determinations.
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The results o f this experiment shown in Table 3.2.1 indicated that plating densities as low as 
1 x  102 cells/w ell could still give detectable levels o f growth after a seven day incubation. The 
amount o f growth was determined by measuring cell colony area (Section 2 .12 .4 ). The data in 
this experiment formed the basis for the choice of plating density used in Section 3 .1 .6 .4 .
The next experiment was performed to define the minimum plating densities at low  
concentrations o f serum. HEp-2 were plated at two densities, 4  x Iff and 2 x 1(F cells per 
w ell in four different batches o f calf serum. Three concentrations o f  serum (1 ,2 ,  and 3%) were 
used in each case. The combination o f low serum and plating densities was designed to 
determine the most stringent conditions that would still support HEp-2 cell growth in 1 m l of 
medium on the 24-w ell plate.
Cells were trypsinised and counted as described (Sections 2 .2 .4  and 2 .2 .5 ). Cell suspensions 
were diluted to 2x  the desired final concentration per ml in serum-free DM EM . Test sera were 
prepared in Ham’s F12 at 2x the desired final concentration plus 2x L-glutamine. 0.5 ml o f the 
test sera (three foetal and one newborn calf serum) were plated in 0 .5  m l o f cell suspension on 
24-w ell plates. Each determination was performed in quadruplicate. After incubating for 7 days 
at 37°C  in an atmosphere o f 5% C 0 2 the plates were washed and stained with 0.25%  crystal 
violet stain (Section 2 .12 .4 .1 ) and the colony area o f each w ell was measured by image analysis 
(Section 2 .12 .4 .2 ). The mean and the standard error on each determination was calculated. The 
results are presented in Table 3 .2 .1 .(i).
Table 3.2.1.(i) Determination of the minimum plating density for HEp-2 at low 
concentrations of newborn and foetal calf serum
Plating Density 2 x  10* Cells/well
Percentage Serum 1% 1% 3%
Serum Type:Batch N*
Colony ±  S.E.M. 
Area
mm1 mm2
Colony ±  S.E.M. 
Area
mm* mm1
Colony ±  S.E.M. 
Area
nun* m ni1
FCS:801017 0.29 ±  0.03 0.17 ±  0.06 0.12 ±  0.03
NCS:10F6182 0.29 +  0.14 0.90 ±  0.16 1.89 ±  0.31
FCS-.10F 0.80 ±  0 .2 1 2.04 ±  0.33 1.85 ±  0.29
FCS:701113 0.56 ±  0.15 1.35 ±  0.30 1.60 +  0.40
Plating density 4 x 1 0 1 Cells/well
FCS:801017 0 .6 6  ±  0.26 0.90 ±  0.17 1.27 ±  0.18
NCS:10F6182 0.96 ±  0.11 3.18 ±  0.17 5.80 + 0.45
FCS:10F 2 .0 0  ±  0.28 4.70 ±  0.22 5.00 ±  0.44
FCS:701113 2.31 ±  0.20 4.09 ±  0.76 5.26 ±  0.46
n=4 for all determinations. Abbreviations: FCS, foetal calf serum; NCS, newborn calf serum; 
S.E.M, standard error of the mean.
165
The results indicated that growth o f HEp-2 was negligible with all batches o f serum tested under 
the most stringent conditions used (1 % serum and 2 x  102 cells per well). Given the inherent 
variability between replicate bioassays performed under identical conditions, such low readings 
could translate into zero growth in subsequent experiments.
The difference in growth supported by different batches o f serum at the same concentrations and 
cell plating densities illustrated the importance o f serum batch selection. Foetal calf serum  
(FCS) batch N2 801017 was a poor stimulator o f HEp-2 growth in these low  serum  
concentrations at both plating densities consistent with previous experimental results (Section
3 .1 .6 .4 ). Newborn calf serum (NCS) batch N2 10F6182 was as good as the more expensive FCS 
batch N2s 10F and 701113 at high concentrations, but a linear increase in growth in response to 
increasing serum concentration was obtained with NCS batch 10F6182 at both plating densities. 
Batches 10F (FCS) and 10F6182 (NCS) were chosen as candidate batches in a preliminary 
autocrine experiment with conditioned medium (CM).
3 .2 .1 .1  Prelim inary evidence for autocrine stim ulation in the HEp-2 system
This experiment was designed to look for an autocrine stimulator(s) in medium conditioned by 
HEp-2. A  number o f parameters were examined. HEp-2 were assayed at two plating densities 
with two different batches o f serum. Cell suspensions were prepared in DMEM as described 
(Section 2 .12 .4 .2 ) to give 1 and 2% background levels at both plating densities. HEp-2 
conditioned medium (CM2, i.e  the second collection as described in Section 2 .7 .2) was assayed 
neat or diluted in serum-free Ham’s F12. Non-conditioned Ham’s F12 was included as a 
control. The assay was incubated as described in Section 3 .2 .1  above and the colony area 
measured by image analysis as before. The results are presented in Table 3 .2.1.1a.
Table 3 .2 .1 .1 a  Prelim inary detection o f autocrine stim ulatory activity in HEp-2 
conditioned m edium
Plating Density 2 x  101 celb/well
Scrum Type NCS:10F6182 FCS:10F
Percentage Serum 1% 2 % 1 % 2 %
SAMPLES
Colony ±  S.E.M. 
Area
mm1 mm1
Colony ±  S.E.M. 
Area
mm1 mm1
Colony ±  S.E.M.
Area
1 1 mm mm
Colony ±  S.E.M.
Area
1 1 mm mm
CM2 undiluted 0.55 ±  0.11 1.79 ±  0.35 0.76 ±  0.13 1.61 ±  0.18
CM2 diluted Vi 0.52 ±  0.05 1.41 ±  0.29 0.33 ±  0.19 0.96 ±  0.13
Control 0.36 ±  0.18 0.68 ±  0.15 0.34 ±  0.05 0.92 ±  0.37
Plating Density 4 x  10* cells/well
CM2 undiluted 1.82 ±  0.23 3.48 ±  0.41 2.36 ±  0.46 4.29 ±  0.48
CM2 diluted V2 1.37 +  0.33 2.51 ±  0.47 0.90 ±  0.30 1.87 + 0.36
Control 0.77 ±  0.02 2.05 +  0.34 0.54 ±  0.20 2.29 ±  0.27
n=4 for all determinations. Abbreviations: CM2, 2nd Collection of HEp-2 conditioned medium.
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Significant stimulation above the control level of growth was measured in the undiluted CM2 
sample with all combinations of the assay parameters, with the exception o f 2  x 1 0 s cells/w ell 
in 1% NCS. When the CM2 was diluted Vi, stimulation over control was detected only under 
two sets o f conditions both incorporating the NCS batch, (1) at 2% NCS and 2  x 102 
cells/well; and (2) at 1 % NCS and 4  x 102 cells/well.
Because the background level o f  growth in the controls varied between the different assay 
conditions, the degree o f stimulation in the undiluted CM2 samples were expressed as fo ld  
stimulation over control (i.e. sample mean h- control mean). This data is presented in Table 
3.2 .1 .1b .
Table 3.2.1.1b Fold stimulation detected in HEp-2 CM under different assay 
conditions
PLATING DENSITY 2  x 10s cells/well 4 x 10J ceils/well
PERCENTAGE SERUM 1% 2 % 1% 2 %
SERUM TYPE FOLD STIMULATION WITH RESPECT TO CONTROL
NCS:10F6182 N.S. 2.63 2.36 1.70
FCS:10F 2.24 1.75 4.37 1.87
n= 4 for all determinations. N.S; Not significant allowing for standard errors.
Analysis of the above data indicate that although autocrine stimulation can be detected in the 
HEp-2 CM2 under all but one set o f assay parameters tested. W hen the degree o f stimulation 
is expressed as fo ld  stimulation with respect (w .r.t.) to the control (for the sake o f comparison) 
it becomes apparent that the magnitude o f stimulation measured w .r.t. the control is greater for 
some combinations o f serum and cell plating density. Increasing the plating density in 1 % serum 
from 2 X 102 to 4  x 102 cells/w ell resulted in an increase in the fold stimulation detected. At 
2%  serum, such an increase in sensitivity could only be achieved by reducing the cell plating 
density in medium (substituted with 10F6182-NCS). Due to the technical limitations associated 
with the measurement o f low densities of HEp-2 in some circumstances, a combination o f 4  x 
102 cells/w ell with 1% serum (10F6182) were the preferred parameters for detecting autocrine 
activity in subsequent experiments. The degree o f stimulation is greater (with respect to the 
control) at the lower serum concentration. Reduction o f the plating density appeared to reduce 
the fold stimulation detected, except for cells plated in 2% NCS.
In subsequent HEp-2 autocrine assays in the 24-well system, a plating density o f 4 x 1CP 
cells/w ell was used in medium with a final serum concentration o f 1% (v/v).
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3.2.1.2 Endpoint measurement in the HEp-2 autocrine assay - comparison of 
colony area and colony number
The following experiment was designed to determine the range o f stimulation that might be 
detected with a plating density o f 4 x  102 cells/w ell and to compare the linearity o f  the 
proliferative response as measured by colony area and colony number.
HEp-2 proliferation was stimulated with increasing concentrations o f serum in the range 1-20% 
(v/v) under the assay conditions outlined above (Section 3 .2 .1 ). Three different serum batches 
and one serum substitute (which contained serum at 0.25% v/v) were used. The plates were 
stained after seven days and the colony area and colony number determined by image analysis. 
The mean and standard errors were calculated and colony area and colony number were plotted 
against percentage serum in figure 3 .2 .1 .2 .
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Figure 3.2.1.2 The growth of HEp-2 in monolayer in response to increasing concentrations of three bovine 
sera and a serum substitute: growth response measured by colony area, A; and colony 
number, B. (*—*) FCS 701051; (A—A) Serum substitute NuSerum IV; ( • —• )  FCS 701113; 
(0-0) NCS 10F6182.
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The plot o f colony area versus percentage serum concentration (figure 3 .2 .1 .2 ,A ) clearly 
demonstrates a dose response relationship between increasing serum concentration and HEp-2 
growth. Using colony area as an endpoint for quantification also distinguishes batches o f serum  
which are ‘good’ stimulators o f HEp-2 growth from poorer ones. In addition, the response to 
three o f the samples (NCS-10F6182, FCS-701113, and the serum substitute NuSerumTV) tested, 
demonstrated good linearity up to 1 0 %.
Colony number measured on the same plates did not demonstrate any dose response to serum  
stimulation over the concentration range tested (figure 3 .2 .1 .2 ,B). Colony number was therefore 
not considered a useful parameter for quantifying cell growth. Colony area was used instead for 
all subsequent experiments using the 24-well plate system.
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Ham’s F12 was the initial choice for use in the collection o f conditioned medium (CM) from 
HEp-2 for a number o f reasons. This medium contains a rich nutrient mixture compared to 
other formulations (e.g.DM EM ) and it was used in combination with DM EM  for routine 
maintenance o f cell stocks.
The following experiment was devised to investigate the effect o f other basal media 
combinations in the HEp-2 autocrine assay. Briefly, cells were plated under HEp-2 autocrine 
assay conditions (Section 2 .12 .4 .2 ) in DMEM and then one o f four conditioned media prepared 
from different basal media (in 75 cm2 flasks, see Section 2 .7 .1 ) was tested for stimulatory 
activity. Two collections o f CM prepared after 48 hours and 72 hours respectively in DMEM, 
Ham’s F12, MEM, and RPMI-1650 respectively were assayed. The results o f this experiment 
are presented in Table 3 .2 .1 .3 . Fold stimulation was calculated with respect to the relevant 
medium control (as in Section 3 .2 .1 .1  above).
Table 3.2.1.3 Comparison of fold stimulation over control detected in different 
basal media conditioned by HEp-2
3.2.1.3 Choice of basal medium type for the HEp-2 autocrine assay
SAMPLE
Colony ±  S.E.M. 
Area
mm’ mnr
Fold Stimulation 
with respect to the 
control
MEM CM1 13.25 ±  0.64 2.17
MEM CM2 13.74 ±  2.04 2.25
MEM Control 6.10 ±  3.05
DMEM CM1 16.76 ±  1.69 2.71
DMEM CM2 17.98 ±  2.59 2.90
DMEM Control 6.19 ±  0.41 -
RPMI-1640 CM1 14.37 + 2.44 1.95
RPMI-1640 CM2 14.32 ±  0.66 1.94
RPMI-1640 Control 7.37 ±  0.87 -
Ham’s F12 CM1 17.97 ±  0.91 2.98
Ham’s F12 CM2 18.35 ±  1.30 3.05
Ham’s F12 Control 6.02 ±  0.24 -
n=3 for all determinations.
The results indicated that the highest apparent fold stimulation was detected in conditioned 
Ham’s F12. Although the level o f stimulation was only slightly lower in DM EM , collection of 
CM using Ham’s F12 was continued because this conditioned medium displayed neligible 
amounts of protease activity when the four different CMs were assayed for a battery o f serine 
proteinases (see Appendix D for table o f activities) in collaboration with Rhona O ’Leary 
{O’Leary et al., (1991),}. In that study high protease activity correlated with a high calcium  
concentration in the basal medium. Ham’s F12 contains the lowest calcium concentration o f the
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four media assayed.
During the collection o f CM in 75 cm2 flasks it was observed that HEp-2 continued to 
proliferate to confluency after transfer to serum-ftee medium. Thus cells which were 
semiconfluent (i.e. 70-80% confluent) at the start o f  CM collection reached confluency after five 
days in serum-free medium. This was true for all the basal media used. The survival o f  viable 
cells in serum-free medium was pertinent to the question of CM collection.
The next experiment was designed to monitor the proliferation and viability o f HEp-2 in serum- 
free medium with respect to time. The effect o f regular medium change was examined and the 
pH was measured at the time o f collection. Serum-free MEM was used as the basal medium for 
CM collection (supplemented with 2 mM L-glutamine).
On day 1, twelve 75 cm2 flasks were each seeded with 1.36 x 106 cells in DM EM /Ham’s F12 
supplemented with 5% FCS and 2 mM L-glutamine. The following day, one flask was 
trypsinised and cell number counted by haemcytometer (Sections 2 .2 .4  & 2 .2 .5  respectively). 
On day 5 the flasks had reached 70-80% confluency (as judged by eye) and another flask was 
harvested and the total cell number determined. A ll the remaining flasks were washed with  
sterile phosphate buffered saline (PBS) and 20 mis o f serum-free MEM added for CM collection  
per flask (Section 2 .7 .1 ). In six o f these flasks the medium was changed every day for six days. 
Each day one o f the flasks was trypsinised (after CM collection) and the total cell number and 
the percentage viability determined by trypan blue dye exclusion (Section 2 .2 .5 ). Longer 
incubation periods for CM collection (i.e. without medium change) were examined in the three 
remaining flasks and cell number and viability determined as before.
Table 3 .2 .1 .4  contains the results o f the measurements in this experiment. In figure 3 .2 .1 .4 , 
total cell number per flask is plotted versus the number of days in culture.
3.2.1.4 Growth of HEp-2 cells during conditioned medium production
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Table 3.2.1.4 Proliferation and percentage viability of HEp-2 cultures in serum-free 
medium during the collection of conditioned medium
CULTURES IN GROWTH MEDIUM
DAYS IN 
CULTURE
CELL N* 
Per Flask
% VIABILITY CM pH Incubation 
Time for CM
0 1.36 x 106 N.D. N.D. -
2 2.00 X 106 N.D. N.D. -
5 8.08 X 10" N.D. N.D. -
CULTURES IN SERUM-FREE MEDIUM CHANGED DAILY
6 1.60 x 107 98.40 7.50 1
7 2.23 X 107 95.85 7.46 1
8 2.64 X 107 95.93 7.50 1
9 3.57 X 107 98.50 7.42 1
10 4.15 x 107 95.18 7.20 1
11 4.28 X 107 92.50 7.22 1
12 3.42 x 107 95.03 7.30 1
CULTURES IN SERUM-FREE MEDIUM NOT CHANGED DAILY
6 2.01 X 107 94.00 7.38 2
7 2.31 X 107 93.00 7.31 3
8 2.27 X 107 94.50 7.31 4
n=3 for all determinations. N.D; Not determined.
These results indicate that HEp-2 cells could be maintained in exponential growth i f  they are 
refed every 24 hours with fresh serum-free medium. Under these conditions cultures o f HEp-2 
continued to proliferate for up to six days after transfer into serum-free medium while 
maintaning a relatively high percentage viability at 95.5% on average. If the medium was not 
changed, these cultures ceased to divide after three days, but the viability was only slightly 
lower at 94%. This data would indicate that HEp-2 are capable o f sustained cell proliferation 
in the absence o f serum stimulation, suggesting that they produce self-stimulating growth 
factors. The inclusion o f 20 mM HEPES buffer ensured that the pH o f the CM did not fall 
below 7 .2 , even after four days incubation with medium change.
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Figure 3.2.1.4. The growth of Hep-2 cells in serum-free MEM following 5 days growth 
in 5% serum-supplemented DMEM/Ham’s F12 (1:1).
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In order to determine how reproducible the autocrine effect was, a series o f lots o f HEp-2 CM 
were prepared (in Ham’sF12) over a two month period and assayed for autocrine activity. The 
results are presented in Table 3 .2 .1 .5 .
3.2.1.5 Reproducibility of the autocrine effect in HEp-2 CM
Table 3.2.1.5 Autocrine stimulatory activity in a several lots of HEp-2 CM
CM Batch
Colony ±  S.E.M 
Area
mm1 ram*
Fold Stimulation over 
experiment control mean
A 16.41 ±  1.20 2.70
B 17.39 ±  1.98 2.86
C 20.94 ±  2.58 3.45
D 13.72 ±  2.42 2.26
E 14.37 ± 1 . 1 7 2.37
F 12.28 ±  0.97 2.02
G 16.70 ±  1.16 2.75
H 26.44 ±  3.08 4.36
I 19.86 ±  0.63 3.27
J 23.27 ±  0.83 3.83
K 15.27 ±  1.80 2.52
L 15.31 ±  1.98 2.52
M 16.02 ±  2.76 2.64
N 21.92 ±  1.41 3.61
O 22.62 ±  2.14 3.73
P 17.62 ±  2.35 2.90
Q 17.68 ±  1.46 2.91
Ham’s F12 6.07 ±  0.62 -
The autocrine effect was measure in 17 separate lots o f the unconcentrated (crude) CM assayed 
in this experiment. An average 2.98 fold increase in growth over control was demonstrated for 
all the CM lots assayed. There was no correlation between the degree o f stimulation and the 
time in storage before assay (maximum time in storage was 2 months). Similarly, differences 
in the level o f autocrine activity observed could not be attributed to the collection system used  
(e.g roller bottle, tissue culture flask, cell factory, or spinner culture).
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I3.2.2 USE OF ACID PHOSPHATASE AS AN ENDPOINT FOR THE MEASUREMENT 
OF AUTOCRINE GROWTH STIMULATION IN HEp-2 CELLS
Measurement o f lysosomal acid phosphatase activity has been used as an indicator o f cell 
number {Connolly et al., (1986)}. This technique has been applied to the quantification o f cell 
number in this laboratory in a 96-w ell plate system {Martin & Clynes (1991)} and the method 
also demonstrated good correlation with viable cell number (determined by colony forming 
efficiency) {Martin & Clynes (1993)}.
The advantages o f the 96-well system over the 24-well assay are firstly one o f scale. The 
maximum volume used per w ell on the 96-well plate is 0 .2  ml compared to the 1 ml used in 
the 24-well plate HEp-2 assay. Therefore smaller quantities o f  materials are required for 
experimentation, an important consideration where limiting quantities o f high cost materials are 
used. The number o f replicates and/or samples which can practically be handled in a typical 96- 
w ell assay experiment is also greater and the assay can be semi-automated. Another reason for 
using acid phosphatase was to provide an additional verification o f  the autocrine effect observed 
in the 24-well plate assay. In this case, a qualitatively different endpoint was used to measure 
cell proliferation.
In order to apply this method to the measurement o f the HEp-2 autocrine activity, it was first 
necessary to define the optimum assay parameters for detecting HEp-2 autocrine stimulatory 
activity in the 96-well plate. To this end, the parameters used for the 24-w ell system were 
scaled down to a final volume o f 0 .2  ml. A ll the other procedures were the same as for the 24- 
w ell assay except that the cell densities were adjusted.
The following experiment measured the growth o f HEp-2 plated over a range o f plating 
densities from 2 X 102 to 7 x 102 cells per well. Two lots o f HEp-2 CM, shown to be active 
in the 24-well autocrine assay, were added to the same range o f  cell concentrations up to 
6  x  102 cells/w ell in separate experiments. Acid phosphatase activity was measured after a 
seven day incubation period as described in Section 2 .1 2 .5 . The results o f this experiment are 
shown in Table 3 .2 .2 .
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Table 3.2.2 Detection of autocrine stimulation in Hep-2 using Acid Phosphatase 
as an endpoint for growth measurement
CELL N® 
PER WELL
CONTROL MEDIUM 
ABS ±  S.D.'
CONDITIONED MEDIUM 
ABS ±  S.D.*
Fold Stimulation 
w.r.tb the Control
Experiment 1 Lot 3 Unconcentrated CM
2  x 102 0.084 ±  0.016 0.193 ±  0.028 2.29
3 x  102 0.088 ±  0.016 0.238 +  0.046 2.70
4 x 102 0.198 +  0.016 0.368 ±  0.155 1 .8 6
5 x  102 0.214 ±  0.025 0.449 +  0.088 2 .1 0
6  x  102 0.275 ±  0.117 0.443 ±  0.274 1.61
7 x  102 0.336 ±  0.034 N.D.C
Experiment 2 Lot 9 Unconcentrated CM
2  x 102 0.088 + 0.006 0.192 ±  0.083 2.18
3 x 102 0.141 + 0.013 0.313 + 0.099 2 .2 2
4 x 102 0.230 ±  0.021 0.450 ±  0.048 1.96
5 x  102 0.291 ±  0.024 0.547 ±  0.050 1 .8 8
6  x  1 0 2 0.346 ±  0.042 0.711 ±  0.066 2.05
7 x  102 0.426 ±  0.015 N.D. N.D.
n=8 for all determinations. a Absorbance + standard deviation measured at 405 nm. b with respect to.
N.D; not determined.
These results demonstrated that an autocrine effect could be measured over the range of plating 
densities assayed here. The fold stimulation over the medium control was in the same order at 
every plating density examined (two-fold on average). A plot o f initial plating density versus 
absorbance at 405 nm for control and CM-stimulated growth (i.e. acid phosphatase activity 
measured after 7 days) was Unear, as seen in figure 3 .2 .2 .
The application o f acid phosphatase as a method of endpoint determination was employed in the 
latter part of this project for experiments which required the use o f expensive components (e.g. 
the oligodeoxynucleotides).
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Figure 3.2.2 A plot of HEp-2 cell inoculum plating densities in 96-well plates versus acid 
phosphatase activity measured after seven days in CM-stimulated and 
unstimulated wells.
3.2.3 ULTRAFILTRATION OF HEp-2 CONDITIONED MEDIUM
3.2.3.1 Concentration of conditioned medium by ultrafiltration
The nature of the HEp-2 autocrine effect was investigated further by attempting to concentrate 
the mitogenic species in CM using ultrafiltration. The aim o f this experiment was to rule out 
the involvement o f small molecules such as the metabolic waste products lactate and ammonia 
which are toxic to animal cells in vitro (i.e. <  10 0 0  daltons which are removed in the 
ultrafiltration process) and to look for a concentration dépendance with autocrine activity. Two 
lots o f HEp-2 CM were combined 1:1 (v/v) and concentrated lOx with a 1000 dalton MW  cut­
o ff membrane (described in Section 2 .8 .1 ). Separate aliquots o f the resulting concentrate 
{R l(10x)} were dialysed in dialysis tubing (Section 2 .8 .2 ) with respective MW cut-off points 
at 1,200 daltons and 10,000 daltons (aproximately). Dialysis was performed after ultrafiltration 
to ensure the complete removal of small molecules not removed by ultrafiltration. The 
ultrafiltration filtrate (FI) was also retained for assay. Samples were filter-sterilised (Section  
2.1 .3) and then assayed. The results are shown in Table 3 .2 .3 .1 .
Table 3.2.3.1 Autocrine activity in HEp-2 CM concentrated by ultrafiltration
Sample Dilution
Colony ;fc S.E.M. 
Area
mm1 mm1
Sample Dilution
Colony ±  S.E.M. 
Area
mma mniJ
None 10.87 ±  0.54 None 11.41 ±  0.40
CM Lot 1 1 /2 8.77 ±  0.77 CM Lot 2 1 /2 6.99 ±  0.39
1/4 8.16 ±  0.70 1/4 4.05 (n=l)
1 /8 4.93 ±  0.47 1 /8 2.96 ±  0.77
None 1.13 ±  0.56 None 2.82 ±  0.25
R l (lOx) 1 /2 2.14 ±  0.36 Filtrate 1 /2 2.18 ±  0.23
Not
Dialysed 1/4 3.02 ±  0.45
(Rl) 1/4 1.23 ±  0.44
1 /8 0.13 ±  0.08 1 /8 2.10 ±  0.19
None 0 .0 0  ±  0 .0 0 None 0 .0 1  +  0 .0 1
R l (lOx) 1 /2 0.29 + 0.13 R l (lOx) 1 /2 0.70 ±  0.34
Dialysed 
(1200 MW) 1/4 5.89 +  0.41
Dialysed 
(12000 MW) 1/4 4.45 +  0.92
1 /8 6.15 ±  0.93 1 /8 4.73 ±  0.61
Experiment Control Mean (Ham’s F12) 2.25 ±  0.26
n=4 for all determinations.
The results o f this experiment indicated that there was autocrine stimulatory activity in both lots 
of CM before they were combined and concentrated. However, the undiluted lOx concentrate 
of CM (R l) assayed without dialysis was inhibitory (i.e. resulting in growth below the Ham’s 
F12 control value). Further dilution of this sample brought the level o f growth back to that in
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the control range (at dilutions o f %, and V2) but it did not restore the autocrine effect. The 
almost negligible level o f growth at the lk  dilution was not consistent with this trend and may 
be a consequence o f some other factor such as a plating error (see Section 3 .2 .3 .2 ). Growth in 
the filtrate sample was in the same order as that o f the control.
Dialysis o f the R l(10x) concentrate (retentate) with either o f the dialysis tubings increased the 
apparent inhibition observed in the undiluted sample. However, subsequent dilution o f these 
dialysed retentates resulted in the restoration o f the autocrine stimulatory activity. It was 
necessary to dilute both o f the dialysates by at least lA to remove the inhibition. The restoration 
of stimulatory activity was maximal at higher dilution ( 1 /8  was the highest dilution assayed). 
More stimulatory activity appeared to be restored in the samples dialysed with low  MW  cut-off 
tubing (comparing the mean values at the 1 /8  dilution) but this difference was not significant 
when standard errors are taken into account.
It was concluded from these results that the autocrine stimulatory species was retained by an 
ultrafiltration membrane with a MW cut-off o f 1 kDa. Concentration with this membrane 
resulted in apparent inhibition (when the concentrate was assayed without dilution), suggesting 
the concentration o f an inhibitor. This inhibitory species was not removed by dialysis, but after 
dilution o f the dialysed retentate by a factor of 14 it was demonstrated that autocrine stimulatory 
activity was still detectable after these treatments.
The origin o f the concentratable inhibitory species was unclear. It may have been present in the 
CM to begin with, but the possibility remained that it resulted from the ultrafiltration and/or 
the dialysis steps employed. In order to better understand the composition o f HEp-2 CM, it was 
fractionated farther by ultrafiltration and the respective fractions were assayed in the following  
experiment.
3.2.3.2 Size fractionation of HEp-2 conditioned medium using ultrafiltration
Ten fold concentrations of HEp-2 CM were prepared by ultrafiltration (described in Section  
2 .8 .1 .1 ). By using membranes with progressively lower nominal molecular weight cut-offs it 
was possible to generate CM retentates that concentrated molecules within defined 
(approximately) molecular weight ranges.
A  single lot o f CM (Lot A) was used to produce concentrated fractions (retentates) with  
molecules o f molecular weights between 1 and 5 kDa, 5 and 10 kDa and 10 and 30 kDa 
(designated R l-5 , R5-10 & R10-30 respectively). In addition, concentrates with all molecules 
above the cut-off points 1, 5, 10, and 30 kDa (designated R l, R5, R10 & R30 respectively) 
were also prepared. F1(F5) is the filtrate from the passage o f CM through a 5 kDa cut-off 
membrane followed by filtration through a 1 kDa membrane. Similarily F5(F10) and F10(F30) 
represent double filtrates.
The retention o f autocrine activity after dialysis (Section 3 .2 .3 .1  above) in  tubing with a cut-off 
o f 12 kDa suggested that autocrine activity should be retained by the 10 kDa ultrafiltration 
membrane. Therefore, an additional R10-30 concentrate was made with a separate lot o f Hep-2 
CM (Lot B) and included as a control in this experiment together with three other 
unconcentrated (crude) lots o f HEp-2 CM (Lots C, D & E).
The activity o f these samples was measured in the 24-well image analysis assay as described in 
Section 2 .12 .4 .2 . In this experiment a medium control on each plate was included to check for
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inter-plate variation in growth (arising from plating errors). The results are presented in Table 
3.2 .3 .2(i).
Table 3.2.3.2(i) Autocrine activity of HEp-2 CM fractionated on the basis of 
molecular size using ultrafiltration
Conditioned Medium 
Lot A 
IOx Retentâtes
Colony ±  S.E.M. 
Area
mm' mm2
Fold Stimulation 
w.r.t Experiment 
Control Mcan-
Fold Stimulation 
w.r.t Plate 
Control Meanu
Unconcentrated 10.41 ±  1.03 3.29 3.23
R1 0 .0 2  ±  0 .0 1 0 .0 1 0 .0 1
Rl-5 0.65 ±  0.17 0 .2 1 0.26
R5 0 .0 1  ±  0 .0 2 0 .0 0 0 .0 0
R5-10 4.06 ±  0.72 1.28 1.61
RIO 1.19 ±  1.04 0.38 0.47
R10-30 14.11 ±  1.63 4.46 3.15e
R30 | 0.07 ±  0.06 3.29 3.23
Lot A Filtrates
F1(F5) 5.42 ± 1 .8 1 1.72 1 .2 0 e
F5(F10) 5.23 ±  0.90 1 .6 6 1.17e
F10(F30) 5.81 + 1.08 1.84 1.30e
Conditioned Medium Controls
Lot B Unconcentrated 14.19 ±  1.63 4.49 5.92
Lot B R10-30 (lOx) 10.65 ±  1.33 3.37 3.31
Lot C Unconcentrated 12.06 +  1.80 3.82 3.74
Lot D Unconcentrated 17.33 ±  1.32 5.48 5.38
Lot E Unconcentrated 11.95 ±  0.69 3.78 3.71
Experiment Control Mean (Ham’s F12) =  3.16 ±  0.83 mm
a Fold stimulation with respect to the experiment control mean (i.e. = 3.16). b Fold stimulation with 
respect to the mean value for growth in Ham’s F12 on the same plate as the sample determination. 
c Indicates a high control value on this plate relative to the overall experiment control mean.
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Autocrine activity was detected in all lots o f crude HEp-2 CM assayed but the degree of 
stimulation over the control varied between lots. Significant autocrine stimulatory activity was 
detected in only the R10-30 retentate. The absence o f inhibitory activity was noted in the R10- 
30 concentrate, even at lOx. However, neither o f R10-30 fractions assayed demonstrated a ten 
fold increase in stimulatory activity at lOx compared to the respective crude CM 
(unconcentrated CM from which they had been concentrated).
The appearance o f inhibition in all but the R5-10 fraction of lOx concentrates was consistent 
with the preliminary results in Section 3 .2 .3 .1  above. Two results were informative. Inhibition 
detected in the R30 fraction suggested the existence o f a large molecular weight inhibitory 
species which would be expected to be retained by all the single-membrane concentrates 
prepared with lower MW cut-off membranes. Masking o f the 10-30 kDa autocrine stimulatory 
species by such a large MW concentratable inhibitor would explain the absence o f stimulatory 
activities expected in the R l, R5 and RIO retentates, due to the R10-30 stimulatory species. 
However, such an inhibitor could not account for the detection o f inhibition which manifested 
in the R l-5  fraction. This suggested a separate low molecular weight species.
The low levels o f stimulatory activity in the double filtrates F5(F10) and F10(F30) (see Section
2 .8 .1.1 for details) are only significant with respect to the overall experiment control. If the 
relatively high control on the same plate was used to score activity in these samples 
(=  4 .5  ±  0 .74  mm2) then no stimulatory activity could be detected in these fractions. Such 
anomalies in plating densities are more likely to occur in larger experiments due to technical 
reasons. A number o f factors which become more prevalent with time after preparation o f  single 
cell suspensions may contribute to this problem. These include cell clumping, adhesion to vessel 
surfaces, or sedimentation, all o f which may lead to changes in cell density. This was in spite 
of all efforts to the contrary to minimise cell density changes such as regular mixing during 
plating etc. Plate controls were included in all subsequent experiments to check for such inter­
plate variation.
The same lOx concentrates (Lot A) were assayed again in the following experiment. In this case 
the effect o f dilution was examined. All dilutions were made in serum-free Ham’s F12. The 
results are shown in Table 3 .2 .3 .2(ii).
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Table 3.2.3.2(H) The effect of dilution on the detection of autocrine activity in 
ultrafiltrated Hep-2 conditioned medium concentrates
LOT A CONDITIONED MEDIUM CONCENTRATES
Fraction Dilution
Colony ±  S.E.M. 
Area
mm: mmJ
Fraction Dilution
Colony ±  
S.E.M.
Area
mm2 mm*
R1'III I" ;• V 
... • ■ ’
lO.Ox 0 .0 0  ±  0 .0 0 1 0 .Ox 0.29 ±  0.28
7.5x 0 .0 0  ±  0 .0 0 7.5x 0.36 ±  0.41
5.Ox 5.11 ±  0.14 Rl-S 5.Ox 0.24 ±  0.14
2.5x 12.16 ±  2.57 : 2.5x 1.47 ±  0.38
l.Ox 14.53 ±  1.75 l.Ox 6.14 ±  0.77
j:
R5
: . i: . : v.;.:
1 0 .Ox 0 .0 0  ±  0 .0 0
RS-10
lO.Ox 5.66 ±  0.55
7.5x 0.59 ±  0.19 7.5x 6.07 +  1.07
5.Ox 15.71 ±  2.46 5.Ox 6.52 ±  1.22
2.5x 13.11 ±  0.82 2.5x 7.79 ±  0.91
l.Ox 13.01 ±  1.91 l.Ox 6.07 ±  1.84
R1Q
1 0 .Ox 1.05 ±  0.58
RI0-30
lO.Ox 15.43 ±  0.65
7.5x 19.09 ±  2.33 7.5x 14.99 ±  1.10
5.Ox 18.76 ±  1.09 5.Ox 15.24 ±  0.44
2.5x 16.84 ±  1.49 2.5x 8.90 ±  0.87
l.Ox 13.90 ±  2.11 l.Ox 8.26 ±  1.09
1 0 .Ox 0 .0 0  ±  0 .0 0
Unconcd 
CM 
Lot A
None 10.57 ±  1.19
R30
7.5x 12.26 ± 1 .3 5 3/4 7.10 ±  0.53
5.Ox 17.21 ±  0.87 1 /2 7.90 ±  1.14
2.5x 16.86 ±  2.74 1/4 7.48 ±  1.09
l.Ox 13.68 ±  2.94 1 /1 0 5.73 ±  0.41
EXPERIMENT CONTROL MEAN (Ham’s F12) = 7.41 ±  1.08 mm2
Table 3.2.3.2(H) Continued overleaf.
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Table 3.2.3.2(H) continued.
LOT A FILTRATES F1(F5) FS(F10) F10(F30)
Dilutioas
Colony ±  S.E.M. 
Area
mm2 mm*
Colony ±  S.E.M. 
Area
mm2 mm2
Colony ±  S.E.M. 
Area
mm2 mm2
None 9.71 + 1 .1 0 4.34 ±  1.29 6.21 ±  0.54
3/4 9.67 + 1.68 3.33 + 0.50 5.40 +  0.81
1 /2 9.27 + 0.44 5.80 +  1.61 9.64 ±  1.14
1/4 9.76 +  0.51 7.81 +  2.64 8.16 ±  1.67
1 /1 0 9.90 +  1.28 5.65 ±  1.58 8.54 ±  1.55
EXPERIMENT CONTROL MEAN (Ham’s F12) =  7.41 ±  1.08 mm2
n=4 unless otherwise stated.
The overall growth level was higher in this than in the previous experiment. This was 
attributable to the longer incubation period used (eight days instead o f  seven). The data in Table 
3.2 .3 .2(ii) are presented graphically in figure 3 .2 .3 .2 ,(i),(ii), & (iii).
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Figure 3.2.3.2,(i) The effect of dilution on the autocrine stimulatory activity retained in 
different molecular weight fractions of HEp-2 CM separated, by 
ultrafiltration. A, > 1  kDa; B, > 5  kDa; C, > 10  kDa, D, > 30  kDa.
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Figure 3.2.3.2,(ii) The effect of dilution on the autocrine growth stimulatory activity in 
different molecular weight fractions of HEp-2 CM, separated by 
ultrafiltration. E, 1-5 kDa; F, 5-10 kDa; G, 10-30 kDa; F, crude CM.
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Figure 3.2.3.2,(iii) The effect of double filtrates of HEp-2 CM (from MW fractionation 
of CM) on HEp-2 proliferation. I, R l-5 filtrate; J, R5-10 filtrate;
K, filtrate from the R10-30 fraction.
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These results confirmed the presence of autocrine stimulatory activity and lack of inhibitory 
activity in the 10-30 kDa CM fraction. Again stimulatory activity appeared to be concentrated 
in this lOx fraction, but the growth response of HEp-2 was not linear. This R10-30 stimulatory 
activity was dilutable, but at dilutions less than 5x growth was the same as in the control.
Inhibition was detected again in the R30 at lOx, but with further dilution o f this fraction 
autocrine stimulatory activity appeared at 7 .5x, and was maximal at concentrations between 2 .5  
and 5x. The R30 autocrine stimulatory activity was also dilutable, but in this case at a lx  
dilution it was in the same order as that in the crude CM.
A  similar pattern was seen with dilution o f the retentates R l, R5 and RIO. Inhibition was 
detected in all lOx concentrates of these fractions but was abolished with progressively higher 
dilutions thereof. Autocrine stimulation became detectable with increasing dilution of these 
samples. The magnitude o f dilution required to abolish inhibition and/or manifest stimulation 
in any o f these concentrates was inversely related to the nominal MW  cut-off o f the membrane 
used to concentrate the CM. This suggested the retention o f increasingly greater amounts o f  a 
lower MW  inhibitory species with lower nominal MW cut-off membranes. It was also noted that 
the largest degree o f stimulation over control was detected in the RIO fraction. Like the R30 
fraction this activity was dilutable, but stimulation of the same order as that in the crude CM 
was still present at lx . Taken together with the result o f  the R30 fraction, this suggested that 
the stimulator active in crude HEp-2 CM was larger than 30 kDa.
Evidence for a low molecular weight inhibitor in HEp-2 CM was given by the results of the R l-  
5 fraction. Inhibition was detected in all dilutions o f this sample down to lx , although the trend 
in growth with increasing dilution was upwards towards the control level, suggesting that this 
species was not inhibitory at the expected concentration in crude CM.
Only control levels o f growth were detected in the R5-10 fraction at lOx and all dilutions 
thereof.
Similarity in the double filtrates F10(F30) and F1(F5) only control growth was detected at all 
dilutions. Dilutable inhibitory activity was detected in the F5(F10) filtrate, consistent with the 
presence of a low MW species detected in the R l-5  fraction.
Autocrine stimulatory activity detected in crude CM was lost after dilution.
3.2.3.3 Determination of autocrine activity in relation to protein concentration in 
conditioned medium fractionated and concentrated by ultrafiltration
The BioRad protein (macro) assay described in Section 2 .1 1 .6  was used to measure the protein 
concentration o f the CM concentrates assayed in the previous section. The data in table 
3 .2 .3 .2(ii) representing ‘active’ fractions were expressed as fo ld  stimulation over the experiment 
control ( =  sample mean control mean) in Table 3 .2 .3 .3 (i). The data for the BioRad assay 
are presented in Table 3 .2 .3 .3 (ii) and a plot o f the standard curve for this assay is shown in 
Appendix C.
Table 3.2.3.3(i) Fold stimulation of lOx HEp-2 conditioned medium concentrates 
in the autocrine assay
Conditioned Medium Lot A Fold Stimulation with respect to Control Growth
CM Fractions lO.Ox 7.5x S.Ox 2.5x l.Ox
Unconcentrated CM 1.43 N.S. N.S. N.S. N.S.
R1 0 .0 0 0 .0 0 0.69 1.64 1.96
R5 0 .0 0 0.08 2 .1 2 1.77 1.76
RIO 0.14 2.58 2.53 2.27 1 .8 8
R10-30 2.08 2 .0 2 2.06 N.S. N.S.
R30 0 .0 0 1.65 2.32 2.28 1.85
N.S; Not significant with respect to standard errors.
Table 3.2.3.3(ii) Determination of protein concentration in HEp-2 CM using the 
BioRad macro assay
Protein Standard 
[BSA] mg/mi
Absorbance 
@ 595nm
Lot A CM Samples1 Absorbance 
@ 595 nm
0 .0 0 .0 0 0 Unconcentrated 0.026
0 .2 0.288 R1 0.234
0.4 0.505 Rl-5 0.008
0 .6 0.691 R5 0.365
0 .8 0.908 R5-10 0 .0 0 1
1 .0 1.073 R10 0.350
1 .2 1.177 R10-30 0.108
1.4 1.258 R30 0.307
a All retentâtes were concentrated lOx with respect to the unconcentrated conditioned medium.
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Definition of a unit of autocrine activity
For the purpose of comparing specific autocrine stimulatory activity in different fractions o f  
HEp-2 CM, a unit o f autocrine activity was arbitrarily defined as ‘that activity which gives a 
single fold increase in growth over the experiment control mean’.
Autocrine stimulatory activités were expressed as ‘units’ per milligram of protein (m g/ml) for 
the different fractions and compared in Table 3 .2 .3 .3(iii) below. The protein concentrations of 
the lOx concentrates were determined from the stanard curve (Appendix C). Protein 
concentrations of diluted retentâtes were deduced by extrapolation from the respective lOx 
concentrate (by dividing by the relevant dilution factor).
Table 3.2.3.3(iii) Comparison of specific autocrine activity in different HEp-2 
ultrafiltration concentrates
Sample [Protein]
mg/ml
Autocrine activity of retentâtes per micrograin of protein 
Units/mg Protein
Concentrations lO.Ox 7.5x 5.0x 2.5x LOx
UC 0.025 N.D. N.D. N.D. N.D. 57.20
Rl 0 .2 0 0 N.D. N.D. N.D. 32.80 98.00
R5 0.326 N.D. N.D. 13.00 21.85 55.00
R10 0.305 N.D. 11.27 16.54 29.87 62.67
R10-30 0 .1 0 0 20.80 26.93 41.20 N.D. N.D.
R30 0.265 N.D. 8.29 17.44 34.55 71.15
Abbreviations: UC, Unconcentrated conditioned medium; N.D, Not determined.
In Table 3 .2 .3 .3(ii) the stimulatory activities in all ‘active’ fractions, with the exception o f R l,  
were maximal at a 5x dilution. Comparing the activities per mg o f protein at 5x, more activity 
was detected in the R 10-30 fraction per mg protein than for any o f the other fractions. On this 
basis the activities in the RIO and R30 fractions were in same order. However, at a dilution 
equivalent to that in crude CM (i.e lx ) the R10-30 species is no longer mitogenic. This does 
not rule out the involvement o f the 10-30 kDa activity in the autocrine effect measured in 
unconcentrated (crude) CM but the activity o f the R30 species at the same concentration 
supports the involvement o f a large molecular species (i.e >  30 kDa) in this effect. The loss 
of the 10-30 kDa species may reflect its stability, or its denaturation at low concentrations. If 
this is the case, then perhaps the larger MW species may act as a stabilising factor for the 10-30 
kDa species. The question o f stability of autocrine activities in crude and fractionated CM is 
addressed in Section 3 .2 .4  below. It is noteworthy that all the other singly filtered concentrates 
(R l, R5 and R10) remained active at lx .
190
3.2.3 A  Measurement of autocrine activity in the R10-30 fraction of HEp-2 
conditioned medium using acid phosphatase as an endpoint
The following experiment was performed to confirm that the autocrine effect measured in 
fractionated CM using the 24-w ell assay could also be measured using a qualitatively different 
method for endpoint determination. Using the acid phosphatase assay described in Section  
2 .1 2 .5  the stimulatory activity in two R10-30 (lOx) retentates (prepared from different lots o f  
active HEp-2 CM) was assayed.
HEp-2 were plated at a number of cell densities in control medium. The same range o f plating 
densities were used here as in the preliminary autocrine experiment using acid phosphatase 
(Section 3 .2 .2  above). The CM concentrates were assayed at every plating density in the range 
and the fold increase over the respective control growth was deteremined. The results are 
presented in Table 3 .2 .3 .4 .
Table 3.2.3.4 Measurement of HEp-2 autocrine activity in the R10-30 fraction of 
CM using acid phosphatase
. . . . . .
Plating 
Density 
per well
CONTROL Lot 3 R10-30 
(10x)
Fold
stimulation
w.r.t.c*
Lot 9 R10-30 
(10x)
Fold
stimulation
w.r.t.c1’ABS ±  S.D.* ABS ±  S.D.* ABS ±  S.D.*
2  x  102 0.048 + 0.012 0.140 ±  0.012 2.92 0.169 ±  0.016 3.52
3 x  102 0 .1 2 1  ±  0.016 0.228 ±  0 .0 1 1 1 .8 8 0.298 ±  0.015 2.46
4 X 102 0.133 ±  0.022 0.302 ±  0.026 2.27 0.359 ±  0.021 2.69
5 x  102 0.182 + 0.019 0.335 ±  0.007 1.84 0.440 ±  0.027 2.42
6  x  10 2 0.273 ±  0.112 0.434 ±  0.014 1.59 0.461 + 0.037 1.69
7 x 102 0.365 ±  0.054 N.D.C - N.D.C -
n= 8  unless otherwise stated. a Absorbance + standard deviation measured at 405 nm. b Fold stimulation with respect 
to control. 0 Not determined.
This experiment showed that autocrine stimulatory activity in fractionated CM could also be 
measured using the acid phosphatase assay. The apparent fold increase in cell growth over 
control was detected at the lowest plating density, 2 x  l t f  cells/w ell. Increasing the plating 
density reduced the sensitivity of the assay.
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3.2.4 PHYSICOCHEMICAL STABILITY PROPERTIES OF THE HEp-2 
AUTOCRINE ACTIVITY
In order to characterise the nature o f the factor(s) responsible for autocrine growth factor activity 
in HEp-2 CM, a series of physicochemical treatments were performed on crude (unconcentrated) 
CM as well as two ultraflltration fractions o f HEp-2 CM, designated R10-30 and R30 respectively. 
All three CM had previously been shown to be active in the HEp-2 assay. Serum-free cell culture 
medium (Ham’s F12) was used as control medium. Samples o f Ham’s F12 were exposed to the 
same treatments as CM samples and therefore acted as treatment controls.
Some treatments o f Ham’s F12 had a negative effect on growth, that is, the level o f growth in the 
‘treated’ control was lower than that in the untreated Ham’s F I2. To facilitate the interpretation of  
the stability data in such cases, the measured growth o f HEp-2 in response to treated and untreated 
CM was expressed as the growth supported by the respective CM sample in excess o f growth in the 
corresponding treated medium (Ham’s F12). In this analysis it is assumed that any negative effect 
on the control medium is independent of the observed effects on the autocrine species.
Where treatments had a negative effect on control growth (e .g . experiments with pH, heat, and 
protease treatments), the data are presented in two separate tables. The first table presents the 
original results, together with the standard errors on those mean determinations. The second table 
presents the same data expressed as the growth in excess o f control for every CM treatment. 
‘Growth in excess o f control’ is calculated by subtracting the respective ‘treated control’ (Ham’s 
F12) value from the correspondingly treated CM sample value. The resulting data are then 
expressed as a percentage o f the growth in untreated CM.
Because the physicochemical treatments did not necessarily reduce autocrine activity (and in some 
cases potentiated it), the data for growth in excess o f control were expressed as percentage activity 
remaining after treatment. This was calculated as a percentage o f the untreated CM value.
3.2.4.1 pH stability
In a preliminary experiment crude HEp-2 CM was exposed to two extremes o f pH for 1 hour at 
4°C . The pH of the CM and control Ham’s F12 was reduced to pH 3.6  and raised to pH 11.0 in 
separate aliquots, using 1M HC1 and 1.5 M NaOH respectively (Section 2 .9 .2). After treatment the 
pH was restored to pH 7.5  and the samples were freeze-dried (Section 2 .8 .3 ), reconstituted in their 
starting volume, and filter-sterilised before assay. The results are presented in Table 3 .2 .4 . l(i)a.
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Table 3.2.4.1(i)a pH stability of HEp-2 autocrine activity
Untreated Samples Colony ±  S.E.M. 
Area
mm5 mm1
Conditioned medium 17.31 ±  0.89
Ham’s F12 4.64 ±  1.12
pH Treatments
3.6 CM 3.35 ±  0.87
3.6 Ham’s F12 3.80 ±  2.21
1 1 .0 CM 9.66 ±  2.34
1 1 .0 Ham’s F12 3.32 ±  0.46
n= 4 for all determinations
The results from this pilot experiment with pH stability are presented as ‘growth in excess o f the 
respective controls’ and the activity remaining after pH treatment is shown as a percentage o f the 
untreated samples in Table 3 .2 .4 .l(i)b.
Table 3.2.4.1(i)b Percentage autocrine activity remaining after pH treatment
Sample Treatment
Absolute Excess 
Growth in CM over 
Control Medium'
% Autocrine Activity 
Remaining After 
Treatment
None 12.67 1 0 0
pH 3.6 -0.45b 0
pH 11.0 6.34 50
a Sample (CM) mean minus control (Ham’s F12) mean. b The level of growth 
in conditioned medium was less than that in the control medium.
The data indicated that the autocrine activity in crude HEp-2 CM was acid labile at pH 3 .6  and 
aproximately 50% was base stable at pH 11.0.
In order to define the pH stability more precisely a range o f pH tests from 2 .5  to 11.5 were 
performed in the next experiment. The pH exposure time at 4°C  was extended from 1 to 2  hours. 
The stability o f the autocrine stimulatory activity in two lOx ultrafiltration concentrates, R10-30 and 
R30, was also determined in this experiment. To avoid significant volum e changes during pH  
adjustment (which then calls for a freeze-drying step), 5M HC1 and 5M  NaOH were used. The
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results of this experiment are shown in Table 3 .2 .4 . l(ii).
Table 3.2.4.l(ii) The stability of crude and ultrafiltrated HEp-2 CM exposed to a 
range of pHs
pH
Lot 4 CM R10-30 (lOx) R30 (lOx) Ham's FI 2
Colony ±  S.E.M. 
Area
mm2 mm1
Colony ±  S.E.M. 
Area
mm1 mm1
Colony ±  S.E.M. 
Area
mm1 mm2
Colony ±  S.E.M. 
Area
mm3 mm1
Untreated 34.39 +  1.69 20.11 ±  3.69 20.42 ±  2.02 13.08 ±  3.66
ACID TREATMEN'r
2.50 4.96 ±  0.66 3.42 ±  0.86 0.91 ±  0.32 4.50 ±  1.03
3.5» 9.50 ±  0.32 2.80 ±  0.48 0.00 ±  0.00 N.D.
5.00 16.57 +  2.63 4.60 ±  1.20 0.00 ±  0.00 N.D.
6.50 8.83 ±  0.78 3.71 ±  0.86 0.00 ±  0.00 N.D.
BASE TREATMENT
8.55 21.27 ±  2.37 11.42 ±  0.96 0.00 ±  0.00 N.D.
9.50 18.52 ±  1.04 17.69 ±  1.80 0.00 ±  0.00 N.D.
10.50 6 .6 6  ±  1.58 17.34 ±  1.93 3.79 ±  0.94 N.D.
11.50 0.00 +  0.00 12.68 ±  1.05 0.00 ±  0.00 0.00 ±  0.00
n=3 for all determinations. N.D; Not determined.
This experiment indicated that adjusting pH with 5M acid and base significantly reduced growth 
in the control medium. Acid treatment reduced control growth by 6 6 % and no growth was seen in 
the control exposed to base. It was thought that a possible explanation for this effect might have 
been an increase in osmotic pressure, resulting from the greater quantities o f acid and base needed 
to adjust pH at these extremes (pH 2 .5  and 11.5).
Due to this treatment effect, it was not possible to draw definitive conclusions about sample stability 
in the alkaline range. However, when growth in these samples is compared to the respective 
untreated CM and untreated Ham’s F12 control, the indications were that autocrine stimulatory 
activity appears to be stable in crude CM up to pH 9 .5 , and as high as pH 10.5 in the R10-30 
fraction. Zero growth in this pH range was seen with the R30 fraction, except at pH 10.5. The 
apparently complete loss o f autocrine activity in the R30 fraction at alkaline pH appears to 
distinguish this activity from that in the R10-30 fraction, but this experiment needs to be repeated.
Exposure of crude CM and the R10-30 fraction to pH 2.5  abolished autocrine activity in these 
fractions. However, in the R30 fraction exposed to pH 2 .5 , autocrine stimulation was not only
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abolished but complete growth inhibition was seen.
Acid treatment o f Ham’s F12 alone reduced growth in the only pH control assayed. A s there was 
no independent control for the effect o f pH adjustment on Ham’s F12 exposed to other acid pHs, 
definitive conclusions about stability in acid pH could only be made at pH 2 .5 . However, 
comparing the level o f growth in these samples with their untreated counterparts, no evidence for 
acid resistant autocrine activity in the R10-30 fraction was apparent. A  single sample o f  crude CM 
exposed to pH 5 .0  shows evidence o f acid-resistant stimulatory activity, but the lack o f such activity 
at pH 6.5  cannot easily be explained. Complete growth inhibition was seen for the R30 fraction at 
all acid pHs.
The next experiment was performed on a single lot o f  crude HEp-2 CM. The effect o f  possible 
changes in osmotic pressure (particularily at extremes of pH) on cell growth was examined by 
measuring osmolarity after pH adjustment. In this case a separate pH control was performed (on 
Ham’s F12) for every pH treatment o f CM. The results of this experiment are presented in Table 
3.2 .4 . l(iii)a.
Table 3.2.4.1(iii)a The effect of osmolarity and pH changes on HEp-2 
autocrine activity
Lot C2/3 Conditioned Medium Ham’s F12 Control Medium
pH Colony ±  S.E.M. Areaî
Osmolarity*
OsMol/Kg
Colony ±  S.E.M. 
Area
mm1 mm2
Osmolarity*
OsMol/Kg
nun mni
ACID TREATMENT
2.5 1.68 ±  0.51 N.D. 0.37 + 0.06 0.409
3.5 4.60 ±  0.26 0.478 1.14 ±  0.22 0.456
5.0 5.11 ±  1.01 0.467 1.93 ±  0.53 0.381
6.5 3.70 +  0.47 0.311 0.76 ±  0.23 N.D.
BASE TREATMENT
8.5 11.24 + 1.19 0.368 3.22 ±  1.04 0.354
9.5 12.95 ±  1.18 N.D. 3.97 ±  0.53 N.D.
10.5 10.77 ±  0.28 0.367 4.30 + 0.43 0.404
11.5 0.96 ±  0.27 0.419 3.25 ±  0.63 0.456
NO TREATMENT
15.90 ±  2.65 N.D, 4.44 +  1.52 N.D.
n=3 for all determinations. a Osmolarity was determined before dilution (Vi) in assay. N.D; Not determined.
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This experiment demonstrated that pH adjustment using 5M HC1 and 5M  NaOH raises the 
osmolarity o f CM and control medium above the normal range for animal cell culture media which  
is 0 .280-0.320 OsMol/Kg. However, higher osmolarity values did not correlate with the growth 
inhibition (observed here in acid treated control medium). This implied that the reduction in growth 
due to acid treatment o f the control medium was independent o f osmolarity changes. The cause o f  
this inhibition is not known, but a possible explanation might be the appearance o f toxins produced 
by the chemical reaction o f media components in acid pH.
Table 3 .2 .4 . l(iii)b  presents the results of this experiment {Table 3 .2 .4 . l(iii)a} in terms o f ‘growth 
in excess o f the respective control’. These values are also expressed as ‘percentage autocrine 
activity remaining’.
Table 3.2.4.1(iii)b Percentage autocrine activity remaining in HEp-2 CM after pH 
treatment
SAMPLE TREATMENT
CM Growth in Excess of 
that in Control Medium
% Autocrine 
Activity 
Remaining
None 11.46 10 0
pH Acid
2.5 1.30 11
3.5 3.46 30
5.0 3.18 28
6.5 2.94 26
pH Alkali
8.5 8 .0 2 70
9.5 7.07 62
10.5 6.47 56
11.5 -2.29a 0
a Level of growth in CM sample was less than the level of growth in the control 
medium at pH 11.5.
The data indicated that up to 30% of the autocrine activity in crude CM is stable down to pH 3.5 . 
At pH 2.5  there was an apparent 11% residual activity. However, this result was contrary to 
indications from the previous experiment {Table 3 .2 .4 .l(i)} which showed a complete loss o f  
autocrine stimulatory activity after only 1 hour at pH 3.6. The use o f a freeze-drying step employed  
in that experiment may account for the discrepancy between the two results. In the latter case, all 
autocrine activity was abolished after exposure to pH 11.5, but approximately 60-70% remained 
active between pH 8.5 and 10.5.
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The following experiment was performed in conjunction with the previous one {Table 3 .2 .4 . l(iii)a} 
and the same lot o f CM was used (Lot C2/3). Samples were exposed to acid and base exactly as 
before, except for the inclusion here of heparin at 10 ng/m l in all cases (see Section 2 .9 .5 ). Sample 
osmolarity was also measured after pH treatment.
The experiment was designed to assess the potential o f heparin as a stabilising agent for autocrine 
activity exposed to acid and base treatments. Heparin had been reported to stabilise acidic and basic 
fibroblast growth factors to inactivation by heat and acid {Gospodarowicz & Cheng (1986)}. The 
results are shown in Table 3 .2 .4 .2 .a.
Table 3.2.4.2a pH stability of HEp-2 autocrine activity in the presence of heparin
3.2.4.2 The effect of heparin on the pH stability of HEp-2 autocrine activity
Lot C2/3 Conditioned Medium Ham’s F12 Control Medium
pH Colony ±  S.E.M, Area
min1 mm1
Osmolarity"
OsMol/Kg
: :Colony ±  S.E.M. 
Area
mm2 mm1
Osmolarity*
OsMol/Kg
ACID TREATMENT
2.5 1.76 ±  0.03 1.546 0 .1 2  ±  0 .0 2 0.384
3.5 2.43 ±  0.13 0.464 0.18 ±  0.04 0.489
5.0 0 .0 0  ±  0 .0 0 0.429 0.19 ±  0.08 0.362
6.5 2.50 ±  0.31 0.383 0.42 ±  0.09 0.367
BASE TREATMENT
8.5 11.51 ±  1.34 0.375 4.06 +  0.48 0.351
9.5 9.34 ±  0.52 0.409 2.48 ±  0.23 0.397
10.5 7.27 ±  1.91 0.367 4.30 ±  0.43 0.404
11.5 1.36 + 0.62 0.419 3.25 + 0.63 0.456
NO TREATMENT
10.12 ±  1.85 N.D. 3.26 ±  0.88 N.D.b
n= 3 for all determinations. a Osmolarity was determined before dilution (Vi) in assay. N.D; Not determined.
These results demonstrated that added heparin alone reduces overall growth in the HEp-2 autocrine 
assay. When compared to the levels in the absence of heparin {Table 3 .2 .4 . l(iii)a) the growth in 
untreated CM, and untreated control samples plus heparin, was 30-40% lower. The same 
percentage, reduction was seen in the base-treated samples. High osmolarity values did not correlate 
with growth reduction.
Addition of heparin to the acid treatments appeared to augment the effect of acid exposure already 
noted. The cumulative effect o f heparin and acid treatment reduced control growth to a barely
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detectable level. The linearity o f the assay in this range cannot be assured and therefore no 
definitive conclusions could be drawn for autocrine stability with heparin in acid pH.
The data for this experiment are presented in Table 3 .2 .4 .2b  as percentage autocrine activity 
remaining.
Table 3.2.4.2b Percentage autocrine activity remaining after pH treatment in the 
presence of heparin
SAMPLE TREATMENT
CM Growth in Excess 
of that in Control Medium
% Autocrine 
Activity 
Remaining
None 6 .8 6 1 00
pH Acid
2.5 1.64 24
3.5 2.25 33
5.0 N.D. N.D.
6.5 2.08 30
pH Alkali
8.5 7.45 109
9.5 6 .8 6 1 00
10.5 4.32 63
11.5 -0.81* 0
N.D; Not determined (Due to zero growth in CM sample). 2 Level of growth in CM 
sample was less than the level of growth in the control medium at pH 11.5.
An extra 30-40% of the autocrine activity in crude CM was stabilised against pH inactivation by 
heparin in the range pH 8 .5-9.5, resulting in 100% stability up to pH 9 .5 . At pH 10.5 the 
percentage activity remaining was not significantly changed (60% aproximately) in the presence or 
absence of heparin {ref. Table 3 .2 .4 .1(iii)b}. Complete loss o f  autocrine activity at pH 11.5 was 
not prevented by added heparin. No significant protective role was implied for heparin in the 
stability of the autocrine stimulatory activity to acid exposure. However, for the reasons outlined 
above this observation was not conclusive.
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The HEp-2 autocrine species was characterised further by exposing crude CM to the protease 
trypsin in the presence and absence of heparin. The stability o f  the active stimulatory species in CM 
was measured thereafter in the HEp-2 autocrine assay.
CM and control medium samples were mixed with purified bovine trypsin (Section 2 .9 .4 ) to a final 
concentration o f 10 /xg/ml, with and without added heparin at 10 /xg/ml. After 2 hours at 3 7 °C the 
samples, with heparin were each split into two aliquots and one o f these set aside for assay directly. 
The action o f trypsin was inhibited by the addition o f soyabean trypsin inhibitor (TI) to all other 
samples to a final concentration o f 2 0  /¿g/ml.The following controls were included in this 
experiment: (1) 20 /¿g/ml soyabean trypsin inhibitor only: (2) Premixed trypsin (10 /xg/ml) and TI 
(20 /ig/ml); (3) Untreated samples o f CM and Ham’s F12. Heparin only was added to CM and 
control medium to act as a separate heparin control. The samples were assayed in the HEp-2 
autocrine assay and the results are presented in Table 3 .2 .4 .3(i).
3.2.4.3 Proteinase sensitivity of the HEp-2 autocrine activity
Table 3.2.4.3(i) The sensitivity of the HEp-2 autocrine activity to trypsin in the presence and 
absence of heparin
:
TREATMENT
1
Lot C2/3 Conditioned Medium Ham’s F12 Control Medium
Colony ±  S.E.M. 
Area
mm1 mm2
% Change in Abs 
Growth over Ctrl 
w.r.t Untreated*
Colony ±  S.E.M. 
Area
mm1 mm2
% C h » * , i„ 
Control Growth 
w.r.t. UT Ctrlb
MINUS HEPARIN
None 26.88 ±  1.58 0 11.00 ±  0.31 0
Trypsin, 2 hrs, +TT 
post 2  hrs. 23.12 ±  1.83 -24 10.84 ±  1.75
N.S.
Premix TI + Trypsin, 
2  hrs. 23.75 ±  1.07 N.S. 9.15 ±  1.99 N.S.
TI only, 2 hrs. 32.28 ±  4.34 N.S.C 13.06 ±  0.63 +  19
PLUS HEPARIN
None 20.01 ±  2.67 -43 10.31 ±  1.03 N.S.
Trypsin, 2 hrs, + H  
post 2  hrs. 17.89 + 2.24 -43 5.92 ±  1.66 -37
Trypsin, 2 hrs, 
No TI 16.39 ±  2.67 -6 6 2.99 ±  0.19 -73
n=3 for all determinations. N.S; Not significant. 11; Soyabean trypsin inhibitor. a % Change in absolute growth over 
control with respect to that in the untreated CM sample. b With respect to the level of growth in untreated Ham’s F12. 
0 Ignoring the standard errors on this determination the % change was +20% (i.e. the same as the control).
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Heparin alone reduced growth in untreated CM by 43% (with respect to untreated control). This 
level o f reduction was consistent with that observed in the previous section (at 30-40% ). However, 
there was no significant reduction in control growth (i.e. Ham’s F12) with added heparin as noted 
above (Section 3 .2 .4 .2 ). This experiment indicated that trypsin treatment abolished 24% of the 
autocrine stimulatory activity in crude CM in the absence o f heparin.
The separate negative effects o f heparin and trypsin on HEp-2 growth were additive when these 
agents were combined. Therefore, heparin does not appear to protect autocrine stimulatory activity 
from proteolytic degradation. Using this combination in the absence o f TI, the levels o f reduction 
in control and CM-stimulated growth were quantitatively similar at 73% and 6 6 % respectively. The 
addition o f TI to the ‘trypsin and heparin’ sample after treatment brought growth in the CM- 
stimulated sample backup to the same level as the ‘heparin alone’ sample (i.e. to a 43% reduction). 
This suggests that the extra 23% o f activity saved here was due to the interaction o f TI with a 
negative regulatory factor produced by HEp-2 whose activity is mediated by heparin. In the control, 
the percentage reduction was also lessened in the presence o f TI (from 73% to 37%). This might 
imply that a trypsin-like enzyme is active in the presence o f heparin under the conditions o f the 
HEp-2 assay. A  modest increase in control growth by 19% in the presence o f TI would seem to 
support this hypothesis, however, in subsequent experiments TI alone did not support such an 
increase in HEp-2 growth. Premixing trypsin with TI effectively blocked the protease effect on CM- 
stimulated growth in the absence o f heparin.
The next experiment was performed to determine the trypsin sensitivity o f the autocrine species in 
the R10-30 and R30 ultrafiltration fractions, and to compare their stability profiles to that o f the 
autocrine stimulatory activity in crude CM. The R10-30 and R30 fractions at lOx concentration 
were the same as those used in the pH stability determination (Section 3 .2 .4 .1 ), but a different lot 
of crude CM was used here (Lot C4) than in the preliminary experiment above. Sample treatments 
and reagents were the same as those described in the preliminary experiment {3 .2 .4 .3 (i)} . The 
results are presented in Table 3 .2.4.3(ii)a .
Table 3.2.4.3(ii)a The sensitivity of HEp-2 autocrine activity in crude and ultrafiltrated 
CM to trypsin exposure
SAMPLE Lot C4 CM R10-30 (lOx) R30 (lOx) Control*
TREATMENT
Colony ±  S.E.M. 
Area
mm3 mm2
Colony ±  S.E.M. 
Area
mm2 mm3
Colony ±  S.E.M. 
Area
mm1 mm3
Colony ±  S.E.M. 
Area
mm1 nim2
Untreated1* 34.39 + 1.69 20.11 ±  3.69 20.42 ±  2.02 13.08 ±  3.66
Trypsin, 2 hrs, +TT 
post 2  hrs. 14.71 + 1.72 13.42 ±  2.08 14.20 ±  0.36 6.59 ±  0.62
Premix TI +  Trypsin, 
2  hrs. 30.77 + 4.06 13.42 + 2.08 10.96 ±  2.25 14.65 ±  2.57
TI only 31.09 ±  4.96 12.74 ±  1.40 17.36 ±  1.16 14.76 ±  1.34
n=3 for all determinations; TI :- Soyabean trypsin inhibitor. a Ham’s F12. b This sample was also used for pH 
stability studies in Section 3.2.5.1.
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These results indicated that the 2 hour incubation with trypsin follow ed by TI addition had a 
negative effect on the control growth level. Other treatments did not display a significant ‘treatment 
effect’. A  reduction in control growth in this case is difficult to explain given that the premixed 
trypsin and TI had no effect on the control growth. The reduction in growth may be explained by 
ineffective mixing o f TI after the trypsin treatment, thereby leaving residual tryptic activity in the 
control, or perhaps the low reading is explained by plating errors. It was assumed that this was a 
real effect on control growth and autocrine growth stimulation was therefore calculated with respect 
to the corresponding treatment control. If such is not the case then the data presented in Table 
3.2 .4 .3(ii)b  w ill overestimate the percentage activity remaining after trypsin treatment. Trypsin 
inhibitor did not alter control growth as observed in the previous experiment.
In Table 3.2.4.3(ii)b  the percentage reduction in autocrine activity was calculated with respect to 
untreated CM as follows:
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% Decrease in Autocrine A ctivity =  Treated CM - Treated Ham’s F12 .  j  x  1 0 0
Untreated CM - Untreated Ham’s F12
The degree to which a particular treatment affects control growth was determined by calculating 
the percentage reduction in control growth. This is given by:
% Reduction in  control growth =  Treated Ham’s F12 _ j  *  1 0 0
Untreated Ham’s F12
Table 3.2.4.3(ii)b Percentage autocrine activity remaining in crude and ultrafiltrated 
HEp-2 CM after exposure to trypsin
SAMPLE
TREATMENT
CM' % ACTIVITY 
REMAINING
R10-30 
(10v)
% ACTIVITY 
REMAINING
R30
(10x)
% ACTIVITY 
REMAINING
None 21.31 100 7.03 10 0 7.34 10 0
Trypsin-2 hrs 
+TI 8 .1 2 38 1.72 25 7.61 104
Premix TI +  
Trypsin 16.12 76” -1.23° 0 -3.69° 0
TI only 16.33 78b -2 .0 2 ° 0 2.60 35
a Unconcentrated conditioned medium. b These values are equivalent to 100% activity remaining allowing for standard 
errors. c Conditioned medium growth levels were less than the corresponding control levels.
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In this lot o f crude CM (Lot C4) at least 62% of the autocrine activity was abolished after exposure 
to trypsin. This is more than double the amount that was sensitive to trypsin in Lot C2/3 CM {used 
in the earlier experiment, Table 3 .2 .4 .3(i)}. The level o f growth in this sample after treatment was 
in the same order as the untreated control and all other ‘treatment controls’ suggesting that in  fact 
all the autocrine stimulatory activity in this lot o f CM was abolished by exposure to trypsin. While 
the premixed trypsin plus TI control and TI alone appeared to reduce activity slightly in crude CM. 
This effect was not significant in terms o f standard errors.
Trypsin abolished 75% of the R10-30 autocrine activity, but the R30 autocrine stimulatory activity 
was apparently stable to tryptic digestion.
The premixed trypsin and TI however, were able to abolish all autocrine stimulatory activity in both 
ultrafiltration fractions. Similarly TI alone had this effect on the R10-30 fraction and reduced the 
activity in R30 by 65 %.
3.2.4.4 Comparative sensitivities to trypsin of autocrine activity in early versus late collections 
of HEp-2 conditioned medium
This experiment was performed to confirm the indications (Section 3 .2 .4 .3 .)  that the autocrine 
stimulatory activity in early collections of HEp-2 CM (i.e. Lot C2/3, a pool o f a 2nd and 3rd 
collection) were less sensitive to trypsin inactivation than later collections (Lot C4, a fourth 
collection). Using the same stocks o f purified trypsin and TI as before, CM samples were exposed  
for 3 hours to trypsin (10/xg/ml) before the addition of TI (20 ¿ig/ml). An extra sample o f each CM  
was exposed to crude trypsin (GIBCO at 250 fig/ml, total protein). Separate treatment controls were 
not performed in this case. The change in autocrine activity in the two CM samples was expressed 
as the percentage decrease in autocrine activity with respect to the untreated CM. The results are 
presented in Table 3 .2 .4 .4 .
Table 3.2.4.4 A comparison of trypsin sensitivity of autocrine activities in different 
lots of HEp-2 conditioned media
SAMPLE Lot C2/3 Conditioned Medium Lot C4 Conditioned Medium
TREATMENT Colony ±  S.E.M. 
Area
mm1 nun5
%Reduction in the 
Absolute Growth 
over the Control
Colony ±  S.E.M. 
Area
mm1 nun1
%Rcduction in the 
Absolute Growth 
over the Control
Untreated 15.97 ± 0.75 0  ( = 1 0 0 %) 16.81 ±  2 .1 1 O III 8
Trypsin (p), 3 hrs 
+  IT post 3 hrs 15.71 ±  0.75 N.S. 9.92 ±  0.66 47
Premixed TI and 
Trypsin (p), 3 hrs 17.82 ±  3.09 N.S. 13.40 ±  1.52 N.S.
Trypsin (p), 3 hrs 
No TI 14.20 ±  0.42 13 10.22 ±  0.55 45
Trypsin (c), 3 hrs 
+  TI post 3 hrs 6 .6 8  +  1.71 67 3.29 ±  0.83 91
Premixed TI and 
Trypsin (c), 3 hrs 7.83 ±  0.60 58 3.79 + 0.60 88
TI only 16.97 + 2.07 N.S. 16.18 + 1.06 N.S.
Control Growth (Ham’s FI2) — 2.03 ±  0.33 mm1
n=3 for all determinations. N.S; Not significant.
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This experiment confirmed that the later collection (C4) o f CM was more sensitive to trypsin 
inactivation than the earlier lot (C2/3). No stimulatory activity was lost in Lot C2/3 after exposure 
to pure trypsin for three hours, compared to the 47% lost in  Lot C4. Soyabean trypsin inhibitor 
(TI) effectively blocked the action o f purified trypsin while TI alone had no effect on growth. 
However if  TI was omitted after treatment, then 13% of the stimulatory activity in lot C2/3 was 
abolished. The omission o f TI from Lot C4 did not significantly alter the percentage activity 
remaining.
Crude trypsin more effectively inactivated autocrine stimulatory activity in both lots o f CM. This 
probably reflects the higher concentration o f total preparation (crude trypsin) used, but the 
contribution o f other degredative enzymes in this crude enzyme cannot be excluded. 67% of the 
autocrine stimulatory activity in the early collection CM lot C2/3 was abolished by exposure to 
crude trypsin compared to the 91 % lost in lot C4. The concentration o f TI used was insufficient 
to completely block the action o f the crude trypsin preparation.
3.2.4.5 Heat stability of the HEp-2 autocrine activity
The stability of the autocrine activity in crude HEp-2 CM was addressed first. A  single lot o f CM 
(Lot C2/3) was heated in separate aliquots at 6 5 °C for 10, 20, 30 and 60 minute intervals. The 
same CM was also boiled for 5 minutes. Aliquots o f Ham’s F12 were exposed to the same 
treatment. A ll CM and control treatments were duplicated with added heparin at 10 /¿g/ml to 
determine its potential to protect autocrine activity from heat inactivation. The results o f this 
preliminary experiment are presented in Table 3.2.4.5(i)a.
Table 3.2.4.5(i)a Heat stability of HEp-2 autocrine activity in crude CM in the
presence and absence of heparin
TREATMENT Lot C2/3 CM Ham’s F12
TEMPERATURE
°C
TIME
mins
Colony ±  S.E.M. 
Area
ram1 mm1
Colony ±  S.E.M. 
Area
mm1 mm1
Untreated
(n=39) 0
MINUS HEPARIN
15.90 ±  1.87 4.44 ±  1.52
65°
10 12.15 ±  1.87 4.57 ±  0.03
2 0 14.92 ±  3.15 4.35 + 0.53
30 14.88 ±  4.64 5.13 ±  0.75
60 17.99 ±  0.28 5.69 ±  1.01
100° 5 11.51 ±  1.16 3.52 ±  0.31
Untreated
(n=6) 0
PLUS HEPARIN
10.12 ±  1.85 3.26 ±  0.88
65°
10 14.54 ±  0.36 3.82 ±  0.34
2 0 20.38 ±  1.41 5.33 ±  1.02
30 18.68 ±  0.40 6.01 ±  0.39
60 15.60 ±  1.81 0 .0 0  ±  0 .0 0
1 0 0 ° 5 7.06 ±  0.02 1.34 ±  0.63
n=3 for all detereminations unless otherwise stated.
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These data indicate that both heating and added heparin have an effect on control medium  
irrespective o f their effects on autocrine stability. Three trends emerge when the data in Table 
3.2 .4 .5(i)a  are analysed.
1. Added heparin reduces overall growth in CM and control medium by 30-40% (confirming 
observations in Sections 3 .2 .4 .3  & 3 .2 .4 .4  ).
2. Boiling control medium with added heparin results in a 70% reduction in growth in this sample 
compared to untreated control medium.
3. Heating control medium at 6 5 °C increases overall growth after 10, 20, and 30 minute 
incubations.
The relative changes in control growth are mirrored by quantitatively similar changes in CM- 
stimulated growth, suggesting that the effects o f heating and heparin together are additive. The 
excess growth over control supported in CM samples is thus best determined by subtracting the 
value for growth in the corresponding treatment control. The values for excess growth over control 
are then presented in Table 3.2.4.5(i)b  as percentage autocrine activity remaining w ith respect to 
that in the untreated control.
The absence of growth in the control medium after 1 hour at 65 °C cannot be explained. It was 
noted that some o f the heat treatments (particularly those at 65 °C) resulted in barely significant 
reductions in growth. Given the inherent variation in bioassay growth the trends observed in these 
cases may reflect varitaion about the respective means.
Table 3.2.4.5(i)b Percentage autocrine activity remaining in heat-treated HEp-2 CM 
with and without added heparin
SAMPLE
TREATMENT
Unconccntrated 
CM Minus Heparin
% ACTIVITY 
REMAINING
Unconcentrated 
CM Plus Heparin
% ACTIVllTY 
REMAINING
None 11.46 100 6 .8 6 10 0
65°C, 10 mins 7.58 6 6 10.72 156
65 °C, 20 mins 10.57 92 15.05 219
65°C, 30 mins 9.75 85 12.67 185
65°C, 60 mins 12.30 107 N.D. N.D.
100°C, 5 mins 7.99 70 5.72 83
N.D; Not determined.
This experiment indicated that 30% of the autocrine stimulatory activity was abolished after boiling 
for 5 minutes. When boiled for 5 minutes in the presence o f heparin, an additional 10% of the 
stimulatory activity was stable. Heating at 65 °C for 10 minutes also led to a 30% reduction in
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autocrine activity. However, heating at 6 5 °C for longer times brought the activity back to 100%. 
Added heparin augmented the autocrine activity when CM was heated to 6 5 °C. A  combination of 
heating at 65°C  and added heparin for 30 minutes, or 1 hour, resulted in a two fold increase in the 
relative amount o f autocrine stimulatory activity remaining.
The heat-treated samples o f CM and control medium tested in the previous experiment were stored 
at 4°C  for 4 days, and then assayed again for autocrine activity. The results are shown in Table 
3.2.4.5(ii)a.
Table 3.2.4.5(ii)a Stability of heat-treated HEp-2 autocrine activity in crude CM 
after storage at 4°C
TREATMENT Lot C2/3 CM Ham’s F12
TEMPERATURE
°C
TIME
niins
Colony ±  S.E.M. 
Area
mm2 mm2
Colony ±  S.E.M. 
Area
mm2 mm1
Untreated
(n=35)
MINUS 1IEPARIN
0 24.49 ±  4.24 10.90 +  1.54
10 27.37 ±  1.86 11.44 +  0.71
65° 2 0 26.30 ±  3.41 11.86 ±  1.44
30 26.81 ±  2.99 11.76 ±  1.03
60 24.39 ±  0.78 10.30 ±  1.19
1 0 0 ° 5 16.55 ±  0.92 10.12 +  0.43
Untreated
(a= 6)
PLUSHEPARIN
0 19.80 +  1.74 10.31 + 1.03
10 23.28 ±  1.76 9.64 ±  0.95
65° 2 0 23.19 ±  1.98 6.98 +  0.94
30 20.00 ±  2.36 4.33 ±  0.98
60 20.89 +  1.63 0 .0 0  +  0 .0 0
1 0 0 ° 5 13.54 + 1.90 5.51 ±  0.27
n=3 for all determinations unless otherwise stated.
This data was expressed as growth in excess o f the control value and presented as percentage 
autocrine activity remaining in Table 3.2.4.5(ii)b .
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Table 3.2.4.5(ii)b Percentage autocrine activity remaining in heat-treated crude HEp-2 CM
after storage at 4°C
SAMPLE
TREATMENT
Unconcentrated 
CM Minus Heparin
% ACTIVITY 
REMAINING
Unconcentrated 
CM Plus Heparin
% ACTIVIITY 
REMAINING
None 13.59 1 0 0 9.49 1 0 0
65°C, 10 mins 15.93 117 13.64 144
65 °C, 20 mins 14.44 106 16.21 171
65°C, 30 mins 15.05 110 15.67 165
65°C, 60 mins 14.09 104 N.D. N.D.
100°C, 5 mins 6.43 47 8.03 85
N.D; Not determined.
In this experiment an apparent 50% o f the autocrine activity was lost in the CM boiled for 5 
minutes. However, the level o f activity remaining in the CM boiled with heparin was unchanged, 
suggesting a protective role for heparin under these conditions. N o reduction in stimulatory activity 
was apparent in the CM treated at 65 °C, in this case. On the contrary, treatment at this temperature 
increased the relative stimulatory activity as observed in the previous experiment {Table 
3 .2 .4 .5 .(i)b}.
It was concluded that 30-50% of the autocrine activity in crude HEp-2 CM was labile after boiling 
for 5  minutes, and that heparin can protect a portion o f this heat labile activity from inactivation. 
The results o f the 6 5 °C treatment were inconclusive.
3.2.4.6 A comparison of the heat stability of autocrine activities in crude CM with that in 
the R10-30 and R30 ultrafiltration fractions
The next experiment compared the heat stability o f autocrine stimulatory activity in crude CM to 
that in two ‘active’ ultrafiltration fractions, R10-30 and R30. The more sensitive Lot C4 o f crude 
HEp-2 CM was used here (Section 3 .2 .4 .4 ).
Samples of CM and control Ham’s F12 were heated for 1 hour at 65 °C in the presence and absence 
o f 10 /xg/ml heparin. Separate aliquots were boiled for 5 minutes with and without added heparin. 
The activity of these samples was determined in the HEp-2 autocrine assay and the results are 
presented in Table 3 .2 .4 .6a.
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Table 3.2.4.6a Comparison of the heat stability profiles for autocrine activity in crude
HEp-2 CM and the R10-30 and R30 ultrafiltration fractions
SAMPLE Ixjt C4 CM R1Ö-30 (lOx) R30 (lOx) Control*
TREATMENT
TEMPERATURE
°C
Colony ±  S.E.M. 
Area
mm3 ram2
Colony ±  S.E.M. 
Area
ram2 mm1
Colony ±  S.E.M. 
Area
mm2 mm1
Colony ±  S.E.M. 
Area
mmJ mm2
UNTREATED 34.39 ±  1.69 20.11 ±  3.69 20.42 ±  2.02 13.08 ±  3.66
100°C +  Heparin 13.53 ±  2.97 10.53 ±  0.87 12.77 ±  0.90 7.97 ±  1.30
100°C - Heparin 8.29 ±  1.39 15.10 ±  1.17 18.93 ± 1 .1 2 13.30 ±  0.03
65 °C + Heparin N.D. 10.92 ±  1.83 N.D. 10.26 ± 1 .8 9
65 °C - Heparin 19.59 ±  2.26 7.89 ±  0.60 19.61 ±  2.67 13.00 ±  1.89
a Ham’s F12. N.D; Not determined.
Negative treatment effects on control growth were observed when heating was performed with 
added heparin. The data in table 3 .2 .4 .6a  were therefore expressed as ‘growth in excess o f  the 
respective treatment control value’ to allow for this treatment effect. These values are presented in 
Table 3 .2.4.6b  as percentage autocrine activity remaining.
Table 3.2.4.6b Percentage autocrine activity remaining in heat-treated crude and 
ultrafiltrated HEp-2 CM
SAMPLE
TREATMENT
CM- % ACTIVITY 
REMAINING
R10-30
(lOx)
% ACTIVITY 
REMAINING
R30
(1 0 x)
% ACTIVITY 
REMAINING
None 21.31 100 7.03 1 0 0 7.34 100
65 °C, 1 hour, 
+  Heparin 5.56 70 2.56 36 4.80 65
65°C, 1 hour, 
- Heparin -5.01” 0 1.80 26 5.63 77
100°C - H, 
5 minutes N.D. N.D. 0 .6 6 9 N.D. N.D.
100°C + H, 
5 minutes 6.59 31 -5.11b 0 6 .1 90
a Lot C4. b Negative values indicate that growth in CM samples were less than those in the corresponding control. 
N.D; Not determined.
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The autocrine stimulatory activity in Lot C4 crude CM, assayed for heat stability in this 
experiment, was more labile to heating than Lot C2/3 assayed in the preliminary heat stability 
experiment {Table 3.2.4 .5(i)a}. Therefore, the trypsin resistant early collection CM is also more 
heat resistant. Boiling Lot C4 reduced all activity in the absence o f added heparin. Heparin 
protected 70% of the autocrine stimulatory activity in this lot o f  crude CM from heat inactivation 
at 100°C. After 1 hour at 6 5 °C, 69% o f the autocrine stimulatory activity was lost in Lot C4 CM.
A ll the R10-30 stimulatory activity was abolished after 1 hour at 65 °C, and added heparin protected 
only a farther 10% from inactivation by this treatment. However, the degree o f heparin protection 
is not significant, 10% being within the margin of error for mean determinations. Boiling abolished 
74% of the R10-30 autocrine activity, and in the presence o f heparin a further 10% was lost. This 
again was within the margin of error for mean determinations.
The R30 autocrine stimulatory activity was almost completely stable to heating at 6 5 °C, but 30% 
of this activity was lost after boiling. Apparently more activity was lost in  the presence o f heparin, 
but this cannot be considered conclusive.
In conclusion, the 6 5 °C treatment distinguishes the R10-30 and the R30 autocrine activities. R30 
autocrine stimulatory activity is stable at 65 °C for 1 hour, but R10-30 activity is completely labile.
3 .2 .4 .7  Trypsin sensitivity o f heat resistant autocrine activity in early collection crude CM
The stability o f the heat and trypsin resistant autocrine stimulatory activity observed in the early 
collection lot o f HEp-2 CM (Lot C2/3) was examined after exposure to extended boiling time, 
followed by trypsin treatment.
Briefly, a sample o f Lot C2/3 CM was boiled for 10 minutes. H alf o f this boiled CM was then 
incubated with 10 /¿g/ml trypsin (purified Sigma grade III) at 3 7 °C for three hours. Soyabean 
trypsin inhibitor was added (to a final concentration o f 2 0  /zg/ml) to an aliquot o f ‘boiled and 
trypsin treated’ CM, as w ell as to a ‘boiled only’ sample (to act as a TI control).
The excess growth in the untreated CM over the untreated Ham’s F12 control was used as a 
reference in calculating the reduction in CM-stimulated growth after treatment. The level o f growth 
supported by the treated CM over the untreated control Ham’s F12 value was expressed as a 
percentage of that obtained in the untreated sample. The results o f are presented in Table 3 .2 .4 .7 .
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Table 3.2.4.7 The effect of trypsin on heat resistant autocrine activity in early 
collection crude CM
SAMPLE Lot C2/3 Conditioned Medium Ham’s F12 Control Medium
TREATMENT Colony ±  S.E.M. 
Area
mm1 mm1
%Reduction in the 
Absolute Growth 
over the Control
Colony +  S.E.M. 
Area
mm1 mm1
% Reduction in 
Control Growth 
w.r.t UT Ctrl"
Untreated 15.97 ±  0.75 0 2.03 ±  0.33 0
Boiled, 10 mins 10.62 ±  0.47 38 2.90 ±  0.72 N.S.
Boiled, 10 mins,
+ Trypsin (p)‘ 3 hrs 
+ TIb post 3 hrs
7.21 ±  0.63 63 2.67 ±  0.50 N.S.
Boiled, 10 mins 
+  Trypsin (p) 3 hrs 7.90 ±  1.01 58 2.34 ±  0.06 N.S
Boiled, 10 mins +  
T1  only 7.91 ±  0.49 50 1.06 ±  0.17 50
a Purified trypsin (Sigma). b Soyabean trypsin inhibitor. N.S:- Not significant. c With respect to untreated control.
The results indicated that approximately 40% of the autocrine stimulatory activity was labile to 
boiling for 10 minutes. This confirms the findings of previous experiments with this lot o f HEp-2 
CM where 30-50% autocrine stimulatory activity was lost after boiling for 5 minutes (Section
3 .2 .4 .5 ).
After trypsin treatment of boiled CM, total autocrine stimulatory activity was reduced by another 
20%. This suggested that 40% of the total autocrine stimulatory activity was resistant to both 
boiling and trypsin exposure. It also indicated that 1/3  (33%) o f the heat resistant activity was also 
trypsin sensitive.
Soyabean trypsin inhibitor alone had a negative effect on growth in the boiled control medium, 
when present in the absence o f  trypsin. This phenomenon was independent of the autocrine effect 
because a proportionate reduction in growth was observed in the correspondingly treated CM.
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3.2.5 THE EFFECT OF HEPARIN ON CELL GROWTH IN THE HEp-2 ASSAY
This experiment was performed to confirm the inhibitory effect o f heparin on HEp-2 growth 
observed in earlier experiments (Section 3 .2 .4) and to determine whether or not this was dose 
dependent. To this end, a range o f heparin concentrations (diluted from a stock solution in 
Ham’s F12 at 1 mg/ml, Section 2 .9 .5 ) were tested on HEp-2 under autocrine assay conditions. 
The results o f this experiment are presented in Table 3 .2 .5 .
Table 3.2.5 The effect of heparin on HEp-2 growth
[HEPARIN]
Mg/ml
Colony ±  S.E.M. 
Area
mm2 mm1
2 0 .0 5.56 ±  0.73
15.0 5.58 ±  0 .54
1 0 .0 6 .1 2  ±  1 .0 0
7.5 6.28 ±  1.32
5.0 4.93 ±  0 .79
2.5 5.74 ± 1 .1 7
0.5 5.90 ±  1.36
Ham’s F12 control 9.77 ±  1.01
The results indicated that heparin was inhibitory for HEp-2 cell growth at all concentrations 
assayed. However, no dose response relationship was apparent in this experiment.
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3.2.6 PURE GROWTH FACTORS IN THE HEp-2 ASSAY
Polypeptides from a number o f different growth factor classes, with known biochemical 
properties and characterised biological activities, were purchased commercially (Section 2 .13 .1 )  
and tested in the Hep-2 assay to determine their mitogenic potential in this system. Stock  
solutions of growth factors were prepared from stocks at 4°C  or freshly thawed frozen stocks 
at -20 °C as described in Section 2 .13 .2 . Working stocks were prepared by dilution in Ham’s 
F12 plus 1 mg/ml BSA to 2x the desired final concentration immediately before their addition 
to the assay (resulting in a Vi dilution in concentration).
In the following set of experiments growth factors were tested on HEp-2 cells under autocrine 
assay conditions. A  control for the effect o f BSA was included because this fraction o f serum  
albumin is not necessarily inert in biological assays {Melsert et al., (1989)}. The choice o f  
concentrations used for the respective growth factors in preliminary experiments were based on 
those quoted for other cell systems in the literature. Growth stimulation is expressed as the fo ld  
stimulation over control ( = sample value control value).
3.2.6.1 Epidermal growth Factor and Transforming growth factor a
The ability o f EGF and TG Fa to stimulate HEp-2 cell growth above the control level (Ham’s 
F12 +  0.5 mg/ml BSA) was examined in the following preliminary experiment. The results are 
presented in Table 3 .2 .6 . l(i).
Table 3.2.6.1(i) Proliferation of Hep-2 cells in response to EGF and TGFa
CONCENTRATION Colony ±  S.E.M. Fold Stimulation
GROWTH FACTOR ng/uil Area
mm1 mm1
w.r.t. Control“
4.0 16.24 ±  3.03 1.87
EGF
2 .0 24.30 ±  1.21 2.80
1 .0 27.95 ±  5.20 3.22
50.0 2.43 ± 1 .1 0 -
TGFa 5.0 11.98 ±  1.95 1.34
0.5 30.37 ±  3.37 3.49
Ham’s F12 MEDIUM CONTROLS
+  0.50 mg/ml BSA 8.69 ±  3.93
+ 0.25 mg/ml BSA 12.96 ±  0.44
No BSA 6.32 ±  2.12
a The increase in growth induced by growth factors was calculated with respect to the level of growth in the 
control medium (Ham’s F12) containing 0.5 mg/ml bovine serum albumin (Sigma, fraction V).
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BSA alone caused stimulation o f growth in the HEp-2 assay with respect to growth in control 
medium without BSA. This highlighted the need to use the correct BSA control when scoring 
stimulation due to growth factors in the assay.
EGF and TG Fa were stimulatory for HEp-2 cells in a dose dependent manner. Fold stimulation 
was maximal at the lowest concentrations assayed (1 .0  and 0 .5  ng/m l for EGF and T G Fa  
respectively). Higher concentrations o f both polypeptides resulted in lower growth measured. 
The degree o f reduction was in the same order for both growth factors at concentrations up to 
4 ng/m l for EGF and 5 ng/ml for TGFa. 50 ng/ml TG Fa was inhibitory.
Because of the potential autocrine role of TG Fa in many carcinoma cell lines, the follow ing  
experiments aimed to define the active stimulatory range o f  concentrations for TG Fa, 
particularly its minimum active concentration, in the HEp-2 system. A  range o f TG Fa  
concentrations from 1-500 pg/m l were tested. The experiment was performed in duplicate with 
three days between assays and using the same working dilutions o f growth factor. The same 
stock o f cells, pretreated identically, was used in both assays in an effort to minimise variation 
in assay conditions. On each occasion the effect o f TG Fa on HEp-2 growth was deteremined 
in the 24-well plate and 96-well plate system (i.e. in parallel using the same stock o f indicator 
cells). The results o f the replicate 24-well assays are presented in Table 3 .2 .6 . l(ii).
Table 3.2.6.1(ii) The effect of TGFa on HEp-2 growth as measured in the 24-well 
assay system
TGFa
pg/ml
EXPERIMENT 1 EXPERIMENT 2
Colony ±  S.E.M. 
Area
mm1 mm1
Fold Stimulation 
w.r.t. Control*
Colony i;  S.E.M. 
Area
mm2 mm1
Fold
Stimulation 
w.r.t. Control*
500 5.38 + 1.00 1.58 15.13 ±  3.99 2.32
250 9.06 ±  1.35 2 .6 6 14.41 ±  2.77 2 .2 1
100 8.78 + 0.43 2.58 13.16 ±  0.69 2 .0 2
50 7.15 ±  0.95 2 .1 0 11.47 + 1.30 1.76
10 6.82 ±  0.58 2 .0 1 9.92 ±  2.69 1.52
5 7.00 ±  1.05 2.06 8.23 ±  0.10 1.26
1 5.48 +  1.47 1.61 8.11 ±  2.24 1.25
Ham’s F12 MEDIUM CONTROLS
Experiment 1 Experiment 2
0.5 mg/ml BSA 3.54 ±  0.62 mm2 5.68 ±  1.43 mm2
No BSA N.D. 2.69 ±  0.51 mm2
a The increase in growth induced by growth factors was calculated with respect to the level of growth in the control 
medium (Ham’s F12) containing 0.5 mg/ml bovine serum albumin (Sigma, fraction V). N.D; Not determined.
215
The level of control growth was lower in the first experiment than in the repeat. This probably 
reflects the metabolic status and/or viability o f the cells at the time o f plating. This example 
highlights the degree o f inter-assay variation and the need for appropriate internal controls.
The mitogenic activity of TG Fa on HEp-2 was confirmed in both experiments. The minimum 
active concentration o f TG Fa was 5 pg/ml. Maximal activity was reached between 250 and 
500 pg/ml, with a sharp reduction in fold stimulation above this value, in agreement with 
preliminary results. The response of HEp-2 to the same range o f TG Fa concentrations in 
replicate 96-well assays is shown in Table 3 .2 .6 . l(iii).
Table 3.2.6.1(iii) The effect of TGFa on HEp-2 growth as measured in the 96-well
assay system
TGFa EXPERIMENT 1 EXPERIMENT 2
pg/ml ABS ±  S J V X FOLD" ABS ±  S.D." X FOLDb
500 0.121 ±  0.039 2 .1 2 0.017 ±  0.032 N.S.
250 0.109 + 0.022 1.91 0.063 ±  0.052 N.S.
100 0.084 + 0.033 1.47 0.085 + 0.007 1.54
50 0.081 + 0.009 1.42 0.071 ±  0.005 1.29
10 0.063 + 0.011 N.S. 0.057 ±  0.010 N.S.
5 0.060 + 0.008 N.S. 0.054 ±  0.007 N.S.
1 0.054 + 0.005 N.S. 0.042 ±  0.010 N.S.
Ham's F12 Medium Controls ■ : : : ■: ; ■ . : : °...... : ■ : -■ :: : -
+  0.5 mg/ml BSA 0.057 ±  0.009 0.055 + 0.007
NoBSA 0.050 + 0.006 0.044 +  0.006
n= 8  for all determinations. a Absorbance ±  the standard deviation measured at 405nm. b Fold stimulation over 
control. N.S. no significant stimulation over control.
The inter-assay variation between the level o f growth in the controls was not significant in the 
96-well system as that observed above in the 24-well plate assay. However, the lowest 
mitogenic concentration o f TG Fa was between 50 and 100 pg/m l. This implied that the acid 
phosphatase method o f was less sensitive in detecting the mitogenic response to this growth 
factor. The lack o f activity at 250 and 500 pg/m l in experiment 2 may be due to inhibition by 
TGFa at these concentrations. However, this was more likely to have arisen due to plating 
errors, or as a result o f cell detachment during the washing step (Section 2 .12 .5 ), because there 
was good reproducibility at other concentrations between the replicate experiments. In 
experiment 1, maximal mitogenic activity with TG Fa was at 500 pg/m l in agreement with the 
result of the 24-well assay (performed in parallel).
Taken together these results indicate that TGFa is mitogenic for HEp-2 with maximal mitogenic 
activity in the range 50-500 pg/m l and with a lower limit, possibly as low as 5 pg/ml.
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The response o f HEp-2 cells to TGF/3 under autocrine assay conditions was examined using  
three concentrations o f the polypeptide, spanning a broad concentration range. The experiment 
was part of the assay described in Section 3 .2 .6 . l(i) above. The results are presented in Table 
3 .2 .6 .2.
3.2.6.2 Transforming growth factor 0
Table 3.2.6.2 The effect of TGF/3 on the proliferation of HEp-2 cells
GROWTH FACTOR
CONCENTRATION
ng/ml
Colony ±  S.E.M. 
Area
mm1 mm3 -----------------------------------------
TGF/3
2 .0 0 10.34 ±  2.42
0 .2 0 13.76 +  1.19
0 .0 2 13.34 + 1.79
Ham’s F12 MEDIUM CONTROLS
+ 0.50 mg/ml BSA 8.69 ±  3.93
+  0.25 mg/ml BSA 12.96 + 0 .4 4
No BSA 6.32 + 2.12
The results indicate that TGF/3 is not inhibitory for HEp-2 cells over the concentration range 
assayed. The mean values for growth in the presence o f this polypeptide appeared higher than 
the control but this was not significant. No dose-response relationship was apparent in this 
experiment.
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The effect o f Insulin and insulin-like growth factors I and II on HEp-2 proliferation was 
examined in parallel with the determination o f TG Fa and /3 in the experiment outlined in 
Sections 3 .2 .6 .1  and 3 .2 .6 .2 above. The results are presented in Table 3 .2 .6 .3.
3.2.6.3 Insulin and Insulin-like growth factors I & II
Table 3.2.6.3 The effect of Insulin and Insulin-like growth factors I & II on 
HEp-2 proliferation
GROWTH FACTOR
CONCENTRATION
ng/ml
Colony ±  S.E.M. 
Area
mm1 mm1
Fold Stimulation 
w.r.t. Control“
500 0 .0 0  ±  0 .0 0 -
INSULIN 50 17.94 ±  3.62 2.06
5 16.62 ±  0.65 1.91
100 19.33 + 0.50 2 .2 2
IGF-I 50 23.41 ±  2.40 2.69
10 23.21 ±  2.32 2.67
1 16.47 + 1.27 1.90
IGF-II
100 15.55 ±  1.38 1.79
50 16.22 + 1 .1 1 1.87
10 13.45 ±  0.75 1.55
Ham’s F12 MEDIUM CONTROLS
+ 0.50 mg/ml BSA 8.69 ±  3.93
+ 0.25 mg/ml BSA 12.96 +  0.44
No BSA 6.32 ±  2.12
a The increase in growth induced by growth factors was calculated with respect to the level of growth in the 
control medium (Ham’s F12) containing 0.5 mg/ml bovine serum albumin (Sigma, fraction V).
All three growth factors stimulated proliferation o f HEp-2. The most potent member o f this 
family in the HEp-2 assay was IGF-II. This protein was stimulatory at all concentrations tested 
but maximal stimulation was seen in the range 10-50 ng/ml.
Insulin was the second most potent stimulator in this concentration range with a two fold  
stimulation over control apparent at 5 and 50 ng/m l. The inhibition at 500 ng/m l probably 
reflects the acidity o f the less diluted stock insulin (acidification was necessary to dissolve this 
protein in the preparation o f the stock, see Section 2 .13 .2).
The peak level of stimulation for IGF-II was higher than IGF-I and maximal stimulation with 
IGF-I was achieved between 50-100 ng/ml with this growth factor.
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3.2.6A Acidic and Basic Fibroblast Growth Factors
The mitogenic potential of acidic and basic FGFs in the HEp-2 assay were examined over a 
range of concentrations in the following set o f o f  replicate experiments. The results are 
presented in Table 3 .2 .6 .4.
Table 3.2.6.4 The effect of aFGF and bFGF on the proliferation of HEp-2
GROWTH
FACTOR
(Concentration)
EXPERIMENT 1 EXPERIMENT 2
Colony ±  S.Ë.M. 
Area
mm1 mm2
Fold Stimulation 
w.r.t. Control1*
Colony ±  S.E.M. 
Area
mm1 mm1
Fold Stimulation 
w.r.t. Control*
aFGF (ng/ml)
25.00 4.81 ±  0.68 - 8.43 ±  0.34 1.48
5.00 6.21 ±  1.47 1.75 9.24 + 0.63 1.63
2.50 5.15 ±  0.69 1.45 7.08 + 0.73 1.25
1.50 3.34 ±  0.44 - 6.63 +  0.56 1.17
0.50 3.83 ±  0.97 - 5.02 ±  0.82 -
0.25 3.82 ±  0.47 - 5.41 ±  1.45 -
0 .1 0 0 .0 0  +  0 .0 0 - 6.22 ±  0.99 -
bFGF (pg/ml) EXPERIMENT 1 EXPERIMENT 2
500 4.94 ±  0.28 1.40 8.30 +  0.74 1.46
250 7.62 ±  1.14 2.15 11.54 ±  2.41 2.03
100 6.13 + 0.53 1.73 9.69 + 0.45 1.70
50 6.38 + 0.38 1.80 8.69 +  0.87 1.53
10 3.78 + 1.00 - 7.55 ±  1.90 -
5 5.14 + 0.72 1.45 9.36 +  2.30 1.65
1 4.19 ±  0.48 - 6.10 ±  0.70 -
Ham’s F12 MEDIUM CONI' ROUS
+ 0.5 mg/ml BSA 3.54 ±  0.62 mm2 5.68 + 1.43 mm2
No BSA N.D. 2.69 ±  0.51 mm2
n=3 unless otherwise stated. N.D:- Not determined. a The increase in growth induced by growth factors was 
calculated with respect to the level of growth in the control medium (Ham’s F12) containing 0.5 mg/ml bovine serum 
albumin (Sigma, fraction V). N.D; Not determined.
Both growth factors were active mitogenically over a narrow concentration range. Acidic FGF 
was active maximally between 2 .5  - 5 .0  ng/ml with the greatest fold stimulation over control 
at 5 .0  ng/ml. Basic FGF was maximally active at a 10-50 fold lower concentration between 50- 
250 pg/ml with the highest fold stimulation at 250 pg/ml. Mitogenic activity indicated at 
5 pg/ml bFGF was only significant in the first experiment (with respect to standard errors).
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3.2.6.5 Interleukins la  and 1/8
Interleukin l a  (IL -la ) and Interleukin 1/3 (IL 1/3) were characterised initially as hematopoietic 
growth factors but have since been been shown to be active on epithelial cells. They were 
included in the replicate assays outlined in Section 3 .2 .6 .1  above using the same working stocks 
of the growth factors. The results o f these experiments are presented in Table 3 .2 .6 .5.
Table 3 .2 .6 .5  The response o f HEp-2 to IL -la  and IL-10
GROWTH
FACTOR
(Concentration)
l l r l a  (pg/ml)
EXPERIMENT 1 EXPERIMENT 2
Colony ±  S.E.M. 
Area
nun5 nun1
Fold Stimulation 
w.r.t. Control*
Colony ±  S.E.M. 
Area
mm1 mm2
Fold Stimulation 
w.r.t. Control*
500 0.23 ±  0.17 - 7.08 ±  2.31 -
250 4.92 ±  1.11 - 7.53 ±  1.76 -
100 3.62 ±  0.30 - 8.97 ±  1.50 1.58
50 3.82 +  0.87 - 9.14 ±  1.17 1.61
10 4.50 ±  0.70 - 7.40 ±  0.52 -
5 5.55 ±  0.35 1.57 6.36 +  1.09 -
1 3.99 ±  0.94 - 7.00 ±  0.50 -
IL-1/3 (pg/ml) EXPERIIVIENI’ 1 EXPERIMENT 2
500 4.48 + 0.52 - 5.94 ±  0.99 -
250 7.00 + 0.90 1.98 5.62 +  1.73 -
100 5.01 ±  1.59 - 7.01 ±  0.11 -
50 4.55 +  1.00 - 9.10 +  0.84 1.60
10 5 .4 4  ±  1.40 - 6.08 ±  0.37 -
5 5.36 ±  0.60 1.51 7.27 ±  0.40 -
1 5.86 ±  0.43 1 .6 6 6.64 ±  1.57 -
Ham’s F12 MEDIUM CONTROLS ■
+ 0.5 mg/ml BSA 3.54 ±  0.62 mm2 5.68 ±  1.43 mm2
No BSA N.D. 2.69 +  0.51 mm2
n=3 unless otherwise stated. N.D, Not determined. a The increase in growth induced by growth factors was 
calculated with respect to the level of growth in the control medium (Ham’s F12) containing 0.5 mg/ml bovine serum 
albumin (Sigma, fraction V). N.D; Not determined.
IL -la  and IL-1/3 both demonstrated mitogenic activity in the HEp-2 assay. However, the doses 
required to effect this stimulation varied between experiments. Fold stimulation was scored 
where a particular concentration of the polypeptide resulted in growth significantly above the 
control.
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On this basis IL -la  was active at 5 pg/ml in the first experiment, but 50 - 100 pg/m l o f this 
factor was required to produce the same fold stimultion in the repeat experiment. Similarly, IL- 
1/3 was mitogenically active at 1 - 5 pg/m l in the first determination but a 10 fold higher 
concentrataion was required to reproduce this level o f stimulation in the repeat. An identical 
shift in sensitivity was also seen between assays with TG Fa which was analysed in the same 
assay (Section 3 .2 .6 .1 ). Evidence for a biphasic response to IL-1/3 was noted in experiment 1 
because a larger fold stimulation was seen at 250 pg/ml with this growth factor. However, this 
was not reproduced in the second experiment, possibly due to the change in sensitivity to the 
cytokines.
3 .2 .6 .6  Platelet-derived growth factor
The main target cells for platelet-derived growth factor (PDGF) are mesenchymal and glial 
cells. The diluent medium for this growth factor was Ham’s F12 but the concentration o f bovine 
serum albumin used was 0 .5  mg% ( =  0.005 mg/ml BSA). The respective BSA control 
contained 0.005 mg/ml BSA. The results o f this experiment are shown in Table 3 .2 .6 .6 .
Table 3 .2 .6 .6  The response o f HEp-2 to PD G F in the autocrine assay
GROWTH FACTOR
CONCENTRATION
Units/ml"
Colony ±  S.E.M. 
Area
mm2 mm1
Fold Stimulation 
w.r.t. Control11
2 .0 0 2.11 ±  0.49 -
PDGF
0 .2 0 7.35 ±  0.66 1.41
0 .0 2 5.34 ± 1 .1 2 -
Ham’s F12 MEDIUM CONTROLS
+ 0.50 mg% BSA 5.22 ±  0.17 mm2
No BSA 6.26 + 0.54 mm2
a A unit of PDGF activity. b The increase in growth induced by growth factors was calculated with respect 
to the level of growth in the control medium (Ham’s F12) containing 0.5 mg% bovine serum albumin 
(Sigma, fraction V).
In this case control growth was inhibited in the presence of BSA. Stimulation was scored with 
respect to the BSA control. Therefore, at 2 U /m l this protein was inhibitory, but at 0 .2  U/m l 
there was a slight increase in growth over the BSA control (but not with respect to the 
experiment control) equivalent to a 1.4 fold increase. The lowest concentration assayed, 
0.02 U/ml supported only a control (BSA) level o f growth. It was concluded from this data that 
PDGF may be weakly stimulatory at concentrations around 0 .2  U /m l.
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3.2.6.7 Bombesin/Gastrin-Related Peptide (GRP)
The effect o f  the peptide gastrin-related peptide (GRP or Bombesin) in the H Ep-2 system  was 
examined in  the follow ing experiment. Stock solutions and dilutions were made in  H am ’s F12  
plus 1 m g/m l BSA. The results o f  this investigation are shown in Table 3 .2 .6 .7 .
Table 3.2.6.7 The effect of GRP on the proliferation of HEp-2
.
GROWTH FACTOR
: .
CONCENTRATION
ng/ml
Colony ±  S.E.M. 
Area
mm' mm1
Fold Stimulation 
w.r.t. Control“
Bombesin
100 16.28 ±  1.01 1.87
10 16.03 ±  1.79 1.84
1 16.51 ±  1.98 1.90
Ham’s F12 MEDIUM CONTROLS
+  0.50 mg/ml BSA 8.69 ±  3.93 mm2
+  0.25 mg/ml BSA 12.96 + 0.44 mm2
No BSA 6.32 ±  2.12 mm2
a The increase in growth induced by growth factors was calculated with respect to the level of growth in the 
control medium (Ham’s F12) containing 0.5 mg/ml bovine serum albumin (Sigma, fraction V).
This neuropeptide gave an almost tw o-fold increase in growth relative to the control (plus BSA) 
at all concentrations tested. H ow ever, the fold  stimulation was the same over the entire 
concentration range assayed.
*
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3.2.7 DETERMINATION OF THE TOXICITY OF CHAPS TO HEp-2 CELLS UNDER 
AUTOCRINE ASSAY CONDITIONS
The zwitterionic detergent, 3-[(3-Cholamidopropyl) dim ethylam onio]-l-propane sulfonate or 
CH APS, has been reported to stabilise purified fibroblast growth factors during frozen storage 
and in  solution {Matuo et al., (1988)} where it was found to be less toxic than a series o f  other 
detergents w hen tested on balb/c 3T3 cells in vitro. It has been em ployed in  the purification o f  
an FGF-like growth factor from medium conditioned by a clone o f the Shionogi carcinoma cell 
line SC 115 (derived from a mouse mammary tumour) {Nonomura et al., (1988) and Sato et 
al., (1988)}.
The next experiment was designed to assess the toxicity o f  this detergent on H Ep-2, grown  
under autocrine assay conditions, w ith a v iew  to using this detergent as a stabilising agent in 
the purification o f HEp-2 autocrine activity. HEp-2 were exposed to 0.1%  (w /v) CHAPS and 
a series o f  dilutions thereof. The optimum concentration o f CHAPS reported for stabilising the 
activity o f  fibroblast growth factors was 0.1%  w /v . The results o f  this investigation are 
presented in Table 3 .2 .7 .1 .
Table 3.2.7.1 The growth of HEp-2 in the presence of CHAPS
[CHAPS]
% w/v
Colony ±  S.E.M  
Area
mm1 mm1
0.001 6.85 +  0.65
0.005 7.54 +  2.50
0.010 6.50 ±  0.54
0.050 9.60 ±  0.73
0.100 | 7.24 ±  1.06
Ham’s F12" 6.80 ±  0.65
a Control medium without added CHAPS.
CHAPS did not exhibit any toxic effects on HEp-2 under autocrine assay conditions. In the 
follow ing experiment the same concentration range o f CHAPS was assayed again, but in  this 
case the effect o f  the detergent on the detection o f the autocrine stimulatory effect in  crude CM  
was also examined. The results are show n in Table 3 .2 .7 .2 .
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Table 3.2.7.2 The effect of CHAPS on the measured HEp-2 autocrine activity
■ : : :
[CHAPS]
% w/v
Ham’s FI2 Control Lot 8 CM
Colony ±  S.E.M. 
Area
mm1 mm1
Colony ±  S.E.M. 
Area
mm1 mm2
0.100 7.90 ±  1.16 27.87 ±  3.66
0.050 8.54 +  0.76 39.56 ±  5.40
0.010 11.93 +  1.22 42.59 ±  4.72
0.005 12.61 ±  0.75 38.05 ±  3.78
0.001 12.69 +  0.80 40.45 ±  1.90
Ham’s F12* 13.69 ±  1.56 37.44 ±  5.13
a Control medium without added CHAPS.
Toxicity on H Ep-2 cells was detected in  control medium at concentrations o f CHAPS greater 
than 0.01 % (w /v). Toxicity in the presence o f  crude HEp-2 CM was only detected at the highest 
concentration o f detergent assayed, 0.1%  (w /v). These results suggested that CHAPS might be 
included as a potential stabilisng agent in  the chromatographic separation o f the HEp-2 autocrine 
stimulatory activity.
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3.3.1 SEPARATION OF CONCENTRATED HEp-2 CM ON A BIOGEL P30 
COLUMN
A  58 x  1.9 cm  Bio-G el P30 column described in Section 2 .11 .1  was used to separate a 20x  
sample o f HEp-2 CM {prepared by ultrafiltration using a 1000 kD a molecular w eight cut-off 
membrane (R l)} . The column was run in  100 mM phosphate buffer containing 100 m M  NaCl 
at 4°C  and 110 x  1.5 m l fractions were collected at a flow  rate o f  8 m ls/hour. The absorbance 
o f each fraction was measured at 280 nm.
Fractions 1-3, 4-7 , 7-9 , etc. and every three consecutive fractions thereafter w ere pooled  and 
dialysed against distilled H20  overnight before they were lyophilised (Section 2 .8 .3 )  and 
reconstituted in  2 .5  mis o f  serum-free H am ’s F12. A ll samples w ere filter-sterilised by passage 
through 0 .22  /xm filters (M illex, low  protein binding, M illipore). 0 .5  m is o f  each fraction was 
assayed in the H Ep-2 autocrine assay without prior dilution. H ow ever, it was not possible to 
determine activity in these samples due to contamination but the elution profile o f  CM illustrated 
that this column separated proteins in several size ranges (figure 3 .1 .1 ,A ).
The same colum n was used to separate a second sample o f H ep-2 concentrated CM. A  2 ml 
sample o f a 60x  CM concentrate (prepared by ultrafiltration w ith  a 1000 M W  cut-off 
membrane) was loaded onto the column in 25 mM phosphate running buffer at pH 7 .4  (without 
NaCl). 60 x  2 ml fractions were collected and lyophilised. These w ere then reconstituted into 
4  mis o f  Ham’s F12, filter-sterilised and tested in the autocrine assay. In this experiment protein  
concentration was measured using the BioRad Protein A ssay (see Section 2 .1 1 .6 ) . The results 
o f  these determinations are presented in  Table 3 .3 .1  and the elution profiles for protein and 
autocrine activity are shown in figure 3 .3 .1,B.
%
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Table 3.3.1 Separation of 60x R1 HEp-2 CM on a BioGel P30 gel-filtration column
FRACTION
NUMBER
[PROTEIN] 
M lm l
Colony ±  S.E.M. 
Area
mm2 nun2
FRACTION
NUMBER
[PROTEIN]
Mg/ml
Colony ±  S.E.M. 
Area
mm* mm2
1 < 0.02 13.64 + 0.37 26 0.09 9.28 ±  1.14
2 0.04 11.60 + 1.70 27 0.04 13.66 ±  0.94
3 0.03 13.12 ±  0.73 28 < 0.02 18.04 ±  0.06
4 0.04 11.00 + 0.22 29 0.02 18.21 ±  1.00
5 < 0.02 11.37 ±  0.24 30 0.02 11.50 ±  1.47
6 < 0.02 12.73 ±  0.94 31 0.08 13.26 ±  1.73
7 0.03 16.20 ±  0.62 32 0.05 16.27 ±  5.10
8 < 0.02 10.89 +  0.10 33 0.08 14.81 ±  1.01
9 0.02 10.58 ±  2.45 34 0.06 9.34 ±  0.02
10 < 0.02 13.96 ±  0.76 35 0.02 6.60 ±  0.19
11 < 0.02 13.53 ±  2.36 36 0.09 0.00 ±  0.00
12 ' 1.78 10.92 +  0.04 37 0.10 0.00 ±  0.00
13 >1.80 16.02 ±  1.19 38 0.11 0.72 ±  0.04
14 1.04 20.70 ±  1.42 39 0.10 5.39 ±  1.00
15 0.64 14.95 ±  0.14 40 0.09 5.31 ±  0.64
16 0.62 13.35 ±  1.42 41 0.09 2.98 ±  0.49
17 0.50 15.82 ±  0.02 42 0.03 8.42 ±  0.18
18 0.34 12.97 ±  0.64 43 0.09 6.64 ±  0.48
19 0.30 12.06 ±  1.76 44 0.05 7.28 ±  0.53
20 0.26 12.91 ±  1.02 45 0.09 7.03 +  0.37
21 0.33 12.16 ±  2.75 46 0.09 5.89 ±  1.05
22 0.18 14.17 ±  2.43 47 0.02 8.29 ±  0.89
23 0.11 13.93 ±  2.52 48 0.07 8.59 +  0.13
24 0.09 15.42 ±  2.89 49 0.04 9.43 ±  0.27
25 0.06 11.26 ±  2.48 50 0.02 11.98 ±  0.36
HEp-2 CM (lx)‘ 17.61 ±  1.14 Ham’s F12 Control 10.70 ±  1.62
a This was diluted from a 60x concentrate of HEp-2 CM prepared with a 1000 MW cut-off membrane.
226
A
bs
or
ba
nc
e 
2
8
0
n
m
F r a c t i o n  N u m b e r
F r a c t i o n  N u m b e r
Figure 3.3.1 Separation of HEp-2 CM, concentrated by ultrafiltration, on a BioGel P30 
gel-filtration column. A; elution profile of a 20x (RI) CM concentrate.
B; elution profile and growth stimulatory activity profile in a 63x (Rl) 
CM concentrate.
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Autocrine activity eluted in  a number o f  fractions containing different molecular w eight species. 
Fractions 1 & 7 contained some stimulatory activity w hich eluted within the expected void  
volum e. The principal stimulatory activity in the high molecular w eight range was associated  
with fractions 13-15, eluting between 26-30 mis on the chromatogram, and this too is close  to 
the expected exclusion lim it for this gel (figure 3 .3 .1,B). M itogenic activity in  a single fraction  
(N2 17) elutes at 34 m is. In the intermediate size range on this coulmn, three stimulatory 
activities elute. The first at 48 mis in fraction 24 , and then tw o bands o f  activity in  fractions 
27-29 (54-58 m is) and 32 & 33 (64-66 mis). A  broad band o f inhibitory activity eluted from  
fraction 35 to 46  (70-92 m is).
Although molecular weight markers were not run on this colum n, the data confirm  the 
predictions for the size o f  autocrine stimulatory and inhibitory activity. It w ould appear that at 
least one large (i.e  >  30 kDa) and at least three intermediate molecular weight stimulators (i.e , 
10-30 kDa) are present in HEp-2 CM, as w ell as a low  M W  inhibitory activity.
3 .3 .2  TH E U SE  O F H EPA R IN -SEPH A R O SE A F F IN IT Y  C H R O M A T O G R A PH Y  
IN  TH E P U R IF IC A T IO N  O F HEp-2 A U T O C R IN E  A C T IV IT Y
Several classes o f  growth factors have been shown to have an affinity for im m obilised heparin. 
Am ong those w ith the greatest affinity are the so-called fibroblast growth factors (FG Fs). 
Heparin affinity chromatographic systems has been successfully applied to the purification o f  
FGFs because o f their tight binding and differential elution from  this matrix. The follow ing  
experiment was performed to determine whether the autocrine activity in HEp-2 CM was 
heparin binding.
3.3.2.1 Preliminary evidence for heparin-binding autocrine activity in concentrated 
HEp-2 CM: Batch elution in NaCl from heparin-Sepharose
A  2 m l sample o f  the 60x concentrate o f HEp-2 CM used in  Section 3 .3 .1  was applied to a 5 m l 
heparin-Sepharose colum n and bound material was eluted by successive batches o f  running 
buffer containing NaCl with incremental increases in molarity from 0.1 - 5 .0  M  N aC l as 
described in Section 2 .1 1 .2 .1 . Sample dilutions were made in  serum-free H am ’s F12 such that 
the final concentration was equivalent to lx  w ith respect to the 60 x  sample loaded. D ialysed and 
filter-sterilised fractions from this separation were assayed for autocrine activity and the results 
are presented in  Table 3 .3 .2 .1 .
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Table 3.3.2.1 Elution of HEp-2 CM autocrine activity from a heparin-Sepharose 
column with a 0 - 5M NaCl step gradient.
Fraction
[NaCl]
Molar
Dilution
Equivalent"
Colony ±  S.E.M. 
Area
mm1 mm1
Fold Stimulation 
w .rX  Control1'
Wash 1/20 0.52 ±  0.13 N.S.
0.1 M lx 0.65 ±  0.21 N.S.
0.5 M lx 0.66 ±  0.12 N.S.
1.0 M lx 1.07 ±  0.43 3.24
1.5 M lx 2.18 ±  1.18 6.61
2.0 M lx 2.55 + 0.87 7.73
5.0 M lx 1.42 ±  0.48 4.30
Ham’s FI2 Control 0.33 ±  0.18 -
a Dilutions were made to ensure that all samples were at a concentration equivalent to 
the untreated CM (i.e. lx). b Fold stimulation was calculated with respect to the level 
of growth in the control medium. N.S; No significant increase with respect to the control.
The control level o f  growth in  this experiment was very low . H ow ever, significant stimulation 
above the control value was apparent in  all eluates greater than 1.0 M  NaCl. The largest fold  
stimulation over control eluted in  the 1.5 and 2 .0  M  NaCl fractions respectively.
3.3.2.2 Separation of autocrine activity in HEp-2 CM by heparin-Sepharose 
chromatography using a 0 - 2.5 M continuous NaCl gradient
The aim o f this experiment was to define the precise affinity o f  the heparin-binding autocrine 
mitogens. 300 mis o f  crude HEp-2 CM was pre-equilibrated in  running buffer (lOOmM 
phosphate pH 7 .4  using a Sephadex G-15 as described in Section 2 .1 1 .1 .1 )  and then loaded onto 
a 10 m l heparin-Sepharose column. A  continuous NaCl gradient o f  0 -2 .5  M salt was applied 
as described in Section 2 .1 1 .2 .2 . The bulk o f  the protein in the CM  washed through the column  
in  the first 150 m is before the application o f the gradient. 28  x  5 m l fractions were collected  
after 132 mis had run through. The elution profile from  82 m is to the end o f the chromatogram  
is shown in figure 3 .3 .2 .2 .
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Figure 3.3.2.2 The separation of concentrated (63x) Hep-2 CM on a 10 ml 
heparin-Sepharose column using a 0-2.5 M NaCl gradient.
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Tw o heparin-bound protein peaks eluted from the colum n on the NaCl gradient. The first from  
0-0 .7  M  salt, the second from 0 .7 -1 .8  M  salt.
A ll fractions were dialysed and filter-sterilised before assay as described in Sections 2 .8 .2  and
2 .1 .3  respectively. The results o f the experiment are presented in Table 3 .3 .2 .2  parts a, b 
and c.
Table 3.3.2.2a Separation of HEp-2 autocrine activity using a continuous NaCl 
gradient on heparin-Sepharose
-  --------------------- ■ ■
Fraction Dilutions None 1/5
FRACTION
NUMBER
Corresponding [NaCl] 
at gradient elution 
MOLAR
Colony ±  S.E.M. 
Area
mm1 mm1
Colony ±  S.E.M. 
Area
nun1 mm2
1 0.00 0.00 ±  0.00 3.80 ±  1.09
2 0.00 0.00 ±  0.00 3.92 ±  0.73
3 0.00 0.00 ±  0.00 3.24 ±  0.27
Table 3.3.2.2b
Fraction Dilutions 1/2 1/4 1/10
FRACTION
NUMBER
Corresponding [NaCl] 
at gradient elution 
MOLAR
Colony ±  S.E.M. 
Area
mm2 mm1
Colony ±  S.E.M. 
Area
ram2 mm2
Colony ±  S.E.M. 
Area
mm4 mnr
4 0.00 0.85 ±  0.34 2.62 ±  0.40 2.80 ±  1.16
5 0.00 2.79 ±  0.37 2.28 + 0.80 3.14 ±  0.40
6 0.10 0.17 ±  0.10 1.84 + 0.58 2.62 +  0.35
7 0.33 0.59 +  0.15 2.91 + 0.06 2.90 ±  0.87
8 0.50 4.20 ±  0.43 4.95 ±  1.34 3.75 ±  0.24
9 0.70 0.00 ±  0.00 2.77 ±  0.23 5.69 ±  0.86
10 0.86 0.18 +  0.06 3.02 ±  0.10 4.34 ±  0.39
11 1.00 1.02 ±  0.39 4.73 ±  0.59 6.08 ±  0.73
12 1.20 2.93 + 0.92 6.54 ±  1.48 6.39 ±  1.32
13 1.30 6.79 ±  1.07 6.52 + 1.94 5.67 + 1.07
14 1.50 7.52 ±  1.63 6.68 ±  0.84 4.42 ±  0.57
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Table 3.3.2.2c
Fraction Dilutions None 1/5
FRACTION
NUMBER
Corresponding [NaCl] 
at gradient elution 
MOLAR
Colony ±  S.E.M. 
Area
mm2 mm2
Colony ±  S.E.M. 
Area
mni2 mm2
15 1.50 0.00 ±  0.00 7.86 ±  0.68
16 1.73 0.00 ±  0.00 8.20 ±  0.85
17 1.86 0.00 +  0.00 0.00 ±  0.00
18 1.96 0.00 ±  0.00 4.06 ±  0.88
19 2.10 0.00 ±  0.00 7.41 ±  1.71
20 2.20 0.00 ±  0.00 2.43 ±  0.27
21 2.30 0.00 ±  0.00 3.09 ±  0.93
22 2.40 0.00 +  0.00 3.84 ±  1.11
23 2.45 0.00 ±  0.00 5.11 ±  0.59
24 2.48 0.00 + 0.00 6.17 ±  0.85
25 2.50 0.00 ±  0.00 6.08 ±  0.85
26 2.50 0.00 ±  0.00 6.90 ±  0.73
27 2.50 0.00 ±  0.00 2.01 ±  0.23
28 2.50 0.00 ±  0.00 4.03 ±  0.82
EXPERIMENT CONTROLS
Dialysed Conditioned Medium 0.00 ±  0.00
Conditioned Medium - Column Wash Through 0.00 ±  0.00
Conditioned Medium - Post Gel filtration" 0.00 ±  0.00
Ham’s F12 Control Medium 3.84 ±  0.69
n=3 for all determinations unless otherwise stated. 2 Sample of CM after desalting 
procedure on Sephadex G-15 column.
Inhibition was apparent in fractions eluted from the column which had been assayed without 
dilution. This was unlikely to be due to high osmolarity because o f the extensive dialysis 
performed. The only practical alternative to desalting large numbers o f fractions from a heparin- 
Sepharose colum n was to increase the magnitude o f dilution used. Klagsbrun et al., (1987) 
recommend that no more than 10 /xl o f  a fraction containing 1.5 M  NaCl should be added to 
200 fil o f  medium on top o f cells. In this experiment the complete inhibition o f growth in CM  
dialysed as a control indicates that dialysis and not high salt concentration caused the reduction 
in growth. At dilutions o f lA and greater, inhibition was eliminated. Nevertheless, in one 
fraction complete inhibition was still detected at a 1/5 dilution. This inhibitory activity eluted  
at a concentration o f 1 .86-1 .96  M NaCl in fraction 17.
232
Autocrine stimulatory activity was detected as growth over control in two major regions o f  the 
gradient. The first eluted in fractions 11-16, between 1.0 and 1.9 M  NaCl and the second  
activity eluted at 2 .4 5 -2 .5 0  M NaCl in fractions 24-26. Tw o mitogens eluted in  single fractions 
from die gradient at 0 .70  M and 2.1  M NaCl in  fractions 9 and 19 respectively.
3 .3 .3  H EPA R IN -SE PH A R O SE  C H R O M A T O G R A PH Y  O F H E p-2 C ELL  
EX TR A C T S
In other cell systems where the heparin-binding acidic and basic fibroblast growth factors are 
produced, higher concentrations o f these species have been measured intracellularly {Klagsbrun 
et al., (1987)}. The evidence for autocrine stimulatory activities w ith high affinities for heparin 
prompted the next experiments with HEp-2 extracts.
Tw o HEp-2 cell extracts were prepared in buffers with high and low  salt respectively. Both  
contained a cocktail o f  protease inhibitors and 1 % w /v  CHAPS detergent (to avoid protein  
degradation and dénaturation). The pH was buffered with 20  mM  HEPES to pH 7 .5  as 
described in Section 2 .1 0 .1 . Before heparin-Sepharose chromatography, extracts were 
equilibrated in  running buffer using a Sephadex G-15 column as described in  Section 2 .1 1 .1 .1 . 
Protein in high salt extract was retrieved in 10 mis o f  100 mM phosphate (pH 7 .4 ) and that in 
low  salt extract in  13 m is.
3 .3 .3 .1  The separation o f  H igh Salt H Ep-2 C ell Extract on heparin-Sepharose
A n 8 ml sample o f high salt extract was applied to a 10 m l column and a 0 - 3 M  NaCl gradient 
developed at a flow  rate o f  1 ml/minute as described in Section 2 .1 1 .2 .2 . A  total o f  64  X 3 ml 
fractions were collected from the start o f  the wash through to 192 m is eluted in total. The 
elution profile is show n in figure 3 .3 .3 .1 .
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Figure 3.3.3.1 The separation of HEp-2 cell extract (in 1.5 M  NaCl) using a
0-3 M NaCI gradient on a 10 ml heparin-Sepharose column.
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Three protein peaks separated on the heparin column. The first, eluting after 40  m is had no 
affinity for heparin. A  broad band o f protein eluted from the start o f  the gradient up to
1.0 M NaCl. A  second sharper band w ith higher affinity eluted betw een 1.0 and 1.65 M NaCl. 
The latter peak was centered at 1.4 M  NaCl on the gradient.
The follow ing fractions were dialysed (see Section 2 .8 .2  for details) and assayed after filter- 
sterilisation in the HEp-2 autocrine assay. Fractions 1-19, (0-57 m is, inclusive o f  the non-bound 
protein peak); fractions 23-39 (66-117 m is, inclusive o f the two heparin-binding protein peaks); 
fraction 42, and every third fraction thereafter. 1 ml o f cell extract (from the Sephadex G-15 
column) was dialysed as a control. Samples w ere serially diluted in  serum-free H am ’s F12 to 
a final volum e o f  0 .5  ml before being plated in the assay, the results o f w hich are presented in  
Table 3 .3 .3 .1a .
Table 3.3.3.1a Elution of autocrine activity in HEp-2 high salt extract from 
heparin-Sepharose
Fraction Dilutions 1/5 1/25 1/50
FRACTION
NUMBER
Corresponding [NaClJ 
at gradient elution 
MOLAR
Colony ±  S.E.M. 
Area
mm3 mm1
Colony ±  S.E.M. 
Area
mm1 ram*
Colony ±  S.E.M. 
Area
mm1 mm*
1 0.00 2.10 ±  0.71 2.92 ±  0.97 2.11 ±  0.62
2 0.00 1.43 ±  0.28 2.86 ±  0.38 2.91 ±  0.66
3 0.00 2.79 ±  0.68 2.39 ±  0.63 3.12 ±  0.71
4 0.00 4.20 ±  0.88 4.53 ±  0.46 4.30 ±  0.45
5 0.00 2.79 ±  0.52 5.56 ±  1.26 0.00 ±  0.00
6 0.00 2.44 + 0.56 4.93 ±  0.91 5.38 ±  1.01
7 0.00 4.00 ±  0.72 4.83 ±  0.92 4.74 ±  1.02
8 0.00 4.04 + 0.65 4.61 ±  0.78 5.39 ±  0.99
9 0.00 5.70 ±  0.91 4.63 ±  0.44 3.35 ±  0.81
10 0.00 3.06 ±  0.63 2.15 ±  0.41 5.40 ±  0.36
11 0.00 4.91 ±  0.50 4.67 +  0.83 3.80 ±  0.84
12 0.00 4.17 ±  0.24 4.30 ±  1.17 3.28 ±  0.53
13 0.00 3.18 ±  0.43 4.77 ±  0.63 4.14 ±  0.97
14 0.00 2.57 ±  0.47 4.90 ±  0.92 5.20 ±  0.85
15 0.00 4.03 ±  0.46 4.32 ±  0.76 5.47 ±  0.69
16 0.00 4.23 ±  0.85 4.90 +  0.50 5.76 ±  0.93
17 0.00 3.22 ± 0.48 4.37 ±  0.61 6.63 ±  0.57
18 0.00 1.41 ±  0.25 3.98 +  0.39 3.65 ±  0.71
19 0.00 4.20 ±  0.69 7.30 ±  0.90 4.77 ±  0.90
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Fraction Dilutions 1/5 1/25 1/50
FRACTION
NUMBER
..................  -- ... i
Corresponding [NaClj 
at gradient elution 
MOLAR
Colony +  S.E.M. 
Area
nun1 mm3
Colony ±  S.E.M. 
Area
mm3 mm2
Colony ±  S.E.M. 
Area
mm! mm2
22 0.00 5.67 ±  0.73 8.20 ±  2.23 5.97 ±  1.18
23 0.00 4.37 ±  1.27 5.66 ±  0.74 6.79 ±  1.70
24 0.00 5.45 ±  1.49 4.97 +  1.16 3.96 ±  1.69
25 0.10 N.D. 4.25 ± 1 .1 0 6.30 +  1.67
26 0.25 4.24 ±  0.77 6.38 ±  0.81 7.49 ±  2.24
27 0.40 2.96 + 0.89 6.85 ±  2.46 5.08 ±  0.97
28 0.62 0.32 ±  0.21 3.59 ±  1.80 4.00 ±  0.94
29 0.70 4.04 ±  1.02 8.69 ±  3.18 7.07 ±  2.17
30 0.90 2.08 ±  0.75 4.00 ±  0.57 3.92 ±  1.23
31 1.00 0.00 ±  0.00 0.18 ±  0.13 3.28 ±  1.79
32 1.16 4.72 ±  1.62 2.27 ±  0.42 2.52 ±  0.59
33 1.36 3.60 ±  1.02 2.39 ±  0.75 1.26 ±  0.45
34 1.50 3.64 ±  1.49 2.58 ±  1.19 2.26 ±  0.32
35 1.63 4.16 ±  0.62 3.90 ±  0.41 1.73 ±  0.61
36 1.70 3.71 ±  0.72 3.96 ±  0.88 3.71 ±  0.79
37 1.78 2.15 ±  0.20 3.42 ±  0.89 4.04 ±  0.30
38 1.89 3.62 ±  0.99 2.94 ±  0.79 4.18 ±  0.57
39 2.00 4.82 ±  0.55 0.49 ±  0.11 0.72 ±  0.19
42 2.26 1.33 ±  0.09 0.32 ±  0.10 0.91 ±  0.46
45 2.50 1.79 ±  0.68 0.71 ±  0.38 1.18 ±  0.36
48 2.72 2.84 ±  0.71 1.92 ±  0.69 1.08 ±  0.50
51 2.90 1.45 ±  0.69 1.99 ±  0.94 1.62 ±  0.94
54 3.00 3.43 ±  0.40 3.93 ±  0.76 3.93 ±  0.69
57 3.00 3.06 ±  0.42 3.34 ±  1.07 3.83 ±  1.56
60 3.00 4.15 ±  1.01 3.73 ±  0.65 4.88 ±  0.95
CELL EXTRACT* 3.77 ±  1.97 6.46 ±  1.64 5.89 ±  1.38
Ham’s F12 Experiment Control Mean =  2.35 ±  1.34 mm2
a Desalted by passage through a Sephadex G-15 column. N.D; not determined.
236
The significant inhibiton detected in 1/25 and 1/50 dilutions of fractions 39 and 42 (eluting at
2.0 and 2.26 M NaCl respectively) is most likely explained by poor growth on the particular 
plate on which these samples were analysed. The plate control in this case at 0.01 mm2 was 
barely detectable (compared to the experiment control). For technical reasons mentioned in 
Section 3 .2 .3 .2 , interplate variations in plating densities are more likely to occur in large 
experiments where many plates must be seeded.
Growth in the assayed fractions was only considered significantly greater than control if  the 
sample mean value minus the standard error on that determination, was greater than the value 
for the experiment control mean value plus the standard error on that determination. The levels 
of growth supported by the fractions eluted in this separation were at best only slightly in excess 
of the control. In order to analyse these results with greater clarity the original data in Table 
3.3.3.1a are presented in Table 3.3.3.1b as absolute growth in excess o f the control mean 
{sample mean - control mean}. Only fractions which demonstrated significant stimulation as 
outlined above were treated in this way.
Table 3.3.3.1b Absolute growth over control in High Salt HEp-2 extract separated 
on heparin-Sepharose
FRACTION
NUMBER
Corresponding [NaCl] 
at gradient elution 
MOLAR
FOLD STIMULATION IN SAMPLES RELATIVE 
TO T ins Ham’s F12 MEDIUM CONTROL
SAMPLE DILUTIONS 1/5 1/25 1/50
4 0.00 - 2.18 1.95
5 0.00 - 3.21 -
6 0.00 - 2.58 3.03
7 0.00 - 2.48 2.39
8 0.00 - 2.26 3.04
9 0.00 3.35 2.28 -
10 0.00 - - 3.05
11 0.00 2.56 2.32 -
12 0.00 1.82 - -
13 0.00 - 2.42 -
14 0.00 - 2.55 2.85
15 0.00 - - 3.12
16 0.00 - 2.55 3.41
17 0.00 - 2.02 4.28
19 0.00 - 4.95 2.42
22 0.00 3.32 5.85 3.62
23 0.00 - 3.31 4.44
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FRACTION
NUMBER
Corresponding [NaCl] 
at gradient elution 
MOLAR
FOLD STIMULATION IN SAMPLES RELATIVE 
TO THE Ham’s F12 MEDIUM CONTROL
SAMPLE DILUTIONS 1/5 1/25 1/50
24 0.00 3.10 2.62 .
25 0.10 - - 3.95
26 0.25 - 4.03 5.14
27 0.40 - 4.50 2.73
29 0.70 - 6.34 4.72
37 1.78 - - 1.69
39 2.00 2.47 - -
60 3.00 - - 2.53
Cell Extract 1.50 - 4.11 3.54
On the basis of the data in Table 3.3.3.1b there was some evidence for the presence of high 
affinity heparin-binding stimulatory activity in the HEp-2 (high salt) extract, although it should 
be noted that fractions were stored at 4°C for 7 days before being assayed which may have 
reduced the activity of the heparin-binding species particularly. Stimulatory activity was also 
recovered from this separation in the non-heparin binding eluate.
Three heparin-binding stimulatory activities appeared to elute on the gradient. The first was 
associated with the weak to moderate affinity heparin-binding protein peak. Autocrine 
stimulatory activity with weak affinity for heparin eluting between 0.10-0.40 M NaCl (fractions 
25-27, after 72 mis), and activity with moderate affinity eluting between 0.70-0.85 M NaCl 
(fraction 29, after 84 mis), account for the first species. The second activity eluted at the 
trailing end of the high affinity protein peak at 1.78 and 2.0 M NaCl (fractions 37 & 39, 
between 108 and 114 mis). The third activity with very high affinity, eluted at 3.0 M NaCl 
(fraction 60, after 180 mis).
Mitogenic activities eluting from the gradient at 0.7 and 2 .1M NaCl were also detected in HEp- 
2 CM separated on a 10 ml heparin-Sepharose column developed with a 0-2.5 M NaCl 
continuous gradient (Section 3.3.2.2). However, a low affinity heparin-binding mitogen similar 
to the one detected in the cell extract was not isolated from the CM sample.
In the case of the crude ‘desalted’ cell extract control, evidence for the presence of stimulatory 
activity was only clear at a 1/25 dilution of this sample. Further dilution to 1/50 did not appear 
to significantly reduce this level o f growth.
3.3.3.2 The separation of Low Salt HEp-2 Cell Extract on heparin-Sepharose
A  10 ml sample of low salt HEp-2 cell extract was loaded onto the same 10 ml heparin- 
Sepharose column described in the separation of high salt extract (after suitable washing in high 
salt buffer, see Section 2.11.2.2). The column was run under the same conditions on the FPLC 
system and sixty 3 ml fractions were collected. The elution profile is shown in figure 3.3.3.2.
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Figure 3.3.3.2 The separation of HEp-2 cell extract (in Ham’s F12) using a 0-3 M 
NaCl gradient on a 10 ml heparin-Sepharose column.
Unbound protein eluted in the first 40 mis as with the high salt extract. In this case however, 
only a weak affinity heparin-binding peak eluted from the gradient between 0-1.0 M NaCl, and 
centered at 0.5 M NaCl. The high affinity binding mitogenic species present in the high salt 
extract was absent from this separation.
Several representative fractions were selected from the non-bound protein (N2s 2 ,6 ,9  and 12) and 
heparin-bound protein (N2s 24,26,29,30,32,34,36,38,and 40) eluting from the column. These 
were dialysed as described in Section 2.8 .2 and assayed in the same assay as the high salt 
fractions in Section 3.3 .3.1 . The original data of this experiment are shown in Table 3 .3 .3 .2(i)a.
Table 3.3.3.2(i)a Autocrine activity in Low Salt HEp-2 Cell Extract separated on 
heparin-Sepharose
Fraction Dilutions 1/5 1/25 1/50
FRACTION
NUMBER
Corresponding [NaCi] 
at gradient elution 
MOLAR
Colony ±  S.E.M. 
Area
mm5 mm2
Colony ±  S.E.M. 
Area
mm1 mm1
Colony ±  S.E.M, 
Area
mm2 mm2
2 0.00 5.84 ±  0.04 3.56 ±  0.31 5.36 ±  0.36
6 0.00 4.75 ±  0.34 3.46 ±  0.06 2.62 ±  0.34
9 0.00 4.22 ±  0.01 3.76 ±  0.08 0.14 ±  0.06
12 0.00 1.52 ±  0.02 3.84 ±  0.43 5.24 ±  0.55
24 0.00 6.95 ±  0.94 4.67 ±  0.61 3.13 ±  0.59
26 0.25 5.42 ±  0.18 6.17 ±  1.66 0.50 ±  0.19
29 0.79 1.32 ±  0.47 1.08 ±  0.47 0.44 ±  0.05
30 0.94 1.01 ±  0.06 1.08 ±  0.15 1.06 ±  0.16
32 1.23 1.48 ±  0.70 1.52 ±  0.27 2.01 ±  0.59
34 1.51 2.02 ±  0.79 1.31 ±  0.47 1.63 ±  0.54
36 1.70 2.49 +  0.43 3.56 ±  0.98 3.32 ±  0.66
38 1.86 5.20 ±  0.32 4.05 ± 0.26 2.24 ±  0.74
40 2.11 4.65 ±  1.48 4.27 ±  1.32 4.68 ± 1 .1 2
Ham’s F12 Experiment Control Medium = 2.35 ±  1.34 nun2
Table 3.3.3.2(i)b presents these results as absolute growth over the control (scored on the same 
basis as in Section 3.3.3.1).
Table 3.3.3.2(i)b Absolute autocrine stimulation over control in Low Salt HEp-2 
extract separated on heparin-Sepharose
FRACTION
NUMBER
Corresponding [NaCfl 
at gradient elution 
MOLAR
FOLD STIMULATION IN SAMPLES RELATIVE 
TO THE Ham's FI2 MEDIUM CONTROL
SAMPLE DILUTIONS 1/5 1/25 1/50
2 0.00 3.49 - 3.01
6 0.00 2.40 - -
9 0.00 1.87 - -
12 0.00 - - 2.89
24 0.00 4.60 2.32 -
26 0.25 3.07 3.82 -
38 1.86 2.85 1.70 -
Two heparin-binding autocrine stimulatory activities eluted from the gradient in this case. The 
first was associated with the weakly heparin-bound peak in fractions 24 & 26 (from 0- 
0.5 M NaCl). A second tightly bound activity eluted at 1.95 M NaCl in fraction 38. Autocrine 
stimulatory activity eluted from the column at the same NaCl concentrations during the 
separation of high salt extract.
Non-bound autocrine activity was also detected in the eluate of this extract (fractions 2 ,6 ,9 , and 
12) consistent with the result of the high salt extract separation.
In the following assay the low salt extract fractions were assayed again. All fractions up to and 
including fraction 44 were included and every second fraction thereafter. To avoid the dialysis 
step, fractions not already dialysed were diluted directly into the assay. For this reason, higher 
dilutions were used in this experiment. Appropriate dilution controls included the equivalent 
volume for dilution of phosphate buffer with and without 3 M NaCl.
The original data for this experiment are presented in Table 3.3.3.2(ii)a, & b and fractions 
dialysed before the assay are denoted by shading in the tables.
Table 3.3.3.2(ii)a Autocrine activity in Low Salt HEp-2 Extract after separation
on a heparin-Sepharose column
Fraction Ditutioas 1/50 1/100
FRACTION
NUMBER
Corresponding [NaCl] 
at gradient eiution 
MOLAR
Colony ±  S.E.M. 
Area
mm1 mm1
Colony ±  S.E.M. 
Area
mra1 nun*
1 0.00 18.38 ±  2.43 20.30 ±  1.36
2 0.00 18.50 ±  0.31 16.25 ± 1 .7 6
3 0.00 22.66 + 1.83 19.70 ±  2.54
4 0.00 22.26 ± 2.00 20.08 ±  0.97
5 0.00 22.96 ±  1.44 23.01 ±  0.58
6 0.00 20.27 ±  3.75 16.04 ±  3.16
1 0.00 21.06 ±  3.86 25.18 ±  2.00
8 0.00 21.70 ±  4.04 26.28 ±  1.57
9 O.(H) 25.28 ±  4.91 18.86 ±  2.19
10 0.00 22.31 ±  2.11 24.48 ±  0.73
11 0.00 23.91 ±  2.98 21.55 ±  0.45
12 0.00 23.63 ±  1.94 23.56 ±  2.80
13 0.00 20.41 ±  0.05 24.51 ±  1.88
14 0.00 25.46 ±  4.37 23.23 ±  2.21
15 0.00 15.93 ±  3.23 21.15 ±  0.86
16 0.00 18.11 ±  3.34 18.00 ±  2.88
17 0.00 15.71 ±  2.55 17.73 ±  2.53
18 0.00 18.65 ±  1.82 19.94 ±  3.24
19 0.00 21.90 ±  1.45 20.65 ±  2.77
20 0.00 17.61 ±  1.53 18.31 ±  5.60
21 0.00 20.27 ±  0.39 20.20 ±  2.00
22 0.00 16.72 ±  1.99 24.70 ±  2.26
23 0.00 19.69 ±  1.46 15.18 + 0.83
24 0.00 17.97 ±  2.92 21.24 ±  3.13
25 0.08 19.57 ±  2.40 15.78 ±  4.61
26 0.25 25.29 ±  4.24 23.68 ±  3.39
27 0.47 22.81 ±  2.35 23.87 ±  2.93
28 0.64 20.12 ±  1.02 25.08 ±  3.56
29 0.79 12.84 ±  2.77 17.14 ±  1.05
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Fraction Dilutions 1/50 1/100
FRACTION
NUMBER
Corresponding [NaCl] 
at gradient elution 
MOLAR
Colony ±  S.E.M. 
Area
mm1 inni1
Colony ±  S.E.M. 
Area
ram1 mm*
30 0.94 18.88 ±  2.95 16.07 ±  2.48
31 1.06 5.21 ±  0.88 16.27 ±  0.39
32 1.23 22.54 ±  3.54 11.39 ±  2.55
33 1.36 9.03 ±  1.37 16.20 + 3.00
34 1.51 22.39 ±  1.83 14.67 ±  0.18
35 1.59 6.54 ±  1.39 13.66 ±  2.13
36 1.70 13.59 ±  4,48 18.42 ±  1.09
31 1.78 6.86 ±  1.87 11.79 ±  3.06
38 1.86 8.21 ±  4.71 1S.48 n - l
39 1.97 0.00 ±  0.00 7.19 ±  2.10
40 2.11 20.60 ±  1.73 18.85 ±  1.69
41 2.16 2.31 ±  0.14 6.27 ±  4.22
42 2.24 0.09 ±  0.05 11.43 ±  5.31
43 2.32 0.58 +  0.24 10.95 ±  4.00
44 2.40 1.36 ±  0.82 6.95 ±  3.40
46 2.55 0.12 ±  0.04 4.97 ±  2.54
48 2.70 0.81 ±  0.58 4.66 ±  1.18
50 2.85 0.52 ±  0.14 6.59 +  1.03
52 2.95 0.20 ±  0.01 2.34 ±  1.70
54 2.99 0.23 ±  0.15 3.10 ±  1.45
56 3.00 0.02 ±  0.02 1.00 ±  0.80
58 3.00 0.00 ±  0.00 0.10 ±  0.02
60 3.00 0.39 +  0.36 5.67 ± 2 .9 2
EXPERIMENT CONTROLS
CELL EXTRACT 5.10 +  0.44 16.48 ±  2.09
Gel-filtered CELL EXTRACT 6.48 ±  2.65 27.59 ±  0.56
Phosphate Buffer - NaCl 21.54 ±  3.57 21.29 + 4.53
Phosphate Buffer +  3M NaCI 0.17 ±  0.11 2.54 ± 1 .1 6
MEDIUM (DMEM/Ham’F12) 16.87 ±  4.94 16.58 ±  5.01
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Table 3.3.3.2(ii)b
Fraction Dilutions 1/200 Absolute Growth 
in Excess of the 
Control levelFRACTION
NUMBER
Corresponding [NaCl] 
at gradient elution 
MOLAR
Colony ±  S.E.M. 
Area
mm1 mm’
37 1.78 30.48 ±  8.05 12.81
38 1.86 34.52 ±  3.15 16.85
39 1.97 27.15 ±  3.49 9.48
40 2.11 30.59 ± 1 .1 6 12.92
41 2.16 28.99 ±  1.70 11.32
42 2.24 32.29 ±  1.98 14.62
43 2.32 31.38 ±  1.21 13.71
44 2.40 17.00 ±  2.57 -
46 2.55 19.48 ±  1.73 -
48 2.70 20.31 ±  1.14 -
50 2.85 15.82 ±  2.24 -
Phosphate Buffer +  3 M NaCl 17.67 ±  2.74 -
Overall growth was higher in this experiment than the first experiment with heparin-purified 
extracts (3.3.3.1a). The controls with phosphate buffer plus 3 M NaCl were significantly 
reduced with respect to the medium control at 1/50 and 1/100 dilutions but at 1/200 the growth 
was in the same order as the medium control. Phosphate buffer without NaCl did not alter the 
level of control growth significantly with the volumes used to dilute undialysed samples. When 
the same criteria are used to score autocrine stimulation as outlined in Section 3 .3 .3 .1 , the 
following pattern emerges.
No autocrine stimulation was detected in fractions 1-30 (i.e. up to 1.1 M NaCl) at either 
dilution tested with respect to the phosphate controls. In fractions 3 M 0  inhibition (perhaps due 
to high osmolarity) becomes apparent at a 1/50 dilution but not in the dialysed fractions. No 
evidence for autocrine stimulation however was evident in the dialysed fractions. All fractions 
after N2 40 show inhibition of growth which increases along with increasing NaCl concentration 
in later fractions from the gradient. It is impossible to draw any conclusions about stimulatory 
acitivity in fractions from this part of the separation (in the absence of proper controls for the 
salt inhibition).
No inhibition was apparent in fractions diluted 1/200. Significant stimulation over the phosphate 
control (with 3M NaCl) was observed in fractions 37-43 eluting between 1.8 and 2 .4  M NaCl. 
This was consistent with the previous analysis o f these fractions {Table 3.3.3.2(i)b} In Table 
3.3.3.2(ii)b the excess growth over control is also presented.
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In summary these experiments indicate that HEp-2 autocrine stimulatory activity may be 
recovered from the intracellular compartment of HEp-2 cells. Part o f this activity has affinity 
for heparin. The heparin-binding autocrine activity can be divided into three classes. The first 
has a relatively low affinity for heparin, eluting from heparin-Sepahrose between 0- 
0.55 M NaCl. The second with an intermediate affinity for heparin and was recovered between 
0.75-0.85 M NaCl. A  third autocrine mitogenic species with high affinity eluted between 1.8 
and 2.4 M NaCl. The intermediate affinity species was only recovered in the high salt HEp-2 
extract.
3.3.4 CATION EXCHANGE CHROMATOGRAPHY
A two-step purification procedure using cation exchange followed by heparin-Sepharose 
chromatography has been successfully employed in the purification of several growth factors 
including a chondrosarcoma-derived basic FGF which was purified to apparent homogeneity 
using just these two steps {Shing et al., (1983); Shing et al., (1984)}. Given that at least part 
of the autocrine stimulatory activity in HEp-2 CM was heparin-binding, the use of this 
technique as a purification step in the separation of the HEp-2 autocrine mitogenic activity was 
investigated.
3.3.4.1 The use of CM-Sepharose fastflow in the purification of autocrine activity 
in HEp-2 conditioned medium
The conductivity of a 200 ml sample of HEp-2 conditioned medium was adjusted to 6 mS and 
the pH adjusted to 6.0 before it was applied to a 10 ml column of CM-Sepharose fastflow 
(Pharmacia). The column was developed as described in Section 2.11.3 and bound material 
eluted with 40 ml batches of buffer containing KC1 with concentrations increasing incrementally. 
Because of its ability to stabilise heparin-binding growth factors and other unstable proteins, the 
detergent CHAPS was included in the running buffer (50 mM potassium phosphate) at a final 
concentration of 0.1% w/v. The elution profile for this separation is shown in figure 3.3.4.1.
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Figure 3.3.4.1 The separation of crude HEp-2 CM on a cation exchange column 
(CM-Sepharose Fastflow)
The elution profile showed that the bulk of the protein in HEp-2 CM did not bind to the 
column. Batch elution with KC1 resulted in the separation of three protein peaks eluting at 
0.25 M, 0.5 M, and 0.75 M KC1 respectively.
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Fractions of 20 mis were collected from the column after the start of the gradient. 5 mis of each 
fraction was dialysed as described in Section 2 .8 .2  and filter-sterilised before assay. As a 
control for the combined effects of dilution and dialysis, separate 5 ml aliquots of the same CM 
lot were (1) diluted in potassium phosphate, and (2) diluted in potassium phosphate and also 
dialysed with fractions from the column separation. The results o f this experiment are presented 
in Table 3.3.4.1.
Table 3.3.4.1 The separation of HEp-2 autocrine activity using cation exchange 
chromatography
DILUTIONS 1/S 1/10 1/20
.
Fraction Number
Colony ±  S.E.M. 
Area
mm1 mm1
Colony ±  S.E.M. 
Area
mm* mm1
Colony + S.E.M. 
Area
nun1 mm5
1 3.21 + 0.24 3.07 ±  0.50 2.61 ±  0.75
2 5.13 ±  0.42 4.94 ±  0.67 3.80 ±  0.52
3 2.68 ±  0.36 2.54 ±  0.23 2.34 ±  0.14
4 2.25 ±  0.21 2.92 ±  0.50 2.18 ±  0.09
5 2.77 ±  0.37 2.33 ±  0.30 1.80 ±  0.34
6 1.80 ±  0.12 1.59 ±  0.19 1.28 ±  0.14
7 0.00 + 0.00 0.00 ±  0.00 0.00 + 0.00
8 1.97 ±  0.31 1.81 ±  0.30 2.22 ±  0.75
9 1.63 ±  0.14 1.68 ±  0.27 1.71 ±  0.17
10 0.85 +  0.21 1.28 +  0.34 1.46 ±  0.16
. ........... ' EXPERIMENT’ CONTROLS
Ham’s F12 +0.02% CHAPS 1.57 ±  0.25 1.84 + 0.34 2.15 + 0.17
Unbound Protein N.D. IId 1.31 n = l
Column Wash through N.D. 2.83 n = l 2.63 n = l
Dialysed CM 9.10 ±  0.94 5.46 ±  1.06 4.01 ±  0.96
Diluted1 & Dialysed CM N.D. 4.83 ±  0.28 4.52 ±  0.90
Diluted & Dialysed CM at a dilution equiva]ent to 1/40 2.43 ±  0.97
Unconcentrated Lot 8 CM (n=37) 30.00 +  2.35
Ham’s F12 Experiment Control Mean (n=32) 1.33 ±  0.25
n=3 unless otherwise stated. a Dilutions of this CM sample take into account that it had already been 
diluted Vi prior to the final Vi dilution in the assay. The actual dilution of this sample was half of that 
of the ‘Dialysed CM’ sample above it. N.D; not determined.
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Autocrine stimulatory activity was recovered from the column in the first five fractions. Most 
of the stimulatory activity was present in fraction 2 , which contains the bulk of the protein 
eluting at 0.25 M KC1. Significant stimulatory activity was also detected either side of this in 
fractions 1 & 3, but the activity in these fractions was lower than in fraction 2. A  second 
stimulatory autocrine activity eluted in fractions 4 & 5 associated with the second band of 
protein to elute from the gradient in the 0.5 M KC1 batch. Complete inhibition was associated 
with fraction 7 at all dilutions assayed. This corresponds to the third protein band which eluted 
from the column at 0.75 M KC1. There was evidence that stimulatory activity came through the 
column in the wash, however because of contamination in the assay only one determination was 
readable. No evidence for stimulatory activity was apparent in the bulk of unbound protein, but 
the same problem with contamination in replicate wells prevented the significance of this result 
being evaluated.
Dilution of the CM before dialysis did not significantly alter the autocrine stimulatory activity 
with respect to the ‘dialysed only’ CM at an equivalent dilution.
3 .3 .4 .2  Reconstitution of HEp-2 CM fractions separated by cation exchange 
chromatography
Separation of two autocrine stimulatory and one inhibitory activity using cation exchange 
chromatography suggested that the overall autocrine effect might derive from the interaction of 
synergistic as well as antagonistic species in HEp-2 CM. To investigate this possibility the 
following experiment was performed.
In this pilot experiment every fraction from the separation in Section 3.3.4.1 was mixed 1:1 
with the most active stimulatory fraction, fraction 2. All combinations were assayed at dilutions 
of 1/5 and 1/10 in the HEp-2 assay. CM controls included ‘dialysed only’, ‘diluted Vfc and 
dialysed’, ‘untreated CM’. The results of this experiment are presented in Table 3.3 .4 .2 .
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Table 3.3.4.2 The activity of reconstituted HEp-2 CM fractions separated by 
cation exchange chromatography
DILUTIONS 1/5 1/10
SAMPLE
Colony ±  S.E.M. 
Area
nmi! mm1
Colony ±  S.E.M. 
Area
mm2 mm2
Fractions 2 + 1 9.99 ±  1.10 11.08 +  0.77
Fractions 2 +  3 9.54 ±  0.56 10.20 ±  0.15
Fractions 3 + 4 11.50 + 0.81 9.49 ±  1.00
Fractions 2 +  5 7.70 ±  1.34 12.43 ±  0.45
Fractions 2 +  6 11.29 ±  0.28 9.94 ±  0.25
Fractions 2 +  7 11.18 +  0.08 11.76 ±  1.15
Fractions 2 +  8 11.79 ±  1.82 12.98 + 0.93
Fractions 2 +  9 11.52 ±  0.89 11.66 +  0.20
Fractions 2 + 1 0 11.79 +  0.81 11.39 ±  1.79
Fractions 2 +  Unbound 8.13 ±  0.25 9.33 ±  0.46
Fraction 2 +  Wash 9.08 ±  0.89 9.33 ±  0.05
EXPERIMENT CONTROLS
Dialysed CM 4.76 + 1.24 8.91 ±  1.66
Diluted & Dialysed CM 0.05 ±  0.03 9.18 ±  1.72
Untreated CM 11.37 ±  0.79 10.70 + 1.75
Untreated CM, diluted Vi 11.48 ±  1.13
Untreated & Undiluted CM 17.62 +  2.89
Ham’s F12 Experiment Control Mean = 6.62 ±  0.86 mm2
11=3 for all determinations.
Dialysis of CM caused the growth stimulatory response in this sample to be reduced. The 
inhibition was apparent at a dilution of 1/5 where growth in the dialysed CM was reduced 
significantly with respect to the untreated CM at an equivalent dilution. This ‘dialysis effect’ 
resulted in almost complete inhibition where the CM had been diluted prior to dialysis. Despite 
the effect of dialysis, stimulation over the control was detected in all of the fraction 
combinations. A 1/5 dilution of the fraction 5/fraction 2 combination supported only a control 
level of growth. This may suggest that the respective autocrine stimulatory species in these 
fractions are mutually antagonistic at this particular concentration. Alternatively, the dialysis 
effect noted above may account for the loss of stimulatory activity, because the same 
combination was mitogenic at a 1/10 dilution. The inhibitory species in fraction 7 (see previous 
Section 3.3.4.1) was masked by the addition of fraction 2.
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The following experiment was performed to establish whether the autocrine stimulatory activity 
separated on the CM-Sepharose fastflow column at 0.25 M KC1 (fraction N*2, Section 3.3.4.1) 
could be further purified by heparin-Sepharose chromatography.
Briefly, a 10 ml sample of the 0.25 M KC1 eluate from the CM-Sepharose separation above 
(Section 3.3.4.1) was diluted lA with 50 mM potassium phosphate buffer, pH 7.4. The diluted 
CM was applied to a 10 ml heparin-Sepharose column and a 0 - 3 M linear NaCl gradient was 
developed in the running buffer (100 mM phosphate, pH 7.4). Sixty 3 ml fractions were 
collected at a flow rate of 1 ml/minute. The elution profile is shown in figure 3.3.3.5.
3.3.5 A TWO STEP PURIFICATION OF THE HEp-2 AUTOCRINE ACTIVITY
0 2 5  5 0  7 5  1 0 0  1 2 5  1 5 0  1 7 5
E l u t i o n  v o l u m e  ( m is )
Figure 3.3.3.5 The separation of a partially purified fraction of HEp-2 CM (eluted 
from CM-Sepharose fastflow column at 0.25 M KC1) using a 0-3 M 
NaCl gradient on a 10 ml heparin-Sepharose column
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The bulk of the protein in this sample did not bind to heparin, but eluted in the first 50 mis of 
the separation, and before the gradient. No discernable protein peaks eluted with the gradient.
Fractions (stored at -20°C before assay) were diluted 1/100 in serum-free Ham’s F12 before 
the final V2 dilution in the assay. The 0.25 M KC1 eluate was included as a control in this 
experiment. The results are presented in Table 3.3.5.
Table 3 .3 .5  A utocrine activ ity from  the 0 .25  M  KC1 cation exchange eluate  
separated on heparin-Sepharose
Dilution 1/100 Dilution 1/ 10(1
Fraction N*
{[NaCI]}
Colony ±  S.E.M. 
Area
mm1 mm3
Fraction N* 
{[NaCIJ}
Colony ±  S.E.M. 
Area
mn,1 nun1
1 {0 .00} 7.01 ±  0.64 24 {0.00} 17.54 + 1.83
2 {0 .00} 14.37 ±  0.21 25 {0.00} 0.08 ±  0.05
3 {0.00} 16.28 ±  1.55 26 {0 .00} 16.64 ±  1.24
4 {0.00} 16.31 ±  2.08 27 {0.00-0.07} 0.00 ±  0.00
5 {0.00} 10.62 ±  0.85 28 {0.07-0.26} 18.97 ±  1.65
6 {0 .00} 13.87 ±  1.26 29 {0.26-0.38} 14.38 ±  1.03
7 {0.00} 15.05 +  1.98 30 {0.38-0.58} 15.76 ±  1.78
8 {0 .00} 12.43 ±  0.30 31 {0.58-0.74} 0.00 ±  0.00
9 {0.00} 13.97 ±  0.62 32 {0.74-0.90} 15.20 ±  1.58
10 {0 .00} 14.65 + 0.88 33 {0.90-1.05} 16.14 ±  1.73
11 {0 .00} 13.71 + 2.13 34 {1.05-1.16} 17.13 ±  0.45
12 {0 .00} 12.39 ±  1.04 35 {1.16-1.28} 17.71 ±  1.53
13 {0.00} 14.40 ±  2.30 36 {1.28-1.46} 12.91 ±  3.34
14 {0.00} 17.68 ±  1.49 37 {1.46-1.57} 16.92 + 0.16
15 {0.00} 11.47 ±  0.85 38 {1.57-1.66} 16.92 ±  1.15
16 {0 .00} 15.19 ±  1.56 39 {1.66-1.77} 15.44 ±  2.24
17 {0.00} 16.86 ±  1.33 40 {1.77-1.89} 14.78 ±  1.16
18 {0 .00} 16.33 ±  1.18 41 {1.89-1.97} 17.81 ±  2.49
19 {0.00} 13.67 ±  1.24 42 {1.97-2.07} 18.05 ±  2.17
20 {0 .00} 15.50 ±  0.86 43 {2.07-2.17} 14.26 ±  0.71
21 {0 .00} 17.21 ±  1.08 44 {2.17-2.21} 15.69 ±  1.81
22 {0 .00} 0.00 ±  0.00 45 {2.21-2.35} 10.87 ±  0.22
23 {0.00} 16.06 + 1.69 46 {2.35-2.42} 13.31 + 1.00
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Dilution 1/100 Dilution 1/100
Fraction N“ 
{[NaCl]}
Colony ±  S.E.M. 
Area
Fraction N* 
{[NaCH}
Colony ±  S.E.M.
Area
* 2mru mm
47 {2.42-2.46} 9.14 +  0.90 54 {2.88-2.96} 12.29 ±  0.07
48 {2.46-2.53} 7.91 ±  0.78 55 {2.96-3.00} 13.18 ±  1.53
49 {2.53-2.64} 16.60 +  2.74 56 {3.00} 4.28 ±  0.17
50 {2.64-2.68} 14.26 ±  1.54 57 {3.00} 8.85 ±  0.18
51 {2.68-2.75} 15.56 ±  1.05 58 {3.00} 0.86 ±  0.42
52 {2.75-2.80} 9.43 ±  0.56 59 {3.00} 5.23 ±  0.76
53 {2.80-2.88} 12.42 ±  0.59 60 {3.00} 0.63 + 0.25
EXPERIMENT (CONTROLS
Fraction 2 (0.25 M KCl Eluate) Diluted 1/5 29.70 ±  1.65
Fraction 2 0'25 M KCl Eluate) Diluted 1/100 21.46 ±  1.05
Ham’s F12 Experiment Control Mean (n = 8) 12.61 ±  1.72 mm2
n=3 unless otherwise stated.
Significant growth over the control was scored as autocrine stimulation using the same criteria 
as outlined in Section 3.3.3.1. On this basis, stimulatory activity was recovered in the bound 
and unbound eluate. Activity was also detected in the 0.25 M KC1 fraction down to a dilution 
of 1/ 100.
Non-bound stimulatory activity was found in fractions 3 & 14, at the start, and the trailing end 
of the major non-bound protein peak (figure 3.3.3.5). Stimulatory activity eluted in several 
other places before the start of the gradient in fractions 17 & 18, 21, 24, and 26.
Loosely bound stimulatory activity came off the column in fraction 28 (0.25 M NaCl).
Tightly bound autocrine stimulatory activity eluted from the column on the gradient in fractions 
34 & 35 (1.05 - 1.28 M NaCl), 37 & 38 (1.46 - 1.66 M NaCl), and in fractions 41 & 42 
(1.89 - 2.07 M NaCl). There was also an indication of autocrine stimulatory activity eluting at
2.7 M NaCl (fraction 51) but the level of growth over control is barely significant in this case. 
The apparent inhibition seen in the last five fractions off the column may be due incomplete 
dialysis of these high salt containing fractions.
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3.3.6 HYDROPHOBIC INTERACTION CHROMATOGRAPHY
A 2 ml sample of an R10-30 (lOx) HEp-2 CM concentrate was applied to a 1 ml phenyl- 
Sepharose column as described in Section 2.11.4. Fractions of 2 ml were collected as the 
column was washed through sequentially with 1M, and 0.5M  (NH4)2S0 4 through to zero salt. 
The column was then developed with increasing concentrations of glycerol. After dialysis 
(Section 2.8.2) and filter-sterilisation the fractions were diluted xh  and xk  in Ham’s F12 and 
tested in the 24-well HEp-2 autocrine assay. The resulting activity in these fractions together 
with the corresponding buffer composition at this elution volume are tabulated in Table 3.3.6. 
In this experiment the same R10-30 sample was included as a control together with a sample 
of the crude CM used to make the R10-30 concentrate. An R30 (lOx) prepared from the same 
CM lot was also included in this experiment.
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Table 3 .3 .6  A utocrine activity in the 10-30 kDa fraction o f  H E p-2 C M  eluted  
from  a phenyl-Sepharose colum n
DILUTIONS % «
FRACTION FRACTION Colony ±  S.E.M. Colony +  S.E.M.
NUMBER ELUATE Area
mm1 nun*
Area
mm1 mm1
1 2.61 .1 0.86 4.14 ±  0.54
2
Running Buffer
4.08 ±  0.57 2.36 ±  0.05
3
1.0 M (NH^jSO^
2.79 ±  1.43 2.57 ±  0.90
4 0.71 ±  0.46 3.68 ±  1.50
5 3.84 ±  0.58 1.82 ±  0.52
6 N.D. 3.61 ±  0.32
7
0.5 M (NH^SO,
0.76 ±  0.49 2.72 ±  1.60
8 2.18 ±  0.20 4.20 ±  1.31
9
0SALT
3.34 ±  0.43 2.38 ±  0.26
10 0.00 ±  0.00 0.00 +  0.00
11 2.31 ±  0.67 4.58 ±  1.29
12
10% GLYCEROL
0.00 ±  0.00 0.00 ±  0.00
13 0.00 ±  0.00 0.00 ±  0.00
14 0.00 ±  0.00 0.00 ±  0.00
15
20% GLYCEROL
0.00 ±  0.00 0.00 ±  0.00
16 0.00 ±  0.00 0.00 ±  0.00
17 0.80 ±  0.29 2.64 ±  0.66
18 30% GLYCEROL 2.33 ±  1.21 1.30 ±  0.37
19 1.17 ±  0.66 2.33 ±  1.41
20 0.00 ±  0.00 0.86 ±  0.65
EXPERIMENT CONTROLS j
Lot 3 R10-30 (lOx) 4.33 ±  1.34
Lot 3 R30 (lOx) 0.18 ±  0.04
Unconcentrated Lot 3 CM 8.60 ±  1.61
Ham’s F12 Experiment Control Mean 1.57 ±  0.49
n=3 for all determinations. N.D; Not determined.
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The amount of stimulation in the R10-30 fraction was not greater than that in the crude lot of 
CM from which it had been prepared. The lOx concentrate of the R30 fraction was inhibitory, 
consistent with earlier observations (Section 3.2.3.2). Four autocrine stimulatory activities 
appeared in the eluate from this column. The first washed through in fractions 1 & 2, a second 
activity came off in 0.5 M (NH4)2S 0 2 {fraction 5}, and a third in fractions 8 & 9 at zero salt. 
The fourth eluted in more hydrophobic conditions at 10% glycerol {fraction 11}. Complete 
inhibition was detected in fractions 12-16 (in both dilutions of these samples) eluted at 20% 
glycerol. This was unlikely to be due to incomplete dialysis becasue control growth was restored 
in subsequent fractions eluted by 30% glycerol. These results indicated that at least one of the 
autocrine stimulatory species in the R10-30 HEp-2 CM fraction is hydrophobic, but that the 
remainder are hydrophillic in nature. There was also evidence for a hydrophobic inhibitory 
species eluting in 20% glycerol.
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3.4.1 ANTI-FIBROBLAST GROWTH FACTOR NEUTRALISING ANTIBODIES
Studies with purified growth factors (Section 3.2.6) provided indirect evidence for the presence 
of FGF receptors on HEp-2 cells and partial purification of HEp-2 CM separated two heparin- 
binding autocrine stimulatory activities with affinites for immobilised heparin that were 
coincidental with those reported for aFGF and bFGF respectively (Section 3.3.2). Taken 
together, these findings suggested the possibility o f an FGF autocrine loop in HEp-2 cells. To 
investigate this hypothesis, polyclonal anti-FGF neutralising antibodies incubated with three 
stimulatory fractions of HEp-2 CM in an attempt to assess their potential to block their 
endogenous mitogenic activities. Concentrations of the respective neutralising antibodies used 
were based the efficacies quoted by the manufacturers as effective in the NR6-3T3 fibroblast 
cell line system (see Section 2.14.1).
3.4.1.1 Preliminary evidence for FGF-neutralisable autocrine activity in HEp-2 CM
Initially crude HEp-2 CM and an R10-30 ultrafiltration fraction were incubated with anti-acidic 
or anti-basic FGF antibodies (see Section 2.14.3 for details) Mitogenic concentrations of the 
relevant growth factors were used as controls for antibody function. Because FGFs are 
mitogenic over a narrow concentration range (Section 3.2.6), three concentrations were tested 
with and without antibody to ensure that activity was measured in the control. To check for 
possible growth regulatory activity in the antibody preparation, a separate control with antibody 
only in control medium was included.
Anti-acidic FGF antibody in crude HEp-2 CM
The effect of anti-acidic FGF on the autocrine stimulatory activity in crude CM (Lot C4) was 
determined in the first part of this experiment. Due to the limited quantity of this antibody 
available, only 25 /xg/ml could be used for the controls for antibody function. However, this 
was still within the quoted efficacy range (Section 2.14.1). The results with this antibody are 
shown in Table 3 .4 .1.1a.
Table 3.4.1.1a The effect of Anti-acidic FGF neutralising antibody on the autocrine 
stimulatory activity in crude HEp-2 CM
SAMPLE NO ANTIBODY +  25 ng/ml ANTIBODY
Acidic FGF 
ng/ml
Colony ±  S.E.M. 
Area
nun1 mm1
Colony ±  S.E.M. 
Area
mm’ mm2
5 6.64 ±  0.83 6.73 ±  0.62
4 6.57 ±  0.61 6.93 +  1.61
3 N.D. 6.68 ±  1.34
CONDITIONED MEDIUM AND CONTROL
SAMPLE NO ANTIBODY +  50 ng/ml ANTIBODY
Lot C4 CM 11.14 ±  1.54 7.61 ±  0.42
Ham’s F12‘ 5.92 ±  0.94 8.28 ±  0.90
n=3 unless otherwise stated. a n=9. N.D; Not determined.
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Anti-aFGF antibody alone increased the overall control growth by 40%. In addition, the purified 
aFGF used was inactive mitogenically at all concentrations tested, making a definitive 
conclusion about the inhibitable mitogenic activity in crude CM impossible. Nevertheless, at 50 
/xg/ml anti-acidic FGF antibody significantly neutralised the autocrine stimulatory activity in 
crude HEp-2 CM.
Anti-basic FGF antibody in crude HEp-2 CM
The second part of the experiment looked at the effect of anti-basic FGF neutralising antibody 
on the autocrine stimulatory activity in Lot C4 HEp-2 CM under the same assay conditions. In 
this case the same concentration of antibody was used for control and CM samples. The results 
are presented in Table 3.4.1.1b.
Table 3.4.1.1b The effect of Anti-basic FGF neutralising antibody on the autocrine 
stimulatory activity in crude HEp-2 CM
SAMPLE NO ANTIBODY +  50 fig/ml ANTIBODY
Basic FGF 
pg/ml
Colony ±  S.E.M. 
Area
mm1 mm1
Colony ±  SJE.M. 
Area
mm2 mm1
250 11.92 ±  1.46 7.17 ±  1.36
200 7.68 ±  1.06 4.60 ±  0.85
150 6.75 ±  0.78 3.53 ±  0.50
COND1TIONED MEDIUM AND CONTROL
SAMPLE NO ANTIBODY -f 50 Mg/ml ANTIBODY
Lot C4 CM 11.14 ±  1.54 8.95 ±  0.67
Ham’s F12‘ 5.92 + 0.94 8.79 ±  1.67
n=3 unless otherwise stated. a n=9.
Purified bFGF was active mitogenically above 200 pg/ml with maximal activity at 250 pg/ml. 
This was in good agreement with previous results with this growth factor (Section 3.2.6). The 
antibody alone was mitogenic for HEp-2 when added to the control medium; at 50 ¿ig/ml anti- 
bFGF antibody control growth was increased by 48%.
The data in Tables 3.4.1.1a & 3.4.1.1b above were expressed as sample growth in excess of 
control growth and the relative amount of inhibition with respect to the untreated sample was 
calculated. These are shown in Table 3.4.1.1c.
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Table 3.4.1.1c The percentage mitogenic activity remaining in HEp-2 CM and growth 
factor controls after addition of anti-FGF antibodies
TREATMENT NO ANTIBODY ANTIBODY (MU/ml) % Autocrine 
Activity 
RemainingSAMPLE ABSOLUTE GROWTH OVER CONTROL*
Basic FGF 50 /tg/ml Anti-bFGF
250 pg/ml 6.00 1.25 21
200 pg/ml 1.76 -1.32b 0
150 pg/ml 0.83 -2.39" 0
Crude HEp-2 CM 5.62 3.03 54
Acidic FGF 25 ng/ml Anti-aFGF
5 ng/ml 0.72 0.81 113
4 ng/ml 0.65 1.01 155
3 ng/ml - 0.76 -
Crude HEp-2 CM 5.22 1.69c 32
a This figure was calculated by subtracting the value for the control from that of the treated sample value. 
b The growth values for these treatments were less then the control. c 50 /ig/ml of anti-aFGF was used in the 
CM sample.
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These results indicate that 50 /xg/ml of the neutralising anti-acidic FGF antibody inhibited 68 % 
of the total autocrine activity in crude CM (calculated with respect to Ham’s F12 without 
antibody). However, this observation was inconclusive due the absence of a positive control for 
antibody function. The stimulation indicated in the anti-acidic FGF antibody controls suggests 
that a contaminating mitogen in this antibody preparation is active at the relatively high 
concentration of antibody used. The same was true for the anti-basic FGF antibody.
Anti-basic FGF neutralising antibody inhibited 80% of the maximal stimulation with the bFGF 
control (i.e 250 pg/ml bFGF). At lower bFGF concentrations, inhibition with 50 /xg/ml anti- 
basic FGF antibody was greater. 100% inhibition of mitogenic respose to 200 pg/ml bFGF was 
seen, and at 150 pg/ml bFGF the level o f growth in the presence of antibody was less than the 
control value. The apparent reduction in autocrine stimulation in CM under these conditions was 
46% (with respect to Ham’s F12 control).
Control growth was increased by 40% with anti-acidic FGF and by 48% in the presence of anti- 
basic FGF. These growth factors were purified from rabbit serum and may therefore contain 
mitogens for HEp-2. No mitogenic activity was reported in these antibody preparations by the 
suppliers, but they had used a different indicator cell line.
3.4.1.2 Neutralisation of R10-30 autocrine activity with anti-FGF antibodies
In the third part of this preliminary experiment the effect of the anti-FGFs on the autocrine 
stimulatory activity in a lOx R10-30 ultrafiltration fraction of HEp-2 CM was examined. A  
range of antibody concentrations from 5-50 /ig/ml was incubated with the CM fraction before 
assay (see Section 2.14.3 for details). The results are presented in Table 3 .4 .1 .2a. These results 
were then expressed as sample growth in excess o f control and the residual activity was 
presented as a percentage of that in untreated R10-30 fraction (minus antibody) in Table 
3.4.1.2b.
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Table 3.4.1.2a Inhibition of autocrine activity in the R10-30 fraction of HEp-2 CM
using anti-FGF antibodies
SAMPLE ANTIBODY
R10-30 (I Ox) Anti-Acidic FGF Anti-Basic FGF
[ANTIBODY]
Mg/ml
Colony ±  S.E.M. 
Area
mm1 mm1
Colony ±  S.E.M. 
Area
mm2 mm2
5 8.01 ±  0.19 5.97 ±  0.88
10 9.56 +  1.05 8.57 ±  0.09
25 9.02 ±  0.75 8.82 ±  0.45
50 7.72 ±  0.96 7.76 ±  1.39
EXPERIMENT CONTROL,5
R10-30 (lOx) - No Antibody 11.28 ±  1.78
Crude HEp-2 CM (Lot C4) 11.12 ±  1.54
Ham’s F12 (n=9) 5.92 ±  0.94
n=3 unless otherwise stated.
Table 3.4.1.2b Percentage autocrine activity remaining in the R10-30 fraction of 
HEp-2 CM after addition of anti-FGF antibodies
[ANTIBODY]
i<g/ml
Absolute Growth in 
Excess of Control*
% Autocrine Activity 
Remaining
No Antibody 5.36 100
Anti-Acidic FGF
5 2.09 39
10 3.64 68
25 3.10 58
50 1.80 34
Anti-Basic FGF
5 0.05 1
10 2.65 49
25 2.90 54
50 1.84 34
a This figure was calculated by subtracting the value for the control from 
that of the treated sample value.
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This data indicated that 99% of the autocrine stimulatory activity in the R10-30 fraction of HEp- 
2 CM could be inhibited by 5 /xg/ml anti-basic FGF antibody. At higher antibody concentrations 
the percentage reduction in activity was less. This may reflect the effect of contaminating 
mitogenic activity in the antibody preparation or non-specific interactions at higher 
concentrations.
The inhibition of 61 % of the R10-30 autocrine stimulatory activity by 5 /xg/ml anti-acidic FGF 
appeared indicated cross-reactivity with one or both of the antibodies under the conditions used 
in this experiment. If only anti-basic FGF were cross-reactive, this would imply that an aFGF- 
like and a bFGF-like activity were present in the R10-30 fraction. However, if  cross-reactivity 
were confined to the anti-acidic FGF antibody, then this would imply that at least 99% of the 
autocrine activity in this fraction could be attributed to a bFGF-like factor. This question of 
cross-reactivity was addressed in Section 3.4 .1.4 .
3.4.1.3 Determination of the ND50 values for two commercially available Anti-FGF 
neutralising antibodies in the HEp-2 assay system
Preliminary results suggested that the efficacies and cross-reactivity patterns of the commercial 
neutralising anti-FGF antibodies should be determined in the HEp-2 assay system. Antibody 
efficacy was addressed in the following experiment with a second lot of antibodies purchased 
from the same supplier. The suppliers expressed the efficacy of the second lot of antibodies in 
terms of their ‘ND^’values (see Section 2.14.1 for details).
Concentrations of purified aFGF and bFGF required to give maximal stimulation in this assay 
(2.5 ng/ml and 250 pg/ml respectively) were titrated against a range of both antibody 
concentrations from 0.1-10.0 /xg/ml. BSA carrier protein was omitted from the incubations with 
growth factors (see Section 2.14.3 for details) because of its stimulatory effect on HEp-2 growth 
reported in Section 3.2.6 above.
Controls
The question of FGF stability under these incubation conditions (without BSA) was examined. 
To this end, two concentrations of FGFs without BSA and antibody were assayed. The same 
concentrations of FGFs incubated with BSA without antibody were also tested. The activity of 
antibody preparation alone was investigated by the addition of 10 /xg/ml of the respective lots 
to control medium. A sample of Lot C4 HEp-2 CM (used in the stability studies, Section 3.2 .4  
above) was included to check for assay function. The results of this experiment are presented 
in Table 3.4.1.3.
Table 3.4.1.3 Determination of the NDS0 for two commercially available anti-FGF 
neutralising antibodies in the HEp-2 assay system
2.5 ng/ml Acidic FGF 250 pg/ml Basic FGF
+  Anti-Acidic FGF 
ANTIBODY 
Mg/ml
Colony ±  S.E.M. 
Area
nun mnr
+ Anti Basic FGF 
ANTIBODY 
pg/ml
Colony ±  S.E.M. 
Area
mm2 mm3
0.1 6.57 ±  0.96 0.1 6.57 ±  0.89
0.5 5.71 +  0.57 0.5 6.25 ±  0.43
1.0 6.10 ±  0.41 1.0 6.93 ±  0.36
5.0 5.42 ±  0.32 5.0 3.55 ±  0.27
10.0 5.82 ±  0.33 10.0 3.42 ±  0.43
No Acidic FGF No Basic FGF
10.0 4.35 ±  0.43 10.0 3.21 ±  1.18
ÎROWTH FACTOR C()NTROLS MINUS BSA v\V ■ . * . .-*:v5vt,
5.0 ng/ml aFGF 7.55 + 0.21 250 pg/ml bFGF 7.12 ±  0.69
2.5 ng/ml aFGF 6.96 ±  0.93 125 pg/ml bFGF 4.94 + 0.44
Ham’s F12 Control - BSA (n=25) =  4.81 ±  1.13 nun1
GROWTH FACTOR CONTROLS PLUS 0.25 mg/ml BSA
5.0 ng/ml aFGF 0.00 ±  0.00 250 pg/ml bFGF 11.22 ±  2.05
2.5 ng/ml aFGF 0.00 +  0.00 125 pg/ml bFGF 11.02 ±  0.63
Ham’s F12 Control +  0.25 mg/ml BSA (n= 8) =  9.47 ±  1.07 mm2
Crude HEp-2 Conditioned Medium Lot C4 (n=6) =  15.55 ±  1.02 mm2
n=3 unless otherwise stated.
The overall level o f growth in the assay was greater in the growth factor samples when BSA  
was present. However, the relative increase over the respective control measured with growth 
factors was greater in the absence of BSA. This suggested that the absence of BSA did not 
adversely affect the stability of the growth factors during the short preparation period in low 
protein conditions (i.e. dilution from stocks). The complete lack of growth in the aFGF controls 
plus BSA cannot easily be explained. Neither antibody alone was mitogenic for HEp-2 cells at 
10 /xg/ml. Purified aFGF and bFGF gave significant stimulation over the control at 2.5 ng/ml 
and 250 pg/ml in the absence of BSA, respectively. The bFGF-stimulated growth was 
completely inhibited by 5 /xg/ml of anti-basic FGF antibody, but no reduction was achieved with 
1 /xg/ml of the same antibody. The ND» value for the anti-basic FGF antibody therefore was 
determined to be between 1 and 5 /xg/ml in the HEp-2 system. This was in good agreement with 
the value of 2 ng/ml quoted by the supplier’s in the NR6 system (Section 2.14.1). At 5 /xg/ml 
anti-aFGF antibody (close to the 2 /xg/ml ND^ specified for this antibody by the supplier’s) 
partial inhibition of the response to 2.5 ng/ml aFGF was detected. The level of inhibition 
observed was not significant however, and no titratible inhibition was detected with the anti- 
aFGF antibody at other concentrations tested.
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3.4.1.4 Neutralisation of autocrine activity in HEp-2 CM with anti-FGF antibodies of 
known efficacy in the HEp-2 system
The neutralising anti-FGF antibodies tested for their efficacy in the HEp-2 system (Section
3.4.1.3) above were used in to assess their ability to neutralise the autocrine stimulatory activity 
in crude HEp-2 CM (lot C4). This experiment was designed to address the question of cross- 
reactivity of both antibodies. The possibility of non-specific inhibition of growth stimulation was 
also investigated. To this end, TGFa (a known stimulator of HEp-2, Section 3.2.6) at 1 ng/ml 
was preincubated with both antibodies independently (see Section 2.14.3) and then tested for 
activity in the HEp-2 assay. The results of this experiment are shown in Table 3.4.1.4.
Table 3.4.1.4a The effect of anti-FGF antibodies on the autocrine activity in crude 
HEp-2 CM
SAMPLE Lot C4 CM Ham’s FI2* 2.5 ng/ml aFGF 250 pfi/ml 1>FGF
[ANTIBODY]
Mg/ml
Colony ±  S.E.M. 
Area
mm1 mm’
Colony ±  S.E.M. 
Area
mm1 mm1
Colony ±  S.E.M. 
Area
mm2 ram3
Colony ±  S.E.M. 
Area
mm3 mm*
ANTI-ACIDIC FGF NEUTRALISING ANTIBODY
5 11.63 ±  3.01 3.21 .1 0.71 3.81 ±  0.38 3.01 ±  0.78
10 13.00 ±  2.72 3.15 ±  0.11 N.D. N.D.
ANTI-BASIC FGF NEUTRALISING ANTIBODY
5 8.88 ±  0.19 3.63 .1 0.56 5.30 +  0.83 2.94 ±  0.73
10 9.74 ±  0.98 3.39 ±  0.36 N.D. N.D.
ANTI-ACIDIC & ANTI-BASIC FGF NEUTRALISING ANTIBODIES COMBINED6
5 9.08 ±  0.41 N.D. N.D. N.D.
10 9.63 ±  0.52 N.D. N.D. N.D.
NO ANTIBODY
0 11.47 ±  1.57" 2.53 ±  0.61d 4.72 ±  0.39' 3.82 ±  0.44e
Transforming growth factor « (I ng/ml) Control
No Antibody 8.30 ±  2.96
10 ¿ig/ml Anti-Acidic FGF 9.10 ±  3.08
10 ng/ml Anti-Basic FGF 12.46 ±  0.41
n=3 unless otherwise stated. a Control medium. b 5 /ig/ml and 10 /xg/ml of each amtibody were used in 
combination. 0 n=15. d n=12. e n = 6. N.D; Not determined.
The level of stimulation in response to acidic and basic FGF was low with respect to the control 
in this experiment. It was nevertheless significant (allowing for standard errors). Neither 
antibody alone significantly altered the control level of growth (Ham’s F 12) up to concentrations 
of 10 /xg/ml (consistent with the result in Section 3.4.1.3). The amount of growth in all samples 
was expressed as sample growth in excess o f control (Ham’s F12) and in Table 3 .4 .1 ,4b below 
the effects of the respective antibodies can be judged by comparing the percentage activity
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remaining in CM and growth factor samples after addition of antibody. The excess growth in 
samples without antibody were taken as 100% activity.
Table 3.4.1.4b Percentage mitogenic activity remaining in crude HEp-2 CM and purified 
FGFs after incubation with anti-FGF neutralising antibodies
Sample CM aFGF bFGF TGF«
(2.5 ng/ral) (250 pg/mi) (1 ng/ml)
[Antibody] G.E.* % G.E. % G.E, % G.E. %
/ig/ml A.R.b A.R. A.R. A.R.
None 8.94 100 2.19 100 1.29 100 5.77 100
Anti-Acidic FGF neutralising antibody
5 9.10 102 1.28 58 0.48 37 N.D. N.D.
10 10.47 117 N.D. N.D. N.D. N.D. 6.57 114
Anti-BasiC FGF neutralising antibody
5 6.35 71 2.77 126 0.41 32 N.D. N.D.
10 7.21 81 N.D. N.D. N.D. N.D. 9.93 178
Anti-Acidic and Anti-Basic FGF neutralising antibodies in combination
5 6.55 73 N.D. N.D. N.D, N.D. N.D. N.D.
10 7.10 79 N.D. N.D. N.D N.D. N.D. N.D.
a Absolute growth in sample in excess of the control. This figure was calculated by subtracting the value for the control 
from that of the treated sample value. b % Autocrine activity remaining after treatment. N.D; Not determined.
This data indicated that the anti-acidic FGF antibody was cross-reactive with the anti-basic FGF 
antibody because the former could neutralise an equivalent amount of the mitogenic response 
of HEp-2 to bFGF (i.e. 63%). The converse was not true. In the control for antibody function, 
anti-basic FGF neutralised 68 % of the mitogenic response to bFGF but it did not inhibit the 
stimulation due to aFGF. In fact, an apparent increase in growth was detected when anti-basic 
FGF was preincubated with aFGF.
Anti-basic FGF antibody alone was capable of inhibiting 27 % of the total autocrine stimulatory 
activity in this lot of crude CM (lot C4) when it was present at 5 ng/ml. The higher 
concentration tested was less effective (21% of the stimulatory activity was inhibited by 
10 /xg/ml).
The anti-aFGF antibody was less effective in neutralising the mitogenic response to aFGF than 
its anti-bFGF counterpart was with bFGF. In the control for function, only 42% of the 
mitogenic response to 2.5 ng/ml aFGF was inhibited by the antibody. Anti-acidic FGF alone 
had no inhibitory effect on the autocrine stimulatory activity in crude CM.
A combination of both antibodies (both at 5 /¿g/ml) inhibited autocrine growth by the same 
degree as 5 /xg/ml of anti-basic FGF alone (i.e by 27%). Inhibition was less with the higher 
concentrations of both antibodies (i.e. 10 /¿g/ml of each antibody caused 21% inhibition) but 
again the magnitude of inhibition was in the same order as anti-bFGF alone.
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In the control for non-specific growth inhibition using TGFa:, the presence of anti-acidic-FGF 
antibody, and to a greater extent the presence of anti-basic FGF, resulted in an increase in the 
level of stimulation detected at 1 ng/ml TGFa.
In summary this experiment indicates that under the conditions used here, aproximately 30% 
of the total autocrine activity in crude HEp-2 CM was bFGF-like. This data suggests that only 
the anti-basic FGF antibody can effectively inhibit autocrine activity to any significant degree 
in crude HEp-2 CM. The results also raise the question of the specificity and efficacy of this 
particular anti-acidic FGF neutralising antibody.
3.4.1.5 Neutralisation of autocrine stimulatory activity in the HEp-2 CM ultrafiltration 
fractions R10-30 and R30 with anti-FGF antibodies of known efficacy in the 
HEp-2 system
The following experiment was designed to confirm the observation (Section 3.4.1.2) that almost 
all autocrine activity (99%) in the R10-30 fraction could be blocked by an anti-bFGF 
neutralising antibody. The difference between this experiment and that in Section 3.1 .4 .2  is that 
the efficacy of both anti-FGF antibodies used had been determined in the HEp-2 system (Section
3.1.4 .3). The effect of both neutralising antibodies on an R10-30 was tested again. An R30 
fraction (previously demonstrated to be mitogenic in the HEp-2 autocrine assay) was also 
assayed for FGF-like autocrine stimulatory activity. The combined effect of the antibodies was 
also addressed in this experiment. Antibodies were incubated with the samples before assay, as 
described in Section 2.14.3. The results are shown in Table 3.4.1.5a.
Table 3.4.1.5a Neutralisation of autocrine activity in R10-30 and R30 ultrafiltration 
fractions of HEp-2 CM with anti-FGF antibodies
SAMPLE R10-30 R30
[ANTIBODY] Colony ±  S.E.M. Colony ±  S.E.M.
W/ml Area Area
ram2 mm3 nun2 mm*
None 2.97 ±  0.31 4.68 ±  0.59
Anti-aFGF 5 /xg/ml 2.63 ±  0.32 3.66 ±  1.42
Anti-bFGF 5 /<g/ml 1.97 ± 0.40 3.28 ±  0.27
Anti-aFGF + Anti-bFGF1 (5 /ig/ml) 1.99 ±  0.17 2.21 + 0.33
EXPERIMENT CONTROL (No Antibody)
Ham’s F12 (n=6) 1.34 ±  0.60 mm2
n=3 unless otherwise stated. a 5 /¿g/ml of each antibody was used in combination.
The overall level of growth in this assay was low. However, autocrine stimulation in both 
fractions of CM was significantly higher than in the control Ham’s F12 medium. In Table 
3.4.1.5b the excess growth over control for every sample is shown. This data is also expressed 
as the percentage activity remaining after antibody treatment. Activity in CM without antibody 
was taken as 100%.
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Table 3.4.1.5b Percentage autocrine activity remaining in R10-30 and R30 fractions 
of HEp-2 CM after preincubation with anti-FGF neutralising 
antibodies.
SAMPLE Rt0-30 R30
[ANTIBODY]
jig/ml
Absolute Growth in 
Excess of Control"
% A.R.’’ Absolute Growth in 
Excess of Control
% A.R.
None 1.63 100 3.34 100
5 ng/ml Anti-aFGF 1.29 21° 2.32 30°
5 fig/ml Anti-bFGF 0.63 61 1.94 42
5 j«g/ml Anti-aFGF +  
5/ig/ml Anti-bFGF 0.65 60 0.87 74
a This figure was calculated by subtracting the value for the control from that of the treated sample value. 
b Percentage autocrine activity remaining. c These calues are not significant allowing for standard errors.
Only the anti-bFGF antibody was able to significantly reduce autocrine stimulatory activity in 
the R10-30 fraction. This amounted to 60% inhibition of the total R10-30 mitogenic activity 
measured in this experiment, compared to the 99% inhibition observed with 5 /tg/ml of the first 
lot of anti-bFGF (Section 3.4.1.2). No more inhibition was detected when anti-acidic FGF was 
combined with anti-basic FGF, consistent with the results in the previous experiment 
(Section 3.4.1.4).
Anti-acidic FGF alone did not inhibit the R10-30 autocrine activity. The apparent reduction of 
21 % was not significantly lower than the untreated R10-30, allowing for standard errors on this 
determination.
Similarly the apparent 30% reduction in the activity of the R30 fraction in the presence of anti- 
acidic FGF was within the margin of error. However, the 42% inhibition of the R30 autocrine 
activity by anti-basic FGF was significant. The level of inhibition was increased by a farther 
32% in this fraction when anti-acidic FGF antibody was added in combination with anti-basic 
FGF.
This experiment confirmed that a large portion of the autocrine activity in the R10-30 fraction 
of HEp-2 CM was bFGF-like. It also indicated that bFGF-like activities and possibly aFGF-like 
activities may contribute to the autocrine effect in the R30 fraction.
A summary of all the results with neutralising antibodies is presented in Table 3.4.1.5c.
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Table 3.4.1.5c Summary of the percentage of autocrine activity neutralised by
anti-FGF antibodies in crude and ultrafiltrated HEp-2 CM
[ANTIBODY]
^g/ml
PERCENTAGE OF TOTAL AUTOCRINE ACTIVITY NEUTRALISED IN CM
CRUDE CM R10-30 R30
Anti-Acidic FGF Neutralising Antibody
50 68 66 N.D.
25 N.D. 42 N.D.
10 0 32 N.D.
5 0 21-61 30
Anti-Basic FGF Neutralising Antibody
50 46 66 N.D.
25 N.D. 46 N.D.
10 19 51 N.D.
5 29 61-99 42
N.D; Not determined.
It can be concluded from these studies therefore that between 30-50% of the total autocrine 
growth stimulatory activity in crude HEp-2 CM is a bFGF-like species. At least 60% (if not 
more) of the mitogenic activity in the R10-30 fraction can also be attributed to a similar factor. 
Approximately 40% of the R30 activity was neutralised by 5 /¿g/ml anti-bFGF antibody, but 
the nature of the extra 30% activity neutralised by the presence of 5 /xg/ml anti-acidic FGF 
cannot be ascribed to acidic or basic FGF because of the cross-reactivity shown with the anti- 
aFGF antibody.
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3.4.2 FGF ANTISENSE OLIGODEOXYNUCLEOTIDES
The evidence for aFGF and bFGF-like autocrine activity in HEp-2 CM, provided by the results 
of experiments with neutralising antibodies in the previous Section (3.4.1), suggested that one 
or both of these growth factors might play a significant role in the autocrine control o f HEp-2 
growth.
Basic FGF has been implicated as an autocrine growth regulator for malignant melanoma and 
gliomas. Further proof for the autocrine role of bFGF in these systems was provided using the 
recently developed antisense technology. The basis of this technology is the ability to arrest 
protein translation in a gene specific fashion. Arrest of translation is thought to occur by the 
hybridisation of the complementary (antisense) oligodeoxynucleotide sequence to mRNA, 
resulting in its subsequent degradation by RNAses.
The following experiments set out to investigate the potential of antisense bFGF and antisense 
aFGF oligodeoxynucleotides to inhibit the proliferation of HEp-2. A  number of important 
considerations pertaining to the use of oligodeoxynucleotides in cell culture were addressed in 
the approach to the experimental design. These included, (1) Oligomer stability; (2) Oligomer 
uptake and potential toxicity; (3) Quantity of oligomer required/scale of the experiment 
(i.e. volume of tissue culture media used per determination);
(4) Time of addition of oligomer.
The choice of oligomer sequence and length influence the effectiveness of translation arrest. 
Fifteenmers (sequences 15 base pairs in length) antisense to the translation initiation start sites 
for aFGF and bFGF mRNA were chosen as targets on the basis of work published by Becker 
et a l., (1989), and Morrison (1991). Both workers were able to inhibit bFGF-induced cell 
proliferation using the same oligodeoxynucleotide sequence which is 5' to and overlapping the 
initial methionine codon.
In this work a 15 base pair sequence antisense to the sequence beginning at the initiation codon 
of aFGF was chosen to investigate its potential for inhibition of HEp-2 proliferation. 
Unmodified oligodeoxynucleotide sequences were used here to avoid potential problems with 
specific hybridisation (due to chemical modifications).
The sequences used in this work were synthesised commercially by British Biotechnoloty Ltd 
(see Section 2.15.1 for details, and appendix B for sequence data). The limiting quantities of 
oligomers available necessitated the use of a miniturised assay system. For this reason the 96- 
well plate assay was chosen to reduce the scale of the experiment. Concentrations in the 0- 
200 ftM range have been reported in the literature as effective in arresting protein translation 
in cell culture systems. Sense sequences complementary to the antisense sequences were used 
as controls for non-specific inhibition (resulting from toxicity of the oligomer preparation et 
cetera).
To improve oligomer stability, foetal calf serum to be used in the experiment was heated at 
65°C for 45 minutes to inactivate endogenous nucleases.
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3.4.2.1 Determination of assay parameters for HEp-2 with 1% heat-inactivated serum 
in the 96-well plate system
The 96-well acid phosphatase HEp-2 assay (described in Section 2.12.5) used 200 /¿I of culture 
medium per well. New parameters for HEp-2 growth were investigated for the 96-well plate 
system in a preliminary experiment designed to optimise growth in 1 % heat-inactivated serum. 
The volume of culture medium was reduced to 50 /¿I to reduce the quantity of oligos required. 
This assay looked at the growth of HEp-2 cells at three plating densities, and in two separate 
batches of serum. These plating densities were higher than those employed in the HEp-2 assay 
because it is difficult to measure growth inhibition at low cell densities. Proliferation under the 
same conditions with the same sera untreated was also examined. The results are presented in 
Table 3.4.2.1.
Table 3.4.2.1 The growth of HEp-2 in 1% heat-inactivated serum and reduced assay 
volume in the 96-well plate system
CELLS/WELL 1 x  101 2 .5  x  103 5  x  10s
SERUM BATCH ABS ±  S.D.* ABS ±  S.D.* ABS ±  S.D.'
Untreated Batch AF1201 0 .0 19  ±  0 .0 0 7 b 0 .0 36  ±  0 .0 14 0 .0 8 9  ±  0 .0 2 4
Heat-inactivated Batch AF1201 0 .0 83  ±  0 .0 1 7 c 0 .1 76  ±  0 .025 0 .2 3 2  ±  0 .0 52
Untreated Batch 48 0 .1 05  ±  0 .0 2 8 b 0 .211 ±  0 .0 27 0 .2 57  ±  0 .0 52
Heat-inactivated Batch 48 0 .0 39  ±  0 .0 0 9 ' 0 .0 4 0  ±  0 .0 17 0 .0 6 2  ±  0 .0 16
a Absorbance at 405 nm + standard deviation. b n=22. 0 n=24. n = 30-32 for all other determinations.
Heat-treatment of batch N2AF1201 improved the growth supported by this FCS batch over the 
range of cell plating densities tested. The converse was true for FCS batch N248. Batch AF1201 
was used therefore in subsequent experiments. In order to ensure a relatively high (readable) 
absorbance value under these assay conditions the loading density was raised to 104 cells per 
well for the subsequent antisense experiments.
3.4.2.2 Preliminary evidence for the arrest of HEp-2 proliferation using FGF antisense 
oligodeoxynucleotides
Oligonucleotides were reconstituted in HPLC grade H20  and quantified spectrophotometrically 
as described in Section 2.15.3. All dilutions were in DMEM/Ham’s F12 (1:1) mixture (plus 1 % 
heat-inactivated serum, 1 % L-glutamine and 500 U/ml penicillin/500 /xg/ml streptomycin) just 
before addition in the assay. The assay protocol is described in Section 2.15.5.
The first lots of oligonucleotides were found to be acidic after reconstitution in 100 /il of 
distilled HjO (pH 3.5-4.5 as judged by indicator paper). This only became apparent when the 
top concentration of oligos were diluted in cell culture medium (to 75 /xM). In an effort to avoid 
pH problems these top stock solutions were diluted to 50 /xM and subsequent serial dilutions 
made from these. The assay was read after a 6 day incubation. Briefly, cell culture medium was 
removed carefully and the cells were washed once with PBS. Acid phosphatase activity was
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measured as described in Section 2.12.5.1. The results of this experiment are presented in Table 
3.4.2.2(i).
Table 3.4.2.2(i) The effect of Antisense Oligodeoxynucleotides directed against the start 
sites of acidic and basic FGF mRNAs on the proliferation of HEp-2
Acidic FGF Basic FGF
[OLIGO]
Sense Antisensc Sense Antisensc
ABS ±  S.D.* AUS ±  S.D.’ ABS ±  S.D." ABS ±  S.D.*
50 0.006 ±  0.005 0.002 ±  0.002 0.006 ±  0.002 0.014 ±  0.002
30 0.007 ±  0.003 0.012 ±  0.005 0.009 ±  0.005 0.006 ±  0.002
25 0.034 ±  0.007 0.046 +  0.029 0.064 ±  0.014 0.020 ±  0.005
10 0.233 ±  0.010 0.252 ±  0.021 0.259 ±  0.030 0.216 ±  0.110
5 0.164 ±  0.034 0.189 + 0.048 0.222 +  0.059 0.289 ±  0.028
1 0.189 ±  0.020 0.189 ±  0.045 0.217 ±  0.062 0.261 ±  0.016
Control1" 0.244 ±  0.046 (n=6) 0.275 ±  0.020 (n=6)
a Absobance at 405 nm ±  standard deviation. b plate control. n=3 unless otherwise stated.
At concentrations of oligo greater than 25 /¿M HEp-2 growth was inhibited significantly with 
respect to the corresponding plate control. At 50 /xM complete inhibition was seen in all sense 
and antisense samples, suggesting that this was due to the residual acid. Where growth was 
measurable (i.e. in the 1-25 nM oligo concentration range), only the bFGF antisense 
oligodeoxynucleotide at 25 /zM appeared to significantly reduce HEp-2 proliferation with respect 
to the sense oligo. However, as both samples were already reduced with respect to the control 
a definitive conclusion could not be reached. No reduction in growth was detected at any 
concentration of antisense aFGF (with respect to the sense control).
Technical problems with the commercial oligodeoxynucleotides were overcome with the 
purchase of a second lot of oligos which did not contain acid residue. Nevertheless, 1 fil 
aliquots o f all the reconstituted oligos (identical sequences as above) were tested for acidity 
before dilution in culture medium. The assay was repeated as outlined above, except that the 
top concentration of oligos assayed was 100 /xM, based on the preliminary observation with 25 
/¿M of antisense bFGF. In an effort to minimise plating errors, manual and electronic 
multichannel micropipettes were compared as described in Section2.15.4. The electronic model 
gave the lowest errors on plating and was used in this experiment. The assay was incubated for 
4 days and read as before using acid phosphatase as an endpoint. The results are shown in Table 
3.4.2.2(ii).
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Table 3.4.2.2(H) The effect of antisense acidic and basic FGF oligodeoxynucleotides on 
HEp-2 cell proliferation
[OLIGO]
/tM
Acidic FGF Basic FGF
Sense Antisense Sense Antisense
ABS ±  S.D.“ ABS ±  S.D." ABS ±  S.D.* ABS ±  S.D.*
100 0.234 ±  0.187 0.147 ±  0.035 0.608 ±  0.038 0.608 ±  0.021
33.3 0.245 ±  0.082 0.199 ±  0.008 0.610 ±  0.012 0.576 ±  0.036
13.3 0.214 ±  0.049 0.204 ±  0.071 0.586 ±  0.000 0.597 +  0.059
6.6 0.176 ±  0.097 0.271 ±  0.056 0.617 ±  0.065 0.604 ±  0.068
1.3 0.347 ±  0.146 0.423 ±  0.055 0.541 ±  0.012 0.542 ±  0.040
Controlb 0.252 ±  0.052 (n=5) 0.377 ±  0.120 (n=6)
a Absorbance at 405 nm ±  standard deviation. b plate control. n=3 unless otherwise stated.
Toxicity due to oligos was not detected in this experiment. However, despite efforts to the 
contrary the standard errors remained high. No reduction in HEp-2 proliferation was seen in 
the presence of antisense bFGF (with respect to the sense control) over the entire concentration 
range assayed. This contradicts the observation in the previous experiment indicating a reduction 
at 25 /xM. However, because the control level of HEp-2 cell growth was lower in that case the 
lack of inhibition in this experiment might be explained by a lower ratio of oligo: cell number 
(i.e.a lower effective dose per cell).
The mean value for cell growth in the presence of 100 /xM antisense aFGF suggests a reduction 
in growth with respect to the control growth and the corresponding aFGF oligo sense control. 
However, this is only significantly reduced with respect to the plate control because the standard 
error on the 100 /xM aFGF sense oligo control was too large to permit a definitive conclusion.
Because the standard errors in this experiment were unacceptably high, no definitive conclusions 
could be drawn from the trends which emerged. However, the highest concentration of antisense 
aFGF did indicate a reduction in HEp-2 growth of 50% (if the standard errors are discounted 
and only the mean values are compared). No reduction was indicated with the antisense bFGF, 
but higher cell densities were observed by eye on this plate before the addition of 
oligodeoxynucleotides — a factor which may support a dose effect as mentioned above.
In conclusion, the experiment did not indicate a role for bFGF in HEp-2 proliferation as implied 
by the antibody studies, but there were indications that aFGF is involved in this process. 
However, it should be pointed out that the cell density used in this experiment was 30 fold 
higher than that in the autocrine assay. Under these conditions the doses of antisense bFGF used 
may not have been sufficient to significantly arrest translation of bFGF mRNA and/or the 
timing of the addition of the antisense bFGF may have allowed sufficient time for the expression 
and deposition of the growth factor in the extracellular matrix which is believed to act as a 
storage site for this and other growth factors.
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3.5 MEASUREMENT OF TRANSFORMING GROWTH FACTOR a  IN  HEp-2 CM
Transforming growth factor a  (TGFa) was shown to be active in stimulating the proliferation 
of HEp-2 cells under autocrine assay conditions (Section 3.2.6). Two established assays were 
used in this work to screen HEp-2 CM for TGFa-like activity. The first is based on the ability 
of TGFa to stimulate the colony forming efficiency of NRK (normal rat kidney) cells in soft 
agar {Todaro & deLarco (1978)} in a concentration dependant manner.
The second, a radioreceptor assay utilising the human cell line A431, is described in Section
2.12.6 and the results with HEp-2 CM in this assay are presented in Section 3 .1 .6.3 .
3 .5.1  The NRK soft agar assay for TGFa
A range of concentrations of TGFa (Genentech) were prepared from a stock solution of 
10 f i g / m l  in serum-free DMEM/Ham’s F12 (1:1) plus 1 mg/ml BSA (see Section 2.13.2 for 
details). Dilutions were made in the same medium as the stock TGFa and were used generate 
a standard curve in the NRK soft agar assay (described in Section 2.12.3.2). DMEM/Ham’sF12 
plus 1 mg/ml BSA was used as a control.
HEp-2 CM sample concentrates (prepared by ultrafiltration using the 30 kDa and the 10 kDa 
‘cut-off membranes, Section 2.8.1 .1) were assayed together with an unconcentrated CM 
sample. All of these samples were first shown to be active in the HEp-2 autocrine assay. Mature 
TGFa with a MW of 6 kDa should have been recovered in the 5-10 kDa fraction if it were 
present in HEp-2 CM. On the contrary, no stimulatory activity was detected in this fraction of 
HEp-2 CM (Section 3.2.3.2). Ham’s F12 was used as the control for HEp-2 CM samples.
CM from the cell line RPMI-2650 was also assayed in a concentrated form. MEM was used in 
the collection of RPMI-2650 CM and therefore this medium was included as a control. This 
experiment was performed in duplicate and the results of both determinations are shown in 
Table 3.5.1.
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Table 3 .5 .1  M easurem em t o f T G F a-like activity in H Ep-2 C M  using the N R K  soft 
agar assay
STANDARD CURVE EXPERIMENT 1 EXPERIMENT 2
[TGFa] (ng/ml) % C.F.E. ±  S.E.M.* % C.F.E. ±  S.E.M.
50.00 27.29 ±  0.83 20.66 ±  0.86
25.00 23.59 ±  1.54 18.89 +  0.73
10.00 22.58 ±  3.21 16.10 ±  0.62
5.00 19.69 ±  2.20 14.26 ±  1.93
1.00 15.03 ±  0.31 6.68 ±  0.84
0.50 14.89 ±  0.48 5.89 ±  0.73
0.05 1.29 ±  0.49 0.12 ±  0.00
Control Medium +  BSA 0.00 ±  0.00 0.04 ±  0.05
CONDITIONED MEDIA
RPMI-2650 R1 (lOx) 7.95 ±  1.47 1.18 ±  0.19
RPMI-2650 R1 (5x) 3.23 ±  0.29 0.39 ±  0.06
RPMI-2650 R1 (lx) 0.67 ±  0.07 0.00 ±  0.00
Control MEM 0.00 ±  0.00 0.04 ±  0.05
HEp-2 R30 (lOx) 0.00 ±  0.00 0.00 ±  0.00
HEp-2 R10-30 (lOx) 0.00 ±  0.00 0.00 ±  0.00
HEp-2 Unconcentrated 0.00 ±  0.00 0.00 ±  0.00
Control Ham’s F12 0.00 ±  0.00 0.00 ±  0.00
a Percentage colony forming efficiency ±  standard error of the mean. n=3 for all determinations.
Transforming growth factor a  was detected in the NRK assay at the lowest concentration tested, 
0.05 ng/ml ( = 5 0  pg/ml). No TGFa-like activity was detected in any of the HEp-2 CM 
samples. Maximal stimulation with TGFa in the autocrine assay was at 500 pg/ml, but lower 
concentrations of the growth factor were active depending on the assay conditions (see Section
3.2.6.1).
Concentrated CM from the cell line RPMI-2650 contains a TGFa-like activity which is 
dilutable.
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DISCUSSION
4.1 PRIMARY CELL CULTURE
Successful establishment of primary cell cultures and continuous cell lines from commonly 
occuring carcinomas would have important clinical and scientific applications. However, 
establishment of continuous human cell lines is a rare event, and the phenotypic and/or the 
genetic alterations that may be necessary to predispose a tumour to this potential are not yet 
clearly defined. Genetic selection in tumour populations favouring in vivo metastasis may also 
confer growth advantages on such cells in vitro and facilitate their establishment as continuous 
cell lines.
Earlier work in this field suggests that no universal strategy can be applied to optimise the in 
vitro culture of all tumours or even tumours of the same histological type {Dietal et al., (1987); 
Leibovitz (1986); Fogh (1975)}. In this project, efforts to establish primary cell cultures from 
thorasic tumours (predominantly of lung origin), support this consensus.
Mechanical disaggregation of tumour tissue proved more successful in releasing epithelal cells 
than the use of proteolytic enzymes. This was consistent with the findings of Dietal et 
a l., (1987) who also reported that collagenase/dispase was superior to trypsin in cases where 
mechanical dissaggregation alone gave insufficient cell numbers. A  frequent observation with 
primary cultures from different tissues was the better success, in terms of growth performance, 
achieved with small cell clumps released during mechanical disaggregation {Freshney (1987)}. 
This observation was noted with samples processed in this project too. However, the explant 
technique was found to be of limited use in establishment primary epithelial cultures.
In agreement with the findings of Miyazaki et al., (1984) working with bronchogenic squamous 
cell carcinomas, incubation in collagenase for prolonged periods also resulted in higher yields 
of fibroblasts in this study.
In the majority of primary cultures of malignant epithelial cells handled in this work, it was not 
possible to prevent the eventual loss of these cultures through senescence and/or terminal 
differentiation, despite vigilant attempts to remove fibroblasts. No obvious benefits accruing 
from the presence of even small numbers of fibroblasts for the growth of epithelial cells were 
observed. There were preliminary indications (n=3) that substituting foetal calf serum with 
autologus serum resulted in reduced numbers of fibroblasts. However, no significant benefit for 
tumour cell growth was observed in this small set of samples and the routine use of donor
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human serum from cancer patients was not a practical consideration for ethical reasons.
The use of growth-arrested 3T3 feeder layers was not found to be a satisfactory technique for 
the inhibition of fibroblast overgrowth in primary lung epithelial cultures. This was consistent 
with the findings of others {Jorissen et al., (1991)}. In contrast, a more recent publication by 
de Jong et al., (1993) reported the successful use of such feeder layers for limiting fibroblast 
growth and establishing succesful cultures from explants in vitro o f normal human bronchial 
epithelial cells. These workers used a DMEM/Ham’s F12 basal medium (3:1) supplemented 
with insulin, hydrocortisone, L-isoproterenol, as well as 5% foetal bovine serum. A possible 
explanation for the inability of 3T3-feeder layers to prevent the overgrowth of malignant lung 
epithelial cells by their stromal counterparts in primary tumours, is the ability of the former to 
stimulte the latter by producing the potent fibroblast mitogen, platelet-derived growth factor (see 
Section 1.4 above). Similarly collagen-coating of culture flasks was ineffective as a method of 
reducing fibroblast proliferation.
Differential removal of fibroblasts was attempted using different formulations of the standard 
trypsin/EDTA mixture routinely used to subculture cell lines. This approach was met with some 
success by other workers in this laboratory {Me Donnell, Ph.D thesis, National Institute for 
Higher Education, Dublin [NIHED] (1987)} and further improved upon here. Selective 
trypsinisation at 37°C proceeded rapidly and often the interval between the removal of 
fibroblasts and epithelial cells was too short in practice to stop the reaction with growth 
medium. However, by incubating at 4°C better control of the detachment process was obtained. 
In agreement with the findings of Martin, Ph.D thesis [DCU], (1992), the most effective 
mixture for the removal of fibroblasts was 0.01% trypsin/0.04% EDTA at 4°C. However, it 
was also found that 0.25% trypsin alone (also at 4°C) was effective in selectively removing 
epithelial cells. The use of 0.25% trypsin at low temperature may prove to be more generally 
useful in the selective selection of epithelial cells from fibroblasts given that Hodges et al., 
(1973) found that entry of the protease into cells at 4°C was negligible, but the enzyme still had 
some effect on the cell surface at this temperature.
The results obtained with primary cultures of non-small cell lung carcinomas was disappointing 
in the context of long-term survival and propagation of tumour cells in vitro, with only 9.5% 
of all samples classes received being subcultured for at least one passage after initiation of the 
primary culture. In agreement with the findings of Martin {Ph.D thesis, 1992} small-sized 
samples taken at bronchoscopy or mediastinoscopy were the least reliable source for successful
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primary lung tumour cells in vitro. Compared to an 65% ‘take’ with the generally larger 
resection samples from lobectomies and pneumenectomies, only 30% of all 
bronchoscopy/mediastinoscopy samples yielded epithelial cells in culture after tissue processing. 
Of this 30%, none were subcultured further, compared to 20% of the initially succesful 
lobectomy/pneumonectomy samples (equivalent to 13% of all samples processed in this 
category, i.e lung tumours).
Although fewer oesophageal samples were cultivated, these tumour types appear to establish 
with greater facility as in vitro cultures (in 4/6 cases, epithelial cells were obtained from 
primary oesophageal tumours) than the lung tumours processed. This may be a reflection of the 
inherent biolgical make-up of these tumours and/or the nature of the samples obtained (large 
resection as opposed to smaller biopsy-sized samples).
Consistent with the observation that cell lines tend to establish in vitro more easily from 
metastatic tumours than from the same tumours at their primary sites {Shaw et al., (1993)}, and 
from poorly differentiated rather than well differentiated NSCLC tumours {Liu & Tsao (1993)}, 
a metastatic poorly differentiated squamous cell lung carcinoma was established as a continuous 
cell line in this work. A second permanent cell line was established from a culture derived from 
a malignant effusion associated with a metastatic breast adenocarcinoma. The better success 
rates for epithelial cultures seen with the effusion-derived cells (5/8 gave epithelial growth 
excluding one which was established as a permanent cell line) also supports the observation that 
metastatic carcinomas are easier to establish in culture, most likely due to the their reduced 
requirements for external growth stimuli.
4.1.1 CELL LINE CHARACTERISATION
4.1.1.1 DNA fingerprinting
The integrity of the newly established cell lines DLRP and BAC was verified by DNA  
fingerprint analysis performed commercially by Cellmark Diagnostics. In the case of DLRP, 
single locus probes were used to distinguish this cell line from all of the other cell lines in use 
at the time of its inception (see figure 3.1.13). BAC was matched to its donor using multilocus 
probes to screen the fingerprint patterns of cell line DNA with that of cells harvested from the 
original effusion. These were found to be identical (figure 3.1.14).
276
4.1 .1 .2  Cytogenetic and histological analysis
In work carried out in this laboratory, Gilvarry et a l., (1990) found that the presence of  
abnormal mitoses could be used to distinguish normal epithelial from tumour cells in early 
passage primary cultures. In this study, which also included DLRP, no abnormal mitotic indices 
were detected in a variety of normal epithelial cells during mitosis. However, early passage 
DLRP cells were shown to exhibit tripolar and multipolar mitoses — a phenomenon 
characteristic of some malignant cell divisions (see figure 3.1.15).
Cytogenetic analysis of DLRP by Law et al., (1992) revealed that this cell line had eight marker 
chromosomes, including two deletions of chromosome 3. Three of the additional markers 
d e l(l)(q ll) , del(2)(p 11. 1) and del(2)(ql 1. 1) are shared with another squamous cell lung 
carcinoma cell line established in this laboratory, DLKP, but otherwise the chromosomal 
karyotypes were markedly different. A prominent feature in metaphase chromosome spreads of 
DLRP was the detection of telomeric association. This feature was not observed in DLKP. The 
frequent chromosome breakage found in DLRP metaphases made it difficult to analyse 
cytologically, but a modal number of 66 was ascribed to this cell line on the basis of a 
composite chromosome profile.
4.1 .1 .3  Immunohistochemical analysis
Epithelial-specific antibodies
Relative to the positive staining pattern demonstrated by SCC-9 (a squamous cell carcinoma of 
the tongue), and the negative staining pattern of the human embryonic lung fibroblast cell line 
MRC-5, DLRP stained very weakly with the Ep-16 antibody directed against a surface epithelial 
antigen (figures 3.1.16. 3.1.17, and 3.1.18 respectively). However, using the anti-cytokeratin 
N2 18, antibody a more defined cytokeratin staining pattern was seen with DLRP (figures 3.1.21  
& 3.1.22) confirming its epithelial origin. This staining pattern is expected for epithelial cells 
(see SCC-9 figure 3.1.19), which unlike fibroblasts (e.g. MRC-5 figure 3.1.20) incorporate 
keratin into the intermediate filaments of their cytoskeleton. BAC cells produced a particularly 
strong staining pattern with anti-cytokeratin N2 18, demonstrating well defined filaments and 
confirming the epithelial origin of these cells (figures 3.1.23 & 3 .1.24).
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NSCLC-specific antibodies
The immunoreactivity of two murine monoclonal antibodies, 703D 4 and 704A1, recognising 
the same epitope on NSCLC, but not SCLC cells, were used to confirm the NSCLC phenotype 
of the newly established DLRP. The staining pattern of BAC with these antibodies was also 
determined.
As expected, 704A1 did not demonstrate reactivity with the SCLC cell line HTB 120 (i.e. the 
negative control) but a positive staining pattern was demonstrated with the human NSCLC cell 
line SK-MES-1, a squamous cell carcinoma used as a positive control (figures 3.1.31 & 3.1.32  
respectively). By comparison, DLRP also stained positively with 704A1, butMRC-5 fibroblasts 
were negative for this epitope (figures 3.1.33 & 3.1.34 respectively).
The positive staining of the breast adenocarcinoma cell line BAC with 704A1 was unexpected 
in view of the original report that another breast carcinoma cell line (MCF-7) did not stain 
positively with this antibody {Mulshine et al., (1983)}. However, the positive reaction with 
BAC is unlikely to be artifactual because the second NSCLC-specific antibody used, 703D4 
recognises the same epitope as 704A1, and this too recognised an epitope on BAC cells (figure 
3.1.30).
DLRP also stained positively for 703D4 (figure 3.1.29) compared to the negative pattern for 
HTB 120 (figure 3.1.26). The NSCLC control cell lines used with this antibody, SK-LU-1 
(adenocarcinoma) and SK-MES-1, were also shown to stain positively (figures 3.1.25 & 3.1.28  
respectively).
In conclusion, these antibodies were useful in establishing the epithelial origin of DLRP and 
BAC. The positive reactive patterns of both cell lines to the tumour-specific epitope expressed 
by NSCLC but not SCLC cells confirmed the ‘non-small cell status’ of DLRP.
4.1.1.4 Mycoplasma status of new cell lines
Given the ubiquitous distribution of mycoplasma species, and the nature of the primary sample 
collection protocol, together with the fact that certain mycoplasma species are endemic to the 
human lung, it was not surprising that a cell line established from such a source proved to be 
mycoplasma positive at an early passage number. DLRP cultures were quarantined until they 
had been successfully treated with an anti-mycoplasma agent and tested negative. The human
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breast adenocarcinoma cell line BAC, established from a sterile effusion, was mycoplasma 
negative at the earliest passage tested.
4.1.1.5 Clonogenicity in soft agar
The ability of tumour cells, but not normal cells, to form colonies from single cells when grown 
in semi-solid agar medium has been used as a criterion for defining the malignant phenotype 
of tumour cells {Bergh et a l., (1981); Luster et al., (1985)}. The ability of DLRP to form 
colonies in soft agar also confirmed the malignant character of this cell line. Determination of 
DLRP colony forming efficieny at various plating densities indicated that the percentage colony 
forming efficiency was directly related to cell density. Increasing the cell number per plate 
resulted in increased %CFE up to a maximum level between 1 and 2 X 105 cells/plate in the 
35mm system used. A lower limit to plating density was detected between 1 and 5 x  10* 
cells/plate, below which there was zero colony formation. The cut-off point for colony 
formation with DLRP was matched by a similar limit to colony formation at reduced plating 
densities with another human lung squamous cell line, DLKP. The cell density-dependence of 
colony formation in soft agar may be indicative of autocrine growth factor production by these 
cell lines. However, at a plating density higher than that required for maximal colony forming 
efficiency with DLRP, a reduction in the %CFE was noted. This may be indicative of the 
production of an autocrine inhibitory species by these cells at high cell densities. This inhibitory 
effect was not matched by DLKP at high density where the increase in colony number was such 
that it made colony counting impractical.
4.1.1.6 Growth factor responsiveness of DLRP and DLKP
Although TGFa has been implicated as an autocrine growth factor in lung squamous cell 
carcinomas, it did not display mitogenic activity on DLRP and DLKP; two cell lines derived 
from poorly differentiated SCC lung tumours in this laboratory (Section 3.1 .7 .1). This was in 
spite of the evidence suggesting that DLRP may secrete a TGFa-like species into its culture 
medium (Section 3.1.6.3). An explanation for the lack of activity with exogenously supplied 
TGFa in this case, may be that the receptors for this growth factor were already saturated 
and/or down-regulated with endogenously produced ligand. This would render the cells 
insensitive to further stimulation by exogenous TGFa.
Another possible explanation is that the combination of assay parameters used (low plating 
density and low serum concentration) may not have provided sufficiently stringent growth
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conditions with which to detect the mitogenic response to TGFa. An inappropriate combination 
of assay parameters may also explain the lack of an autocrine growth response by DLRP in 
monolayer culture, to DLRP-conditioned medium (Section 3 .1 .8 .1), even though the growth of 
this cell line in agar indicated the possible production of such a species. Similarly, there was 
no evidence for the production of positive autocrine growth factor activity by DLKP in 
monolayer culture under the conditions assayed. On the contrary, there was evidence for an 
autocrine growth inhibitory species in medium conditioned by DLKP (Section 3.1.8.2).
DLRP and DLKP demonstrated markedly different respones to acidic and basic FGF (Section
3.1.7.1). When the fold stimulation in DLRP growth was calculated with respect to the 
experimental control mean, a maximal response to acidic FGF of almost three fold (i.e, 2.85  
fold) was detected. The maximal mitogenic response to basic FGF (at 1 pg/ml) was 1.7 fold, 
and this was measured at a 250-fold lower concentration than that required to induce maximal 
stimulation with aFGF. In addition, no obvious dose response was seen with either FGF, but 
this may be attributable to the narrow concentration range for mitogenic activity reported with 
these growth factors. The differential in concentrations of growth factor required to elicit 
maximal stimulation with acidic and basic FGF in DLRP cells is also consistent with the effects 
of these FGFs in other cell types in vitro where bFGF has been reported to be 10- to 30-fold 
more potent than aFGF {Gospodarowicz (1987); Joseph-Silverstein & Rifkin (1987)}.
There was some evidence for weak stimulation of DLKP growth in the presence of 0.25 ng/ml 
aFGF. However, unlike DLRP, increasing concentrations of this growth factor above 0.5 ng/ml 
were progressively more inhibitory to DLKP proliferation (Section 3.1.7.2). A  similar pattern 
of inhibiton was detected with bFGF at concentrations in excess of 10 pg/ml, but growth 
stimulation of DLKP was indicated at 1 and 5 pg/ml bFGF, with fold stimulation measured as 
1.56 and 1.87 at these concentrations respectively.
Interleukins-la and -1/3 were both stimulatory for DLRP. IL -la  induced a two-fold increase 
in cell growth between 100 and 250 pg/ml, but IL-l/S was mitogenic only at a concentration of 
250 pg/ml, where the fold induction in growth (at 1.68 fold), was less than that achieved in 
response to IL -la  at the same concentration. In contrast, DLKP was unresponsive mitogenically 
to IL -la , but IL-l/S induced a 1.92 fold increase in growth at 5 pg/ml.
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4.1.2 NEGATIVE REGULATORS OF NSCLC GROW TH
4.1.2.1 Transforming growth factor /5
Although TGF-/31 inhibits normal bronchial epithelial cells, a direct role for TGF-/31 as an 
inhibitor, and/or inducer of terminal differentiation in NSCLC cells in vitro is not clearly 
established. Moroever, the results of studies with TGF-/3 on cell lines may not be representative 
of the potentially more complex interactive network of growth factors found in the mixed 
population of cell types present in primary tumour cultures. It is well known that many of the 
biological effects of TGF-/3s are mediated indirectly, by the antagonism of other growth factor 
signalling pathways, and that the eventual cellular response to TGF-/3 may depend on its context 
with respect to other growth factors {Sporn & Roberts (1988)}. In support of this concept, 
Matsumoto et al., (1992) found that TGF/3 (and glucocorticoids such as hydrocortisone) 
suppressed the expression of the HGF/SF gene in the human lung embryo fibroblast cell line 
MRC-5. By analogy with the actively dividing embryonic lung tissue, it is possible that 
‘stimulated’ fibroblasts which are actively dividing in lung tumours, produce TGF/3 which may 
exert a negative paracrine effect on the autocrine production of autocrine HGF/SF by the 
malignant epithelial component in these tumours (see Section 1.6). The ability to inhibit the 
production of an autocrine stimulator for NSCLC may be one mechanism whereby TGF/3 can 
indirectly modulate tumour cell proliferation.
A recent publication by Kirk et al., (1993) would support this idea. These authors have 
presented evidence suggesting that the inhibition of many tumour cell types may be mediated 
by TGF-/31 secreted by fibroblasts. There are a number of other possible sources of TGF-/3 in 
culture systems for NSCLCs. Apart from fibroblasts, tumour cells are known to produce TGF-/3 
{Derynck et al., (1985)}, and high levels of TGF-/3 are also found in serum {Masui et al., 
(1986)}. Although the tumour- and serum-derived TGF-/3 (from platelets) may be present in an 
inactive form, physiologically relevant processing mechanisms, such as proteolytic activation 
by plasmin, may be operative in primary cultures.
4.1.2.2 Antiproliferative effects of interleukins
The activity of cytokines in solid tumour malignancies has recently come to light. When tested 
on DLRP cells in a monolayer assay, interleukins l a  and 1/3 were mitogenically active to 
varying degrees on these cell lines. Production of IL-l-like activity by a variety of different 
carcinomas, including NSCLC cell lines, has been documented in a study by Miyauchi et al., 
(1988). Contrary to the results obtained with DLRP, Nakane et al ., (1990) reported that IL-1
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had a negative effect on thymidine uptake and cell proliferation in the lung adenocarcinoma cell 
line A-549. However, other investigators have reported both stimulatory and inibitory effects 
on the growth of primary NSCLC tissue samples using recombinant human IL -la  {Hanauske 
e t a l ,  (1992)}.
Another cytokine which may have a negative effect on the proliferation of NSCLC cells in vitro 
and in vivo is interleukin-4. In a comparative study by Tungekar et al., (1991), the IL-4 
receptor was detected in both normal bronchial epithelium and NSCLC tissue sections, but was 
undetectable in SCLC and carcinoid lung tissues. In this study, coexpression of IL-4 receptors 
together with EGF receptors was reported in 10/29 lung squamous cell carcinomas and 6/17 
adenocarcinomas. These findings were underscored by a more recent report demonstrating the 
antiproliferative effect of recombinant human (rh) IL-4 on NSCLC cell lines in vitro and in vivo 
{Topp et al., (1993)}. In this study, rhIL-4 inhibited the growth of two human NSCLC cell 
lines — CCL 185 and to a lesser extent HTB 56. The in vitro inhibition correlated with the 
level of IL-4 receptor mRNA expression and protein levels in these cell lines, and it could be 
blocked by the addition of anti-rhIL-4 neutralising antibody. In the same study, the in vitro 
growth of two SCLC cell lines, HTB 119 and HTB 120, was unaffected by rhlL^. In the 
absence of evidence for IL-4 production by nonhematopoietic cells, a role for this cytokine in 
the negative regulation of NSCLCs in vitro can only be guessed at. However, in view of the 
evidence for receptor expression on NSCLC cells, the prospect of paracrine and/or autocrine 
production of IL-4 cannot be ruled out.
Another recent publication suggests that the multifunctional cytokine IL-6 can also act as a 
negative autocrine growth regulator for NSCLC cell lines in vitro {Takizawa et a l., (1993)}. 
These workers showed that BEAS-2B, a noncarcinogenic transformed bronchial epithelial cell 
line, and the adenocarcinoma cell line A-549, were inhibited by exogenously added IL-6 . Three 
other NSCLC cell lines examined, RERF-LC-MS (adenocarcinoma), YMRC-LCP and LC-1 sq 
(both squamous cell carcinomas), were also inhibited by this cytokine — but to a lesser extent. 
In the same study, A-549, VMRC-LCP and BEAS-2B expressed specific cell surface IL-6 
receptors, and all the NSCLC lines expressed and released immunoreactive IL-6 . However, 
significantly more IL-6 was detected in A-549 conditioned medium and this cell line was also 
more sensitive to IL-6-induced inhibition than the other NSCLC cell lines. The inhibition 
induced by IL-6 could be neutralised by an anti-IL-6 specific antibody, and the growth of A-549 
cells plated at higher plating densities was accelerated in the presence of anti-IL-6 antibody.
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TGF/3 also inhibited the proliferation of A-549, but an anti-TGF/3 antibody did not affect the 
growth-inhibitory effect of IL-6. In addition, the effects of TGF/3 and IL-6 were additive, 
suggesting that these cytokines act through different signalling pathways. The noncarcinogenic 
transformed bronchial epithelial cell line used in this study was also more sensitive to inhibition 
by IL-6 than any of the NSCLC cell lines. This confirmined previous studies by this group 
{Takizawa et a l, (1992)}, which indicated that normal bronchial epithelial cells were inhibited 
by IL-6, and led the authors to suggest that the relative loss of responsiveness to an autocrine 
IL-6 inhibitor may contribute to the carcinogenic process in the human lung {Takizawa et al., 
(1993)}.
In another report using 64 different malignant cell lines including HEp-2, and four of the cell 
lines used in the study of Takizawa et al., (1993) {i.e the three NSCLC cell lines A-549, 
RERF-LC-MS, YMRC-LCP and the vulval squamous cell carcinoma line A-431}, all of the cell 
lines examined secreted an IL-l-like activity into their respective culture supernatants {Miyauchi 
et a l ,  (1988)}. Among the IL-6 producing NSCLC cell lines identified by Takizawa et al., 
(1993), the levels of IL-l-like activity secreted by the squamous cell carcinoma cell lines 
YMRC-LCP and A-431, were significantly higher than those of the adenocarcinoma cell lines 
A-549 and RERF-LC-MS {Miyauchi et a l , (1988)}. The observed induction of steady state 
levels of IL-6 and IL-6 receptor mRNA levels in A-549 by exogenously added IL-la {Takizawa 
et a l, (1993)} were consistent with previous demonstrations that IL-1 can enhance the 
expression of IL-6 in some cell types {Seghal et al., (1987)}. The relatively higher levels of IL-
l-like activity detected by Miyauchi et a l ,  (1988) in the lung squamous cell carcinoma line 
YMRC-LCP, may induce levels of endogenous IL-6 production sufficiently to result in the 
down-regulation of the IL-6 receptor in such cells. This might explain why these cell lines were 
less sensitive to inhibition by exogenous IL-6 in the study of Takizawa et al., (1993).
4.1.2.3 Growth regulatory peptides for NSCLCs
Another explanation for the poor growth performance of NSCLCs in vitro may be provided by 
recent reports in the literature concerning the sensitivity of these cells to peptides with growth 
inhibitory effects, and the possible autocrine production of such peptides by NSCLCs. An 
example is the 28-amino acid peptide thymosin a l ,  which has been implicated as a negative 
growth regulator for NSCLCs. This peptide, originally isolated from a crude bovine thymic 
extract {Goldstein et a l , (1977)}, is derived from a 113-amino acid precursor protein called 
prothymosin a, whose NELj-terminal sequence is identical to that of thymosin a l  {Eschenfeldt
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& Berger (1986); Grangou-Laxiridis et al., (1988)}. In a recent report, Moody et al., (1993b) 
were able to inhibit the in vitro and in vivo growth of human cell lines representative of each 
of the three main types of NSCLC using this peptide. The inhibitory effects were dose 
dependent in both circumstances, and were reversible in vivo. Unpublished observations {by 
Moody, T.W.} in the same report, stated that thymosin-like peptides were detected by 
radioimmunoassay in NSCLC extracts and conditioned medium from these cells. However, a 
definitive autocrine inhibitory role for these peptides in NSCLC remains to be established.
Thymosin a l  shares sequence homology with a peptide called vasoactive intestinal polypeptide 
(VIP), which has been shown to stimulate the growth of several NSCLC cell lines examined by 
Moody et al., (1993b). An earlier publication by these authors reported that almost all the 
NSCLC cell lines examined in that study had high affinity receptors for VIP {Moody et al., 
(1993a). Unpublised results in Moody et al., (1993b) indicated that thymosin a l  can compete 
with 123I-VIP for binding to NSCLC cells, albeit with low affinity, and that the in vitro 
stimulation of NSCLC cell lines in soft agar by VIP was blocked in the presence of 
thymosin a l.
4.1.3 ABSENCE OF POSITIVE AUTOCRINE/PARACRINE GROWTH FACTORS IN 
NSCLC CULTURES IN  VITRO
Insulin-like growth factors are known to be mitogenic for human small cell lung cancer in vitro
{Nakanishi et al., (1988)}. However, unlike SCLCs, evidence to support an autocrine role for
IGF-like factors in NSCLC tumours has been scarce and conflicting. Minuto et al., (1986)
found that IGF-I levels were 1.4 - 7.0 fold higher in the NSCLC tissue than in uninvolved lung
tissue from the same donors, but Soderdahl et al., (1988) were unable to detect IGF-I mRNA
in NSCLC cell lines. Another study detected immunoreactive IGF-I secreted by the human lung
adenocarcinoma (NSCLC) cell line CaLu-6 {Minuto et al., (1988)}, but in a subsequent report
IGF-I was not detected in extracts of NSCLC cells {Reeve et al., (1990)}.
IGF-like species have been partially purified from serum-free culture medium conditioned by 
human foetal lung fibroblasts {Stiles & Moats-Staats (1989)}, suggesting a paracrine role for 
IGFs in the regulation of lung epithelia. A more recent publication by Ankrapp & Bevan (1993), 
also supports a paracrine role for IGF-I in NSCLC. In this study, IGF-I receptors were detected 
on the three lung adenocarcinoma cell lines, A-549, A-427, and SK-LU-1. IGF-I stimulated the 
serum-free proliferation of these lines (SK-LU-1 at 0.25% FCS) seeded at low density, but no 
IGF-I could be detected in their respective conditioned media. In the same study, a human adult
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fibroblast cell line (CCD-19Lu), was shown to produce an IGF-I-like protein which stimulated 
an increase in the tyrosine kinase activity of detergent-solubilised IGF-I receptors from A-549. 
The CCD-19Lu conditioned medium also stimulated A-549 cell growth, and both effects were 
neutralised by anti-IGF-I antibody, suggesting a paracrine role for IGF-I in NSCLC.
The possible involvement of IGFs in the growth control of squamous cell lung carcinomas did 
not come to light until recently.
The results of comparative studies performed by Kaiser et al., (1993), using monoclonal 
antibodies against the receptors for IGF-I and IGF-II, found that while the IGF-I receptor was 
detectable in both normal lung and malignant lung, it was particularly prominent in squamous 
cell carcinomas. IGF-II staining however, was weaker in lung cancer than in normal lung.
Although the precise growth requirements for NSCLCs have not been defined, it is becoming 
increasingly clear that growth factors from several classes are important for the maintenance of 
proliferative potential for these cell types in vitro, particularly for squamous cell carcinomas. 
An example of the range of growth factors which may be involved in autocrine growth control 
in NSCLCs in vitro is given by the results of a recent study by Occleston & Walker (1993). 
These workers found that 1PT, a NSCLC cell line derived from an undifferentiated human 
bronchial carcinoma, secretes multiple growth factors into its CM. These included species which 
were immunoreactive to bFGF, IGF-I and IGF-II, EGF and TGFa as well as latent TGF-/32. 
In the same study, PDGF, TNFa and TNF/3 could not be detected.
4.1.4 PROSPECTS FOR IMPROVING IN VITRO GROWTH PERFORMANCE OF 
NSCLC-DERIVED PRIMARY CULTURES
One of the outstanding difficulties in the primary culture of NSCLCs in vitro is the loss of 
successful cultures through growth arrest and differentiation. The factors regulating this process 
need to be more clearly defined if the routine establishment of long-term NSCLC cultures is to 
be realised. The role of TGF-/31 as a negative regulator in these tumours needs to be better 
understood if its effects are to be abrogated. However, Takizawa et al., (1993) recently reported 
that an anti-TGF/3 did not affect the in vitro proliferation of the NSCLC cell line A-549.
The principal sources of TGF-/3 would seem to be the stromal component of the tumour tissue, 
but in serum-supplemented media, TGF-/3 arising from platelets is another source of this 
inhibitor. The use of a selective serum-free media system is an attractive alternative to serum-
285
supplementation, but as yet, this remains an unrealised goal for all NSCLC cultures. In 
addition, the wisdom of attempting to remove fibroblasts from primary NSCLC tumour 
cultures, as a measure designed to improve their growth potential in vitro, remains to be 
validated. This is supported by the emerging role of stromally elaborated positive-acting 
paracrine growth factors such as KGF and HGF/SF which may stimulate NSCLC proliferation 
in vivo and in vitro. However, fibroblasts are known to express IL-6 mRNA and protein 
constitutively {Kohase et al., (1986)} and this cytokine may be responsible for the growth 
inhibition of lung epithelial cells associated with the presence of stromal cells in primary 
cultures. As mentioned above, TGF-01 was also found to have a negative effect on the 
expression of HGF/SF in a normal human embryonic fibroblast cell line {Matsumoto et al.,
(1992)}.
A greater understanding therefore, of the role of autocrine and paracrine negative growth 
regulators, should identify the important inhibitors of NSCLC growth and/or differentiation, and 
suggest ways to overcome their limiting effects on NSCLC growth in vitro. One possibile 
approach might be the use of neutralising antibodies to block the effects of the two recently 
identified inhibitors of NSCLC growth, IL-6 and the peptide thymosin a l. However, simply 
blocking the arrest of cell growth would be unlikely to result in growth promotion, given the 
paradigm for growth regulation in more defined cell systems. In vitro growth stimulation of 
NSCLCs therefore, will undoubtedly require the supplementation of NSCLC growth media with 
additional positive growth stimulators.
Evidence that platelet-derived growth factor may be important in the in vivo progression of 
NSCLC was discussed earlier. The use of PDGF for in vitro culture of primary lung tumours 
was not considered in this work because of its known mitogenic effect on fibroblasts. However, 
in the context of a more defined medium, this growth factor may prove useful for in vitro 
cultures of squamous cell carcinomas and other NSCLCs.
The inclusion of such factors as VIP might also contribute to the improvement of NSCLC 
growth potential in vitro, and perhaps too, the squamous cell carcinoma subtype. Neither IGF-I 
or IGF-II was tested for mitogenic activity on DLRP or DLKP, but this experiment should now 
be done in the light of recent publications detecting the IGF-I receptor in squamous cell lung 
carcinomas {Kaiser et al., (1993)}.
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The detection of bFGF in CM from an undifferentiated human bronchial carcinoma cell line 
(1PT) {Occleston & Walker (1993)}, may indicate a regulatory role for this growth factor in 
NSCLCs. The mitogenic response of DLRP to acidic and basic FGF (and to a lesser extent 
DLKP) supports this hypothesis and suggests that FGFs might be a useful supplement in the 
development of a selective medium for lung SCCs. It is noteworthy that in a recent study by 
Thomassen (1993), only BSA and bovine pituitary extract (BPE) were required to support the 
serum-free growth of neoplastically transformed rat tracheal epithelial cells. BPE is known to 
contain high levels of fibroblast growth factor activity and has been used as a source of these 
factors in their purification to homogeneity {Gospodarowicz et al., (1985)}.
The presence of FGFs in DLRP CM was not measured here, and there was no evidence for 
secretion of autocrine growth factors by DLRP and DLKP. However, given the evidence for 
the existence of ‘private’ FGF autocrine stimulatory loops in other cell lines, the existence of 
similar control mechanisms in DLRP cannot be ruled out. Even if FGF-like growth factor(s) 
are secreted by squamous cell lung carcinoma cell lines such as DLRP, rapid sequestration by 
heparan sulphate proteoglycans of the extracellular matrix by cell surface proteoglycans may 
ensure that these growth factors remain tightly cell-associated {Rapraeger et al., (1991); 
Vlodavsky et al., (1991)}.
Two other mitogens which may also prove useful as growth promotors of NSCLC in vitro are, 
KGF and HGF/SF. Highly purified human recombinant HGF/SF is now available commercially.
4.1.5 GROWTH FACTOR SPECIES IN MALIGNANT EFFUSIONS
Summary of results with malignant effusions
Preliminary results with a malignant effusion (ME) taken from a patient with ovarian carcinoma 
displayed both inhibitory and stimulatory activity on low density cultures of three human 
sqaumous cell carcinoma cell lines in vitro (DLRP, DLKP and SK-MES-1). Both activities were 
concentration dependent with stimulation at greater dilutions, and inhibition at lesser dilutions. 
Inhibition of all three cell lines was absolute down to a 1/5 dilution of the ME (equivalent to 
a final concentration of 10% v/v ME in the assay). However, further dilution of the ME 
(between 1/10 and 1/20), resulted in an average ten-fold increase in growth, with respect to the 
control in the growth assays for DLRP and SK-MES-1. In the case of SK-MES-1 at least, this
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mitogenic activity was dilutable, as indicated by the loss of stimulatory activity at a 1/40 
dilution. DLKP was much less sensitive to the growth-promoting effect of ME than DLRP or 
SK-MES-1 but lesser dilutions of ME were also inhibitory for DLKP.
A similar growth sensitivity pattern was seen with HEp-2, but in this case the order of dilution 
required to abolish the inhibitory activity (and manifest the mitogenic activity), was less (at 1/5). 
Stimulation of HEp-2 cells established that the growth-promoting activity in this ME was not 
specific to lung carcinoma cell lines.
Using HEp-2 cells, a variety of MEs associated with different malignancies were screened for 
growth-promoting activity. The samples assayed included MEs from breast, lung, kidney, and 
ovarian carcinomas. In addition, effusions from a patient with the more benign disease non- 
Hodgkins lymphoma, and another with a non-malignant proliferative disorders were also tested.
A number of observations were made in this series of exploratory experiments.
1. The inhibitory activity noted in two ovarian MEs, and a non-Hodgkins lymphoma- 
associated ME sample, appeared to become more potent with longer storage time at 4°C 
{compare ‘ovarian 1’ sample results in tables 3.1.10(i) and 3.1.10(ii)}.
2. The growth-promoting activity in effusions was not restricted to those associated with 
malignant disorders {see Table 3.1.10(i)}.
3. Lung-derived MEs contained the lowest levels of growth-promoting activity relative to 
the high levels seen in kidney- and breast-associated MEs {see Table 3.1.10(iii)}.
4. Preliminary purification of an ovarian-associated ME using the ammonium sulphate 
technique (with a view to further characterising the growth regulatory species in this 
sample), isolated growth-promoting activity in two fractions, the majority of which was 
found in the 20-30% cut, but there was also significant activity in the 30-50% cut {see 
Table 3.1.10.1}.
5. Comparative studies using serum and/or plasma with MEs from the same donor patients 
indicated that the order of growth stimulatory activity over a range of dilutions was the 
same in autologous plasma or serum, as in the corresponding effusion samples. 
However, although insufficient serum or plasma remained for protein determination 
after bioassays, the expected total protein concentration in normal plasma is 66-87 g/L. 
When this is compared to the protein concentration of 31 g/L in the ME sample ‘breast 
3’, (one of the autologous ‘paired ME samples’ used) {see table 3.1.10(iii)}, then the 
specific activity of the growth-stimulatory activity in this effusion sample might 
reasonably be expected to be higher than in the serum from this patient.
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The original idea of screening MEs for growth factor activities on NSCLC in vitro was re­
evaluated after the findings of these pilot experiments. The comparatively similar growth- 
stimulatory profiles for MEs and serum or plasma from the same donors suggested that the 
effusion-derived growth-promoting species might represent a serum-derived mitogen. This was 
considered likely in view of the fact that a ‘vascular permeability factor’ (VPF) is produced by 
many tumour cells, and is present in high concentrations in tumour ascites {Senger et al., 
(1983)}. It was suggested by these authors that VPF (subsequently identified as the mitogen 
VEGF) might be important in the accumulation of malignant fluid in body cavaties by causing 
blood vessel endothelial cells to leak plasma proteins.
In order to avoid the complex task of trying to purify ‘one among many mitogens’ (which can 
conceiveably include attachment factors) from what was potentially just a more dilute fraction 
of human serum, it was hoped to establish whether or not the active species was solely tumour- 
derived. To do this, it would have been necessary to assay ‘paired samples of effusions and 
serum’ from a set of indivduals with non-proliferative disease (as well as extending the sample 
size of the ‘malignant effusion/serum’ pairs tested) before a conclusion could be reached on the 
merits of further purification. Unfortunately it did not prove possible to obtain any clinical 
samples from individuals presenting with non-proliferative disease-related effusions within the 
time frame of this study. Other laboratories have been able to do similar comparative studies 
on a limited number of samples {see Wilson et al., (1991) discussed below}.
An alternative direction was taken therefore, which involved the elucidation of the autocrine 
growth regulatory system which had come to light in preliminary experiments with the cell line 
HEp-2 (Section 3.2.1.2).
In the context of evidence for the production of autocrine growth factor activity by HEp-2, a 
number of purified growth factors were tested for mitogenic activity under the stringent growth 
conditions employed in this assay (Section 3.2.6). Some of these were found to be mitogenically 
active for HEp-2, and have also been detected in the malignant effusions from patients with 
various malignancies.
TGFa was a powerful mitogen for HEp-2, and displayed bifunctional regulation of these cells 
under autocrine assay conditions; high doses were inhibitory (>  5 ng/ml), but at lower 
concentrations (0.5-5.0 ng/ml) the effect of TGFa was stimulatory. This was reminiscent of the
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effect of ovarian MEs on HEp-2 proliferation, which demonstrated a similar bifunctional, 
concentration-dependent modulation of HEp-2 growth (Section 3.2.6.1). The active species for 
HEp-2 in ovarian MEs may well be TGFa because this growth factor has been detected 
immunologically in effusions from patients with disseminated ovarian cancer {Artega et al.,
(1988)}. Mills et al., (1988) had presented evidence for the presence of an ovarian-specific 
growth factor in ascites fluid from patients with ovarian cancer, and this appeared to be distinct 
from a panel of known growth factors, including EGF. However, the possible contribution of 
the homologus TGFa (to the ovarian-specific growth factor activity observed) was not 
eliminated in this study. Although EGF and TGFa bind to the same high affinity receptor, they 
have been reported to exhibit differential biological responses in some cell systems {Barrondon 
& Green (1987); Pittelkow et al., (1989)}. The similar potencies of EGF and TGFa in the 
HEp-2 assay (Section 3.2.6.1) make it unlikely that such a differential in activities would be 
detected in the HEp-2 assay.
In contrast to the findings of Artega et al., (1988), a subsequent study by Wilson et al., (1991) 
did not detect EGF/TGFa in malignant ovarian fluids. In this comparative study using ascitic 
fluids, cyst fluids, and peritoneal fluids from patients with benign ovarian tumours and non- 
tumour related gynaecological conditions (e.g. fluids from patients with cirrhotic liver disease), 
these authors assessed the ability of such fluids to promote the anchorage independent growth 
of three cell lines. The species responsible for the induction of colony formation with the 
normal cells, NRK-49F (a clone of the normal rat kidney fibroblast cell line), and 58MC (a 
mesothelial cell line established from the ascites of a patient with ovarian cancer), was 
designated ‘transforming activity’ (TA). The stimulation of colony formation in the ovarian 
tumour cell line, OAW-42 was called ‘colony stimulating activity (CSA). CSA was found in 
benign and malignant effusions, and was not therefore specific to tumour-related fluids. 
However, the induction of colony formation in normal cells, measured as ‘transforming 
activity’, was associated with the tumour-related fluids, indicating that it was a tumour-derived 
factor rather than a systemic species, produced as a reaction by the host to the disease. The 
CSA and TA were also distinguished by the observation that added heparin inhibited the CSA 
in tumour cells but not the TA in normal cells. This suggested that the CSA was a coagulation 
factor such as fibrin. The ‘transforming activity’ was unaffected by the addition of heparin, but 
it only detected using normal cells. Transforming growth factor jS levels of 10-100 pg/ml were 
detected in these fluids, and TGF/3 alone at these concentrations was capable of enhancing the 
growth of 58MC in agar. EGF had a similar effect in the 0.1-10 ng/ml concentration range.
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Attempts to characterise the nature of ‘transforming activities’ in other human malignant 
effusions have found that TGFa and TGF/3-like growth factors appear to account for much of 
this activity in many malignant and non-malignant effusions {Seo et al., (1988)}. While 
preliminary work has often suggested the presence of tumour-specific production of 
transforming activities the absence of subsequent reports detailing the purification and cloning 
of these putative novel growth factors implies that it has not been possible to purify them, or 
more likely, that they have been found to be identical to previously characterised growth 
factors.
Watson et al., (1990) have also measured significant levels (>  3ng/ml) of the cytokine IL-6 in 
ascites fluid from ovarian cancer patients. A role for IL-6 in the control of NSCLC proliferation 
was not suspected at the time the ovarian MEs were assayed. However, the emergence of 
evidence for the more widespread involvement of IL-6 in solid tumours has heralded the 
publication of a recent paper reporting the functional expression in HEp-2 cells of IL-6, its 
receptor, and the IL-6 signal transducing glycoprotein gpl30 {Guillaume et al., (1993)}. The 
contribution of IL-6 to the autocrine growth control of HEp-2 cells is discussed in Section 
4.2.3.2). The detection in ovarian MEs of IL-6 may also explain the inhibitory effect of one 
such fluid on the growth of the NSCLC lines examined here, given that others have 
demonstrated an inhibitory role for IL-6 in this cell type in vitro {Takizawa et al., (1993)}. The 
presence of IL-6 in HEp-2 CM may also explain the inhibitory effect of unconcentrated (crude) 
HEp-2 CM on the growth of the NSCLC cell line, DLRP (data not shown). While this was a 
dissapointing result, in view of the original aim of this thesis, it did not preclude the possibility 
that a highly purified fraction of HEp-2 would be found with NSCLC-promoting activity. This 
was supported by the observation that two NSCLC cell lines used in this work responded to two 
heparin-binding mitogens, acidic and basic FGF, and that HEp-2 CM contained an autocrine 
activity which resembeled bFGF. Moreover, evidence for the production of several autocrine 
growth regulatory species in the HEp-2 system was an interesting observation in itself.
HEp-2 cells also responded mitogenically to exogenously supplied acidic and basic FGF (Section 
3.2.6.4). Until recently however, basic FGF had not been detected in biological fluids such as 
serum {Baird et al., (1986); Ylodavsky et al., (1987)}. By using more sensitive EIAs, a number 
of authors have detected this growth factor in urine and serum from cancer patients. Fujimoto 
et al., (1991) reported elevated levels of bFGF in the serum of renal cancer patients using a 
new sandwich EIA for bFGF, and with the same system Watanabe et al., (1992) found
291
abnormally high levels of this factor in serum from breast cancer patients. Elevated urinary 
levels of bFGF were reported by Nguyen e ta l., (1992) in patients with a variety of neoplasms. 
Another improved enzyme immunoassay system for human bFGF was employed by Ii et al., 
(1993), and these authors reported average serum concentrations of bFGF at 5.9 pg/ml in 25 
normal volunteers. By comparison, patients in the same study with renal, lung and brain 
tumours demonstrated elevated serum concentrations of bFGF. While these studies provided 
indirect evidence for secretion of bFGF by tumour cells, Soutter et al., (1993) have recently 
provided more direct evidence to support the idea that the bFGF detected in biological fluids 
of cancer patients is tumour-derived. These investigators presented clear evidence that bFGF 
in tumour-bearing mice arose from the tumour cells, as distinct from other cells in the hosts. 
Using a mouse model system described by Hori et al., (1991) {discussed, Section 4.3.5} nude 
mice were inoculated with tumour cells expressing a mutant form (mutein) of bFGF. By 
applying specific immunoassays for the detection of native and the mutein bFGF, these authors 
were able to distinguish between tumour-derived mutein bFGF, and host-derived native bFGF.
To date, no evidence for tumour-derived bFGF has been reported in MEs but it is not unlikely 
that bFGF will yet be detected in these fluids given that many tumour cells produce the vascular 
permeability factor (VPF), now know to be identical to vascular endothelial growth factor 
(VEGF). An alternative source of FGFs in MEs is suggested by the detection of immunoreactive 
FGF in macrophages from peritoneal exudate {Baird et al., (1985)}.
Despite the high levels of YPF/VEGF reported in ascites fluids, YEGF was not considered to 
act as a mitogen for HEp-2 cells. This was because its target cell specificity seemed to be 
restricted to endothelial cell progenitors and monocytes {Terman et al., (1991); Millauer et al.,
(1993)}. This situation has been reappraised in the light of a recent report which documented 
the detection of VEGF receptors in other cell types, including HeLa cells {Gitay-Goren et al., 
(1992)}. Given that HEp-2 is considered to be a variant of HeLa, the possibile existence of a 
functional VEGF autocrine loop in HEp-2 cells is discussed further, in the context of the 
properties of the partially charcterised HEp-2 autocrine species (Section 4.3.1.2).
The mitogenic response of HEp-2 to the VEGF-related PDGF was barely significant at the 
concentrations tested (Section 3.2.6.6). The relatively low growth-promoting activity for HEp-2, 
detected in two pleural effusion samples associated with NSCLCs, is consistent with the findings 
of Safi et al., (1992). These workers reported higher PDGF levels in pleural effusions
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associated with lung adenocarcinomas than in those from SCLC or non-malignant pleural 
effusions.
The above are but a few of the possible serum-derived mitogens which may be found in 
malignant effusions. Other mitogenic factors in the HEp-2 system include the insulin-like growth 
factors. The detection of an IGF-II-like factor in bovine serum {Li et al., (1990)} and the 
existence of several carrier proteins for IGFs in human serum {Baxter & Martin (1989)}, argue 
strongly that these species may yet be found in malignant effusions.
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4.2 THE HEp-2 AUTOCRINE SYSTEM
4.2.1 Evidence for autocrine growth factor production by HEp-2 cells
The ability of HEp-2 cells to proliferate at very low densities (200 cells/cm2) with reduced 
serum supplementation, suggested the production of autonomous growth stimulators by this cell 
line. More direct evidence for autocrine growth factor production was provided by the finding 
that serum-free medium conditioned by HEp-2, also stimulated their own growth at low cell 
density, and reduced serum concentration (Section 3.2.1.2). Indirect evidence to support the 
existence of autocrine stimulation came from the observation that cultures of HEp-2 in log phase 
growth, continued to proliferate until confluency when these were transferred to serum-free 
medium (Section 3.2.1.5). It was established that the autocrine effect was independent of the 
basal medium and the serum type used, although at low plating densities the sensitivity of cells 
to autocrine stimulatory activity demonstrated a reciprocal relationship between cell density and 
the level of serum-supplementation (Section 3.2.1.2).
An essential part of the pretreatment protocol for the HEp-2 autocrine assay required that the 
cells were harvested from exponentially dividing cultures grown in 10% (v/v) serum. Reducing 
the level of serum substitution in the pretreatment cultures resulted in a complete lack of cell 
growth at the low cell density used in the 24-well autocrine assay (i.e. 4 x  1CF cells/well). This 
probably reflects a lower ‘growth fraction’ in cultures grown in reduced serum, because such 
populations are more likely to contain fewer numbers of actively dividing cells (i.e. as a 
percentage of the total population).
Cell growth in the HEp-2 monolayer assay was quantified by measuring colony area. This 
method was found to give a linear growth response to increasing serum stimulation, with 
concentrations of serum up to 10% (v/v). The size of colonies measured in monolayer is an 
index, not just of cell proliferation, but also of the outward migration of cells from the colony 
edge. Therefore, using colony area as an endpoint to quantify the mitogenic respsonse to growth 
factors may incorporate the contribution of one, or both, of these growth factor properties. In 
a study examining the roles of EGF and TGFa on keratinocyte growth in monolayer, cell 
migration did not become a limiting factor in colony expansion until eight days after seeding 
{Barrandon & Green (1989)}. The growth of keratinocyte colonies was exponential up to that 
point, but thereafter the rate of increase in colony radius was the same in the presence, and 
absence, of either EGF or TGFa. This suggested that in large colonies, the advance of the
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colony perimeter is dependent on the fixed rate of cell migration. The duration of the HEp-2 
autocrine assay was seven days, so it is unlikely that cell migration became a limiting factor in 
this system in that time frame.
An independent index of cell growth was used to confirm the autocrine effect determined by the 
colony area endpoint method. To this end, increases in CM-stimulated HEp-2 cell growth were 
quantified by measuring the level of cellular acid phosphatase. This qualitatively different 
endpoint for the quantification of cell number has been validated in this laboratory by Martin 
et al., (1993), and a Unear correlation was demonstrated between acid phosphatase activity and 
cell number.
4.2.2 Characterisation of the HEp-2 autocrine activity
The autocrine activity in unconcentrated (crude) CM was dilutable. On the basis of size 
fractionation studies, using ultrafiltration membranes of varying pore size, the active autocrine 
stimulatory species could be separated into two molecular weight fractions. The first was 
recovered in the 10-30 kDa MW range, and designated ‘R10-30’. The second, designated ‘R30’, 
was found in a fraction containing molecular species with MWs greater than 30 kDa. In 
addition, evidence for an autocrine inhibitory species was found in a low molecular weight 
fraction. This inhibitory species, with a molecular mass in the range 1-5 kDa, was only manifest 
at concentrations in excess of those found in crude HEp-2 CM (see figure 3.2.3.2). The 1-5 
kDa inhibitory species was not further characterised in this work because the limiting cell 
density used in the HEp-2 autocrine assay was not suited to measuring growth reduction. 
However, independent studies also performed in this laboratory (Angela O’Toole, unpublished), 
confirmed the autocrine inhibitory activity in this fraction. Using HEp-2 plated at 5 x 103 
cells/well (also in 24-well plate system) and in a 1.25% (v/v) serum background, maximal 
inihbition equivalent to a 40% reduction in growth was measured in the lOx concentrate of the 
Rl-5 fraction.
In the work described in this thesis, an autocrine inhibitory species was also recovered from 
HEp-2 CM after separation on a cation exchange resin (Section 3.3.4.1). The effect of this 
inhibitory species, (eluting at 0.75M KC1) was masked when it was reconstituted with a 
stimulatory activity from the same separation (eluting at 0.25 M KC1). This suggests that the 
inhibitory activity responsible for the 0.75 M KC1 effect is only active in an isolated (and 
possibly concentrated) form. In this respect, it similar to the concentration-dependent inhibitory
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activity detected in the R 1-5 ultrafiltration fraction.
The autocrine stimulatory activity (ASA) in the R10-30 fraction was maximally active at a five­
fold greater concentration than that found in crude CM. There were indications that this activity 
might be active at lower dilutions, but the siginficance of R10-30 stimulation, at concentrations 
normally found in crude CM, remains to be verified. However, loss of the R10-30 ASA upon 
dilution may reflect the lability of the active species is this fraction to dilution. In support of 
this idea, the R10-30 ASA was found to be much less stable to storage at 4°C, compared to the 
correpsonding activities in crude or R30 fractions.
The R30 stimulatory species displayed a concentration-dependent inhibitory effect, manifest only 
at a lOx concentration. Dilution of the concentrated R30 fraction revealed the presence of a 
stimulatory activity which, unlike the R10-30 species, was stimulatory at dilutions down to lx. 
Preliminary gel-filtration analysis using a concentrated HEp-2 CM fraction, did not support the 
existence of a separate high MW inhibitory species. Loss of the R30 inhibitory species (but not 
the stimulatory activity) after storage at 4°C, is consistent with the idea of an R30 bifimctional 
modulator. Detection of a low MW inhibitory species in the gel-filtration separation of CM 
seems to support the existence of a concentration-dependent activity in the 1-5 kDa ultrafiltration 
fraction (Section 3.3.1).
Separation of the ASA in HEp-2 CM by gel-filtration (figure 3.3.1,B) confirmed the findings 
of the ultrafiltration studies. The activity in crude CM was separated into several MW species 
by gel-filtration, and indicated that one large (close to, or greater than, the MW exclusion limit 
of the gel, i.e —30 kDa), and at least three intermediate MW stimulators (within the 3-30 kDa 
MW range resolved by the gel) could be recovered by molecular sieving. A small amount of 
stimulatory activity which eluted early in the chromatogram (possibly in the void volume) might 
be any one of a number of species. Extracellular matrix-attachment proteins such as laminin 
(MW ~ 900 kDa) are capable of promoting cell growth in some cell systems {Rizzino (1984)} 
and the large MW ECM heparan sulphate proteoglycans (MW > 800 kDa) are also known to 
bind growth factors (see discussion Section 4.3). This large MW species was not investigated 
further.
Analysis of the R10-30 fraction by hydrophobic interaction chromatography, separated four 
mitogenic species in this fraction. However, the appearance of an inhibitory activity, eluting
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under hydrophobic conditions, could not be confirmed because of a persistant problem with 
inhibition arising from a dialysis step. This problem was also encountered with dialysis steps 
performed in conjunction with the other chromatographic separations used in these studies 
(Section 3.3.6). Repeated attempts to remove the dialysis-related inhibitor, by progressively 
more thorough washing of dialysis tubing, were unsuccessful (Section 2.8.2).
Physicochemical stability studies performed on crude HEp-2 CM, and two of the active 
stimulatory fractions, R10-30 and R30, were designed with the knowledge that mitogenic 
species in HEp-2 had various degrees of affinity for immobilised heparin (see batch elution of 
concentrated HEp-2 CM, Section 3.3.2.1). As mentioned earlier, heparin is reported to stabilise 
acidic and basic FGF to denaturation by heat, proteinase and acid inactivation. It was used here 
to assess its potential to stabilse the HEp-2 ASA against these treatments.
The pH stability profiles for the three CM fractions tested were not informative in the acid pH 
range. This was due to an unexplained inhbitory effect resulting from the acidification process. 
High osmolarity was ruled out as the major cause of this inhibition, on the basis of conductivity 
measurements taken which demonstrated a lack of correlation between high osmolarity and 
inhibition. The prospect of a chemical change in the basal medium is therefore likely, and may 
be informative in the context of some published data, and the evidence presented here for a 
bFGF-like growth factor activity in HEp-2 CM. Rapraeger et al., (1991) have reported that the 
presence of chlorate ions (at 30 mM) inhibit the sulphation of heparan sulphate proteoglycans 
in myoblasts, thereby rendering these cells insensitive to the biological effects of bFGF. The 
concentrated HC1 used here for the pH adjustment of medium samples may contain trace 
quantities of chlorate ions, or they may be produced in a by-reaction with one of the basal 
media components in Ham’s F12. The inhibition of the formation of low affinity cell surface 
binding sites, essential for FGF binding and signal transduction, is only one possible explanation 
for the effect of acid-treated Ham’s F12. This hypothesis remains to be tested.
The following table summarises the stability properties of the respective HEp-2 CM fractions 
containing ASA, and compares these samples to the percentage acidic and basic FGF-like 
autocrine activity which could be neutralised in these samples.
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Table 4.2.2 Relative stabilities of the autocrine activities in crude HEp-2 CM and two 
ultrafiltration fractions, R10-30 and R30: comparison to the percentage 
autocrine activity neutralised by anti-FGF neutralising antibodies
SAMPLE CRUDE CM R10-30 R30
% ACTIVITY OF TOTAL AUTOCRINE REMAINING AFTER TREATMENTS
Acid 30s o3 O3
Acid + heparin 30 N.D. N.D.
Base 60-70 100 0
Base +  heparin 70-100 N.D. N.D.
Trypsin (crude) 10-30b N.D. N.D.
Trypsin (pure) 40-90b 25 100
Trypsin (pure) +  heparin 30 N.D. N.D.
Trypsin Inhibitor 100 0 35
Heat, 65 °C 70-100 26 77
Heat, 65 °C +  heparin 100+° 36 65
Heat, 100°C 30-50,(0-70) 9 N.D.
Heat, 100 °C +  heparin 70-85 0 90
Percentage of total aut<>crine activity remaining after incubation with FGF neutralising antibodies
Anti-basic FGF 54 1-39 58
Anti-acidic FGF 32 39-79 70d
N.D; not determined. a Inconclusive result, due to the limitations described in Section 3.2.4.1. h Differences in 
the heat stabilities of ‘early’ versus ‘late’ CM collections from the same cultures were observed but not confirmed. 
The different heat stabilities were reflected in the tryspsin sensitivities. c Increasing treatment time at 65°C in 
the presence of heparin augmented the stimulatory activity up to a maximum of 219% after 20 mins, (see Section
3.2.4.5, table 3.2.4.5(i)b). d The percentage activity remaining in this fraction may be closer to 100% (Section
3.4.1.5, table 3.4.1.5b).
The existence of several HEp-2 autocrine growth factors activities in the 10-30 kDa MW range, 
suggested from the results of chromatographic separations, make it impossible to draw definitive 
conclusions based on the stability data for ASA in either crude or the ultrafiltration fractions. 
This is because the overall activity remaining after treatment may represent the effect on the 
stability of one or more different growth factors. In theory, these may act synergictically or 
antagonistically to control the growth of HEp-2 cells. Some general distinctions are possible
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however, and these serve to distinguish the 10-30 kDa activities from those in the higher MW 
fraction.
The R10-30 activity is more sensitive to heat treatment and trypsin exposure than the R30 
stimulatory species, raising the question of whether the larger sepcies is a protein or not (table
4.2.2 above). The R30 activity appeared to be completely abolished by acid and base 
treatments, using the same conditions employed for pH treatment of the R10-30 fraction. 
Despite the concomitant reduction in control growth in that experiment, the R10-30 stimulatory 
activity remained stable at high pH (8.5-10.5) but the R30 activity was abolished. This may 
suggest a differential in pH sensitivity between the two fractions, at least in the alkaline pH 
range.
The results of the trypsin treatments of unfractionated (crude) CM were varaible. The early 
collection of CM from HEp-2 cultures appeared to contain more trypsin-resistant ASA relative 
to a later collection from the same culture. Higher concentrations of a less pure grade of trypsin 
abolished some of this ‘resistant’ autocrine activity, but a residual 30% was refractory to further 
degradation by the proteinase (3.2.4.4). The possibility of carry over of serum-derived growth 
factors is unlikely because cultures were rinsed extensively before CM preparation and the first 
collection was discarded in all cases.
Another interesting finding in these experiments was the ability of the soyabean trypsin inhibitor 
to abolish the R10-30 ASA, and to a lesser but nonetheless significant extent, the ASA in the 
R30 fraction. This suggests a role for a trypsin-like proteinase in the mediation of the autocrine 
activity in both fractions. Such an hypothesis is supported by the detection of serine proteinase 
activity in HEp-2 CM {O’Leary et al., (1991)} and is discussed further in Section 4.3.2.
Many of the growth factors identified to date have molecular weights in the 10-30 kDa range 
and several highly purified preparations of these growth factors were mitogenically active on 
HEp-2 cells. This indicates that HEp-2 express the cognate receptors for these growth factors, 
and raises the possibility that autocrine loops involving such mitogens may be operative in HEp- 
2 cells.
The most potent growth factor tested in the HEp-2 assay system was TGFa. Maximal 
stimulation, equivalent to a three fold increase in growth over control, was measured at doses
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between 0.25 and 0.50 ng/ml, but higher concentrations (>  5.0 ng/ml) were inhibitory to HEp- 
2 growth. Despite evidence for TGFa-induced stimulation of HEp-2 (Section 3.2.6.1), no 
TGFa-like biological activity was detected in HEp-2 CM, or in either of the active HEp-2 CM 
fractions tested using the NRK soft agar assay (Section 3.5.1). Similarly, no EGF-like activity 
was detected in a 50x concentrate of HEp-2 CM using a radioreceptor assay for competivitive 
binding to the EGF receptor (3.1.6.3). The size of the mature TGFa (6 kDa) and the absence 
of detectable TGFa-like biolgical activity in HEp-2 CM, make it an unlikely contributor to the 
observed HEp-2 autocrine effect. A similar argument applies to the candidacy of EGF in this 
autocrine system.
In some proliferation-dependent assays, TGFa has been found to be a more potent stimulator 
of growth than EGF. The colony formation of human keratinocytes in monolayer for example, 
has been reported to be induced more by TGFa than EGF {Barrandon & Green (1987); 
Pittelkow et al., (1989)}. No such differential was observed in the HEp-2 system.
Transforming growth factor /3 (TGF/3) had no significant effect on HEp-2 growth even though 
HEp-2 were found to secrete relatively high levels of TGF/3 activity into their culture medium 
(Dr. Margaret Dooley, unpublished results from TGF/3 bioassay). This may suggest that the 
latent form of the inhibitor is secreted by HEp-2, as is the case with many cell lines in culture.
The IGFs also displayed potent mitogenic activity in the HEp-2 system, with maximal fold 
increases over control of 2.7, 2.0 and 1.8, induced by IGF-I, Insulin, and IGF-II respectively. 
Despite the relatively small size of these growth factors, the existence of larger binding 
molecules for this class of mitogen, and the indication that 30% of autocrine stimulatory activity 
might be ‘acid resistant’ does not permit their elimination as potential contributors to the 
autocrine effect.
Interleukins were weaker stimulators of HEp-2 growth than the other growth factors tested. 
Moreover, the sensitivty of cells to these cytokines varyied by a factor of 10 between replicate 
experiments (Section 3.2.6.5), suggesting perhaps that the effect of IL-1 on HEp-2 growth is 
modulated by other factors.
PDGF stimulated a low level fold stimulation over the control (i.e x 1.41 fold) at only one 
concentration, but at higher concentrations than this it was inhibitory, suggesting that it may act
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as a bifunctional regulator of HEp-2 growth. Evidence for an intracellular heparin-binding 
mitogen with low affinity for immobilised heparin-Sepharose is consistent with the value of 
0.5 M NaCl reported to elute PDGF from this matrix {Klagsbrun (1989)}. PDGF has also been 
implicated in ‘private’ autocrine mechanisms of cell stimulation.
The stimulatory efffect of bombesin/GRP in the HEp-2 assay was not dose dependent, 
suggesting either an indirect effect on cell growth, or perhaps that the threshold for maximal 
stimulation with this peptide was exceeded at the lowest concentration tested. No stimulatory 
activity was detected in the low MW fractions of HEp-2 CM to suggest autorine production of 
bombesin/GRP in Hep-2.
Acidic and Basic fibroblast growth factors were stimulatory for HEp-2 over very narrow 
concentration ranges, consistent with the mitogenic activities of these growth factors in other 
cell line systems. Basic FGF, unlike many of the known growth factors, including acidic FGF, 
is labile in acid pH. The mitogenic response of HEp-2 to acidic FGF and basic FGF, together 
with the apparent acid sensitivity of a larger portion of the ASA in the R10-30 and crude HEp-2 
CM fractions, prompted the use of a heparin-Sepharose chromatography system, both as a 
means of characterising the autocrine species, and as a potential step in its purification.
4.2.3 Purification of HEp-2 autocrine activity
Effect of dialysis
The presence of high salt concentrations in the elute of heparin-Sepharose (HS) separations 
necessitated the dialysis of fractions before these could be assayed in the proliferation-based 
HEp-2 autocrine assay. However, this process was found to create problems with inhibition of 
HEp-2 cells (Section 3.2.3.1). The reason for this was unclear, but trace levels of numerous 
impurities can be toxic to animal cells in vitro, and it is theoretically possible that toxic residues 
remained in the particular batch of the dialysis tubing used in these studies, despite the 
pretreatment protocol used.
The problem with dialysis posed a number of difficulties in the detection and interpretation of 
growth regulatory activities eluting during chromatographic separations. Under these 
circumstances, stimulatory activity may fail to be detected because of the masking effect of the 
dialysis-related inhibitory species. It is also impossible to discriminate between what may be a
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‘real’ inhibitory activity, and the artifactual inhibition associated with the separation and/or 
dialysis process. Greater dilutions of column eluates were employed to overcome the inhibitory 
effect of dialysis and/or high salt concentrations. However, at the higher dilutions used, it is 
possible that some activities may not have been detected due to sub-optimal doses or instability 
arising at low concentrations.
Other workers have also reported loss of biological activity due to dialysis, as for example, in 
the purification of fibroblast growth factors {Klagsbrun et al., (1987)}. The loss of FGFs during 
dialysis may be caused by adsorption to the dilaysis tubing. Acidic FGF for example is reported 
to be a ‘sticky’ polypeptide, especially at neutral pH and low salt concentrations {Kan et al.,
(1991)}. Nauro et al., (1993) reported similar problems in the purification of FGF-9. Dialysis 
has also resulted in the loss of other mitogenic activities. A variable loss of partially purified 
IL-3 activity from the myelomonocytic leukemia cell line WEHI-3 was associated with a dialysis 
step {Bazil et al., (1983)}, and a similarly GM-CSF was lost after dialysis during its 
purification from T 19.1 cells {Burgess et al., (1980)}.
In this project, the problem with dialysis appeared to be one of toxicity. This is suggested by 
the fact that inhibition could be diluted out.
Many investigators in this field avoid the problems associated with proliferation based bioassays 
by using different indices for measuring the response to growth factors. A popular alternative 
detection system is based on the incorporation of[3H]thymidine into acid insoluble materials. 
This assay relies on the quantification of DNA synthesis (as determined by pH]thymidine uptake 
into cells), following mitogen-induced cell division. [3H]thymidine incorporation has been 
widely used to measure both positive and negative growth regulation in various cell lines, 
including the detection of FGF activity in the mouse fibroblast cell line 3T3 {Klagsbrun et al.,
(1987)}. By quantifying a more immediate response to growth factors, use of the pH]thymidine 
incorporation assay gives a ‘readout’ before the delterious effects of high salt etc. on cell growth 
are manifest. As a technique however, it is not without limitations. Principal among these, is 
the fact that thymidine uptake by cells reflects not only its incorporation into nascent DNA, but 
also changes in thymidine transport across the plasma membrane. Differences in the 
phosphorylation of thymidine by thymidine kinase can also influence the results obtained with 
this method {Rozengurt (1991)}.
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More direct methods for quantifying cell number, such as the proliferation-based assay 
employed here, have the advantage of detecting real changes in the ‘bulk’ of the culture. 
Therefore, perturbations in cellular biochemistry, such as those which cause aberrations in 
thymidine transport/uptake, are not translated into spurious measurements of cell number. A 
disadvantage of the HEp-2 assay system however, is the minimum requirement that test samples 
are in biologically neutral solutions, or at least that such test solutions do not contain inhibitors 
for the ‘indicator’ cell line. This aspect of the assay becomes a limiting factor when large 
numbers of column fractions need to be assayed (e.g when dialysis of every fraction is 
required).
4.2.3.1 Heparin-Sepharose chromatography
The heparin-binding ASA detected in HEp-2 CM and cell extracts were classified on the basis 
of the NaCl concentration required to elute them from heparin-Sepharose (HS). ‘Weak’ binding 
species eluted between 0-0.5 M NaCl, while those recovered in the 0.5-1.0 M NaCl range were 
considered to display ‘moderate’ binding for the matrix. Species with ‘high affinity’ eluted in 
the 1-2 M NaCl concentration range, and any activity recovered above 2 M NaCl was 
considered to have a ‘very high affinity’ for heparin. Table 4.2.3.1 summarises the activity 
profiles for stimulatory species recovered in HEp-2 CM and cell extracts.
Table 4.2.3.1 Affinity of autocrine stimulatory species in HEp-2 CM and cell extracts for 
the heparin-Sepharose (HS) matrix
HEPARIN AFFINITY Weak Moderate High Very High
- Chromatographic elution system used
NaCl elution profiles (Molar) of autocrine stimuLitors on HS
Concentrated crude HEp-2 CM 
- Batch elution, 5 ml column
NONE NONE 1.0; 1.5; 2.0; 5.0;
Concentrated crude Hep-2 CM 
- Gradient elution, 10 ml column
NONE 0.7; 1.0-1.9; 
2 .1;
2.45-2.50;
0.25 M KC1 eluate of unconcentrated 
crude CM from cation-exchange column 
- Gradient elution, 10 ml column
0.25; NONE 1.05-1.28;
1.46-1.66;
1.89-2.07;
2.7;
HEp-2 ‘high salt’ cell extract - Gradient 0.1-0.40; 0.70-0.85; 1.78-2.0; 3.0;
HEp-2 ‘low salt’ cell extract - Gradient 0.0-0.50; NONE 1.8-2.4; NONE
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Preliminary evidence for heparin-binding ASA in HEp-2 CM with HS affinities in the same 
order as those reported for acidic and basic fibroblast growth factors, suggested that a similar 
purification strategy might be useful for the purification of the active HEp-2 autocrine factor(s). 
This protocol employed the use of a cation-exchange step followed by HS chromatography, and 
has been used to purify aFGF and bFGF to apparent homogeneity {Shing et al., (1983 & 
1984)}. In this work, the ASA in one of two separate fractions (i.e the 0.25 M KC1 fraction) 
purified from crude HEp-2 CM by cation exchange chromatography, was then separated on a 
HS matrix. This separation demonstrated that the greater portion of the total protein therein was 
non-heparin binding. Some autocrine stimulatory activity was associated with this non-bound 
protein.
Non heparin-binding ASA
A possible candidate for the non-heparin binding activity was interluekin-1. This cytokine does 
not bind to immobilised heparin {Besner & Klagsbrun, unpublished observations in Klagsbrun
(1989)} and an interleukin- 1-like activity had been reported in HEp-2 culture medium by 
Miyauchi et al., (1988), as mentioned above (Section 4.1.2.2). Evidence from the results of 
experiments with IL-1 in this project indicated that IL-1 is mitogenic for HEp-2 cells, 
supporting the idea that this cytokine may be active via an autocrine loop in these cells.
The potential benefit of IL-la and IL-1/3 as mitogens for the lung SCC cell lines used in this 
work, was ambiguous (Section 4.1.16 above). This observation has also been substantiated by 
a report in the literature {Hanauske et al., (1992)}. The characterisation of the non-heparin 
binding HEp-2 autocrine activty therefore, was deferred in preference to isolating the heparin- 
binding species. This was because preliminary results with two of the heparin-binding FGFs 
(acidc and basic FGF) had demonstrated signs of mitogenic activity for the NSCLC cell line 
DLRP. Indirect support for an FGF-like autocrine activity in HEp-2 cells was presented in a 
report by Moscatelli et al., (1986). These authors had detected a bFGF-like species in the 
extracts of the HEp-2-related HeLa cell line. However, the basis of this detection was indirect, 
(i.e. based on the ability of bFGF to induce plasminogen activator production in bovine 
capillary endothelial cells). Moreover, these authors were unable to detect any bFGF activity 
in medium conditioned by these cells.
4.2.3.2 Purification of ASA using cation-exchange and heparin-Sepharose chromatography
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Interleukin 6 as an autocrine growth regulator in HEp-2
A second candidate for the non-heparin-binding ASA in HEp-2 CM is IL-6. This stems from 
the findings of a recent study of nonhematopoietic malignant cell lines which included HEp-2 
{Guillaume et al., (1993)}. The coexpression of IL-6 and a functional IL-6 receptor system 
were detected by these investigators in HEp-2. Moreover, significant levels of IL-6 protein (225 
ng/ml) were measured in HEp-2 supernant culture medium by bioassay using the IL-6-dependent 
murine hybridoma 7TD1. Expression of IL-6 protein was corroborated by the detection of IL-6 
gene expression using PCR amplification. HEp-2 were also responsive to stimulation by 
exogenously supplied human recombinant IL-6, as determined by the pH]thymidine 
incorporation assay. At concentrations of 20, 100, and 500 ng/ml, the respective fold induction 
of DNA synthesis in HEp-2 cells was 1.46, 1.65 and 1.36 respectively. These findings 
suggested the existence of a functional IL-6 autocrine loop in HEp-2 cells.
The possibility of a functional IL-6 loop in HEp-2, is interesting in the context of evidence 
presented here for a bFGF-like autocrine loop in the same cells, and a report which documents 
a modulatory role for IL-6 in a bFGF autocrine system. Araujo & Cotman (1992) presented 
evidence supporting a bFGF autocrine loop in astroglial, microglial and neuronal cells.
These workers found that IL-6, but also IL-1 and EGF, enhanced the release of bFGF from 
these cells. It is conceivable therefore that IL-1 and/or IL-6 may mediate their actions on HEp-2 
cells through modulation of the release of the bFGF-like autocrine activity.
Also in the report of Guillaume et al., (1993), GM-CSF and IL-3 were not detected in HEp-2 
medium by ELISA. Similarly, there was evidence no evidence for the expression of GM-CSF 
or IL-3 genes in HEp-2, as determined by PCR analysis. Nevertheless, HEp-2 cells were found 
to express the specific a subunit and the (3 receptor subunit utilised by GM-CSF in the 
formation its high affinty receptor complex. Despite a lack of evidence for HEp-2 stimulation 
by GM-CSF in the report of Guillaume et al., (1993), an autocrine role for this cytokine, under 
the stringent growth conditions used in the HEp-2 autocrine assay, cannot be ruled out for a 
number of reasons. These authors found a lack of evidence for GM-CSF gene expression in 
HEp-2 grown in serum-supplemented medium, however, GM-CSF gene expression might occur 
in the serum-firee conditions employed for the collection of HEp-2 CM in this work. Moreover, 
the absence of detectable immunoreactive GM-CSF in HEp-2 culture medium need not imply 
that the protein is not expressed by these cells. GM-CSF is known to have an affinity for 
heparan sulphate proteoglycans in the extracellular matrix (ECM) {Roberts et al., (1988)}, and
as such may remain bound to the ECM under the conditions used by Guillaume et al., (1993). 
Furthermore, these investigators did not detect stimulation of HEp-2 with exogenously supplied 
recombinant GM-CSF, which in the face of evidence for the expression of the GM-CSF 
receptor genes, they attribute to either ineffective receptor peptide assembly, or dysfunctional 
signal transduction by the receptor complex. However, an alternative explanation (admitted by 
these workers), is that the detection of GM-CSF activity in HEp-2 may have been limited by 
the assay conditions used. In this thesis, the sensitivity of HEp-2 to the autocrine stimulatory 
effects of HEp-2 CM were reduced when the serum concentration or the platining density was 
raised (Section 3.2.1.2). The relatively high plating density (105 cells/ml) and background serum 
concentration (3% v/v) used by Guillaume et al., (1993) therefore may render HEp-2 cells 
insensitive to GM-CSF. If such is the case, then perhaps IL-6 would also be more active 
mitogeniclly in the HEp-2 assay employed here.
Evidence also exists to support an intracrine model for autocrine growth stimulation by GM- 
CSF in some hematopoietic cells {Browder et al., (1989)}. In this context, the detection of an 
intracellular stimulatory activity in HEp-2 cells, with a similar affinity for heparin as that 
reported for GM-CSF (see table 4.2.3.1 below) would be consistent with an a ‘private’ 
autocrine GM-CSF loop in HEp-2 cells.
Heparin-binding ASA
A high order of purification following the two-step protocol used here, was suggested by the 
fact that the heparin-binding ASA separated from the bulk of protein in this fraction. Although 
the level of autocrine stimulation recovered after this second step was low ( ~ 1.4 fold average 
in active fractions from heparin-Sepharose), it was nonetheless significant. This apparently low 
level of activity may reflect a combination of the instability of the active species (in a more 
highly purified form), and the high dilution required for use in the assay. Two of the ‘high 
affinity’ stimulatory activities (eluting between 1 and 1.3 M NaCl, and at 1.4 - 1.7 M NaCl 
respectively) correspond with those reported for acidic and basic FGFs respectively. The 
possibilty that these are in fact aFGF and bFGF proteins would be consistent with the reported 
instability of pure acidic and basic FGF in solution {Gospodarowicz et al., (1985)}. However, 
other growth factors have subesequently been shown to have high affinity for immobilised 
heparin, and included among these are the non-FGF growth factors. A list of the known 
heparin-binding mitogens is presented in table 4.2.3.2 below.
Table 4.2.3.2 Comparison of the salt elution profiles, molecular masses, and pH stabilities
of the major heparin-binding growth factors classes
GROWTH FACTOR 
(Alternative name)
[NaCl]‘ required to elute 
from heparin-Sepharose
SIZE
(kDa)
STABILITY 
Heat/ Acid
FGF GROWTH FACTOR FAMILY
FGF-1 (acidic FGF) 1.0-1.2 16-18 L/Sb
FGF-2 (basic FGF) 1.5-2.0 18 L/L
FGF-3 (int-2) N.R.C 30.5-31.5 N.R.
FGF-4 (/wM/K-fgf) 1.0-1.2 - 2 3 N.R.
FGF-5 1.0 32.5-38.5 N.R.
FGF-6 (hst-2) 1.0 N.R. N.R.
FGF-7 (KGF) 0.6 28 L/L
FGF-8 (AIGF) 1 1.1 28, 32 N.R.
FGF-9 (GAF) 1 0.8 30 L/L
PDGF GROWTH FACTOR FAMILY
VEGF (VPF) 0.3, 0.9; 2.0; 34-42 S/S
PDGF 1 0.5 28-36 S/S
EGF-LIKE GROWTH FACTOR FAMILY
HB-EGF 1 . 0 - 1 . 2 19-23 s/s
INSULIN-LIKE GROWTH FACTORS
IGF-I <0.5 7 s/s
IGF-II 0.5 OO t—‘ ON s/s
OTHER NON-FGF HEPARIN-BINDING GROWTH FACTORS
PLEIOTROPHIN (HBNF) 1.1-1.5 18 ?/L
HGF/SF 1.3-1.4 69 L/S
GM-CSF 0.5 22 S/S
IL-3 0.5 25 S/S
IL-8 0.5 8 S/S
GROa (MGSA) 0.5 8 s/s
a Molar concentration. b L=labile; S=stable. c Not yet reported.
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Although the same batch of heparin-Sepharose was used for all the chromatography work 
described here, and a reproducible FPLC system was employed for gradient elutions, direct 
comparisons with heparin affinities for the well characterised growth factors cannot be made. 
Different retention times of the same growth factors on the matrix were reported to be 
accounted for by batch to batch variations in HS preparations (even among those supplied by 
the same company) {Klagsbrun et al., (1987)}. For more analytical determinations, these 
columns can be calibrated with purified FGFs {Gospodarowicz et al., (1984)}. However, even 
with the use of standardised separation conditions, qualitative predictions based on heparin 
affinities alone, are of limited use in characterising unknown heparin-binding mitogens.
In the absence of data for the size and stability of the different heparin-binding ASAs it was 
difficult to predict which, if any, of the currently identified heparin-binding growth factors 
(FGF and non-FGF) might be responsible for the respective mitogenic activities. Comparing the 
affinities of the ASA in crude and fractionated HEp-2 CM, as well as in HEp-2 cell extract, it 
is clear that a number of growth factors could account for the high affinity ASA.
A similar problem prohibits making an informed prediction about the nature of the loosely 
bound ASA which was recovered at 0.25 M NaCl in this two step purification protocol). 
Recovery of ASA at this low salt concentration is, however, consistent with the detection of a 
similar low affinity ASA in HEp-2 cell extracts, following a single HS separation.
The very high affinity ASA eluting at 2.7 M NaCl (following the two-step purification), was 
detected in all other fractions except the ‘low salt’ extract. This mitogen displayed an unusually 
high affinity for heparin. While this could perhaps be interpreted to suggest the presence of a 
novel heparin-binding growth factor, it was considered that the species might also be attributed 
to the formation FGF multimers. Disulphide bond formation between bFGF molecules has been 
reported to generate heterogenious elution proflies in the separation of recombinant bFGF on 
a heparin-TSK HPLC column. This was evident from the appearance of multiple peaks with 
extended retention times, in samples which had previously single eluted as single peaks from 
the same column {Thompson et al., (1991)}.
A number of findings in this work favour the involvement of a bFGF-like factor in the HEp-2 
autocrine effect. These include the HS-affinity data, the mitogenic responsiveness of HEp-2 to 
bFGF, and (inasmuch as it can be relied upon) the apparent acid sensitivity of a greater portion
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of the ASA in crude CM. Before any further purification was considered, the potential role of 
bFGF in the autocrine effect was explored using an anti-basic FGF neutralising antibody. 
Because aFGF exhibits similar biological activities to bFGF, but is not acid labile, and also 
because a portion of the ASA eluted from the HS matrix at a NaCl concentration coincident 
with that reported for aFGF, the potential autocrine regulation of HEp-2 by an aFGF-like factor 
was investigated using an anti-acidic FGF neutralising antibody.
4.2.4 Inhibition of autocrine activity with anti-FGF antibodies
Confirmation of the production of a bFGF-like ASA by HEp-2, was provided by the 
observation that — 50% of the ASA in crude HEp-2 CM could be effectively neutralised by co­
incubation with two different lots of an anti-basic FGF antibody. A similar portion of the R30 
ASA ( — 40%) in the R30 fraction could also be abolished with this antibody, suggesting the 
presence in this fraction, of a larger MW form of bFGF, or an immunologically similar species 
with a MW > 30 kDa. In contrast, the greater part of the 10-30 kDa ASA appeared to be a 
bFGF-like species. The size of the mature bFGF molecule (18 kDa), together with the lability 
of the R10-30 ASA, are consistent with the presence of a bFGF-like mitogen in this fraction.
Under the conditions used in these studies, the commercial anti-acidic FGF antibody was found 
to cross-react with bFGF. This made it impossible to assign the activities neutralised by this 
antibody to an acidic FGF-like species. However, as specified by the suppliers, the anti-acidic 
FGF antibody did not display cross-reactivity with TGFar, suggesting that the cross reactivity 
observed with bFGF may be accounted for by their similar sequences. If this is the case, then 
the results with the anti-aFGF antibody would seem to confirm the presence of an FGF-like 
ASA in the three HEp-2 CM fractions where bFGF-like ASA was evident.
The inability of either antibody to completely block the ASA in crude HEp-2 CM supports the 
hypothesis that other growth factors in HEp-2 CM combine to mediate this effect. However, 
in one experiment, 99% of the R10-30 ASA was neutralised by the anti-basic FGF antibody. 
This result was not repeated using the same concentration of a different batch of anti-basic FGF 
antibody, but a significant proportion of the R10-30 activity (61%) was confirmed to be 
neutralised by the anti-basic FGF antibody.
Batch-to-batch differences in the neutralising activity of polyclonal antisera have been cited by
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other workers as factors contributing to the difficulties encountered in attempting to inhibit 
tumour cell growth using anti-growth factor antibodies {Herlyn et al., (1990)}.
In another study, using polyclonal anti-K-fgf neutralising antibodies, two alternative explanations 
were proposed to explain the inability of anti-K-fgf to completely block the mitogenic response 
to K-fgf. The first explanation suggested that residual mitogenic activity due to K-FGF (in the 
presence of of the anti-K-FGF antibodies), resulted from the interaction of the growth factor 
with heparan sulphate extracellular cellular matrix components. This interation was proposed 
to prohibit recognition of K-fgf by the anti-K-fgf antibody. The second alternative, which is also 
applicable in the case of bFGF, is that the residual activity might be due to intracellular 
stimulation of the mitogenic pathway {Talarico & Basilico (1991)}.
An interesting result with the anti-FGF antibodies used in this work was the apparent increase 
in the mitogenic response of HEp-2 to TGFa, elicited in the presence of the antibodies. This 
effect, although small, was more significant with the anti-basic FGF antibody. A possible 
interpretation of the affects of anti-basic FGF antibodies on the response to TGFa may be 
explained by the ability of bFGF to modulate the number of cell surface receptors for this 
growth factor (i.e. the EGF receptors). Suchheterologus receptor modulation by bFGF has been 
reported in mouse 3T3 fibroblasts, where bFGF has been shown to reduce EGF receptor 
binding {Hicks et al., (1989)}. More recently bFGF has also been shown to mask the mitogenic 
effect of EGF on porcine skeletal muscle satellite cells {Doumit et al., (1993)}.
The detection of immunoreactive bFGF in conditioned medium has raised the question of how 
such a protein as bFGF, lacking a classical signal sequence, can be secreted. Reports in the 
literature have detected immunoreactive bFGF in culture medium while others have not. Where 
there has been evidence for bFGF secretion, further questions have been posed concerning its 
release mechanism. Detection of a bFGF-like mitogenic activity in HEp-2 CM raises similar 
questions for the HEp-2 system. Moreover, retention of a bFGF-like immunoreactive species 
in the R30 fraction suggested that a larger molecular weight form of the growth factor might 
be present in HEp-2 CM, or that the classical 18 kD form was bound to a larger molecular 
weight species. These hypotheses are discussed in the light of evidence in the literature 
describing FGF binding species as well as a novel secretory mechanism utilised in the export 
of bFGF.
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Higher molecular weight forms of bFGF were initially purified from human placenta 
{Sommer et al., (1987)} and guinea pig brain {Moscatelli et al., (1987)}. The larger MW forms 
arise from the alternative initiation of translation from a single mRNA species using one of 
three CUG codons 5' to the classical AUG start site. Proteins arising from CUG codons result 
in the synthesis of N-terminal extended forms of bFGF with MWs of 22.5, 23.1 and 24.2 kDa 
in addition to the 18 kDa species initiated from the AUG codon {Florkiewicz et al., (1989); 
Prats et al., (1989)}. These high molecular weight forms of bFGF are also expressed in other 
cell line systems {Ensoli et al., (1989); Rifkin & Moscatelli (1989); Renko et al., (1990)}.
The 18 kDa and N-terminally extended forms of bFGF are distributed in different subcellular 
compartments. The former is found in the cytosol and the latter are translocated to the nucleus 
{Renko et al., (1990); Florkiewicz et al., (1991)}. The biological significance of the nuclear 
localisation of high MW bFGF is not clear but recent evidence suggests that bFGF may regulate 
transcription directly in a gene-specific manner {Nakanishi et al., (1992)}.
Multimerisation of recombinant bFGF can produce dimers, trimers and tetramers of the growth 
factor under certain conditions {Fox et al., (1988); Seno et al., (1988)}. This has been shown 
to result from the formation of intermolecular disulphide bridges {Thompson et al., (1991)}.
Pettmann et al., (1991) reported that the biologically active form of natural and recombinant 
bFGF has an apparent MW of 27 kDa.
A 46 kDa form of bFGF has been reported in bovine adrenal glands using two polyclonal 
antibodies which also recognised a 24 kDa and a 30 kDa species in addition to the 17/18 kDa 
double band typical of bovine adrenal bFGF. The formation of multimers was ruled out by the 
authors because the gels were run under denaturing conditions {Grothe et al., (1990)}. This 
46 kDa bFGF-like species was also shown to be biologically active {Westermann et al., 
(1990)}.
With the exception of the 46 kDa bFGF-like species detected by Grothe et al (1990), larger 
MW forms of bFGF isolated to date are smaller in size than the nominal MW cut-off of the 
30 kDa ultrafiltration membrane used to prepare the R30 fraction. However, it is still 
theoretically possible that a species close to this limit, such as the 27 kDa form of bFGF
4.3 HIGHER MOLECULAR W EIGHT FORMS OF BASIC FGF
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reported by Pettmann et al., (1991) would be retained in the R30 fraction if it formed 
aggregates or was bound to a carrier molecule. A number of such bFGF-binding species have 
been described in the literature.
4.3.1 BASIC FGF BINDING SPECIES
4.3.1.1 Miscelaneous binding species for bFGF
a2-Macroglobulin has been shown to bind bFGF covalently. This proteinase inhibitor is unlikely 
to act as a carrier molecule for bFGF because the bound growth factor does not recognise either 
its high or low affinity receptors {Denis et al., (1989)}.
A 17 kDa putative binding protein for acidic and basic FGF was characterised and cloned by 
Wu et al., (1991). Growth factor binding appeared to be non-covalent and reversible, and in 
both cases the biological activities of the respective growth factors were inhibited. Binding was 
abolished in the presence of heparin, and this also removed the inhibition of biological activités.
4.3.1.2 A regulatory role for the interaction of FGFs and other growth factors 
which bind heparan sulphate proteoglycans
A class of proteoglycans which act as low affinity receptors for FGFs has recently been
described. These heparan sulphate proteoglycans (HSPGs) bind FGFs via their heparan sulphate
side chains. Yayon et al., (1991) have shown that such cell surface HSPGs are required as
accessory molecules for the binding of bFGF to its high affinity receptor. This observation was
supported by the findings of Savona et al., (1991) who suggested that heparan sulphates were
necessary for the binding of bFGF to high affinity receptors in adrenocortical cells.
Presta et al., (1991) have demonstrated that this interaction is necessary for the proliferative
response to bFGF and, as mentioned above, the study Rapraeger et al., (1991) showed that
bFGF-mediated fibroblast growth and the differentiation of myoblasts also required the
interaction of bFGF with heparan sulphate. A number of HSPGs that interact with bFGF have
have recently been cloned.
The first, a transmembrane proteoglycan called Syndecan, is expressed on mouse mammary 
epithelial cells and was cloned by Saunders et al., (1989). Syndecan was subsequently shown 
to bind bFGF {Kiefer et al., (1990); Bernfield and Sanderson (1990)}. Studies by Rapraeger 
et al., (1986) had revealed that cultured mouse mammary epithelial cells shed the extracellular
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domain of syndecan leaving all the glycosaminoglycan side chains intact. Syndecan shed by 
epithelial cells was indistinguishable from a molecule released by the same cells in response to 
mild trypsinisation {Jalkanen et al., (1987); Weitzhandler et al., (1988)}. These findings, 
together with the identification of a single dibasic sequence in its extracellular domain adjacent 
to the plasma membrane, prompted Saunders et al., (1989) to propose that a trypsin-like cell 
surface proteinase might be involved in the release of this domain from the cell surface.
Subsequently three other members of this HSPG family of molecules have been identified 
namely Syndecan-2 {Marynen et al., (1989)}, Syndecan-3 {Carey et al., (1993)} andSyndecan- 
4 {Lories et al., (1992)}. The biology of syndecans has been reviewed by Bernfield et al., 
(1992).
Another HSPG with bFGF-binding capacity {Andres et a/.,(1992)} was cloned by Lopez- 
Casillas et al., (1991). This molecule, called betaglycan, binds bFGF via its heparan sulphate 
side chains, but also binds TGF/3 through its core protein. Like Syndecan, betaglycan is released 
into the medium in a soluble form from the membrane of cells which express it 
{Andres et al., (1989)}. A dibasic site in the predicted amino acid sequence of betaglycan was 
suggested by Lopez-Casillas et al., (1991) as a possible target for one of the recently 
characterised dibasic endoproteinases {Barr (1991)}. Another potential cleavage sequence was 
also identified in the ectodomain of betaglycan which is identical to a sequence in the 
membrane-bound TGFa precursor {Lopez-Casillas et al., (1991)}. The latter form of TGFa is 
cleaved by an elastase-like activity to release TGFa into the medium {Pandiella and Massague 
(1991 a & b)}.
Endothelial cells exposed briefly to bFGF rapidly sequester the growth factor into HSPGs in 
their ECM, and these cells show the same mitogenic response as similar cultures continuously 
exposed to bFGF in their medium, suggesting that HSPGs act as a reservoir for bFGF 
{Flaumenhaft et al., (1989)}. It has also been suggested that a pericellular proteinase might 
cleave the core protein of HSPGs, releasing their ectodomins with heparan sulphate-bound 
passenger growth factors {Sommer & Rifkin (1989)}. These and other workers have shown that 
bFGF-glycosaminoglycan complexes are active on sensitive cells {Saksela et al., (1988)}. 
Although the origin of soluble HSPGs remains to be determined, studies with endothelial cells 
indicate that cell surface and ECM HSPGs are distinct molecules, by virtue of their different 
molecular weights. The cell surface HSPG has a MW of 250 kDa, compared to a MW greater
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than 800 kDa for the ECM species {Saksela & Rifkin (1990)}. In addition, Flaumenhaft et al., 
(1990) have shown that soluble HSPGs can neutralise the interaction of bFGF with fixed 
HSPGs, thereby functioning as carriers of bFGF which allow it to diffuse away from the 
producer cell. Moreover, soluble HSPG facilitates bFGF diffusion in a thermally stable 
{Gospodarowicz & Cheng (1986)} and proteinase resistant form {Sommer & Rifkin (1989)}.
The requirement for auxilary binding molecules in the generation of functional growth 
factor/receptor complexes, capable of transmitting the growth factor signal to the nuclei of 
target cells, appears to be a mechanism common to other growth factor signaling pathways apart 
from bFGF. Interleukin 6, for example, will only bind to its receptor when the auxilary 
glycoprotein gpl30 is also present on the cell surface. This accessory molecule is required for 
the formation of a functional signal-transducing complex with IL-6 and its receptor {Taga & 
Kishimoto (1992)}.
Other growth factors interacting with HSPGs
Until recently, an in vivo functional role for the relatively weak binding of some growth factors 
to extracellular matrix and cell surface proteoglycans (compared to FGFs) was not clear. 
However, despite having a low affinity for heparin, the angiogenic protein, vascular endothelial 
growth factor (VEGF) was recently shown to be dependent on cell surface-associated heparin­
like molecules for interaction with its plasma membrane receptor {Gitay-Goren et al., (1992)}. 
In this report, the detection of VEGF receptors (by cross-linking with I125 VEGF) was enhanced 
in the presence of heparin, thereby enabling these workers to detect VEGF receptors on cell 
types other than endothelial cells. These included HeLa cells and NIH3T3 fibroblasts, not 
previously known to express VEGF receptors. The increase in sensitivity was apparently due 
to the induction of high-affinity cell surface binding sites in the presence of heparin at 0.1-10 
/zg/ml. Higher heparin concentrations (10-10000 /zg/ml) were found to inhibit ligand binding.
In the context of the results with the HeLa variant HEp-2, presented in this thesis, the 
possibility of VEGF receptor expression suggests the involvement of one or more forms of this 
growth factor in an autocrine loop in HEp-2 cell regulation. In a series of studies carried out 
by Houck and co-workers, the four alternative transcripts of the VEGF gene were transfected 
into human embryonic kidney cell lines. In the first study, using the 293 kidney cell line, 
differences in the secretion patterns of the various VEGF transcripts was revealed {Houck et 
al., (1991)}. Subsequently, evidence for the bioavailability of three of these VEGF transcripts
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was examined in clones (‘transfectants’) of another human embryonic cell line, CEN4, which 
was transfected with constructs encoding VEGF of different length {Houck et al., (1992)}.
Analysis of VEGF secretion patterns had demonstrated that the two shorter forms, VEGFm and 
VEGF165, were efficiently secreted, and possesed simlar mitogenic activity for endothelial cells. 
The longer transcripts VEGF189 and VEGF205 were also expressed, but were not deteceted as 
soluble proteins in the culture medium, thereby preventing their biological activities from being 
determined. However, in the more recent study, biologically active VEGF189 was recovered 
from a stable transfectant of the CEN4 cell line, by blocking the interaction of the VEGF189 with 
its cell-surface receptors. This was achieved by using suramin, a non-specific inhibitor of 
growth factor/receptor interaction. Comparing the chromatographic behaviour of VEGF189 with 
that in conditioned media from two other CEN4 transfectants, expressing VEGFm and VEGF165 
respectively, it was found that increasing length was associated with increasing affinity for 
VEGF on a cation-exchange matrix (S-Sepharose). The behaviour of the different VEGF forms 
on a heparin-Sepharose matrix was also monitered using a VEGF ELISA, and revealed that 
VEGFm failed to bind heparin whereas VEGF165 eluted at 0.9 M NaCl. The longer VEGF189 
exhibited a binding profile similar to bFGF, with only 20-30% eluting at 0.9M NcCl and the 
remainder eluting with 2M NaCl. Moreover, it was found that the physiolgically relevant serine 
proteinase, plasmin, was capable of releasing biologically active VEGF189 from its cell surface- 
bound sites.
4.3.1.3 Soluble forms of the FGF receptors
The recently characterised Fibroblast Growth Factor Receptor 1 (FGFR1) was predicted to 
generate multiple forms of the receptor by alternative splicing of three alternative exons 
{Johnson, D.E., etal., (1991)}. One of these splice variants was predicted to encode a secreted 
form of the FGFR1. Subsequently the same group isolated a cDNA from a human placenta 
library encoding this protein. This secreted form of the FGFR1 was recently expressed in 
Chinese Hamster Ovary cells and was found to bind bFGF in preference to aFGF {Duan, D-S. 
R., et al., (1992)}. It has also been shown that only heparin-bound bFGF binds to soluble 
receptors {Ornitz et al., (1992)}.
The biological significance of secreted forms of the FGF receptor is not understood at present, 
nor is it known if such FGF-receptor complexes are mitogenic. It would be premature therefore, 
to infer a role for such a soluble receptor in the R30 ASA fraction. Soluble receptors for several
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cytokines including IL-2, IL-4, TNF and Interferon y (gamma), have been reported to inhibit 
the activities of these molecules {Larrick & Wright (1992)}. Other cytokines reported as having 
soluble receptors include those of IL-6 {Novick et al., (1989)} and IL-7 {Goodwin et al., 
(1990)}. Although it is not known whether the soluble forms of the IL-6 and IL-7 receptors can 
inhibit the activity of their respective ligands, it has been suggested that the binding of cytokines 
to such soluble receptors in vivo might increase their half-life in the circulation by protecting 
them from proteolytic inactivation {Fernandez-Botran (1992)}.
Natural forms of soluble receptors for other non-cytokine receptors have been reported 
including those for epidermal growth factor {Weber et al., (1984)}, insulin-like growth factors 
{MacDonald et al., (1989)}, colony-stimulating factor {Downing et al., (1989)} and growth 
hormone {Leung et al., (1987)}. It would appear therefore that regulation of growth factor 
activity by soluble receptors is a widely used mechanism among different growth factor classes.
4.3.2 SECRETORY MECHANISMS FOR THE RELEASE OF BASIC FGF FROM 
CELLS
Other growth factors have been found associated with HSPGs of the ECM, including IL-3 and 
GM-CSF {Roberts et al., (1988)}, Platelet factor 4, and the non-FGF heparin binding and 
neurite-promoting factor, Pleiotrophin. Platelet factor 4 binds heparin-Sepharose with high 
affinity {Li et al., (1990)} but it also has a high affinity for the chondroitin sulphate 
proteoglycan serglycin, with which it forms a complex in the secretory a  granules of platelets 
{Perin et al., (1988)}. Many hematopoietic cells contain serglycin in storage granules, and in 
macrophages at least, it is found to be largely secreted. {Kolset and Gallagher (1990)}. By 
comparison, heparan sulphate proteoglycans appear to be induced as macrophages mature and 
extravasate from the blood stream during wound healing. Syndecans are likely to act as 
mediators in the wound healing process since this type of heparan sulphate proteoglycan on the 
macrophage-like cell line P388D1 have been found to bind to bFGF-Sepharose affinity columns 
{Yeaman and Rapraeger (1993)}.
Heparan sulphate proteoglycans acting as carrier molecules in secretory vesicles, analogus to 
the role of serglycin, may explain how bFGF which lacks a typical secretory signal sequence, 
is released from producer cells. Westermann et al., (1990) have identified immunoreactive 
bFGF species in the secretory granules of medullary chromaffin cells isolated from bovine 
adenal glands. Observations based on work with bFGF in the induction of transmitter synthesis
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and storage in chromaffin cells, together with previous work demonstrating its effect on their 
in vitro survival, led Unsicker & Westermann (1992) to propose an autocrine/paracrine role for 
bFGF in the maintenance of these cells. Interestingly the 46 kDa form of bFGF previously 
identified by this group {Grothe et al., (1990)} was enriched in the secretory granules with 
respect to the lower MW species when levels of the respective MW forms were compared in 
the medulla or cortex {Westermann et al., (1990)}. In contrast to these findings Renko et al., 
(1990) were unable to demonstrate the presence of bFGF in cytoplasmic vesicles isolated by cell 
fractionation.
If secretion of bFGF in secretory granules via exocytosis does explain the release of this growth 
factor from cells, the molecular mechanism by which it is recognised for translocation into 
secretory granules still remains to be determined. In the last few years the number of proteins 
secreted despite the lack of a classical signal sequence has grown. These include Interleukin-1/3 
which was localised in the membrane-bound vesicles of activated monocytes {Rubartelli et al.,
(1990)} and thioredoxin, a disulphide reducing enzyme secreted by normal and transformed 
cells. The latter molecule shares some features of the alternative pathway described for IL-1/3, 
but was localised only in the cytosol, suggesting a direct plasma membrane translocation 
{Rubartelli et al., (1992)}. Evidence for the excretion of a 14.5 kDa muscle lectin (L-14) by 
exocytosis from the cytosol to the extracellular matrix of differentiating myoblasts was reported 
by Cooper & Barondes, (1990). Other plasma membrane activities have been associated with 
the formation of exosomes (released vesicles); Johnston et al., (1987) reported that selective 
externalisation via exocytosis is a mechanism for the shedding of transferrin receptors during 
reticulocyte maturation, and a similar process was described by Hale & Wuthier (1987) during 
the mineralisation of calcifying tissues.
Evidence for a bFGF secretory pathway independant of the endoplasmic recticulum-golgi 
complex was recently reported by Mignatti et al., (1992). These authors had previously 
demonstrated that the migration of NIH 3T3 cells transfected with bFGF cDNA was modulated 
in an autocrine manner by bFGF. The bFGF-mediated migration was established in an isolated 
single cell system in which individual cell migration could only be regulated by bFGF secreted 
from the cell under observation (therefore excluding any possibile contribution of extracellular 
sources of bFGF present in mass culture experiments) {Mignatti et al., (1991)}. Using this 
method (Phagokinetic track assay), cell migration was roughly proportional to the amount of 
extracellular bFGF and therefore was also proportional to bFGF release. These authors were
able to show that drugs or treatments which blocked endo- and exocytosis also inhibited cell 
motility, while those that inhibited protein trafficing in the Endoplasmic Recticulum-Golgi 
complex were ineffective in this respect. Blockers of the MDR protein pump were likewise 
ineffective. Of the treatments used to inhibit endo- and exocytosis in these studies, an interesting 
finding was that treatment with serum-free conditions appeared to inhibit bFGF release, as 
manifested by the inhibition of cell migration. These studies also showed that increases in 
motility by cells under these serum-free conditions were more sensitive to increases in the level 
of cell-secreted (autocrine) bFGF, irrespective of the addition of exogenous recombinant bFGF. 
This implies that bFGF must be concentrated near the cell surface {Mignatti et al., (1992)}.
The observations of Mignatti et al., (1992) raises the question of a mechanism for the release 
of bFGF-like activity detected in HEp-2 CM, given that HEp-2 CM was collected under serum- 
free conditions, and the possibility that secreted bFGF may be rapidly sequestered by producer 
cells. If this is the case in the HEp-2 system, then perhaps the trypsin-like activity in HEp-2 
CM may be involved in a release and/or activation mechanism for the bFGF-like ASA.
Several candidates for this serine proteinase activity were detected in crude HEp-2 CM, 
including, trypsin, chymotrypsin, elastase and cathepsin G (see appendix D for details). The 
effect of a serine proteinase inhibitor (soyabean trypsin inhibitor) on the ASA in crude HEp-2 
CM and its R10-30 and R30 fractions, suggests a complex regulatory role for these proteinase 
activities in modulating the autocrine effect. The stimulatory effect of trypsin inhibitor in the 
crude CM was in direct contrast to the potent inhibitory effect it displayed in the R10-30 and 
the R30 ultrafiltration fractions. These discrepancies may be explained in terms of the relative 
differences in the levels of such endogenous proteinase activities and/or the distribution of 
specific activities in the fractionated and unfractionated CM.
4.3.3 RELEASE OF BASIC FGF FROM EXTRACELLULAR MATRIX 
STORAGE SITES
The trypsin-like serine proteinase plasmin, is very abundant in many tissues. In cultures of 
bovine capillary endothelial cells (BCE) this proteinase has been implicated in the release of 
bFGF from HSPG complexes in the extracellular matrix (ECM) {Rifkin & Moscatelli (1989); 
Saksela et al., (1990)}. Endothelial cells in culture have been shown to synthesise bFGF and 
this growth factor is active in effecting the biological properties of these cells in an autocrine 
manner {Sato & Rifkin., (1988)}. It has also been demonstrated that BCE cells secrete heparan
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sulphate-bound bFGF {Saksela et al., (1988)}. Given the similar role demonstrated for plasmin 
in the release of extracellular matrix bound-YEGF and bFGF, together with the evidence for 
the involvement of a trypsin-like proteinase activity in mediating both the R10-30, and the R30 
autocrine stimulatory activities, it is tempting to suggest that this trypsin-like proteinase may 
function in a similar capacity to effect the autocrine response in HEp-2.
The implication of proteinase activity in the R10-30 ultrafiltration fraction is further supported 
by the work of Ho et al., (1990) who reported the co-purification of serine and thiol-like 
lysosomal proteinases with pituitary-derived bovine bFGF on heparin-Sepharose. Two 
components, with apparent molecular weights of 28 and 30 kDa respectively, were separated 
and found to be immunoreactive against bFGF antisera. N-terminal sequence analysis revealed 
that these proteinases shared no sequence homology with FGFs, but that the 28 kDa component 
was 73 % homologus with human cathepsin L and the 30 kDa component shared 57 % and 47 % 
homologies with human leukocyte elastase and cathepsin G respectively. The authors suggest 
that these extracellular-matrix-degrading enzymes {Sinha et al., (1987), Erickson (1989)}, 
which are produced and secreted by transformed cells {Tryggvason et al., (1987); Troen et al.,
(1988)} may act to release matrix-bound FGFs. Another group reported indirect evidence for 
an endogenous trypsin-like proteinase which converted high MW bFGF species to a ‘trypsin 
resistant’ 18.8 kDa form during the purification of bFGF from bovine and rat brain on a 
heparin-Sepharose matirx. They found that Ca2+ protected the high MW heparin-bound forms 
from truncation by the co-purifying proteinase activity, suggesting that Ca2+ inhibited the 
activity of the proteinase responsible {Doble et al., (1990)}.
A bFGF immunoreactive proteinase similar to that described by Ho et al., (1990) might account 
for some or all of the autocrine stimulatory activity in R10-30 fraction of HEp-2 CM, but 
results of protease measurements in conditioned medium collected using high Ca2+-containing 
basal medium suggest that the trypsin-like activités in HEp-2 CM are stabilised by high Ca2+ 
concentrations {O’Leary etal., (1991)}. Preliminary studies in this thesis, indicated that the fold 
stimulation measured in high Ca2+, MEM conditioned medium, was less than that detected in 
the low Ca2+ media (Section 3.2.1.4). Moreover, ‘high Ca2+’ basal media such as MEM 
demonstrated higher levels of serine proteinase activities (appendix D). Therefore, although 
proteinase levels and ASAs were not correlated directly in the CM prepared from basal media 
with high and low Ca2+ concentrations, it is unlikely that the proteinase activities in HEp-2 are 
similar to the activity described by Doble et al., (1990).
4.3.4 THE ROLE OF BASIC FGF IN VIVO AND IN  VITRO
It is important to establish the ability of tumour cells to secrete a potent angiogenic factor such 
as bFGF if its role in tumourigenesis in vivo is to be understood. It has been reported that 
prolonged in vitro cultivation of normal endothelial cells stimulates the production of 
immunoreactive acidic and basic FGF growth factors above the levels found in primary cultures 
of these cells {Spier et al., (1991)}. This poses a problem with extrapolating the findings of in 
vitro studies to the significance of these factors in vivo. However, studies using a transgenic 
mouse model system for fibrosarcoma correlated the progression from benign to a malignant 
phenotype in fibrosarcomas with changes in the secretory patterns of a bFGF immunoreactive 
species. Cell lines derived from such tumours at different stages in vivo demonstrated that the 
mildly aggressive and less vascularized fibromatosis-derived lines produced large amounts of 
cell associated bFGF, while those lines derived from the more highly vascularized aggressive 
fibromatosis and fibrosarcomas secreted bFGF into the culture medium {Kandel et al., (1991)}.
Experimental evidence continues to support the idea that tumour growth is dependent on 
neovascularisation {Folkman (1990)} and that this process is regulated by a family of diffusible 
angiogenic peptides, including FGFs {Folkman et al., (1987)}, as well as low molecular weight 
nonpeptide angiogenic molecules {Folkman et al., (1992)}.
More compelling evidence for the role of bFGF as an angiogenic factor was presented by Hori 
et al., (1991). In this mouse model system, the gene for a stablilised mutant form of bFGF 
retaining biological activity was fused to the signal sequence for IL-2 and the resulting construct 
used to transform a BALB/c3T3 cell line. A transfectant designated K1000 which secreted the 
bFGF mutein (bFGF CS23) formed solid tumours in BALB/c nude mice after subcutaneous 
implantation. Upon histological examination these tumours were intensely vascularised. The 
angiogenic process could be inhibited in this model system using an immunoneutralising 
monoclonal antibody (3H3) raised against the mutein bFGF CS23 protein, and treatment with 
this antibody also suppressed solid tumour growth. A direct causal relationship between the 
inhibition of angiogenesis and anti-tumour activity in this system was therefore established. 
Direct inhibition of K1000 proliferation by blocking of an autocrine loop in these cells was 
ruled out because the 3H3 antibody did not inhibit the in vitro growth of K1000 cells. The 
alternative possibility that tumour growth was inhibited by a non-specific immune response 
mediated via complement or lymphocyte binding to the tumour-bound 3H3 antibody was 
discounted by the lack of in vivo growth inhibition of the K1000 cells and the absence of any
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induction o f lymphocytes at the tumour periphery.
Taken together, these studies indicate that the acquirement of bFGF secretory and/or release 
mechanisms may be an important step in the tumourigenic process in vivo. This appears to be 
related to the paracrine stimulation of angiogenesis effected by bFGF. However, the induction 
of bFGF secretion in vitro {Spier et al., (1991) suggests that this growth factor is also required 
for cellular adaptation to in vitro culture conditions.
4.3.5 ANTISENSE FGFs - evidence for an autocrine role for bFGF in HEp-2
Although the anti-basic FGF antibody used to neutralise bFGF-like ASA in HEp-2 CM did not 
demonstrate cross-reactivity with acidic FGF, the possibility of recognition by another member 
of the FGF growth factor family cannot be discounted. Attempts to corroborate the putative role 
of the bFGF-like factor in HEp-2 autocrine growth control using antisense 
oligodeoxynucleotides (unmodified) were encouraging, but not definitive. The 15 base pair 
sequences used were directed against the translation initiation site of basic FGF mRNA based 
on similar studies by Becker et al., (1989) and Morrison (1991). These authors had 
demonstrated inhibition of proliferation in melanoma and glioma cell lines respectively with the 
same bFGF antisense sequence. Aside from the technical problems encountered, other 
parameters used in these assays may not have been optimal for detecting the effect of the arrest 
of bFGF protein synthesis in HEp-2. The cell density used for antisense experiments was 30- 
fold higher than that of the autocrine assay. Under these conditions the contribution of autocrine 
bFGF production to cell growth may be redundant. In addition, the fact that cultures of HEp-2 
were allowed to attach overnight, before the oligos were added, may have provided time for the 
deposition of sufficient extracellular stores of bFGF on HSPGs of the extracellular matrix. Such 
a ‘reservoir’ of bFGF may have been ample to supplement for any deficiency in bFGF 
production arising from the addition of the antisense olgonucleotides. It is also important to 
stress that the unmodified oligonucleotides were used in these experiments, and that these were 
not replenished during the assay period. Unmodified oligonucleotides are sensitive to digestion 
by endogenous cellular nucleases, a factor which may have limited the final active intracellular 
concentration of oligonucleotide. Any one or a combination of these parameters may explain 
the failure of the basic FGF antisense sequences to affect the proliferation of HEp-2.
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4.3.6 EFFECT OF HEPARIN ON HEp-2 PROLIFERATION
The negative effect of heparin on HEp-2 growth noted in the stability studies was confirmed in 
an experiment which measured the dose response of HEp-2 to this mucopolysaccharide at 
concentrations in the range 0.5-20 /zg/ml. An average reduction of 40% in growth was 
measured over the entire concentration range with no obvious dose response relationship. This 
may indicate that even at 0.5 /¿g/ml, the threshold for the inhibitory effect of heparin is 
exceeded. The inhibitory effect of heparin on HEp-2 growth is consistent with the work of 
others.
The mitogenic activity of a heparin-binding autocrine stimulator in normal human epidermal 
keratinocytes, identified by Cook et al., (1991a) as amphiregulin (AR), was demonstrated was 
found to be inhibited by heparin {Cook et al., (1991b)}. These workers have subsequently 
shown that other sulphated polysaccharides can abrogate AR-mediated autonomous growth of 
keratinocytes and that sulphation of polysaccharides is necessary for this inhibition {Cook et al.,
(1992)}. Others have also found that the antimitogenic effect of heparin appeares to depend on 
its size and the degree of sulphation {Wright et al., (1989)}. A role for amphiregulin in the 
autocrine stimulation of HEp-2 is unlikely because there was no evidence for such a competitor 
for the EGF receptor in concentrated HEp-2 CM (Section 3.1.6.3).
4.3.6.1 Mechanism of action for heparin
Despite the functional information available, the mechanism of heparin inhibition is not fully 
understood. Pukac et al., (1990) examined heparin inhibition in rat vascular smooth muscle cells 
(VSMC) and demonstrated that it could inhibit the induction of the immediate early gene 
expression of c-fos and c-myc by the phorbol ester, PMA (phorbol 12-myristate 13-acetate). A 
similar induction of c-fos and c-myc by EGF in these cells was unaffected by heparin. PMA is 
an activator of the growth factor signal-transducing protein kinase C (PKC) and was used in 
subsequent studies in VSMC by Pukac et al., (1992) to show that the heparin suppression of 
mitogen-stimulation was operative early on in the cell cycle (i.e. during the G^Gi phase). 
Stimulation through PKC-dependent but not PKC-independent signalling pathways was inhibited 
in this way. In the same study bFGF-stimulation of c-fos and c-myc was only partially sensitive 
to the inhibition by heparin, indicating that the bFGF acts only partially through a PKC- 
dependent pathway in VSMC. In another study using VSMC, heparin did not inhibit the binding 
of PDGF or IGF-I to VSMC {Reilly et al., (1988)}.
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In a more recent study, comparing the effect of heparin and other glycosaminoglycans on the 
growth of normal fibroblasts and a fibrosarcoma cell line, heparin was found to suppress the 
growth of normal cells by 25-35% in the presence of serum. In the same study however, 
heparin did not affect the growth of the fibrosarcoma cell line, and inhibition of cell growth was 
independent of serum and added growth factors. This suggested that heparin-like GAGs act 
directly on cell regulatory components in normal cells {Westergren-Thorsson et al., (1993)}.
4.3.6.2 Possible differential effects of heparin on the mitogenic response to FGFs 
The ability of heparin to bind growth factors of the FGF family is well documented but the 
modulatory role of heparin on the biological activity of individual FGFs is growth factor 
dependent. While heparin has been seen to potentiate the biological effects of aFGF in several 
cell systems {Thornton et al., (1983); Thomas & Gimenez-Gallego (1986)}, its modulation of 
bFGF bioactivity seems to depend on the cell type and experimental conditions used. Some 
studies with heparin have reported an inhibitory effect on bFGF activity while others found that 
it augmented the bioactivity of this growth factor {Gospodarowicz et al., (1990); Neufeld et al., 
(1987)}. This may reflect the signalling pathways used by the particular cells used, as suggested 
by recent evidence with normal cells. However, the high affinity of FGFs for heparin-like 
GAGs, and the involvment of heparan-sulphate moieties in the formation of high affinity 
receptor complexes with FGFs mentioned above, suggest that heparin-like molecules may have 
a complex modulatory role in FGF-signalling.
In the light of evidence for heparin-induced inhibition of bFGF mitogenic activity, it is 
interesting to note that the percentage growth inhibtion of HEp-2 caused by added heparin was 
in the same order ( — 40%) as the percentage reduction in ASA effected by the incubation of 
anti-basic FGF antibody with the crude HEp-2 CM fraction ( — 50%). This would seem to 
support the involvment of a bFGF-like species in the autocrine effect but the negative effect of 
heparin on HEp-2 growth is difficult to reconcile with a role for aFGF in the HEp-2 autocrine 
effect. Factor-specific inhibition of FGF growth factors by heparin has been reported in other 
cell line systems too.
In the SC-3 cell line mentioned earlier (Section 1.3.5.7) Kasayama et al., (1991) found that 
heparin enhanced the bioactivity of low concentrations of acidic and basic FGF, but was 
antagonistic to the mitogenic effects of a distinct FGF-like autocrine activity (AIGF), secreted 
by these cells in response to androgen induction. A 50% reduction in SC-3 growth was reported
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in the presence of 0.1 /xg/ml of heparin with SC-3 cells. This is quantitatively similar to the 
percentage reduction observed at 0.5 ¿ig/ml heparin in the HEp-2 system.
AIGF was later shown to be the sole FGF-like growth factor secreted by SC-3 cells {Nonomura 
et al., (1989)}. The same group found that the SC-3 autocrine activity could be inhibited by 
anti-basic FGF antibodies {Yamanishi et al., (1991)} suggesting a cross-reactivity with bFGF. 
This cross-reactivity between the anti-basic FGF polyclonal antibody and AIGF was confirmed 
by Western blotting (unpublised data) in a publication reporting the cloning and characterisation 
of the SC-3 autocrine growth factor (AIGF) as the eight member of the murine FGF family 
{Tanaka et al., (1992)}.
The possibility that an AIGF-like heparin-binding autocrine growth factor is produced by HEp-2 
cells in culture cannot be ruled out. This is supported by the recovery of an ASA from HEp-2 
CM which eluted from a HS matrix between 1.0 and 1.3 M-NaCl (Section 3.3.5) — an affinity 
which is coincidental to that reported for AIGF (eluting at 1.1 M-NaCl in a buffer containing 
0.1% CHAPS) {Nonomura et al., (1988)}.
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CONCLUSIONS AND FUTURE DIRECTIONS
5.0 CONCLUSIONS AND FUTURE DIRECTIONS
The original aim of this project was to improve the exisiting methodology and culture conditions 
for the establishment of primary non-small cell lung carcinomas (particularly the squamous cell 
subtype), as permanent in vitro cultures. Experience with many NSCLCs made it clear that 
successful cultures could only be derived from large tumour samples, such as those obtained 
at lobectomy etc. Moreover, deficiencies in the growth medium used were found to favour 
growth arrest and terminal differentiation. In a minority of cases, cultures could be subcultured 
beyond the primary stage, but only one continuous cell line was established, and at that, the 
source was a secondary lung metastatsis. Despite their poor performance in vitro, the propensity 
of primary NSCLC tumours to metastasise in vivo is well documented. This suggests that a 
subpopulation of cells in these tumours should have similar potential for continuous proliferation 
in vitro — given the correct growth conditions.
In this project, the lack of proliferative potential of NSCLC growth in vitro was considered in 
terms of insufficient or absent growth factors. In the search for novel growth supplments for 
NSCLCs effusions from cancer patients were considered. The labour-intensive nature of the 
primary culture work mitigated against the use of these cultures as indicators of growth- 
promoting activity for NSCLCs. This was important if sufficient progress was to be made in 
the duration of the project. Therefore a change in the direction of this work was taken.
To this end, an attempt was made to use the established squamous cell lung carcinoma cell lines 
DLRP, SK-MES-1, and DLKP as ‘indicator cell lines’ to screen malignant effusions for growth 
stimulators relevant to NSCLCs. Preliminary investigation of autocrine growth factor production 
in DLRP and DLKP was also attempted. No evidence of autocrine activity was apparent in CM 
from either of these cell lines in the assay systems used. This may reflect the nature of the 
monolayer-based detection systems employed because when seeded in semi-solid agar medium, 
both cell lines demonstrated definite ‘cut-off points, below which no cells formed colonies. 
This density-dependent growth in the more stringent agar system is indicative of autocrine 
growth stimulation, and may provide the basis for developing agar-based assays for detecting 
novel NSCLC growth factors using these cell lines.
The use of DLRP, SK-MES-1 and DLKP as ‘indicator cell lines’ for effusion-derived growth- 
promoting activities also proved impractical. This was due to the slow growing nature of these 
cell lines, and the difficulty in obtaining sufficient numbers of clinical samples. However, when 
the relatively small number of such samples available were assayed in the HEp-2 proliferation 
assay, analysis of the effects of various MEs associated with benign and malignant diseases did 
not indicate that growth-promoting activity was specific to cancer-related diseases. Moreover, 
in two cases where autologous plasma and/or serum was also available, there was evidence that 
the effusion-derived activities were also systemic. A variety of previously characterised growth 
factors have since been identified by others in malignant effussions. The apparent complexity 
of MEs, as well as reports in ovarian effusions of the NSCLC inhibitor IL-6, suggest that it 
would prove difficult to isolate novel growth factors for NSCLC from these biological fluids, 
contrary to our initial expectations.
Recent developments in the literature suggest that some of the commercially available growth 
factors such as HGF/SF, IGF-I, PDGF, and bFGF might prove useful in fresh attempts to
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develop selective serum free media for NSCLC. The same may be true for KGF and the peptide 
VIP when these become avaliable as highly purified preparations.
Use of the HEp-2 cell line led to the discovery of an apparently complex autocrine growth 
control network in this cell system, which in itself was a useful model for the study of autocrine 
growth control. HEp-2 cells produce both autocrine growth inhibitors, and autocrine growth 
stimulators.
The low MW (1-5 kDa) autocrine inhibitory species identified was not investigated further 
because this work was focused on the identification of epithelial growth stimulatory species. 
However, the size of this inhibitor makes it interesting, in that less is known about low MW 
growth inhibitors than larger protein inhibitors such as TGF-/3. It would be of interest also to 
determine the molecular size of the inhibitory activity separated by cation-exchange 
chromatography, given that a low MW inhibitory activity was also recovered by gel-filtration. 
These separation techniques might form the basis of a purification strategy for this inhibitory 
activity if further physicochemical analysis suggested that it might be a novel factor.
Autocrine stimulatory activity (ASA) in HEp-2 can be fractionated into two molecular weight 
classes, a 10-30 kDa MW fraction, and a > 30 kDa MW fraction. A significant portion of the 
ASA in both fractions can be accounted for by a bFGF-like growth factor, but the greater 
portion of the 10-30 kDa MW ASA was attributed to this species. The lability of this fraction 
to heat, acid treatment, and storage, is also consistent with the properties of bFGF. An 
unexpected finding was the evidence for a serine proteinase-like enzyme activity in the 10- 
30 MW kDa fraction. This proteinase appears to mediate the autocrine activity of this fraction, 
but its role in the overall autocrine regulation of HEp-2 growth remains to be validated.
The presence in the larger > 30 kDa MW fraction of a similar enzyme activity, albeit at lower 
levels, supports the hypothesis that a serine proteinase activity may function to release and/or 
activate a growth factor bound to a carrier molecule, or in a larger MW form, analagous to the 
role of plasmin in the release of bFGF from heparan sulphate proteoglycans. Another candidate 
which might be involved in this ‘activation’ mechanism is VEGF. The detection of VEGF 
receptors on the HEp-2-related HeLa cells suggests this possibility.
On the basis of the different stability of the > 30 kDa MW fraction, it is more difficult to 
ascribe the bFGF-like ASA in the > 30 kDa fraction to bFGF. Further characterisation of this 
fraction is needed to distinguish between the possibility that the larger bFGF-like activity 
represents an aggregate of the 18 kDa form of bFGF, or that it may be a complex of the 18 
kDa form and a larger carrier molecule. Treatment with of the > 30 kDa fraction with the 
reducing agent dithiothreitol should help to eliminate the possibile contribution of bFGF 
multimers, and exposure to heparanase and/or other extracellular-matrix-degrading enzymes 
should help to address the second possibility.
The affinities of the ASAs in both MW fractions has yet to be determined and compared with 
those in crude HEp-2 conditioned medium. Before any further purification is considered, more 
physicochemical stability analysis of the MW fractions are needed. The acid stability property 
in particular would be informative, as many of the growth factors characterised to date are acid 
stable. However to do this, the negative effect of HC1 treatments on the control medium needs 
to be circumvented. A useful experiment might be to determine the effect of chlorate ions in 
the HEp-2 system, or to acid treat a CM sample collected in a different basal medium.
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A greater understanding of the role of heparin may also be informative, particularly its effect 
on bFGF-induced stimulation of HEp-2. If heparin does not inhibit the bFGF mitogenic activity, 
then it may be interacting with another growth factor activity such as amphiregulin.
Several mitogens with different affinites for immobilised heparin are recovered from separations 
of HEp-2 CM. The possibility that one or more of the FGF family are active in the HEp-2 
system cannot be eliminated because of the potential for cross-reactivity with these, and perhaps 
previously unidentified FGFs. In an effort to characterise the heparin-binding AS As further, 
qualitiative analysis of heparin-Sepharose-fractionated CM and or its MW fractions might be 
considered using currently the available ELIS As for acidic and basic FGF, as well as several 
other members of this family such as FGF-4 and FGF-6. Further development of the assay 
parameters is required to overcome the technical difficulties associated with the use of the more 
specific antisense oligonucleotides.
Finally, not all of the HEp-2 ASA can be attributed to heparin-binding mitogens. From the 
evidence presented here, demonstrating that IL-1 can stimulate HEp-2 proliferation, and a 
publication in the literature reporting the secretion an IL-l-like activity by HEp-2 cells, the 
potential exists for an autocrine loop involving IL-1. The more recent discovery that functional 
IL-6 cytokine, and its receptor components are expressed in HEp-2, indicates the possibility of 
yet another autocrine growth regulatory mechanism in the HEp-2 system. These mechanisms 
remain to be verified. It would also be ineresting to determine the interactions between IL-1 and 
IL-6, and the putative bFGF autocrine loop, given that both cytokines are known to modulate 
bFGF secretion in other cell types utilising bFGF autocrine mechanisms.
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APPENDICES
APPENDIX A
The following equation is used to calculate the settings on the sorvall for a particular "g" value 
when the SM-24 rotor is used.
g = 0.0000284 x  r  X N2 
Where, r =  radius of the rotor; N =  revelutions/minute (X 1000 on the Sorval).
Calculation o f settings to give a "g" value o f 25,000 using the SM-24 rotor on the Sorval
SM-24 rotor dimensions
i  =  6.48 cm (inner row in rotor) 
r =  8.99 cm (outer row in rotor)
The tubes for centrifugation were placed in the outer row of this rotor and the "g" value at this 
distance from the rotor shaft was calculated as;
.'. 9895 rev/min =  25,000---
8.99 x  0.0000284
The centrifuge was therefore set at 10,000 rev/min to ahieve a "g" force of 25,000.
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APPENDIX B
Sequences o f  Oligodeoxynucleotides Sense and Antisense to Acidic FGF mRNA
ANTISENSE aFGF: (ASA)
5' TTC CCC TTC AGC CAT 3'
SENSE aFGF: (SA)
5' ATG GCT GAA GGG GAA 3'
ANTISENSE bFGF: (ASB)
5' GGC TGC CAT GGT CCC 3'
SENSE bFGF: (SB)
5' GGG ACC ATG GCA GCC 3'
%
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APPENDIX C
[B S A ]  m g / m l
Standard curve for protein concentration versus absorbance @ 595 nm 
— determined using the BioRad protein assay.
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APPENDIX D
The following table o f serine proteinase activities is taken from O’Leary et al., (1991).
Serine proteinase levels in HEp-2 CM grown in five different basal culture media
BASAL MEDIUM
is
Proteinase activity (p.moi PNAareleased/min/ml)— _ - - .
Trypsin Chymotrypsin Ebsta.se Cathcpsin G
RPMI-2650 <0.10 <0.10 <0.10 < 0.10
DMEM 0.81 0.77 0.75 0.85
Ham’s F12 <0.10 <0.10 <0.10 < 0.10
MEM 1.42 1.34 0.98 1.36
DMEM/Ham’s F12b 0.53 0.43 0.40 0.56
a The substrate used was p-nitroanalide. b A l:l(v/v) DMEM/Ham’s F12 mixture.
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